Home The Word Brain My Amedeo FAQ Privacy About   


C49 + CC Journal Club

For more information, please refer to our special emails from April 13 and May 19.


  Bladder Cancer, January 2023

Free Subscription


Abstracts

Retrieve all available abstracts of the following 2497 articles:
HTML format


 

Single Articles

  1. CHAU M, Thia I, Viswambaram P, Hawks C, et al
    Lymph node assessment technique matters in radical cystectomy for bladder cancer.
    ANZ J Surg. 2023 Mar 3. doi: 10.1111/ans.18292.
    Abstract

  2. IMAMVERDIYEV S, Qasimov E, Naghiyev R
    COMPARATIVE RESULTS OF MODERN EXAMINATION METHODS IN EARLY DIAGNOSIS OF BLADDER CANCER, DETERMINATION OF THE DEGREE OF INVASION AND SELECTION OF RADICAL TREATMENT TACTICS.
    Georgian Med News. 2023;:98-102.
    Abstract

  3. XU H, Liu Z, Weng S, Ren Y, et al
    Epigenetically regulated gene expression profiles recognized three molecular classifications with prognostic and therapeutic implications in bladder cancer.
    Clin Transl Med. 2023;13:e1145.
    Abstract

  4. IKEDA M, Uemura K, Araki Y, Iribe Y, et al
    [A Case of Long-Term Survival Following Multidisciplinary Therapy for Small Intestinal Metastasis of Bladder Cancer].
    Hinyokika Kiyo. 2023;69:55-58.
    Abstract

  5. DE HAAR-HOLLEMAN A, van Hoogstraten LMC, C C M Hulshof M, Tascilar M, et al
    Chemoradiation for muscle-invasive bladder cancer using 5-fluorouracil versus capecitabine: a nationwide cohort study.
    Radiother Oncol. 2023 Feb 28:109584. doi: 10.1016/j.radonc.2023.109584.
    Abstract

  6. TACAR SY, Yilmaz M, Baytekin HF, Tural D, et al
    Evaluation of predictive factors in patients with bladder cancer undergoing atezolizumab treatment: Case reports.
    Indian J Cancer. 2022;59:556-559.
    Abstract


  7. Retraction: CircRNA circPDSS1 promotes bladder cancer by downregulating miR-16.
    Biosci Rep. 2023;43:BSR-2019-1961.
    Abstract

  8. AN HW, Hou DY, Yang J, Wang ZQ, et al
    A bispecific glycopeptide spatiotemporally regulates tumor microenvironment for inhibiting bladder cancer recurrence.
    Sci Adv. 2023;9:eabq8225.
    Abstract

  9. YU Z, Lu C, Lai Y
    A serum miRNAs signature for early diagnosis of bladder cancer.
    Ann Med. 2023;55:736-745.
    Abstract

  10. MAZZASCHI G, Giudice GC, Coriano M, Campobasso D, et al
    Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario.
    Technol Cancer Res Treat. 2023;22:15330338231159753.
    Abstract

  11. LI X, Fu C, Li G, He H, et al
    RNA-seq reveals novel mechanistic targets of Livin in bladder cancer.
    BMC Urol. 2023;23:26.
    Abstract

  12. LI SH, Zhai GQ, He RQ, Chen G, et al
    Down-regulation and clinical significance of Sorbin and SH3 domain-containing protein 1 in bladder cancer tissues.
    IET Syst Biol. 2023 Feb 28. doi: 10.1049/syb2.12060.
    Abstract

  13. WANG XF, Liu DL, Geng L
    The PSCA rs2294008 (C/T) Polymorphism Increases the Risk of Gastric and Bladder Cancer: A Meta-Analysis.
    Genet Test Mol Biomarkers. 2023;27:44-55.
    Abstract

  14. MCELREE IM, Steinberg RL, Mott SL, O'Donnell MA, et al
    Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guerin for the Treatment of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer.
    JAMA Netw Open. 2023;6:e230849.
    Abstract

  15. YOUSSIEF MOHAMMED AA, Gamal DA, Abd Elzaher AR, Hasaballah A, et al
    Trimodality Therapy in which Concurrent Chemoradiation with Concomitant Boost in Muscle Invasive TCC Urinary Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:517-524.
    Abstract

  16. FENG R, Li Z, Ge G, Wang C, et al
    Cancer-associated fibroblast-derived extracellular vesicles mediate immune escape of bladder cancer via PD-L1/PD-1 expression.
    Endocr Metab Immune Disord Drug Targets. 2023.
    Abstract

  17. WANG W, Chen L, Yang J, Hu D, et al
    Apatinib Inhibits Bladder Cancer through Suppression of The VEGFR2-PI3K-AKT Signaling Pathway as revealed by Network Pharmacology and In Vitro Experimental Verification.
    Comb Chem High Throughput Screen. 2023.
    Abstract

  18. KOKURA K, Watanabe J, Takuma T, Uketa S, et al
    A case of Avelumab response to multiple bone and lymph node metastases of plasmacytoid variant bladder cancer.
    Urol Case Rep. 2023;47:102358.
    Abstract

  19. LIU Y, Zhao YC, Lu Y, Goodarz D, et al
    The role of smoking in explaining racial/ethnic disparities in bladder cancer incidence in the United States.
    Urol Oncol. 2023 Feb 25:S1078-1439(23)00051.
    Abstract

  20. KERIOUI M, Bertrand J, Desmee S, Le Tourneau C, et al
    Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter?
    JCO Precis Oncol. 2023;7:e2200368.
    Abstract

  21. DUQUESNE I, Benamran D, Masson-Lecomte A, De La Taille A, et al
    Intraoperative complication of radical cystectomy for muscle-invasive bladder cancer: does the surgical approach matter? A retrospective multicenter study using the EAUiaiC classification.
    World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04340.
    Abstract

  22. FRANCO N, Godono A, Clari M, Ciocan C, et al
    Occupational asbestos exposure and urinary bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2023 Feb 27. doi: 10.1007/s00345-023-04327.
    Abstract

  23. GUPTA P, Sarangi SS, Singh M, Pandey H, et al
    To determine correlation between VIRADS scoring and pathological staging in bladder cancer: A prospective study and review of literature.
    Urologia. 2023 Feb 27:3915603231151738. doi: 10.1177/03915603231151738.
    Abstract

  24. WOLF P
    Inhibitor of apoptosis proteins as therapeutic targets in bladder cancer.
    Front Oncol. 2023;13:1124600.
    Abstract

  25. MAJA SG, Slavica KK, Suad A, Rubens J, et al
    Bladder mucinous adenocarcinoma as a diagnostic challenge: a case report.
    Pan Afr Med J. 2022;42:221.
    Abstract

  26. WANG Z, Wang J, Zhang W, Wang D, et al
    Case report: Urothelial carcinoma of the renal pelvis with trophoblastic differentiation: A rare case report and review of literature.
    Pathol Oncol Res. 2023;29:1610856.
    Abstract

  27. GUERRERO-RAMOS F
    BCG unresponsive non-muscle invasive bladder cancer: The beginning of a new era?
    Actas Urol Esp (Engl Ed). 2023 Feb 24:S2173-5786(23)00018.
    Abstract

  28. HE HL, Lai HY, Chan TC, Hsing CH, et al
    Low expression of ZSCAN4 predicts unfavorable outcome in urothelial carcinoma of upper urinary tract and urinary bladder.
    World J Surg Oncol. 2023;21:62.
    Abstract

  29. LIU Z, Song L, Xie J, Wu XR, et al
    Kavalactone Kawain Impedes Urothelial Tumorigenesis in UPII-Mutant Ha-Ras Mice via Inhibition of mTOR Signaling and Alteration of Cancer Metabolism.
    Molecules. 2023;28:1666.
    Abstract

  30. LEMINSKI A, Michalski W, Masojc B, Kaczmarek K, et al
    Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review.
    J Clin Med. 2023;12:1560.
    Abstract

  31. WEN P, Wen J, Huang X, Wang F, et al
    Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program.
    J Clin Med. 2023;12:1314.
    Abstract

  32. BOSCHI F, Malatesta M
    Nanoparticle-Based Techniques for Bladder Cancer Imaging: A Review.
    Int J Mol Sci. 2023;24:3812.
    Abstract

  33. SANGUEDOLCE F, Zanelli M, Palicelli A, Bisagni A, et al
    HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
    Int J Mol Sci. 2023;24:3720.
    Abstract

  34. YANG CC, Chuang FC, Chang CL, Huang CR, et al
    Melatonin-Assisted Cisplatin Suppresses Urinary Bladder Cancer Cell Proliferation and Growth through Inhibiting PrP(C)-Regulated Cell Stress and Cell Proliferation Signaling.
    Int J Mol Sci. 2023;24:3353.
    Abstract

  35. LIN PT, Hung WK, Chang YH, Hsieh ML, et al
    Replacement Instead of Discontinuation of Bacillus Calmette-Guerin Instillation in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:1345.
    Abstract

  36. LEE MC, Wang SY, Pan CT, Chien MY, et al
    Development of Deep Learning with RDA U-Net Network for Bladder Cancer Segmentation.
    Cancers (Basel). 2023;15:1343.
    Abstract

  37. LEE HW, Kwon WA, Nguyen NT, Phan DTT, et al
    Approaches to Clinical Complete Response after Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Possibilities and Limitations.
    Cancers (Basel). 2023;15:1323.
    Abstract

  38. ABOUDARAM A, Chaltiel L, Pouessel D, Graff-Cailleaud P, et al
    Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.
    Cancers (Basel). 2023;15:1161.
    Abstract

  39. GAO Y, Cao H, Huang D, Zheng L, et al
    RNA-Binding Proteins in Bladder Cancer.
    Cancers (Basel). 2023;15:1150.
    Abstract

  40. WANG H, Feng Y, Zheng X, Xu X, et al
    The Diagnostic and Therapeutic Role of snoRNA and lincRNA in Bladder Cancer.
    Cancers (Basel). 2023;15:1007.
    Abstract

  41. KOLL FJ, Metzger E, Hamann J, Ramos-Triguero A, et al
    Overexpression of KMT9alpha Is Associated with Aggressive Basal-like Muscle-Invasive Bladder Cancer.
    Cells. 2023;12:589.
    Abstract

  42. SHI Y, Mathis BJ, He Y, Yang X, et al
    The Current Progress and Future Options of Multiple Therapy and Potential Biomarkers for Muscle-Invasive Bladder Cancer.
    Biomedicines. 2023;11:539.
    Abstract

  43. JAIN M, Tivtikyan A, Kamalov D, Avdonin S, et al
    Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies.
    Biomedicines. 2023;11:495.
    Abstract

  44. GALINIAK S, Molon M, Biesiadecki M, Mokrzynska A, et al
    Oxidative Stress Markers in Urine and Serum of Patients with Bladder Cancer.
    Antioxidants (Basel). 2023;12:277.
    Abstract

  45. ZONA A, Fazzo L, Benedetti M, Bruno C, et al
    [SENTIERI - Epidemiological Study of Residents in National Priority Contaminated Sites. Sixth Report].
    Epidemiol Prev. 2023;47.
    Abstract

  46. CINAR NB, Yilmaz H, Avci IE, Cakmak K, et al
    Reporting perioperative complications of radical cystectomy: the influence of using standard methodology based on ICARUS and EAU quality criteria.
    World J Surg Oncol. 2023;21:58.
    Abstract

  47. MARTINEZ-VIDAL L, Chighizola M, Berardi M, Alchera E, et al
    Micro-mechanical fingerprints of the rat bladder change in actinic cystitis and tumor presence.
    Commun Biol. 2023;6:217.
    Abstract

  48. JOSHI M, Tuanquin L, Zhu J, Walter V, et al
    Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
    J Immunother Cancer. 2023;11:e006551.
    Abstract

  49. TANG Q, Zuo W, Wan C, Xiong S, et al
    Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
    Front Immunol. 2023;13:1097730.
    Abstract

  50. ALRADHI M, Wen S, Safi M, Al-Danakh A, et al
    Molecular genetic and clinical characteristic analysis of primary signet ring cell carcinoma of urinary bladder identified by a novel OR2L5 mutation.
    Cancer Med. 2023;12:3931-3951.
    Abstract

  51. RASPOLLINI MR, Comperat EM, Lopez-Beltran A, Montironi R, et al
    News in the classification of WHO 2022 bladder tumors.
    Pathologica. 2022;115:32-40.
    Abstract

  52. BOULEFTOUR W, Sargos P, Magne N
    Nectin-4: a Tumor Cell Target and Status of Inhibitor Development.
    Curr Oncol Rep. 2023;25:181-188.
    Abstract

  53. HU X, Wang K, Sun M, Li C, et al
    Quantitative MRI in distinguishing bladder paraganglioma from bladder leiomyoma.
    Abdom Radiol (NY). 2023;48:1051-1061.
    Abstract

  54. PEREZ-MONTIEL D, Olivares-Mundo A, Jimenez-Rios MA, Morera CS, et al
    Influence of luminal and basal subtype in prognosis of high-grade non muscle invasive urothelial carcinoma.
    Ann Diagn Pathol. 2023;63:152081.
    Abstract

  55. BABAN F, Auen T, Eschbacher KL, Swanson AA, et al
    Invasive urothelial carcinoma with squamous differentiation and associated high-risk human papilloma virus infection: Clinical, cytologic, and histologic features of a rare entity.
    Ann Diagn Pathol. 2023;63:152103.
    Abstract

  56. FUJIKI T, Sakai Y, Ikawa Y, Takenaka M, et al
    Pediatric inflammatory myofibroblastic tumor of the bladder with ALK-FN1 fusion successfully treated by alectinib.
    Pediatr Blood Cancer. 2023;70:e30172.
    Abstract

  57. PETEINARIS A, Kallidonis P, Tsaturyan A, Pagonis K, et al
    The feasibility of robot-assisted radical cystectomy: an experimental study.
    World J Urol. 2023;41:477-482.
    Abstract

  58. SYED M, Mushtaq S, Loya A, Hassan U, et al
    Prognostic significance of minor high grade component in non-invasive papillary urothelial carcinoma of urinary bladder: (A study of 273 consecutive cases over a period of 3 years).
    Ann Diagn Pathol. 2023;63:152079.
    Abstract

  59. GAO S, Zhou XQ, Wu Q, Chen XD, et al
    Effects of Holliday Junction-Recognition Protein-Mediated C-Jun N-Terminal Kinase/ Signal Transducer and Activator of Transcription 3 Signaling Pathway on Cell Proliferation, Cell Cycle and Cell Apoptosis in Bladder Urothelial Carcinoma.
    Tohoku J Exp Med. 2023;259:209-219.
    Abstract

  60. HEKMAN MCH, Wijn SRW, Lotan Y, Govers TM, et al
    Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis.
    World J Urol. 2023;41:471-476.
    Abstract

  61. BALAR AV, Castellano DE, Grivas P, Vaughn DJ, et al
    Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.
    Ann Oncol. 2023;34:289-299.
    Abstract

  62. BREHMER M
    Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on "Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 20
    Scand J Urol. 2023;57.
    Abstract

  63. BALAWENDER K, Wawrzyniak A, Walocha J, Mazur M, et al
    Leiomyoma: a case of a rare benign mesenchymal neoplasm of the urinary bladder.
    Pol Arch Intern Med. 2023;133:16381.
    Abstract

  64. KARTTUNEN E, Hervonen P, Hosseini Aliabad A, Oldenburg J, et al
    Incidence, mortality and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic countries between 1990 and 2019.
    Scand J Urol. 2023;57.
    Abstract

  65. BOROWCZAK J, Szczerbowski K, Maniewski M, Zdrenka M, et al
    The prognostic role of p53 and its correlation with CDK9 in urothelial carcinoma.
    Clin Transl Oncol. 2023;25:830-840.
    Abstract

  66. ALTIERI MA, Sarmiento-Machado LM, Romualdo GR, de Moura NA, et al
    Dietary Capsaicin Reduces Chemically Induced Rat Urinary Bladder Carcinogenesis.
    Plant Foods Hum Nutr. 2023;78:93-99.
    Abstract

  67. MOEEN AM, Behnsawy HM, Faragallah MA, Gadelkareem RA, et al
    Functional evaluation of a spiral neobladder with an angled chimney; A prospective randomized comparative study.
    Eur J Surg Oncol. 2023;49:491-496.
    Abstract

  68. LIMONNIK V, Samiei A, Abel S, Wegner RE, et al
    Urachal carcinoma: A novel staging system utilizing the National Cancer Database.
    Cancer Med. 2023;12:2752-2760.
    Abstract

  69. MATSUBARA N, Yonese J, Kojima T, Azuma H, et al
    Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma.
    Cancer Med. 2023;12:2761-2771.
    Abstract

  70. SONPAVDE GP, Maughan BL, McGregor BA, Wei XX, et al
    Phase II trial of CV301 vaccine combined with atezolizumab in advanced urothelial carcinoma.
    Cancer Immunol Immunother. 2023;72:775-782.
    Abstract

  71. HUANG J, Huang D, Ruan X, Huang J, et al
    Association between cannabis use with urological cancers: A population-based cohort study and a mendelian randomization study in the UK biobank.
    Cancer Med. 2023;12:3468-3476.
    Abstract

  72. WU Y, Zhu W, Wang J, Liu L, et al
    Using machine learning for mortality prediction and risk stratification in atezolizumab-treated cancer patients: Integrative analysis of eight clinical trials.
    Cancer Med. 2023;12:3744-3757.
    Abstract

  73. ITO K, Kita Y, Yokomizo A, Miki J, et al
    Discontinuation of pembrolizumab for advanced urothelial carcinoma without disease progression: Nationwide cohort study.
    Cancer Med. 2023;12:2325-2332.
    Abstract

  74. BORET S, Lambert E, Charles VP, Philippe T, et al
    Vulvar pagetoid urothelial intraepithelial neoplasia: a case report.
    Acta Chir Belg. 2023;123:174-177.
    Abstract

  75. LENTZSCH AM, Siggel R, Schnorr C, Holtick U, et al
    LONG-TERM FOLLOW-UP OF ASYMMETRIC BILATERAL DIFFUSE UVEAL MELANOCYTIC PROLIFERATION IN A PATIENT WITH METASTASIZED UROTHELIAL CARCINOMA.
    Retin Cases Brief Rep. 2023;17:105-110.
    Abstract

  76. COCKRELL DC, Rose TL
    Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future Directions.
    Curr Oncol Rep. 2023 Mar 10. doi: 10.1007/s11912-023-01390.
    Abstract

  77. YANAGISAWA T, Matsukawa A, Iwatani K, Sato S, et al
    En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
    Ann Surg Oncol. 2023 Mar 10. doi: 10.1245/s10434-023-13227.
    Abstract

  78. GRABE-HEYNE K, Henne C, Odeyemi I, Pohlmann J, et al
    Evaluating the cost-utility of intravesical bacillus calmette-guerin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    J Med Econ. 2023 Mar 10:1-19. doi: 10.1080/13696998.2023.2189860.
    Abstract

  79. HU X, Sun C, Ren X, Ge S, et al
    Contrast-enhanced Ultrasound Combined With Elastography for the Evaluation of Muscle-invasive Bladder Cancer in Rats.
    J Ultrasound Med. 2023 Mar 10. doi: 10.1002/jum.16216.
    Abstract

  80. YAMAMOTO Y, Kawashima A, Morishima T, Uemura T, et al
    Comparative Effectiveness of Radiation Versus Radical Cystectomy for Localized Muscle-Invasive Bladder Cancer.
    Adv Radiat Oncol. 2022;8:101157.
    Abstract

  81. WANG H, Li J, Zi X, Yuan X, et al
    Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis, tumor microenvironment invasion, and drug sensitivity.
    Front Oncol. 2023;13:1116305.
    Abstract

  82. WU S, Hong G, Xu A, Zeng H, et al
    Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
    Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
    Abstract

  83. MANDRIK O, Hahn AI, Catto JWF, Zauber AG, et al
    Critical Appraisal of Decision Models Used for the Economic Evaluation of Bladder Cancer Screening and Diagnosis: A Systematic Review.
    Pharmacoeconomics. 2023 Mar 8. doi: 10.1007/s40273-023-01256.
    Abstract

  84. ZUKOV RA, Savchenko AA, Slepov EV, Semenov EV, et al
    Phenotype of Urine Sediment Cells in Patients with Bladder Cancer.
    Bull Exp Biol Med. 2023 Mar 9. doi: 10.1007/s10517-023-05732.
    Abstract

  85. CARAMELO B, Zagorac S, Corral S, Marques M, et al
    Cancer-associated Fibroblasts in Bladder Cancer: Origin, Biology, and Therapeutic Opportunities.
    Eur Urol Oncol. 2023 Mar 6:S2588-9311(23)00043-3. doi: 10.1016/j.euo.2023.
    Abstract

  86. YAMADA Y, Kume H
    [Frailty and surgical tolerability in elderly patients undergoing robot-assisted radical cystectomy (RARC)].
    Nihon Ronen Igakkai Zasshi. 2023;60:38-42.
    Abstract

  87. JIN D, Qian L, Xia J, Zhang R, et al
    In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer.
    Med Oncol. 2023;40:113.
    Abstract

  88. FAN X, Yu H, Ni X, Chen G, et al
    Systematic radiomics analysis based on multiparameter MRI to preoperatively predict the expression of Ki67 and histological grade in patients with bladder cancer.
    Br J Radiol. 2023 Mar 8:20221086. doi: 10.1259/bjr.20221086.
    Abstract

  89. PASSALACQUA MI, Squeri A, Sciume C, Ieni A, et al
    Enfortumab Vedotin in metastatic bladder cancer: a case report of durable clinical efficacy in a pretreated patient.
    Acta Biomed. 2023;94.
    Abstract

  90. SHU TD, Schumacher FR, Conroy B, Ponsky L, et al
    Disparities in cause-specific mortality by race and sex among bladder cancer patients from the SEER database.
    Cancer Causes Control. 2023 Mar 8. doi: 10.1007/s10552-023-01679.
    Abstract

  91. TAPPERO S, Barletta F, Piccinelli ML, Cano Garcia C, et al
    Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer.
    Urol Oncol. 2023 Mar 5:S1078-1439(23)00015-7. doi: 10.1016/j.urolonc.2023.
    Abstract

  92. AKDEMIR E, Sweegers MG, Vrieling A, Rundqvist H, et al
    EffectiveNess of a multimodal preHAbilitation program in patieNts with bladder canCEr undergoing radical cystectomy: protocol of the ENHANCE multicentre randomised controlled trial.
    BMJ Open. 2023;13:e071304.
    Abstract

  93. JEONG SH, Ku JH
    Treatment strategies for the Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer.
    Investig Clin Urol. 2023;64:103-106.
    Abstract

  94. NAGAHISA C, Iizuka J, Kobari Y, Minoda R, et al
    Efficacy of Combined Pembrolizumab and Pelvic Radiotherapy for Bladder Cancer With Rectal Metastases.
    In Vivo. 2023;37:912-915.
    Abstract

  95. CHEN L, Dong W, Zhou M, Yang C, et al
    PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression.
    Cell Biosci. 2023;13:45.
    Abstract

  96. CIARAMELLA A, Di Nardo E, Terracciano D, Conte L, et al
    A new biomarker panel of ultraconserved long non-coding RNAs for bladder cancer prognosis by a machine learning based methodology.
    BMC Bioinformatics. 2023;23.
    Abstract

  97. LEE YS, Ha MS, Tae JH, Chang IH, et al
    Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study.
    Sci Rep. 2023;13:3682.
    Abstract

  98. SCHMOKEL SS, Nordentoft I, Lindskrog SV, Lamy P, et al
    Improved protocol for single-nucleus RNA-sequencing of frozen human bladder tumor biopsies.
    Nucleus. 2023;14:2186686.
    Abstract

  99. JIN D, Qian L, Xia J, Zhang R, et al
    In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy.
    Cell Oncol (Dordr). 2023 Mar 6. doi: 10.1007/s13402-023-00785.
    Abstract


  100. In brief: Adstiladrin - a gene therapy for bladder cancer.
    Med Lett Drugs Ther. 2023;65:e40-e41.
    Abstract

  101. YOSHIOKA F, Kato T, Shima Y, Hatano K, et al
    Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin administration for bladder cancer with scleroderma.
    IJU Case Rep. 2023;6:133-136.
    Abstract

  102. COLLACOTT H, Krucien N, Heidenreich S, Catto JWF, et al
    Patient Preferences for Treatment of Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: A Cross-country Choice Experiment.
    Eur Urol Open Sci. 2023;49:92-99.
    Abstract

  103. WU Y, Xu Y, He S, Li Y, et al
    Cytoskeleton regulator RNA expression on cancer-associated fibroblasts is associated with prognosis and immunotherapy response in bladder cancer.
    Heliyon. 2023;9:e13707.
    Abstract

  104. LI T, Jiang N, Bai Y, Liu T, et al
    Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature.
    Heliyon. 2023;9:e13661.
    Abstract

  105. CHEN R, Jiang M, Hu B, Fu B, et al
    Comprehensive Analysis of the Expression, Prognosis, and Biological Significance of PLOD Family in Bladder Cancer.
    Int J Gen Med. 2023;16:707-722.
    Abstract

  106. ST-LAURENT MP, Suderman J, Black PC
    Where To Draw the Line: Stratifying Risk for High-grade Ta Bladder Cancer.
    Eur Urol Oncol. 2023 Mar 3:S2588-9311(23)00035-4. doi: 10.1016/j.euo.2023.
    Abstract

  107. ANDRIKOS I, Stefanou K, Bellos C, Stergios G, et al
    EDIT Software: A tool for the semi-automatic 3D reconstruction of bladder cancer and urinary bladder of animal models.
    Comput Methods Programs Biomed. 2023;232:107448.
    Abstract

  108. WHYNOT EG, Tomko AM, Dupre DJ
    Anticancer properties of cannabidiol and Delta(9)-tetrahydrocannabinol and synergistic effects with gemcitabine and cisplatin in bladder cancer cell lines.
    J Cannabis Res. 2023;5:7.
    Abstract

  109. CARVALHO LB, Martinez JLC, Lodeiro C, Bento R, et al
    Biochemical network analysis of protein-protein interactions to follow-up T1 bladder cancer patients.
    J Proteomics. 2023 Mar 2:104865. doi: 10.1016/j.jprot.2023.104865.
    Abstract

  110. IZAWA M, Tanaka N, Murakami T, Anno T, et al
    Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
    Lab Invest. 2023;103:100040.
    Abstract

  111. AMEEN YA, Badary DM, Abonnoor AEI, Hussain KF, et al
    Which data subset should be augmented for deep learning? a simulation study using urothelial cell carcinoma histopathology images.
    BMC Bioinformatics. 2023;24:75.
    Abstract

  112. BUKAVINA L, Isali I, Ginwala R, Sindhani M, et al
    Global Meta-analysis of Urine Microbiome: Colonization of Polycyclic Aromatic Hydrocarbon-degrading Bacteria Among Bladder Cancer Patients.
    Eur Urol Oncol. 2023 Mar 1:S2588-9311(23)00036-6. doi: 10.1016/j.euo.2023.
    Abstract

  113. LI KD, Chu CE, Patel M, Meng MV, et al
    Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer.
    Urol Oncol. 2023 Mar 1:S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.
    Abstract

  114. HERZOG RW, Suzuki M
    Adenoviral gene therapy for bladder cancer.
    Cell. 2023;186:893.
    Abstract

  115. ZENG SP, Sun YF, Ye JB, Zeng K, et al
    Transurethral en bloc resection of a bladder perivascular epithelioid cell tumor (PEComa): a case report.
    BMC Urol. 2023;23:28.
    Abstract

  116. FONTUGNE J, Wong J, Cabel L, Neyret-Kahn H, et al
    Progression-associated molecular changes in basal/squamous and sarcomatoid bladder carcinogenesis.
    J Pathol. 2023;259:455-467.
    Abstract

  117. GERALD T, Margulis V, Meng X, Bagrodia A, et al
    Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
    Urol Oncol. 2023;41:148.
    Abstract

  118. SETYO LC, Donahoe SL, Shearer PL, Wang P, et al
    Immunohistochemical analysis of expression of VEGFR2, KIT, PDGFR-beta, and CDK4 in canine urothelial carcinoma.
    J Vet Diagn Invest. 2023;35:109-115.
    Abstract

  119. MIYAKE M, Shimizu T, Oda Y, Tachibana A, et al
    Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study.
    Jpn J Clin Oncol. 2023;53:253-262.
    Abstract

  120. BARLETTA F, Tappero S, Panunzio A, Incesu RB, et al
    Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis.
    Urol Oncol. 2023;41:147.
    Abstract

  121. WOLDU SL, Labbate C, Murray KS, Rose K, et al
    Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
    Urol Oncol. 2023;41:147.
    Abstract

  122. MIYAKE M, Oda Y, Owari T, Iida K, et al
    Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.
    Cancer Sci. 2023;114:1118-1130.
    Abstract

  123. CHEN Y, Fu J, Li Z, Chen Q, et al
    Cutoff values of PD-L1 expression in urinary cytology samples for predicting response to immune checkpoint inhibitor therapy in upper urinary tract urothelial carcinoma.
    Cancer Cytopathol. 2023;131:179-187.
    Abstract

  124. MATUTE GUERRERO A, Abanses Moreno P, Villasmil Chaparro I
    Pulmonary thrombotic microangiopathy caused by neoplastic urothelial carcinoma cells.
    Med Clin (Barc). 2023;160:226-227.
    Abstract

  125. QIWEI C, Jiajun S, Cheng L, Shengbo H, et al
    Comparison between renal pelvic and ureteral tumors in muscle-invasive upper tract urothelial carcinoma.
    Cancer Sci. 2023;114:984-994.
    Abstract

  126. PIERCONTI F, Rossi ED, Cenci T, Carlino A, et al
    DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group.
    Cancer Cytopathol. 2023;131:158-164.
    Abstract

  127. SEKINE Y, Iwasaki Y, Hakozaki N, Endo M, et al
    Prevalence and risk estimation of cancer-predisposing genes for upper urinary tract urothelial carcinoma in Japanese.
    Jpn J Clin Oncol. 2022;52:1441-1445.
    Abstract

  128. BLINOVA E, Samishina E, Deryabina O, Blinov D, et al
    Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
    Int J Mol Sci. 2021;22:9856.
    Abstract

  129. LEE HW, Seo HK
    Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment.
    Int J Mol Sci. 2021;22:9526.
    Abstract

  130. LOPEZ-CORTES R, Gomez BB, Vazquez-Estevez S, Perez-Fentes D, et al
    Blood-based protein biomarkers in bladder urothelial tumors.
    J Proteomics. 2021;247:104329.
    Abstract

  131. MARANDINO L, Raggi D, Calareso G, Alessi A, et al
    Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Clin Genitourin Cancer. 2021;19:457-465.
    Abstract

  132. POND GR, Agarwal A, Ornstein M, Garcia J, et al
    Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
    Clin Genitourin Cancer. 2021;19:425-433.
    Abstract

  133. STOKKEL LE, Stokkel MPM, Donswijk ML, Lahaye MJ, et al
    The Diagnostic Value of FDG-PET/CT for Urachal Cancer.
    Clin Genitourin Cancer. 2021;19:373-380.
    Abstract

  134. RUNDO F, Bersanelli M, Urzia V, Friedlaender A, et al
    Three-Dimensional Deep Noninvasive Radiomics for the Prediction of Disease Control in Patients With Metastatic Urothelial Carcinoma treated With Immunotherapy.
    Clin Genitourin Cancer. 2021;19:396-404.
    Abstract

  135. CH'NG ES
    Mining The Cancer Genome Atlas gene expression data for lineage markers in distinguishing bladder urothelial carcinoma and prostate adenocarcinoma.
    Sci Rep. 2021;11:6765.
    Abstract

  136. LEE Y, Kim YS, Hong B, Cho YM, et al
    Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
    J Cancer Res Clin Oncol. 2021;147:3421-3429.
    Abstract

  137. AGNIHOTRI MA, Sathe PA
    Coexistent urothelial papilloma and ureteric calculus in an 8-year-old child: A rare co-occurrence.
    J Postgrad Med. 2021;67:182-183.
    Abstract

  138. HUANG Y, Xie C, Li Q, Huang X, et al
    Prognostic factors and nomogram for the overall survival of bladder cancer bone metastasis: A SEER-based study.
    Medicine (Baltimore). 2023;102:e33275.
    Abstract

  139. SEMENIUK-WOJTAS A, Poddebniak-Strama K, Modzelewska M, Baryla M, et al
    Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2023 Mar 16. doi: 10.1007/s00262-023-03376.
    Abstract

  140. KE M, Sun N, Lin Z, Zhang P, et al
    SNHG18 inhibits bladder cancer cell proliferation by increasing p21 transcription through destabilizing c-Myc protein.
    Cancer Cell Int. 2023;23:48.
    Abstract

  141. JARIMBA R, Quaresma V, Pedroso Lima J, Eliseu M, et al
    Predicting bladder cancer risk in patients with hematuria. A single-centre retrospective study.
    Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11026.
    Abstract

  142. TZELVES L, Katsimperis S, Bellos T, Berdempes M, et al
    Anthropometric characteristics and relationship with non-muscle invasive bladder cancer in Greece: A case-control study.
    Arch Ital Urol Androl. 2023 Mar 15. doi: 10.4081/aiua.2023.11266.
    Abstract

  143. LI Z, Zhao J, Huang X, Wang J, et al
    An m7G-related lncRNA signature predicts prognosis and reveals the immune microenvironment in bladder cancer.
    Sci Rep. 2023;13:4302.
    Abstract

  144. VAN GINKEL N, van Gennep EJ, Oosterbaan L, Greidanus J, et al
    Added Clinical Value of (18)F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy.
    Clin Genitourin Cancer. 2023 Feb 22:S1558-7673(23)00037.
    Abstract

  145. ZHANG W, Zhang Z, Xiao W, Wang Y, et al
    Multiple directional DWI combined with T2WI in predicting muscle layer and Ki-67 correlation in bladder cancer in 3.0-T MRI.
    Cancer Med. 2023 Mar 14. doi: 10.1002/cam4.5782.
    Abstract

  146. ZHU J, Livasy C, Donahue EE, Symanowski JT, et al
    Prognostic value of galectin-1 and galectin-3 expression in localized urothelial bladder cancer.
    Transl Androl Urol. 2023;12:228-240.
    Abstract

  147. TAN Z, Chen Z, Yao G, Mumin MA, et al
    Neoadjuvant and adjuvant chemotherapy share equivalent efficacy in improving overall survival and cancer-specific survival among muscle invasive bladder cancer patients who undergo radical cystectomy: a retrospective cohort study based on SEER databas
    Transl Androl Urol. 2023;12:330-346.
    Abstract

  148. YING Y, Wang Z, Tan Y, Cao H, et al
    Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer.
    Transl Androl Urol. 2023;12:176-186.
    Abstract

  149. YUAN F, Yin XY, Huang Y, Cai XW, et al
    Exosomal miR-93-5p as an important driver of bladder cancer progression.
    Transl Androl Urol. 2023;12:286-299.
    Abstract

  150. WANG SS, Zhai GQ, Huang ZG, Luo JY, et al
    Nitidine chloride regulates cell function of bladder cancer in vitro through downregulating Lymphocyte antigen 75.
    Naunyn Schmiedebergs Arch Pharmacol. 2023.
    Abstract

  151. VAN HOOGSTRATEN LMC, Vrieling A, van der Heijden AG, Kogevinas M, et al
    Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice.
    Nat Rev Clin Oncol. 2023 Mar 13. doi: 10.1038/s41571-023-00744.
    Abstract

  152. ZHANG X, Liu H, Zhang J, Wang Z, et al
    Fibronectin-1: A Predictive Immunotherapy Response Biomarker for Muscle‑Invasive Bladder Cancer.
    Arch Esp Urol. 2023;76:70-83.
    Abstract

  153. CATA ED, Andras I, Popa A, Medan P, et al
    Robotic Radical Cystectomy with Intracorporeal Urinary Diversion - Tips and Tricks.
    Chirurgia (Bucur). 2023;118:63-72.
    Abstract

  154. XU Y, Xia Z, Sun X, Wei B, et al
    Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer.
    Front Immunol. 2023;14:1111319.
    Abstract

  155. HU B, Chen R, Chen G, Zheng P, et al
    Prognostic nomogram for estimating survival in patients with resected muscle-invasive bladder cancer receiving chemotherapy.
    Front Surg. 2023;10:1121184.
    Abstract

  156. ILLIAS AM, Yu KJ, Wu SC, Cata JP, et al
    Association of regional anesthesia with oncological outcomes in patients receiving surgery for bladder cancer: A meta-analysis of observational studies.
    Front Oncol. 2023;13:1097637.
    Abstract

  157. BORDELEAU F, Brownell D, Chabaud S, Huot ME, et al
    Recreating heterogeneity of bladder cancer microenvironment to study its recurrences and progression.
    Stem Cell Investig. 2023;10:5.
    Abstract

  158. TIAN YQ, Yang JC, Hu JJ, Ding R, et al
    Trends and risk factors of global incidence, mortality, and disability of genitourinary cancers from 1990 to 2019: Systematic analysis for the Global Burden of Disease Study 2019.
    Front Public Health. 2023;11:1119374.
    Abstract

  159. YANAGISAWA T, Miki J, Matsukawa A, Iwatani K, et al
    ASO Author Reflections: Is T1HG Bladder Cancer a Good Candidate for En Bloc Resection?
    Ann Surg Oncol. 2023 Mar 12. doi: 10.1245/s10434-023-13291.
    Abstract

  160. LI J, Qiu Z, Cao K, Deng L, et al
    Predicting muscle invasion in bladder cancer based on MRI: A comparison of radiomics, and single-task and multi-task deep learning.
    Comput Methods Programs Biomed. 2023;233:107466.
    Abstract

  161. GROBET-JEANDIN E, Lenfant L, Mir C, Giannarini G, et al
    A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Mar 9:S2588-9311(23)00040-8. doi: 10.1016/j.euo.2023.
    Abstract

  162. PHILIPPS L, Porta N, James N, Huddart R, et al
    Differences in Quality of Life and Toxicity for Male and Female Patients following Chemo(radiotherapy) for Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2023 Feb 11:S0936-6555(23)00052.
    Abstract

  163. ZHANG P, Sun Y, Shi L, Sun D, et al
    Effect of isorhamnetin on carbonic anhydrase IX expression and tumorigenesis of bladder cancer by activating PPARgamma/PTEN/AKT pathway.
    Tissue Cell. 2023;82:102048.
    Abstract

  164. ZHU H, Chen Q, Zhang Y, Zhao L, et al
    Glutathione S-transferase zeta 1 alters the HMGB1/GPX4 axis to drive ferroptosis in bladder cancer cells.
    Hum Exp Toxicol. 2023;42:9603271231161606.
    Abstract

  165. HANNA DH, Aziz MM, Shafee EE
    Effective-by-method for the preparation of folic acid coated TiO(2) nanoparticles with high targeting potential for apoptosis induction against bladder cancer cells (T24).
    Biotechnol Appl Biochem. 2023 Mar 11. doi: 10.1002/bab.2456.
    Abstract

  166. PEREIRA IOA, da Silva GN, Almeida TC, Lima APB, et al
    LncRNA JHDM1D-AS1 Is a Key Biomarker for Progression and Modulation of Gemcitabine Sensitivity in Bladder Cancer Cells.
    Molecules. 2023;28:2412.
    Abstract

  167. WANG Z, Wang T, Wu G, Zhu L, et al
    Clinical Significance and Tumor Microenvironment Characterization of a Novel Immune-Related Gene Signature in Bladder Cancer.
    J Clin Med. 2023;12:1892.
    Abstract

  168. FLAMMIA RS, Tufano A, Chierigo F, Wurnschimmel C, et al
    The Effect of Sex on Disease Stage and Survival after Radical Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer.
    J Clin Med. 2023;12:1776.
    Abstract

  169. MURAKAMI K, Furuya H, Hokutan K, Goodison S, et al
    Association of SNPs in the PAI1 Gene with Disease Recurrence and Clinical Outcome in Bladder Cancer.
    Int J Mol Sci. 2023;24:4943.
    Abstract

  170. MA L, Chen H, Yang W, Ji Z, et al
    Crosstalk between Mesenchymal Stem Cells and Cancer Stem Cells Reveals a Novel Stemness-Related Signature to Predict Prognosis and Immunotherapy Responses for Bladder Cancer Patients.
    Int J Mol Sci. 2023;24:4760.
    Abstract

  171. TORTORA F, La Civita E, Trivedi P, Febbraio F, et al
    Emerging RNA-Based Therapeutic and Diagnostic Options: Recent Advances and Future Challenges in Genitourinary Cancers.
    Int J Mol Sci. 2023;24:4601.
    Abstract

  172. ZUCCHI A, Claps F, Pastore AL, Perotti A, et al
    Focus on the Use of Resveratrol in Bladder Cancer.
    Int J Mol Sci. 2023;24:4562.
    Abstract

  173. ZHU J, Li Y, Luo Y, Xu J, et al
    Correction: Zhu et al. A Feedback Loop Formed by ATG7/Autophagy, FOXO3a/miR-145 and PD-L1 Regulates Stem-like Properties and Invasion in Human Bladder Cancer. Cancers 2019, 11, 349.
    Cancers (Basel). 2023;15:1403.
    Abstract

  174. HURLE R, Soria F, Contieri R, Avolio PP, et al
    Evaluating the Protective Effect of Intravesical Bacillus Calmette-Guerin against SARS-CoV-2 in Non-Muscle Invasive Bladder Cancer Patients: A Multicenter Observational Trial.
    Cancers (Basel). 2023;15:1618.
    Abstract

  175. CELADA LUIS G, Albers Acosta E, de la Fuente H, Velasco Balanza C, et al
    A Comprehensive Analysis of Immune Response in Patients with Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:1364.
    Abstract

  176. HU X, Xue Y, Zhu G
    Clinical Characteristics and Current Status of Treatment for Recurrent Bladder Cancer after Surgeries on Upper Tract Urothelial Carcinoma.
    Diagnostics (Basel). 2023;13:1004.
    Abstract

  177. VAROL N, Keles I, Yildiz H, Karaosmanoglu C, et al
    Methylation analysis of histone 4-related gene HIST1H4F and its effect on gene expression in bladder cancer.
    Gene. 2023;866:147352.
    Abstract

  178. ASCIONE CM, Napolitano F, Esposito D, Servetto A, et al
    Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
    Cancer Treat Rev. 2023;115:102530.
    Abstract

  179. WANG J, Meng X, Yu M, Li X, et al
    A novel microfluidic system for enrichment of functional circulating tumor cells in cancer patient blood samples by combining cell size and invasiveness.
    Biosens Bioelectron. 2023;227:115159.
    Abstract

  180. KUMAR R, Harilal S, Abdelgawad MA, Ghoneim MM, et al
    Urachal carcinoma: The journey so far and the road ahead.
    Pathol Res Pract. 2023;243:154379.
    Abstract

  181. WANG P, Shi Y, Zhang J, Shou J, et al
    UCseek: ultrasensitive early detection and recurrence monitoring of urothelial carcinoma by shallow-depth genome-wide bisulfite sequencing of urinary sediment DNA.
    EBioMedicine. 2023;89:104437.
    Abstract

  182. WANG L, Shi G, Zhao G, He W, et al
    Efficacy and safety of enfortumab vedotin in the treatment of advanced urothelial carcinoma: a systematic review and meta-analysis.
    Anticancer Drugs. 2023;34:473-478.
    Abstract

  183. JIN J, Yang Q, Yu Y, Chen L, et al
    Complete response to tislelizumab in a metastatic urothelial carcinoma after surgery associated with high tumor mutational burden: a case report.
    Anticancer Drugs. 2023;34:595-598.
    Abstract

  184. FATIMA A, Russell DH, Epstein JI
    Nested Subtype of Urothelial Carcinoma in the Upper Urinary Tract: A Series of 15 Cases.
    Am J Surg Pathol. 2023;47:461-468.
    Abstract

  185. CALEN L, Mesnard B, Hedhli O, Broudeur L, et al
    Robot-assisted laparoscopic cystectomy with non-continent urinary diversion for neurogenic lower urinary tract dysfunction: Midterm outcomes.
    Neurourol Urodyn. 2023;42:586-596.
    Abstract

  186. ZHAO Q, Wu L, Yang F, Han S, et al
    Application of Transvaginal Natural Orifice Specimen Extraction Surgery in Urological Surgery.
    J Laparoendosc Adv Surg Tech A. 2023;33:231-235.
    Abstract

  187. WU W, Jing Y, Xu Q, Hao J, et al
    MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway.
    Panminerva Med. 2023;65:114-115.
    Abstract

  188. STARRETT GJ, Yu K, Golubeva Y, Lenz P, et al
    Evidence for virus-mediated oncogenesis in bladder cancers arising in solid organ transplant recipients.
    Elife. 2023;12:e82690.
    Abstract

  189. GOLMOHAMMADI M, Elmaghraby DA, Ramirez-Coronel AA, Rakhimov N, et al
    A Comprehensive View on the Quercetin Impact on Bladder Cancer: Focusing on Oxidative stress, Cellular, and Molecular Mechanisms.
    Fundam Clin Pharmacol. 2023 Mar 24. doi: 10.1111/fcp.12896.
    Abstract

  190. WANG C, Cao Q, Zhang S, Liu H, et al
    Anlotinib Enhances the Therapeutic Effect of Bladder Cancer with GSDMB Expression: Analyzed from TCGA Bladder Cancer Database & Mouse Bladder Cancer Cell Line.
    Pharmgenomics Pers Med. 2023;16:219-228.
    Abstract

  191. ZHAO Z, Liu S, Sun R, Zhu W, et al
    The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer.
    Front Immunol. 2023;14:1085476.
    Abstract

  192. ARRABAL POLO MA, Melgarejo Segura MT, Yanez Castillo Y, Morales Martinez A, et al
    Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study.
    J Cancer Res Clin Oncol. 2023 Mar 23:1-7. doi: 10.1007/s00432-023-04688.
    Abstract

  193. BASILE G, de Angelis M, Leni R, Re C, et al
    Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review.
    Minerva Urol Nephrol. 2023 Mar 22. doi: 10.23736/S2724-6051.23.05091.
    Abstract


  194. Corrigendum to "The Significance of Squamous Histology on Clinical Outcomes and PD-L1 Expression in Bladder Cancer".
    Int J Surg Pathol. 2023 Mar 22:10668969231164482. doi: 10.1177/10668969231164482
    Abstract

  195. CHENG F, Hansson VC, Georgolopoulos G, Mani K, et al
    Attenuation of cancer proliferation by suppression of glypican-1 and its pleiotropic effects in neoplastic behavior.
    Oncotarget. 2023;14:219-235.
    Abstract

  196. LI X, Li Y, Liu B, Chen L, et al
    P4HA2-mediated HIF-1alpha stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
    FASEB J. 2023;37:e22840.
    Abstract

  197. LEPARA Z, Alic J, Lepara O, Spahovic H, et al
    Antioxidant status in patients with bladder cancer regarding cancer stage and grade.
    Asian J Urol. 2023;10:182-188.
    Abstract

  198. ARSUFFI S, Cambianica A, Di Filippo E, Ripamonti D, et al
    Vascular graft infections caused by Mycobacterium bovis BCG after BCG immunotherapy for non-muscle-invasive bladder cancer: Case report and review of literature.
    J Clin Tuberc Other Mycobact Dis. 2023;31:100360.
    Abstract

  199. CHANG LW, Hung SC, Chen CS, Li JR, et al
    Geriatric nutritional risk index as a prognostic marker for patients with upper tract urothelial carcinoma receiving radical nephroureterectomy.
    Sci Rep. 2023;13:4554.
    Abstract

  200. DAZA J, Grauer R, Chen S, Lavallee E, et al
    Development of a predictive model for recurrence-free survival in pTa low-grade bladder cancer.
    Urol Oncol. 2023 Mar 18:S1078-1439(23)00047.
    Abstract

  201. EL SHARKAWI FZ, El Sabah M, Atya HB, Khaled HM, et al
    Urinary BLACAT1 as a non-invasive biomarker for bladder cancer.
    Mol Biol Rep. 2023 Mar 20. doi: 10.1007/s11033-023-08370.
    Abstract

  202. DROBNER JC, Lichtbroun BJ, Singer EA, Ghodoussipour S, et al
    Examining the Role of Microbiota-Centered Interventions in Cancer Therapeutics: Applications for Urothelial Carcinoma.
    Technol Cancer Res Treat. 2023;22:15330338231164196.
    Abstract

  203. HU W, Zhang Y, Ning J, Li M, et al
    Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages.
    Heliyon. 2023;9:e14272.
    Abstract

  204. ZHAO Y, Sun W, Ji Z, Liu X, et al
    Serum metabolites as early detection markers of non-muscle invasive bladder cancer in Chinese patients.
    Front Oncol. 2023;13:1061083.
    Abstract

  205. ALSHAHWAN MI, Bin Dukhi MM, Alotaibi SN, Aldarrab R, et al
    Plasmacytoid Variant Urothelial Cell Carcinoma: A Case of a Histological Variant of Urinary Bladder Cancer With Aggressive Behavior.
    Cureus. 2023;15:e36278.
    Abstract

  206. LIU J, Cheng C, Qi T, Xiao J, et al
    ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts.
    Front Genet. 2023;14:1148437.
    Abstract

  207. ANRAKU T, Hashidate H, Nakahara A, Imai T, et al
    Sarcomatoid urothelial carcinoma of the renal pelvis treated with immunotherapy.
    BMC Urol. 2023;23:38.
    Abstract

  208. FAN J, Ding Y, Huang H, Xiong S, et al
    High expression of ABCF1 is an independent predictor of poor prognosis in bladder cancer.
    BMC Urol. 2023;23:37.
    Abstract

  209. BOLGEO T, Ruta F, Gatti D, Gambalunga F, et al
    Management of the patient with urostomy: Caregiver needs during the three months after discharge. A qualitative study.
    Arch Ital Urol Androl. 2023;95.
    Abstract

  210. LEONARDI R, Vecco F, Iacona G, Calarco A, et al
    TULA DUAL: Trans Urethral Laser Ablation of recurrent bladder tumors in outpatient setting.
    Arch Ital Urol Androl. 2023;95.
    Abstract

  211. LAGARDE-LENON MS, Aron M
    Reprint of: Female Urethral Carcinoma: A contemporary review of the clinicopathologic features, with emphasis on the histo-anatomic landmarks and potential staging issues.
    Hum Pathol. 2023;133:126-135.
    Abstract

  212. DE FALCO F, Cuccaro B, De Tullio R, Alberti A, et al
    Possible etiological association of ovine papillomaviruses with bladder tumors in cattle.
    Virus Res. 2023;328:199084.
    Abstract

  213. YOKOTA Y, Suzuki S, Gi M, Yanagiba Y, et al
    o-Toluidine metabolism and effects in the urinary bladder of humanized-liver mice.
    Toxicology. 2023;488:153483.
    Abstract

  214. SHENG Y, Wu J, Li X, Qiu J, et al
    iATMEcell: identification of abnormal tumor microenvironment cells to predict the clinical outcomes in cancer based on cell-cell crosstalk network.
    Brief Bioinform. 2023;24:bbad074.
    Abstract

  215. LEE A
    Nadofaragene Firadenovec: First Approval.
    Drugs. 2023;83:353-357.
    Abstract

  216. ZHAO L, Qi X, Chen Y, Qiao Y, et al
    Biological knowledge graph-guided investigation of immune therapy response in cancer with graph neural network.
    Brief Bioinform. 2023;24:bbad023.
    Abstract

  217. RYSANKOVA K, Hanzlikova P, Zidlik V, Vrtkova A, et al
    Is high accuracy of Vesical Imaging-Reporting and Data System (VI-RADS) sufficient for its implementation in the urological practice?
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2023;167:85-90.
    Abstract

  218. WU J, Gao Y, Xiong Z, Xiao X, et al
    Comparison of different methods of obturator nerve block in transurethral resection of bladder tumors: A systematic review and network meta-analysis.
    Cancer Med. 2023;12:5420-5435.
    Abstract

  219. GOUDOURIS E, Aranda CS, Sole D
    Implications of the non-specific effect induced by Bacillus Calmette-Guerin (BCG) vaccine on vaccine recommendations.
    J Pediatr (Rio J). 2023;99 Suppl 1:S22-S27.
    Abstract

  220. FUKUOKAYA W, Yanagisawa T, Hashimoto M, Yamamoto S, et al
    Effectiveness of pembrolizumab in trial-ineligible patients with metastatic urothelial carcinoma.
    Cancer Immunol Immunother. 2023;72:841-849.
    Abstract

  221. MULLANE P, Joshi S, Bilen M, Osunkoya AO, et al
    Clinicopathologic analysis of patients undergoing repeat transurethral resection of bladder tumour following an initial diagnosis of urothelial carcinoma with lamina propria invasion and variant/divergent histology.
    J Clin Pathol. 2023;76:256-260.
    Abstract

  222. WU W, Jing Y, Xu Q, Hao J, et al
    MiR-9 promotes proliferation and inhibits apoptosis of bladder cancer cells via notch signaling pathway.
    Panminerva Med. 2023;65:114-115.
    Abstract

  223. SONG Q, Zhou Z, Bai J, Liu N, et al
    A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
    Clin Transl Oncol. 2023 Mar 31. doi: 10.1007/s12094-023-03143.
    Abstract

  224. POURKERMAN M, Hajjar M, Naja F, Yunus F, et al
    Nutrient Patterns and Bladder Cancer: A Case-Control Study in Iran.
    Nutr Cancer. 2023 Mar 31:1-7. doi: 10.1080/01635581.2023.2191383.
    Abstract

  225. GHOLAMI L, Momtazi-Borojeni AA, Malaekeh-Nikouei B, Nikfar B, et al
    Selective Cellular Uptake and Cytotoxicity of Curcumin-encapsulated SPC and HSPC Liposome Nanoparticles on Human Bladder Cancer Cells.
    Curr Pharm Des. 2023 Mar 31. doi: 10.2174/1381612829666230331084848.
    Abstract

  226. REN C, Li Y, Cong Z, Li Z, et al
    Bioengineered bacterial outer membrane vesicles encapsulated Polybia-mastoparan I fusion peptide as a promising nanoplatform for bladder cancer immune-modulatory chemotherapy.
    Front Immunol. 2023;14:1129771.
    Abstract

  227. SEITO T, Ishikawa A, Tsuru I, Hikatsu M, et al
    Bladder Preservation After Bilateral Kidney Loss and Bladder Cancer After Renal Transplantation: A Case Report.
    Transplant Proc. 2023 Mar 28:S0041-1345(23)00087.
    Abstract

  228. TOLSTRUP LK, Als AB, Carus A, Dahlrot R, et al
    The iBLAD app protocol - a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care.
    Acta Oncol. 2023 Mar 30:1-5. doi: 10.1080/0284186X.2023.2194031.
    Abstract

  229. CUI X, Zhang C, Zhang L, Yan H, et al
    The prognostic and immunological role of MYB: from bladder cancer validation to pan-cancer analysis.
    Biosci Rep. 2023 Mar 30:BSR20222627. doi: 10.1042/BSR20222627.
    Abstract

  230. ZHAO H, Liu K, Giannakopoulos S, Yuruk E, et al
    Impact of previous malignancy at diagnosis on oncological outcomes of upper tract urothelial carcinoma.
    BMC Urol. 2023;23:49.
    Abstract

  231. AHLSCHLAGER L, McCabe S, Deal AM, Guo A, et al
    The effect of treatment on work productivity in patients with bladder cancer.
    Urol Oncol. 2023 Mar 27:S1078-1439(23)00056.
    Abstract

  232. YU D, Chen C, Sun L, Wu S, et al
    KRT13-expressing epithelial cell population predicts better response to chemotherapy and immunotherapy in bladder cancer: Comprehensive evidences based on BCa database.
    Comput Biol Med. 2023;158:106795.
    Abstract


  233. Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Poster Presentations.
    Can Urol Assoc J. 2023;17.
    Abstract


  234. Canadian Bladder Cancer Forum 2023 Meeting Abstracts - Podium Presentations.
    Can Urol Assoc J. 2023;17.
    Abstract

  235. UFUK F, Yagci AB
    Letter to the Editor: "Prospective assessment of VI-RADS score in multiparametric MRI in bladder cancer: accuracy and the factors affecting the results".
    Diagn Interv Radiol. 2023;29:412-413.
    Abstract

  236. PAN SY, Lai CZ, Chen WC, Chen YH, et al
    Chondrosarcoma of Ureter in an Elderly Patient: A Case Report.
    Medicina (Kaunas). 2023;59:454.
    Abstract

  237. HEIDAR NA, Bhat TA, Shabir U, Hussein AA, et al
    The Urinary Microbiome and Bladder Cancer.
    Life (Basel). 2023;13:812.
    Abstract

  238. BARONE B, Finati M, Cinelli F, Fanelli A, et al
    Bladder Cancer and Risk Factors: Data from a Multi-Institutional Long-Term Analysis on Cardiovascular Disease and Cancer Incidence.
    J Pers Med. 2023;13:512.
    Abstract

  239. OFNER H, Laukhtina E, Hassler MR, Shariat SF, et al
    Blood-Based Biomarkers as Prognostic Factors of Recurrent Disease after Radical Cystectomy: A Systematic Review and Meta-Analysis.
    Int J Mol Sci. 2023;24:5846.
    Abstract

  240. WANG Q, Ke S, Liu Z, Shao H, et al
    HSPA5 Promotes the Proliferation, Metastasis and Regulates Ferroptosis of Bladder Cancer.
    Int J Mol Sci. 2023;24:5144.
    Abstract

  241. MEUNIER S, Frontczak A, Balssa L, Blanc J, et al
    Elevated Baseline Neutrophil Count Correlates with Worse Outcomes in Patients with Muscle-Invasive Bladder Cancer Treated with Chemoradiation.
    Cancers (Basel). 2023;15:1886.
    Abstract

  242. THOMPSON D, Lawrentschuk N, Bolton D
    New Approaches to Targeting Epigenetic Regulation in Bladder Cancer.
    Cancers (Basel). 2023;15:1856.
    Abstract

  243. ENGELMANN SU, Pickl C, Haas M, Kaelble S, et al
    Body Composition of Patients Undergoing Radical Cystectomy for Bladder Cancer: Sarcopenia, Low Psoas Muscle Index, and Myosteatosis Are Independent Risk Factors for Mortality.
    Cancers (Basel). 2023;15:1778.
    Abstract

  244. CULINE S, Harter V, Krucker C, Gravis G, et al
    Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
    Cancers (Basel). 2023;15:1742.
    Abstract

  245. SARKAR S, Min K, Ikram W, Tatton RW, et al
    Performing Automatic Identification and Staging of Urothelial Carcinoma in Bladder Cancer Patients Using a Hybrid Deep-Machine Learning Approach.
    Cancers (Basel). 2023;15:1673.
    Abstract

  246. WOOLBRIGHT BL, Rajendran G, Abbott E, Martin A, et al
    Pyruvate Dehydrogenase Kinase 4 Deficiency Increases Tumorigenesis in a Murine Model of Bladder Cancer.
    Cancers (Basel). 2023;15:1654.
    Abstract

  247. JHUO YC, Cha TL, Kao CC, Tsai YT, et al
    Circulating Tumor Cells Predict Response of Neoadjuvant Chemotherapy in Patients with Bladder Cancer: A Preliminary Study.
    Diagnostics (Basel). 2023;13:1032.
    Abstract

  248. OZDEN-YILMAZ G, Savas B, Bursali A, Eray A, et al
    Differential Occupancy and Regulatory Interactions of KDM6A in Bladder Cell Lines.
    Cells. 2023;12:836.
    Abstract

  249. KUDELSKI J, Tokarzewicz A, Gudowska-Sawczuk M, Mroczko B, et al
    The Significance of Matrix Metalloproteinase 9 (MMP-9) and Metalloproteinase 2 (MMP-2) in Urinary Bladder Cancer.
    Biomedicines. 2023;11:956.
    Abstract

  250. NOWAK L, Krajewski W, Dejnaka E, Malkiewicz B, et al
    Ubiquitin-Specific Proteases as Potential Therapeutic Targets in Bladder Cancer-In Vitro Evaluation of Degrasyn and PR-619 Activity Using Human and Canine Models.
    Biomedicines. 2023;11:759.
    Abstract

  251. XU X, Tian X, Song L, Xie J, et al
    Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation.
    Biomolecules. 2023;13:521.
    Abstract

  252. LIU S, Chen H, Zheng Z, He Y, et al
    Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer.
    Bioengineering (Basel). 2023;10:318.
    Abstract

  253. KO WS, Kim SJ
    Predictive Value of 18F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer.
    Clin Nucl Med. 2023 Mar 27. doi: 10.1097/RLU.0000000000004639.
    Abstract

  254. KARABURUN MC, Ozkaya MF, Erguder BI, Suer E, et al
    Investigation of Atypical Cell Parameter in the Surveillance of Patients with NMIBC; Initial Outcomes of a Single Center Prospective Study.
    J Med Syst. 2023;47:41.
    Abstract

  255. PRATA F, Anceschi U, Taffon C, Rossi SM, et al
    Real-Time Urethral and Ureteral Assessment during Radical Cystectomy Using Ex-Vivo Optical Imaging: A Novel Technique for the Evaluation of Fresh Unfixed Surgical Margins.
    Curr Oncol. 2023;30:3421-3431.
    Abstract

  256. MURTHY PB, Naidu S, Davaro F, Spiess PE, et al
    Survival Benefits of Adjuvant Chemotherapy for Positive Soft Tissue Surgical Margins Following Radical Cystectomy in Bladder Cancer with Extravesical Extension.
    Curr Oncol. 2023;30:3223-3231.
    Abstract

  257. PRIJOVIC N, Acimovic M, Santric V, Stankovic B, et al
    Predictive Value of Inflammatory and Nutritional Indexes in the Pathology of Bladder Cancer Patients Treated with Radical Cystectomy.
    Curr Oncol. 2023;30:2582-2597.
    Abstract


  258. Retraction: MiR-301b promotes the proliferation, mobility, and epithelial-to-mesenchymal transition of bladder cancer cells by targeting EGR1.
    Biochem Cell Biol. 2023 Mar 28. doi: 10.1139/bcb-2023-0074.
    Abstract

  259. TAN Z, Chen X, Zuo J, Fu S, et al
    Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    J Transl Med. 2023;21:223.
    Abstract

  260. LI C, Xie W
    Identification and validation of tumor-infiltrating lymphocyte-related prognosis signature for predicting prognosis and immunotherapeutic response in bladder cancer.
    BMC Bioinformatics. 2023;24:118.
    Abstract

  261. RENNER S, Loussikian P, Foulquie P, Marrel A, et al
    Patient and Caregiver Perceptions of Advanced Bladder Cancer Systemic Treatments: Infodemiology Study Based on Social Media Data.
    JMIR Cancer. 2023;9:e45011.
    Abstract

  262. JIANG L, Sun G, Zou L, Guan Y, et al
    Noncoding RNAs as a potential biomarker for the prognosis of bladder cancer: a systematic review and meta-analysis.
    Expert Rev Mol Diagn. 2023 Mar 27. doi: 10.1080/14737159.2023.2195554.
    Abstract

  263. JHUANG JR, Chiu PC, Hsieh TC, Chen CH, et al
    Latency period of aristolochic acid-induced upper urinary tract urothelial carcinoma.
    Front Public Health. 2023;11:1072864.
    Abstract

  264. ZHU X, Qin R, Qu K, Wang Z, et al
    Corrigendum to 'Atomic force microscopy-based assessment of multimechanical cellular properties for classification of graded bladder cancer cells and cancer early diagnosis using machine learning analysis' Acta Biomaterialia 2023, 158, 358‒373.
    Acta Biomater. 2023 Mar 23:S1742-7061(23)00152.
    Abstract

  265. LONG G, Hu Z, Liu Z, Ye Z, et al
    Partial and radical cystectomy provides equivalent oncologic outcomes in bladder cancer when combined with adequate lymph node dissection: A population-based study.
    Urol Oncol. 2023 Mar 23:S1078-1439(23)00078.
    Abstract

  266. QIU Y, Wang X, Fan Y, Bao Y, et al
    A case of bilateral synchronous double primary lung cancer secondary to bladder cancer: From the next-generation sequencing prospect.
    Thorac Cancer. 2023 Mar 25. doi: 10.1111/1759-7714.14864.
    Abstract

  267. KRISHNATRY R, Maitre P, Kumar A, Telkhade T, et al
    Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle-invasive bladder cancer.
    Cancer Med. 2023 Mar 25. doi: 10.1002/cam4.5840.
    Abstract

  268. TUONG MNE, Prillaman GE, Culp SH, Nelson M, et al
    India Ink Tattooing of Ureteroenteric Anastomoses.
    Tomography. 2023;9:449-458.
    Abstract

  269. GRIMM MO, Grun CB, Niegisch G, Pichler M, et al
    Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2023;24:347-359.
    Abstract

  270. KOMATSU M, Funakoshi T, Aki T, Unuma K, et al
    Aristolochic acid induces an inflammatory response with prostaglandin E2 production and apoptosis in NRK-52E proximal tubular cells.
    Toxicol Lett. 2023;378:39-50.
    Abstract

  271. BERGENGREN O, Belozerov A, Bill-Axelson A, Garmo H, et al
    Short term outcomes after robot assisted and open cystectomy - A nation-wide population-based study.
    Eur J Surg Oncol. 2023;49:868-874.
    Abstract

  272. LEIBRANDT RC, Tu MJ, Yu AM, Lara PN, et al
    ATR Inhibition in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2023;21:203-207.
    Abstract

  273. MAKRAKIS D, Bakaloudi DR, Talukder R, Lin GI, et al
    Treatment Rechallenge With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
    Clin Genitourin Cancer. 2023;21:286-294.
    Abstract

  274. HARRIS KT, Villela NA, Alam R, Wu WJ, et al
    The exstrophy experience: A national survey assessing urinary continence, bladder management, and oncologic outcomes in adults.
    J Pediatr Urol. 2023;19:178.
    Abstract

  275. RAMAHI YO, Shiekh M, Shah AA, Houenstein H, et al
    Uretero-enteric Strictures After Robot Assisted Radical Cystectomy: Prevalence and Management Over Two Decades.
    Clin Genitourin Cancer. 2023;21:e19-e26.
    Abstract

  276. NECCHI A, Joshi M, Bangs R, Makaroff L, et al
    Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly.
    Clin Genitourin Cancer. 2023;21:301-308.
    Abstract

  277. HALD OC, Phan YC, Carter CJM, Klatte T, et al
    Bladder tumor Resection Weight as a Prognostic Factor for Recurrence and Progression in Patients With High-Risk Non-Muscle Invasive Bladder Treated With BCG.
    Clin Genitourin Cancer. 2023;21:e70-e77.
    Abstract

  278. LI DX, Feng DC, Shi X, Wu RC, et al
    Identification of endothelial-related molecular subtypes for bladder cancer patients.
    Front Oncol. 2023;13:1101055.
    Abstract

  279. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Additional oncological benefit of photodynamic diagnosis with blue light cystoscopy in transurethral resection for primary non-muscle-invasive bladder cancer: A comparative study from experienced institutes.
    BJUI Compass. 2023;4:305-313.
    Abstract

  280. CONROY S, Pang K, Jubber I, Hussain SA, et al
    Hyperthermic intravesical chemotherapy with mitomycin-C for the treatment of high-risk non-muscle-invasive bladder cancer patients.
    BJUI Compass. 2022;4:314-321.
    Abstract

  281. WOODCOCK VK, Chen JL, Purshouse K, Butcher C, et al
    PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer.
    BJUI Compass. 2023;4:322-330.
    Abstract

  282. MINAMI T, Fujita K, Hashimoto M, Nishimoto M, et al
    External beam radiotherapy combination is a risk factor for bladder cancer in patients with prostate cancer treated with brachytherapy.
    World J Urol. 2023 Apr 6. doi: 10.1007/s00345-023-04380.
    Abstract

  283. HAN S, Ji Z, Jiang J, Fan X, et al
    Neoadjuvant therapy with camrelizumab plus gemcitabine and cisplatin for patients with muscle-invasive bladder cancer: A multi-center, single-arm, phase 2 study.
    Cancer Med. 2023 Apr 6. doi: 10.1002/cam4.5900.
    Abstract

  284. FAN Y, Hao Y, Zhu C, Hu B, et al
    PLCepsilon promotes the Warburg effect and tumorigenesis through AKT/GSK3beta/Cdc25a in bladder cancer.
    Biotechnol Genet Eng Rev. 2023 Apr 5:1-15. doi: 10.1080/02648725.2023.2199188.
    Abstract

  285. JIN S, Shang Z, Wang W, Gu C, et al
    Immune Co-inhibitory Receptors CTLA-4, PD-1, TIGIT, LAG-3, and TIM-3 in Upper Tract Urothelial Carcinomas: A Large Cohort Study.
    J Immunother. 2023;46:154-159.
    Abstract

  286. VANARSA K, Castillo J, Wang L, Lee KH, et al
    Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.
    BMC Med. 2023;21:133.
    Abstract

  287. LI S, Xin K, Pan S, Wang Y, et al
    Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.
    Cell Mol Biol Lett. 2023;28:28.
    Abstract

  288. LOK W, Zhang J, Zheng X, Lin T, et al
    Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: a propensity score-matched study.
    Chin Med J (Engl). 2023 Apr 5. doi: 10.1097/CM9.0000000000002512.
    Abstract

  289. LING Y, Li J, Zhou L
    Smoking-related epigenetic modifications are associated with the prognosis and chemotherapeutics of patients with bladder cancer.
    Int J Immunopathol Pharmacol. 2023;37:3946320231166774.
    Abstract

  290. HUANG KC, Chandra D, McGrath S, Dixit V, et al
    Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer.
    Mol Cancer Ther. 2023;22:551.
    Abstract

  291. LI L, Zhang J, Zhe X, Chang H, et al
    An MRI-based radiomics nomogram in predicting histologic grade of non-muscle-invasive bladder cancer.
    Front Oncol. 2023;13:1025972.
    Abstract

  292. CHEMI J, Villoldo GM
    Should continuous bladder irrigation be recommended when single instillation of intravesical chemotherapy cannot be used after transurethral resection in low-risk non-muscle invasive bladder cancer?
    Bladder (San Franc). 2023;10:e21200002.
    Abstract

  293. WANG X, Bai Y, Zhang F, Li D, et al
    Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Front Immunol. 2023;14:955949.
    Abstract

  294. JAKUS D, Cepin P, Vrhovac I, Jakus IA, et al
    Influence of the grade and invasiveness of bladder cancer on disease course severity in patients with bladder tamponade resulting from a bleeding bladder cancer.
    Urol Ann. 2023;15:27-30.
    Abstract

  295. ZHENG Q, Guo L, Yang R, Chen Z, et al
    Identification of essential genes and drug discovery in bladder cancer and inflammatory bowel disease via text mining and bioinformatics analysis.
    Curr Comput Aided Drug Des. 2023 Mar 30. doi: 10.2174/1573409919666230330154008.
    Abstract

  296. KOOL R, Marcq G, Breau RH, Black PC, et al
    Radiation-based Therapy for Muscle-invasive Bladder Cancer: Contemporary Outcomes Across Tertiary Centers.
    Eur Urol Oncol. 2023 Mar 31:S2588-9311(23)00068.
    Abstract

  297. GONTERO P, Livoti S, Soria F
    A Restaging Transurethral Resection of the Bladder Is Always Necessary for High-grade T1 Non-muscle-invasive Bladder Cancer: Con.
    Eur Urol Focus. 2023 Mar 31:S2405-4569(23)00076.
    Abstract

  298. YING X, Huang Y, Liu B, Hu W, et al
    Targeted m(6)A demethylation of ITGA6 mRNA by a multisite dCasRx-m(6)A editor inhibits bladder cancer development.
    J Adv Res. 2023 Mar 30:S2090-1232(23)00092-9. doi: 10.1016/j.jare.2023.
    Abstract

  299. GERETTO P, DE Cillis S, Phe V
    Voiding patterns following radical cystectomy and orthotopic neobladder: is intermittent self-catheterization worth the hype?
    Minerva Urol Nephrol. 2023;75:246-247.
    Abstract

  300. SORIA F, Delacruz JE, Aznar-Cervantes SD, Aranda J, et al
    Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma.
    Minerva Urol Nephrol. 2023;75:194-202.
    Abstract

  301. CANCRINI F, Osman N, Doizi S, Guillot-Tantay C, et al
    Incidence of urological cancers in neurological patients: a review of the literature from the EAU Young Academic Urologist Functional Group.
    Minerva Urol Nephrol. 2023;75:163-171.
    Abstract

  302. FALLARA G, Maida FD, Bravi CA, DE Groote R, et al
    A systematic review and meta-analysis of robot-assisted vs. open radical cystectomy: where do we stand and future perspective.
    Minerva Urol Nephrol. 2023;75:134-143.
    Abstract

  303. CO JL, Goco MLL, So JS
    Paraganglioma in The Urinary Bladder: A Pitfall in Histopathologic Diagnosis.
    Acta Med Indones. 2023;55:95-100.
    Abstract

  304. SCHLACK K
    [Perioperative systemic treatment of urothelial cancer].
    Urologie. 2023;62:407-417.
    Abstract

  305. COLE K, Al-Kadhimi Z, Talmadge JE
    Highlights into historical and current immune interventions for cancer.
    Int Immunopharmacol. 2023;117:109882.
    Abstract

  306. HUANG C, Li Y, Ling Q, Wei C, et al
    Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism-related genes and their relationships with immune infiltration.
    FEBS Open Bio. 2023;13:736-750.
    Abstract

  307. EGGER M, Seiler R
    Which Patients To Consider for Bladder Preservation After a Complete Response to Neoadjuvant Chemotherapy.
    Eur Urol Focus. 2023;9:229-231.
    Abstract

  308. KAWADA T, Yanagisawa T, Mostafaei H, Sari Motlagh R, et al
    Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2023;9:264-274.
    Abstract

  309. SUGIYAMA Y, Naiki T, Tasaki Y, Mimura Y, et al
    GNRI Sustainability during One Cycle of First-Line Chemotherapy as a Prognostic Indicator in Patients with Metastatic Urothelial Carcinoma.
    Oncology. 2023;101:224-233.
    Abstract

  310. LANGE S, Calleris G, Matin SF, Roupret M, et al
    Optimizing Lymph Node Dissection at the Time of Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma.
    Eur Urol Focus. 2023;9:280-282.
    Abstract

  311. DENG Q, Xie J, Kong S, Tang T, et al
    Long-Term Retention Microbubbles with Three-Layer Structure for Floating Intravesical Instillation Delivery.
    Small. 2023;19:e2205630.
    Abstract

  312. FELSNER M, Grubmuller B
    [One clip too many].
    Urologie. 2023;62:389-391.
    Abstract

  313. IACOVELLI R, Cicala CM, Ciccarese C, Sacco E, et al
    Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Urologia. 2023;90:3-10.
    Abstract

  314. KAWADA T, Laukhtina E, Quhal F, Yanagisawa T, et al
    Oncologic and Safety Outcomes for Endoscopic Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: An Updated Systematic Review and Meta-analysis.
    Eur Urol Focus. 2023;9:236-240.
    Abstract

  315. ZHAO H, Peng P, Luo Z, Liu H, et al
    Comparison of hexaminolevulinate (HAL) -guided versus white light transurethral resection for NMIBC: A systematic review and meta-analysis of randomized controlled trials.
    Photodiagnosis Photodyn Ther. 2023;41:103220.
    Abstract

  316. INGERSOLL MA
    Does immune cell exhaustion lie at the heart of BCG-unresponsive disease?
    Nat Rev Urol. 2023;20:201-202.
    Abstract

  317. LAUKHTINA E, Kawada T, Quhal F, Yanagisawa T, et al
    Oncologic and Safety Outcomes for Retrograde and Antegrade Endoscopic Surgeries for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-analysis.
    Eur Urol Focus. 2023;9:258-263.
    Abstract

  318. HASUI KI, Kawakami Y, Miyake T, Hirai Y, et al
    Cutaneous toxicity with suprabasal blisters and dyskeratosis following administration of enfortumab vedotin.
    J Dermatol. 2022 Nov 22. doi: 10.1111/1346-8138.16646.
    Abstract

  319. CHEN CJ, Hang JF, Chen YA, Lin SJ, et al
    The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens.
    Cancer Cytopathol. 2023;131:226-233.
    Abstract

  320. SCHONE M, Uhthoff H, Schone S
    [Cystoscopy in the outpatient clinical routine: things to keep in mind].
    Aktuelle Urol. 2023;54:129-134.
    Abstract

  321. AMBEGODA M, Shiyanth S, Vidanapathirana S, Kumara S, et al
    Outcome of transurethral resection of bladder tumour under spinal anaesthesia combined with obturator nerve block in Sri Lanka.
    Urologia. 2023;90:80-82.
    Abstract

  322. LOKESHWAR SD, Rahman SN, Choksi A, Press BH, et al
    Patient tolerability during office cystoscopy and bladder tumor cauterization: a multivariate analysis of risk factors.
    Actas Urol Esp (Engl Ed). 2023;47:165-171.
    Abstract

  323. PENG J, Zhang X, Meng Y, Yang X, et al
    Urachal mucinous cystadenocarcinoma: A case report.
    Asian J Surg. 2023;46:1759-1760.
    Abstract

  324. CONTIERI R, Hurle R, Paciotti M, Casale P, et al
    Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG.
    Minerva Urol Nephrol. 2023;75:180-187.
    Abstract

  325. SUBIELA JD, Rodriguez Faba O, Aumatell J, Gonzalez-Padilla DA, et al
    Long-term Recurrence and Progression Patterns in a Contemporary Series of Patients with Carcinoma In Situ of the Bladder With or Without Associated Ta/T1 Disease Treated with Bacillus Calmette-Guerin: Implications for Risk-adapted Follow-up.
    Eur Urol Focus. 2023;9:325-332.
    Abstract

  326. NI RAGHALLAIGH H, Pineda-Turner A, Mather K, Chetwood A, et al
    Melanosis of the urinary bladder.
    Ann R Coll Surg Engl. 2023;105:386-387.
    Abstract

  327. IPPOLITI S, Bhatt NR, Ilie CP
    Transurethral resection of bladder tumour (TURBT) as a day-case: A real-world practice and patients' perspective from a district general hospital (DGH).
    Urologia. 2023;90:68-74.
    Abstract

  328. W AC, Gj N, T M, A A, et al
    The impact of socio-economic deprivation on recovery following robotic assisted radical cystectomy.
    Urologia. 2023;90:136-140.
    Abstract

  329. BICCI E, Mastrorosato M, Danti G, Lattavo L, et al
    Dual-Energy CT applications in urinary tract cancers: an update.
    Tumori. 2023;109:148-156.
    Abstract

  330. OK F, Durmus E
    Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature.
    Urologia. 2023;90:195-197.
    Abstract

  331. TRENTI E, Palermo S, Pycha A, Comploj E, et al
    [Sigmoid colon conduit volvulus: an extremely rare complication of a sigmoid colon conduit].
    Aktuelle Urol. 2023;54:148-150.
    Abstract

  332. THOLOMIER C, Martini A, Mokkapati S, Dinney CP, et al
    The current status of gene therapy in bladder cancer.
    Expert Rev Anticancer Ther. 2023 Apr 13. doi: 10.1080/14737140.2023.2203385.
    Abstract

  333. ELAYAT G, Punev I, Selim A
    An Overview of Angiogenesis in Bladder Cancer.
    Curr Oncol Rep. 2023 Apr 13. doi: 10.1007/s11912-023-01421.
    Abstract

  334. WU X, Xu Q, Li T, Wei Y, et al
    Correction to: Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2‑Antisense RNA 1/microRNA‑93‑5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis.
    Appl Biochem Biotechnol. 2023 Apr 13. doi: 10.1007/s12010-023-04478.
    Abstract

  335. SHIN HM, Lee J, Lee DH, Kim SH, et al
    CT Evaluation of the Findings of Nutcracker Syndrome in Patients with Bladder Cancer after Radical Cystectomy and Ileal Neobladder Formation: A Correlation with Hematuria.
    J Korean Soc Radiol. 2023;84:409-417.
    Abstract

  336. TEIXEIRA-MARQUES A, Lourenco C, Oliveira MC, Henrique R, et al
    Extracellular Vesicles as Potential Bladder Cancer Biomarkers: Take It or Leave It?
    Int J Mol Sci. 2023;24:6757.
    Abstract

  337. SANGUEDOLCE F, Falagario UG, Zanelli M, Palicelli A, et al
    Clinicopathological Features and Survival Analysis in Molecular Subtypes of Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;24:6610.
    Abstract

  338. GREBOWSKI R, Saluk J, Bijak M, Szemraj J, et al
    Variability, Expression, and Methylation of IL-6 and IL-8 Genes in Bladder Cancer Pathophysiology.
    Int J Mol Sci. 2023;24:6266.
    Abstract

  339. NEUHAUS J, Rabien A, Reinhold A, Koehler L, et al
    3D Tumor Models in Urology.
    Int J Mol Sci. 2023;24:6232.
    Abstract

  340. HU CY, Wu HT, Shan YS, Wang CT, et al
    Evodiamine Exhibits Anti-Bladder Cancer Activity by Suppression of Glutathione Peroxidase 4 and Induction of Ferroptosis.
    Int J Mol Sci. 2023;24:6021.
    Abstract

  341. BLANCA A, Lopez-Beltran A, Lopez-Porcheron K, Gomez-Gomez E, et al
    Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype.
    Cancers (Basel). 2023;15:2149.
    Abstract

  342. BERTUCCI A, Cartier L, Rollet A, Boustany R, et al
    Retrospective Analysis of a Cohort of Patients with Metastatic Bladder Cancer with Metastatic Sites Limited to the Pelvis and Retroperitoneum Treated at a Single Institution between 2009 and 2020.
    Cancers (Basel). 2023;15:2069.
    Abstract

  343. DEL GIUDICE F, Asero V, Bologna E, Scornajenghi CM, et al
    Efficacy of Different Bacillus of Calmette-Guerin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis.
    Cancers (Basel). 2023;15:1937.
    Abstract

  344. KIMURA K, Yoshida S, Tsuchiya J, Kitazume Y, et al
    Novel utility of Vesical Imaging-Reporting and Data System in multimodal treatment for muscle-invasive bladder cancer.
    Eur Radiol. 2023 Apr 13. doi: 10.1007/s00330-023-09627.
    Abstract

  345. GHALI F, Wright JL, Grivas P
    The Pursuit of Intravesical and Systemic Therapies in Non-muscle-invasive Bladder Cancer: Challenges and Opportunities.
    Eur Urol Oncol. 2023 Apr 10:S2588-9311(23)00071.
    Abstract

  346. WANG Z, Kwan ML, Haque R, Goniewicz M, et al
    Associations of dietary isothiocyanate exposure from cruciferous vegetable consumption with recurrence and progression of non-muscle invasive bladder cancer: Findings from The Be-Well Study.
    Am J Clin Nutr. 2023 Apr 10:S0002-9165(23)46835.
    Abstract

  347. ZHANG H, Liu J, Zheng Z
    Molecular subtypes, tumor microenvironment infiltration characterization and prognosis model based on cuproptosis in bladder cancer.
    PeerJ. 2023;11:e15088.
    Abstract

  348. YANAGISAWA T, Matsukawa A, Iwatani K, Sato S, et al
    ASO Visual Abstract: En Bloc Resection Versus Conventional TURBT for T1HG Bladder Cancer: A Propensity Score-Matched Analysis.
    Ann Surg Oncol. 2023 Apr 11. doi: 10.1245/s10434-023-13395.
    Abstract

  349. XIA Y, Xu DF, Huang T, Zhao CH, et al
    Exploring the application of bladder-preservation treatment in patients with T2N0M0 bladder cancer and establish a nomogram model: A SEER-based study.
    Asian J Surg. 2023 Apr 8:S1015-9584(23)00486.
    Abstract

  350. BILE-SILVA A, Lopez-Beltran A, Blanca A, Lopez-Rios F, et al
    Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward.
    Expert Opin Biol Ther. 2023 Apr 10:1-12. doi: 10.1080/14712598.2023.2201371.
    Abstract

  351. QUIGNOT N, Jiang H, Doobaree IU, Lehmann J, et al
    Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.
    Clinicoecon Outcomes Res. 2023;15:227-237.
    Abstract

  352. BAI X, Chen G, Shang S, Li S, et al
    Survival prediction among pathologic T4 bladder cancer patients following cytoreductive cystectomy: A retrospective single-center study.
    Front Surg. 2023;10:1121357.
    Abstract

  353. FRESHOUR SL, Chen THP, Fisk B, Shen H, et al
    Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
    bioRxiv. 2023 Mar 29:2023.03.28.534561. doi: 10.1101/2023.03.28.534561.
    Abstract

  354. ZHANG X, Zhang A, Hu L, Xiong W, et al
    An innovative risk index based on neutrophils and macrophages can effectively predict prognosis and immunotherapy response in patients with muscle-invasive bladder cancer.
    Transl Cancer Res. 2023;12:536-549.
    Abstract

  355. PYRGIDIS N, Sokolakis I, Haltmair G, Hatzichristodoulou G, et al
    The Short- and Long-Term Effect of Radical Cystectomy in Frail Patients With Bladder Cancer.
    Clin Genitourin Cancer. 2023 Mar 11:S1558-7673(23)00063.
    Abstract

  356. DONG ZX, Chan SH, Chen SN, Li M, et al
    TJP1 promotes vascular mimicry in bladder cancer by facilitating VEGFA expression and transcriptional activity through TWIST1.
    Transl Oncol. 2023;32:101666.
    Abstract

  357. MONTORSI F, Moschini M, Briganti A
    Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. Eur Urol Oncol 2022;5:505-16.
    Eur Urol Oncol. 2023 Apr 6:S2588-9311(23)00073-1. doi: 10.1016/j.euo.2023.
    Abstract

  358. WU J, He D, Yu F, Huang Y, et al
    Mycoplasma infection mimicking a malignancy in a waldenstrom macroglobulinemia patient.
    BMC Infect Dis. 2023;23:219.
    Abstract

  359. GAFFNEY CD, Katims A, D'Souza N, Bjurlin MA, et al
    Bladder Cancer Carcinogens: Opportunities for Risk Reduction.
    Eur Urol Focus. 2023 Apr 5:S2405-4569(23)00086-X. doi: 10.1016/j.euf.2023.
    Abstract

  360. ZHANG Y, Li Z, Zhang Y, Shen C, et al
    circSOBP Inhibits Bladder Cancer Proliferation and Metastasis by Regulating the miR-200a-3p/PTEN Axis and Participating in the Immune Response.
    Cell Transplant. 2023;32:9636897231165874.
    Abstract

  361. SHEN D, Deng Z, Liu W, Zhou F, et al
    Melatonin inhibits bladder tumorigenesis by suppressing PPARgamma/ENO1-mediated glycolysis.
    Cell Death Dis. 2023;14:246.
    Abstract

  362. PHILIPPS L, Porta N, James N, Huddart R, et al
    Correlation of Clinician- and Patient-Reported Outcomes in the BC2001 Trial.
    Clin Oncol (R Coll Radiol). 2023;35:331-338.
    Abstract

  363. GONZALEZ-FIERRO A, Romo-Perez A, Chavez-Blanco A, Dominguez-Gomez G, et al
    Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
    Clin Drug Investig. 2023;43:227-239.
    Abstract

  364. JAIN RK, Singh AM, Wang X, Guevara-Patino JA, et al
    Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma.
    Expert Opin Emerg Drugs. 2023;28:17-26.
    Abstract

  365. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open vs robotic intracorporeal Padua ileal bladder: functional outcomes of a single-centre RCT.
    World J Urol. 2023;41:739-746.
    Abstract

  366. YAMADA Y, Nakagawa T, Miyakawa J, Kawai T, et al
    Subclassification of pT3 upper tract urothelial carcinoma: a multicenter retrospective study.
    World J Urol. 2023;41:767-776.
    Abstract

  367. BAHLINGER V, Hartmann A, Eckstein M
    Immunotherapy in Genitourinary Cancers: Role of Surgical Pathologist for Detection of Immunooncologic Predictive Factors.
    Adv Anat Pathol. 2023;30:203-210.
    Abstract

  368. GAYA JM, Territo A, Basile G, Gallioli A, et al
    Optimizing decision-making process of benign uretero-enteric anastomotic stricture treatment after radical cystectomy.
    World J Urol. 2023;41:733-738.
    Abstract

  369. BLACKMUR JP, Chew E, Trail M, Brodie K, et al
    Assessment of association between lower ureteric excision technique and oncological outcomes for upper urinary tract urothelial carcinoma: retrospective analysis from the Scottish Renal Cancer Consortium.
    World J Urol. 2023;41:757-765.
    Abstract

  370. KIM H, Jeong BC, Hong J, Kwon GY, et al
    Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Cancer Res Treat. 2023;55:636-642.
    Abstract

  371. FAN B, Zheng X, Wang Y, Hu X, et al
    Predicting prognosis and clinical efficacy of immune checkpoint blockade therapy via interferon-alpha response in muscle-invasive bladder cancer.
    Pathol Oncol Res. 2023;29:1611117.
    Abstract

  372. TAN D, Jiang W, Hu R, Li Z, et al
    Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR.
    Cancer Med. 2023 Apr 20. doi: 10.1002/cam4.5879.
    Abstract

  373. CATTO JWF, Rogers Z, Downing A, Mason SJ, et al
    Lifestyle Factors in Patients with Bladder Cancer: A Contemporary Picture of Tobacco Smoking, Electronic Cigarette Use, Body Mass Index, and Levels of Physical Activity.
    Eur Urol Focus. 2023 Apr 18:S2405-4569(23)00101.
    Abstract

  374. SONG SH, Lee J, Ko YH, Kim JW, et al
    TNM-Based Head-to-Head Comparison of Urachal Carcinoma and Urothelial Bladder Cancer : Stage-Matched Analysis of a Large Multicenter National Cohort.
    Cancer Res Treat. 2023 Apr 17. doi: 10.4143/crt.2023.
    Abstract

  375. COCKRELL DC, Rose TL
    Correction to: Current Status of Perioperative Therapy in Muscle‑Invasive Bladder Cancer and Future Directions.
    Curr Oncol Rep. 2023 Apr 20. doi: 10.1007/s11912-023-01409.
    Abstract

  376. YOSHINO H, Yokoyama S, Tamai M, Okamura S, et al
    Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
    FEBS Open Bio. 2023 Apr 20. doi: 10.1002/2211-5463.13616.
    Abstract

  377. VERRI P, Baboudjian M, Diana P, Gallioli A, et al
    Reduced- vs full-dose BCG in bladder cancer: A systematic review and meta-analysis.
    Actas Urol Esp (Engl Ed). 2023;47:4-14.
    Abstract

  378. MORENO-CORTES JC, Herranz-Amo F, Bataller-Monfort V, Esteban-Labrador L, et al
    Development of an immune-nutritional prognostic index in patients with muscle-infiltrating bladder cancer candidates for radical cystectomy.
    Actas Urol Esp (Engl Ed). 2023;47:34-40.
    Abstract

  379. SHEENU VS, Paul RS, Pushpa M, Ami EM, et al
    Histopathological spectrum of adult renal tumours: A single center experience and review of literature.
    Indian J Pathol Microbiol. 2023;66:307-313.
    Abstract

  380. SCHALLENBERG S, Dragomir MP, Anders P, Ebner B, et al
    Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
    Eur Urol Focus. 2023 Apr 17:S2405-4569(23)00080.
    Abstract

  381. SANZ GOMEZ I, Huguet J, Bravo A, Robalino J, et al
    Sequential Treatment With Bacillus Calmette-Guerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure.
    Clin Genitourin Cancer. 2023 Mar 17:S1558-7673(23)00061.
    Abstract

  382. YAN CL, Gallo RA, Pandiri M, Gallo SJ, et al
    Bladder squamous cell carcinoma in situ in the background of condyloma acuminatum in a kidney transplant recipient.
    Can J Urol. 2023;30:11505-11508.
    Abstract

  383. WANG W, Jiang X, Xia F, Chen X, et al
    Correction to: HYOU1 promotes cell proliferation, migration, and invasion via the PI3K/AKT/FOXO1 feedback loop in bladder cancer.
    Mol Biol Rep. 2023 Apr 18. doi: 10.1007/s11033-023-08325.
    Abstract

  384. CHEN J, Huang CP, Quan C, Zu X, et al
    The androgen receptor in bladder cancer.
    Nat Rev Urol. 2023 Apr 18. doi: 10.1038/s41585-023-00761.
    Abstract

  385. MINOLI M, Cantore T, Hanhart D, Kiener M, et al
    Bladder cancer organoids as a functional system to model different disease stages and therapy response.
    Nat Commun. 2023;14:2214.
    Abstract

  386. STORMOEN DR, Taarnhoj GA, Friis RB, Johansen C, et al
    Association of patient-reported pain with survival in bladder cancer: a post-hoc analysis of the iBLAD trial.
    Acta Oncol. 2023 Apr 18:1-6. doi: 10.1080/0284186X.2023.2199461.
    Abstract

  387. SU Y, Wang B, Huang J, Huang M, et al
    YTHDC1 positively regulates PTEN expression and plays a critical role in cisplatin resistance of bladder cancer.
    Cell Prolif. 2023 Apr 17:e13404. doi: 10.1111/cpr.13404.
    Abstract

  388. JIANG Y, Zhang M, Wang L, Zhang L, et al
    Potential mechanisms of osthole against bladder cancer cells based on network pharmacology, molecular docking, and experimental validation.
    BMC Complement Med Ther. 2023;23:122.
    Abstract

  389. STONE L
    Going in circles: circMGA-HNRNPL feedback loop in bladder cancer.
    Nat Rev Urol. 2023 Apr 17. doi: 10.1038/s41585-023-00771.
    Abstract

  390. MASONE MC
    Using AI to assist pathologists in bladder cancer metastases detection.
    Nat Rev Urol. 2023 Apr 14. doi: 10.1038/s41585-023-00769.
    Abstract

  391. YU X, Li W, Feng Y, Gao Z, et al
    The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics.
    Sci Rep. 2023;13:6241.
    Abstract

  392. MOHAMMED SA, Hetta HF, Zahran AM, Tolba MEM, et al
    T cell subsets, regulatory T, regulatory B cells and proinflammatory cytokine profile in Schistosoma haematobium associated bladder cancer: First report from Upper Egypt.
    PLoS Negl Trop Dis. 2023;17:e0011258.
    Abstract

  393. JAHAN M, Mittal A, Rao S, Kishore S, et al
    Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCell technology: Potential as a simple cytology test.
    Diagn Cytopathol. 2023 Apr 17. doi: 10.1002/dc.25141.
    Abstract

  394. WANG Y, Chen S, Zhang W, Xiao W, et al
    Image quality evaluation of diffusion-weighted imaging in bladder cancer: a comparison between integrated slice-specific dynamic shimming and single-shot echo-planar imaging.
    Quant Imaging Med Surg. 2023;13:2526-2537.
    Abstract

  395. JAKUS D, Situm M, Cepin P, Vrhovac I, et al
    The impact of antithrombotic therapy on the time of detection of bladder cancer.
    Cent European J Urol. 2023;76:33-37.
    Abstract

  396. XIONG X, Chen C, Li X, Yang J, et al
    Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Front Oncol. 2023;13:972558.
    Abstract

  397. CASTANEDA PR, Theodorescu D, Rosser CJ, Ahdoot M, et al
    Identifying novel biomarkers associated with bladder cancer treatment outcomes.
    Front Oncol. 2023;13:1114203.
    Abstract

  398. CHEN H, Yang W, Ji Z
    Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.
    Front Immunol. 2023;14:1171420.
    Abstract

  399. HE Z, Chen K, An Y, He J, et al
    BSA modification of bacterial surface: a promising anti-cancer therapeutic strategy.
    BMC Microbiol. 2023;23:105.
    Abstract

  400. YANG J, Li K, Zhang Y, Hu J, et al
    Singe intraoperative instillation of chemotherapy during radical cystectomy for bladder cancer: Oncological outcome and survival predictors.
    Cancer Med. 2023 Apr 16. doi: 10.1002/cam4.5895.
    Abstract

  401. WISHAHI M, Hassan S, Hassan M, Badawy M, et al
    Telocytes and ezrin expression in normal-appearing tissues adjacent to urothelial bladder carcinoma as predictors of invasiveness and recurrence.
    Sci Rep. 2023;13:6179.
    Abstract

  402. CHANDRA M, Li R, Parwani A, Carson WE 3rd, et al
    Heterogeneity of BCG unresponsive bladder cancer clinical trials limits patients' access to novel therapeutics.
    Urol Oncol. 2023 Apr 13:S1078-1439(23)00094.
    Abstract

  403. WU R, Li D, Feng D, Han P, et al
    Transmembrane protein 132A (TMEM132A) predicts overall survival for bladder cancer patients.
    Asian J Surg. 2023 Apr 13:S1015-9584(23)00423.
    Abstract

  404. GARCIA-PORRERO G, Paricio Martinez JJ, Alvarez Gigli L, Abengozar Muela M, et al
    Osteoclast-rich undifferentiated carcinoma of the bladder and the diagnostic usefulness of immunohistochemistry. A case report.
    Rev Esp Patol. 2023;56:132-135.
    Abstract

  405. CONTIERI R, Lazzeri M, Hurle R
    When and How To Perform Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 Apr 12:S2405-4569(23)00095.
    Abstract

  406. SUN A, Luo Y, Xiao W, Zhu Z, et al
    Androgen receptor transcriptionally inhibits programmed death ligand-1 (PD-L1) expression and influences immune escape in bladder cancer.
    Lab Invest. 2023 Apr 12:100148. doi: 10.1016/j.labinv.2023.100148.
    Abstract

  407. MAMTANI R, Zhang H, Parikh RB, Patel K, et al
    Uptake of Maintenance Immunotherapy and Changes in Upstream Treatment Selection Among Patients With Urothelial Cancer.
    JAMA Netw Open. 2023;6:e238395.
    Abstract

  408. CHANG YL, Chen YT, Wang HH, Chiang PH, et al
    The prognostic impact of lymphovascular invasion for upper urinary tract urothelial carcinoma: A propensity score-weighted analysis.
    Medicine (Baltimore). 2023;102:e33485.
    Abstract

  409. ZHANG X, G Dapar ML, Zhang X, Chen Y, et al
    A pan-cancer analysis of the oncogenic role of YKT6 in human tumors.
    Medicine (Baltimore). 2023;102:e33546.
    Abstract

  410. JOENSEN UN, Kingo PS, Stormoen D, Carus A, et al
    [Not Available].
    Ugeskr Laeger. 2023;185:V02230082.
    Abstract

  411. OLIUSHINA EM, Zavalishina LE, Alekseenok EY, Oskina NA, et al
    [Investigation of the mutational status of the FGFR3 gene in urothelial bladder carcinoma].
    Arkh Patol. 2023;85:5-12.
    Abstract

  412. JIN X, Wang Q, Luo F, Pan J, et al
    Single-cell transcriptomic analysis of tumor heterogeneity and intercellular networks in human urothelial carcinoma.
    Chin Med J (Engl). 2023;136:690-706.
    Abstract

  413. YAJIMA S, Nakanishi Y, Yasujima R, Hirose K, et al
    Rapid geriatric screening tools predict inability to manage stoma by oneself after urinary diversion: G8 and IADL-modified G8.
    J Geriatr Oncol. 2023;14:101468.
    Abstract

  414. ZHU A, Berends JE, Daignault-Newton S, Kaye DR, et al
    Use of a physical activity monitor to track perioperative activity of radical cystectomy patients. Our first glimpse at what our patients are doing before and after surgery.
    Urol Oncol. 2023;41:206.
    Abstract

  415. SONG E, Suek T, Davaro F, Hamilton Z, et al
    Variant histology in upper tract carcinomas: Analysis of the National Cancer Database.
    Urol Oncol. 2023;41:206.
    Abstract

  416. ROSENZWEIG SJ, Ranti D, Mehrazin R, Sfakianos JP, et al
    Characteristics Contributing to Survival Differences Between Black and White Patients Following Cystectomy.
    Urol Oncol. 2023;41:207.
    Abstract

  417. MORA RM, Ghoreifi A, Ladi-Seyedian SS, Sheybaee Moghaddam F, et al
    Radical cystectomy and urinary diversion outcomes in patients with single vs. double renal unit: A 2:1 matched-pair analysis.
    Urol Oncol. 2023;41:207.
    Abstract

  418. SHORE ND, Gavaghan MB
    Clinical and economic impact of blue light cystoscopy in the management of NMIBC at US ambulatory surgical centers: what is the site-of-service disparity?
    Urol Oncol. 2023;41:207.
    Abstract

  419. HAO Z, Dang W, Zhu Q, Xu J, et al
    Long non-coding RNA UCA1 regulates MPP(+)-induced neuronal damage through the miR-671-5p/KPNA4 pathway in SK-N-SH cells.
    Metab Brain Dis. 2023;38:961-972.
    Abstract

  420. DE JONG JJ, Pijpers OM, van Kessel KEM, Boormans JL, et al
    A Urine-based Genomic Assay Improves Risk Stratification for Patients with High-risk Hematuria Stratified According to the American Urological Association Guidelines.
    Eur Urol Oncol. 2023;6:183-189.
    Abstract

  421. KOBAYASHI G, Hayashi T, Sentani K, Ikeda K, et al
    ANXA10 Expression Is Inversely Associated with Tumor Stage, Grade, and TP53 Expression in Upper and Lower Urothelial Carcinoma.
    Pathobiology. 2023;90:94-103.
    Abstract

  422. CASAGRANDE G, Ibrahimi M, Semproni F, Iacovacci V, et al
    Hydraulic Detrusor for Artificial Bladder Active Voiding.
    Soft Robot. 2023;10:269-279.
    Abstract

  423. GAUTAM KA, Raghav A, Sankhwar SN, Singh R, et al
    Genetic Polymorphisms of Gene Methionine Synthase Reductase (MTRR) and Risk of Urinary Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:1137-1141.
    Abstract

  424. ECKE TH, Wirtz RM, Friedersdorff F, Fussel S, et al
    [Research in bladder cancer: translation into the clinic-report of 13th annual meeting of the German Research Group on Bladder Cancer (DFBK) in Berlin].
    Urologie. 2023 Apr 28. doi: 10.1007/s00120-023-02093.
    Abstract

  425. PENG C, Guo S, Yang Z, Li X, et al
    A prognostic model for bladder cancer based on cytoskeleton-related genes.
    Medicine (Baltimore). 2023;102:e33538.
    Abstract

  426. WU M, Zheng X, Wang X, Li X, et al
    The Efficacy and Safety of Tislelizumab as Adjuvant Treatment for Advanced or Metastatic Bladder Cancer in People Living With HIV: A Retrospective Multi-Center Study.
    Cancer Control. 2023;30:10732748231173475.
    Abstract

  427. AL-AZAB R, Al-Zubi M, Al Demour S, Khaled Al-Jamal S, et al
    Adherence to guidelines in the follow-up of non-muscle-invasive bladder cancer among urology trainers and trainees in Jordan: a cross-sectional study.
    Ann Med Surg (Lond). 2023;85:763-766.
    Abstract

  428. KANG Y, Park C, Lee H, Kang S, et al
    Natural Products as New Approaches for Treating Bladder Cancer: From Traditional Medicine to Novel Drug Discovery.
    Pharmaceutics. 2023;15:1117.
    Abstract

  429. ZHANG-YIN J, Girard A, Marchal E, Lebret T, et al
    PET Imaging in Bladder Cancer: An Update and Future Direction.
    Pharmaceuticals (Basel). 2023;16:606.
    Abstract

  430. WILCZAK M, Surman M, Przybylo M
    Altered Glycosylation in Progression and Management of Bladder Cancer.
    Molecules. 2023;28:3436.
    Abstract

  431. HU B, Chen R, Jiang M, Xiong S, et al
    MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer.
    Int J Mol Sci. 2023;24:7608.
    Abstract

  432. ZHU J, Tong H, Sun Y, Li T, et al
    YTHDF1 Promotes Bladder Cancer Cell Proliferation via the METTL3/YTHDF1-RPN2-PI3K/AKT/mTOR Axis.
    Int J Mol Sci. 2023;24:6905.
    Abstract

  433. PANEBIANCO V
    VI-RADS for the diagnosis and management of urinary bladder cancer.
    Eur Radiol. 2023 Apr 28. doi: 10.1007/s00330-023-09677.
    Abstract

  434. WANG Y, Ju L, Wang G, Qian K, et al
    DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC.
    Nat Commun. 2023;14:2421.
    Abstract

  435. ROBERTSON AG, Meghani K, Cooley LF, McLaughlin KA, et al
    Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer.
    Nat Commun. 2023;14:2126.
    Abstract

  436. MAGEE DE, Cheung DC, Hird AE, Chung P, et al
    Cost of Bladder Cancer Care: A Single Centre Comparison of Radical Cystectomy and Trimodal Therapy.
    Urol Pract. 2023 Apr 4:101097UPJ0000000000000403.
    Abstract

  437. SORIA F, D'Andrea D, Barale M, Gust KM, et al
    Sarcopenia Predicts Disease Progression in Patients with T1 High-grade Non-muscle-invasive Bladder Cancer Treated with Adjuvant Intravesical Bacillus Calmette-Guerin: Implications for Decision-making?
    Eur Urol Open Sci. 2023;50:17-23.
    Abstract

  438. FU Y, Liu K, Zhao L, Jiang X, et al
    Circular RNA Ubiquitin-associated Protein 2 Silencing Suppresses Bladder Cancer Progression by Downregulating DNA Topoisomerase 2-alpha Through Sponging miR-496.
    Eur Urol Open Sci. 2023;50:31-42.
    Abstract

  439. LI J, Qi Y, Li B, Liu Y, et al
    STIL/AURKA axis promotes cell proliferation by influencing primary cilia formation in bladder cancer.
    J Transl Med. 2023;21:281.
    Abstract

  440. HOLTEDAHL K, Borgquist L, Donker GA, Buntinx F, et al
    Symptoms and signs of urogenital cancer in primary care.
    BMC Prim Care. 2023;24:107.
    Abstract

  441. ADAMS-MARDI C, Sparks A, Whalen M
    Impact of Minimally Invasive Approach to Radical Cystectomy in Bladder Cancer Patients with Malnutrition.
    Nutr Cancer. 2023 Apr 26:1-6. doi: 10.1080/01635581.2023.2202432.
    Abstract

  442. GU S, Yang C
    Serum lactate dehydrogenase level predicts the prognosis in bladder cancer patients.
    BMC Urol. 2023;23:65.
    Abstract

  443. LEONG SW, Wang J, Okuda KS, Su Q, et al
    Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells.
    Eur J Med Chem. 2023;254:115335.
    Abstract

  444. HAGGSTROM C, Rowley M, Liedberg F, Coolen ACC, et al
    Latent heterogeneity of muscle-invasive bladder cancer in patient characteristics and survival: A population-based nation-wide study in the Bladder Cancer Data Base Sweden (BladderBaSe).
    Cancer Med. 2023 Apr 25. doi: 10.1002/cam4.5981.
    Abstract

  445. XU H, Lin T, Ai J, Zhang J, et al
    Utilizing the Lactate Dehydrogenase-to-Albumin Ratio for Survival Prediction in Patients with Bladder Cancer After Radical Cystectomy.
    J Inflamm Res. 2023;16:1733-1744.
    Abstract

  446. HALSTUCH D, Lotan P, Karchever I, Rubinshtein D, et al
    Single-Dose Post-Office Fulguration Mitomycin C Instillation Appears to Improve Recurrence-Free Survival in Patients With Low-Grade Noninvasive Bladder Cancer.
    Clin Genitourin Cancer. 2023 Mar 23:S1558-7673(23)00066.
    Abstract

  447. LIN Y, Li T, Li Z, Shen C, et al
    Comprehensive characterization of endoplasmic reticulum stress in bladder cancer revealing the association with tumor immune microenvironment and prognosis.
    Front Genet. 2023;14:1097179.
    Abstract

  448. JAMES C, Gomez K, Desai S, Patel HD, et al
    Impact of intravesical Bacillus Calmette-Guerin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer.
    Front Cell Infect Microbiol. 2023;13:1125809.
    Abstract

  449. ZHAO Y, Li M, Wu W, Miao W, et al
    Downregulated ESRP1/2 promotes lung metastasis of bladder carcinoma through altering FGFR2 splicing and macrophage polarization.
    Front Immunol. 2023;14:1161273.
    Abstract

  450. MARSH GM, Kruchten A
    A reevaluation of selected mortality risks in the updated NCI/NIOSH acrylonitrile cohort study.
    Front Public Health. 2023;11:1122346.
    Abstract

  451. JOYCE DD, Sharma V, Williams SB
    Cost-Effectiveness and Economic Impact of Bladder Cancer Management: An Updated Review of the Literature.
    Pharmacoeconomics. 2023 Apr 23. doi: 10.1007/s40273-023-01273.
    Abstract

  452. WU Q, Zhang H, You S, Xu Z, et al
    NEDD4L inhibits migration, invasion, cisplatin resistance and promotes apoptosis of bladder cancer cells by inactivating the p62/Keap1/Nrf2 pathway.
    Environ Toxicol. 2023 Apr 23. doi: 10.1002/tox.23796.
    Abstract

  453. MODOS O, Varadi M, Der B, Keszthelyi A, et al
    [Current diagnostic and treatment strategies for urachal cancer].
    Orv Hetil. 2023;164:602-609.
    Abstract

  454. CAI T, Lu J, Lin Z, Lup M, et al
    [Intravesical instillation of bacillus Calmette-Guerin for non-muscle invasive bladder cancer: outcomes of 421 patients in a single center].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:488-494.
    Abstract

  455. LU YT, Plets M, Morrison G, Cunha AT, et al
    Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Eur Urol Oncol. 2023 Apr 20:S2588-9311(23)00074.
    Abstract

  456. ASTUDILLO C, Garcia-Perdomo HA
    Electronic cigarette: is it a risk factor for the development of bladder cancer?
    Actas Urol Esp (Engl Ed). 2023 Apr 20:S2173-5786(23)00047.
    Abstract

  457. CHEN N, Li P, Liu L, Zhang J, et al
    Cucurbitacin IIb Extracted from Hemsleya penxianensis Induces Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells by Regulating Cell Cycle Checkpoints and Mitochondrial Apoptotic Pathway.
    Plant Foods Hum Nutr. 2023 Apr 22. doi: 10.1007/s11130-023-01058.
    Abstract

  458. YILDIZ AK, Ozgur BC, Bayraktar AS, Demir DO, et al
    How has the COVID-19 pandemic affected patients with primary bladder cancer?
    Cir Cir. 2023;91:204-211.
    Abstract

  459. YASUI M, Cui L, Miyamoto H
    Recent advances in the understanding of urothelial tumorigenesis.
    Expert Rev Anticancer Ther. 2023;23:485-493.
    Abstract

  460. SHERMAN E, Lee JL, Debruyne PR, Keam B, et al
    Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study.
    ESMO Open. 2023;8:100877.
    Abstract

  461. JING W, Chen C, Wang G, Han M, et al
    Metabolic Modulation of Intracellular Ammonia via Intravesical Instillation of Nanoporter-Encased Hydrogel Eradicates Bladder Carcinoma.
    Adv Sci (Weinh). 2023;10:e2206893.
    Abstract

  462. GUO J, Liang X, Zheng Y, Ma J, et al
    Progress in the treatment of urethral adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:2693-2698.
    Abstract

  463. SUN MY, Peng Y, Liu DW, Wang K, et al
    Ectopic prostate tissue at the bladder trigone accompanied by cystitis glandularis and hemorrhage detected by multiparametric MRI.
    Asian J Androl. 2023;25:438-439.
    Abstract

  464. ABDELRAHMAN I, Aboulkassem H, Elazab A, Abdallah AY, et al
    Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    J Egypt Natl Canc Inst. 2023;35:13.
    Abstract

  465. REESINK DJ, van Melick HHE, van der Nat PB, Los M, et al
    Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
    World J Urol. 2023 May 5. doi: 10.1007/s00345-023-04408.
    Abstract

  466. DU KL, Ji WT, Jiang QH, Wang Y, et al
    Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
    Clin Lab. 2023;69.
    Abstract

  467. JIN Y, Li J, Tang C, He K, et al
    A risk signature of necroptosis-related lncRNA to predict prognosis and probe molecular characteristics for male with bladder cancer.
    Medicine (Baltimore). 2023;102:e33664.
    Abstract

  468. NOVA-CAMACHO LM, Val-Carreres Castellote A, Villafruela Mateos A
    Xanthogranulomatous Ureteritis: A Diagnostic Challenge in a Patient with Bladder Cancer.
    Int J Surg Pathol. 2023 May 4:10668969231169049. doi: 10.1177/10668969231169049.
    Abstract

  469. JIANG YK, Situai YJ, Deng HM, Zhang H, et al
    ARID1A Inactivation Increases Expression of circ0008399 and Promotes Cisplatin Resistance in Bladder Cancer.
    Curr Med Sci. 2023 May 5. doi: 10.1007/s11596-023-2731.
    Abstract

  470. FAULK A, Avulova S, Bree KK, Baak-Kukreja J, et al
    Pelvic Organ Preservation in Non-muscle-invasive Bladder Cancer: Less Is More.
    Eur Urol Focus. 2023 May 2:S2405-4569(23)00103-7. doi: 10.1016/j.euf.2023.
    Abstract

  471. PLAIS H, Dumont C, Gauthier H, Culine S, et al
    Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series.
    Immunotherapy. 2023 May 4. doi: 10.2217/imt-2022-0283.
    Abstract

  472. LI Q, Qing L, Xu W, Yang Y, et al
    Berberine Affects the Proliferation, Migration, Invasion, Cell Cycle, and Apoptosis of Bladder Cancer Cells T24 and 5637 by Down-Regulating the HER2/PI3K/AKT Signaling Pathway.
    Arch Esp Urol. 2023;76:152-160.
    Abstract

  473. OKUCU E, Yucetas U, Karsiyakali N, Koseoglu H, et al
    Higher Serum Endothelial-Specific Molecule-1 (ESM-1/Endocan) Levels are Associated with Poor Pathological Outcomes in Primary Bladder Cancer: A Non-randomized, Prospective, Case-Control Study.
    Arch Esp Urol. 2023;76:132-138.
    Abstract

  474. SANCHEZ VERDES P, Fernandez-Pello Montes S, Gonzalez Rodriguez I, Suarez Sal PJ, et al
    Impact of a One-Stop Hematuria Clinic on Overall Survival and Bladder Tumor Recurrence.
    Arch Esp Urol. 2023;76:114-122.
    Abstract

  475. LU Y, Jiang S, Yin X, Guo J, et al
    Long-term effect of transurethral partial cystectomy with a 2-micrometer continuous-wave laser for non-muscle-invasive bladder cancer.
    Front Surg. 2023;10:1117997.
    Abstract

  476. SHI ZD, Han XX, Song ZJ, Dong Y, et al
    Integrative multi-omics analysis depicts the methylome and hydroxymethylome in recurrent bladder cancers and identifies biomarkers for predicting PD-L1 expression.
    Biomark Res. 2023;11:47.
    Abstract

  477. LONG F, Wang W, Li S, Wang B, et al
    The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer.
    J Transl Med. 2023;21:298.
    Abstract

  478. KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
    The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: A network meta-analysis.
    Urol Oncol. 2023 May 1:S1078-1439(23)00118-7. doi: 10.1016/j.urolonc.2023.
    Abstract

  479. MARTINS PR, Santos TPMD, Menezes LM, Froede AG, et al
    Association of human papillomavirus (HPV), p16, p53 and p63 expression with non-bilharzia-associated squamous cell carcinoma of the bladder and algorithm construction for histopathological grading prediction.
    Einstein (Sao Paulo). 2023;21:eAO0109.
    Abstract

  480. RASTI A, Khalili M, Fakhr Yasseri AM, Nasirian N, et al
    Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer.
    Rep Biochem Mol Biol. 2023;11:710-719.
    Abstract

  481. XIAO D, Xu S, Zhou X, Li D, et al
    Synergistic augmentation of osimertinib-induced autophagic death by proguanil or rapamycin in bladder cancer.
    MedComm (2020). 2023;4:e236.
    Abstract

  482. RAAD E, Helou S, Hage K, Daou M, et al
    Cost of bladder cancer in Lebanon before and after the economic collapse: a probabilistic modeling study.
    Int J Equity Health. 2023;22:77.
    Abstract

  483. LIU F, Han Z, Lu J, Zhong W, et al
    Development and validation of a tobacco smoking-related index for predicting overall survival and immunotherapy response in bladder cancer.
    Environ Sci Pollut Res Int. 2023 May 2. doi: 10.1007/s11356-023-27132.
    Abstract

  484. STANIMIR M, Lorge F, D'Hondt L, Nollevaux MC, et al
    Metastasis to the penis from a bladder carcinoma invading only the lamina propria: case report and description of the morphological aspects.
    Rom J Morphol Embryol. 2023;64:89-94.
    Abstract

  485. BUKAVINA L, Bell S, Packiam VT, Smaldone M, et al
    Sequential intravesical gemcitabine-docetaxel vs. bacillus Calmette-Guerin (BCG) in the treatment of non-muscle invasive bladder cancer: A preliminary cost-effectiveness analysis.
    Urol Oncol. 2023 Apr 29:S1078-1439(23)00119.
    Abstract

  486. YAN R, Shen Y, Zhang X, Xu P, et al
    Histopathological bladder cancer gene mutation prediction with hierarchical deep multiple-instance learning.
    Med Image Anal. 2023;87:102824.
    Abstract

  487. SHAHIDI M, Abazari O, Dayati P, Reza JZ, et al
    Using chitosan-stabilized, hyaluronic acid-modified selenium nanoparticles to deliver CD44-targeted PLK1 siRNAs for treating bladder cancer.
    Nanomedicine (Lond). 2023 Apr 26. doi: 10.2217/nnm-2022-0198.
    Abstract

  488. ZHANG Z, Chen P, Yun J
    Comprehensive analysis of a novel RNA modifications-related model in the prognostic characterization, immune landscape and drug therapy of bladder cancer.
    Front Genet. 2023;14:1156095.
    Abstract

  489. LI T, Hu W, Jin L, Yin X, et al
    Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases.
    Front Oncol. 2023;13:1164368.
    Abstract

  490. CHEN X, He F, Zhang W, Fu Y, et al
    Emerging trends of BCG immunotherapy for bladder cancer in last decade: a bibliometric and visualization analysis.
    Front Oncol. 2023;13:1092969.
    Abstract

  491. HUANG H, Zhang Y, Chen Z, Zeng X, et al
    Neoadjuvant therapy with Disitamab vedotin in treating muscle-invasive bladder cancer: A case report.
    Heliyon. 2023;9:e15157.
    Abstract

  492. SUN X, Dai T, Xu L
    Transurethral resection of bladder tumor-based bladder preservation therapy for refractory high risk non-muscle invasive bladder cancer: Current landscape and future directions.
    Front Surg. 2023;10:1143219.
    Abstract

  493. GAO W, Zhang J, Tian T, Fu Z, et al
    Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    PeerJ. 2023;11:e15284.
    Abstract

  494. MUNGMUNPUNTIPANTIP R, Wiwanitkit V
    Comment on "telomerase reverse transcriptase rs2736098 and rs2736100 in bladder cancer".
    Rep Pract Oncol Radiother. 2023;28:135.
    Abstract

  495. VANCAVAGE R, Siddiqui S, Bernstein A, Avulova S, et al
    Why has sexuality research in women with bladder cancer undergoing radical cystectomy been ignored for so long?
    J Sex Med. 2023;20:580-583.
    Abstract

  496. DE VRIES EGE, Ruschoff J, Lolkema M, Tabernero J, et al
    Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
    Cancer Med. 2023 Apr 29. doi: 10.1002/cam4.5893.
    Abstract

  497. MA X, Zhang L, Liu L, Ruan D, et al
    Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and Metastasis.
    Appl Biochem Biotechnol. 2023 Apr 29. doi: 10.1007/s12010-023-04512.
    Abstract

  498. PARAMANANTHAM Y, B M Said NA, Mun KS
    The correlation of EMT and p53 immunohistochemical markers with cisplatin resistance in muscle invasive bladder cancer patients: A single-centred study.
    Malays J Pathol. 2023;45:19-29.
    Abstract

  499. DU C, Zheng M, Wang Z, Zhang J, et al
    Clinical characteristics and treatment outcomes of kidney transplant recipients with de novo urothelial carcinoma: thirty years of experience from a single center.
    BMC Urol. 2023;23:71.
    Abstract

  500. ZHOU L, Xu G, Huang F, Chen W, et al
    Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
    BMC Med Genomics. 2023;16:88.
    Abstract

  501. LAI HW, Yamamoto S, Fukuhara H, Ogura SI, et al
    Cell senescence-associated porphyrin metabolism affects the efficacy of aminolevulinic acid-photodynamic diagnosis in bladder cancer.
    Photodiagnosis Photodyn Ther. 2023 Apr 26:103581.
    Abstract

  502. SOBHANI S, Ghoreifi A, Douglawi A, Ahmadi H, et al
    Perioperative mortality for radical cystectomy in the modern Era: experience from a tertiary referral center.
    Int Braz J Urol. 2023;49:351-358.
    Abstract

  503. PRIJOVIC N, Santric V, Babic U, Stankovic B, et al
    Inflammatory Myofibroblastic Tumour of the Urinary Bladder in a Middle-Aged Man-A Case Report of an Unusual Localization of a Rare Tumour.
    Medicina (Kaunas). 2023;59:791.
    Abstract

  504. LUO HL, Chang YL, Liu HY, Wu YT, et al
    VCAN Hypomethylation and Expression as Predictive Biomarkers of Drug Sensitivity in Upper Urinary Tract Urothelial Carcinoma.
    Int J Mol Sci. 2023;24:7486.
    Abstract

  505. QIAO L, Zhang L, Wang H
    SPAG9 Expression Predicts Good Prognosis in Patients with Clear-Cell Renal Cell Carcinoma: A Bioinformatics Analysis with Experimental Validation.
    Genes (Basel). 2023;14:944.
    Abstract

  506. KHANJANI N, Moradabadi A, Najafi E, Hayati B, et al
    Geographic variation in urinary tract and genital cancers in Iran: a hypothesis involving exposure to solar radiation.
    BMC Res Notes. 2023;16:65.
    Abstract

  507. XIAO XY, Zhao H, Guo HQ, Wang C, et al
    [Tumor cell-based glycolytic metabolism and single-cell sequencing of urinary exfoliated cells for the diagnosis and molecular profiling of urothelial carcinoma].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:472-479.
    Abstract

  508. ALTINTAS TASLICAY C, Sivrioglu AK
    Urinary Bladder Masslike Lesions.
    Radiographics. 2023;43:e230012.
    Abstract

  509. FARAG CM, Akosman S, Luu J, Haji-Momenian S, et al
    Hemoglobin, Albumin, Lymphocyte, and Platelet Count is a Significant Biomarker Surrogate for Nutritional Status to Predict Overall Survival in Patients Post-radical Cystectomy.
    Urol Pract. 2023;10:262-269.
    Abstract

  510. SHU TD, Prunty MC, Pominville R, Omil-Lima D, et al
    Bladder and Kidney Cancer Diagnosis and Survival Increase With Medicare Eligibility at Age 65.
    Urol Pract. 2023;10:59-65.
    Abstract

  511. ALTINTAS TASLICAY C, Cam I, Civriz AH, Kara O, et al
    18F-FDG PET-Positive Large Pelvic Granuloma Mimicking Malignant Bladder Tumor.
    Clin Nucl Med. 2023 Apr 25. doi: 10.1097/RLU.0000000000004676.
    Abstract

  512. JACKSON-SPENCE F, Toms C, O'Mahony LF, Choy J, et al
    IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery.
    Future Oncol. 2023;19:509-515.
    Abstract

  513. BAJORIN DF, Witjes JA, Gschwend JE, Schenker M, et al
    Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary.
    Future Oncol. 2023;19:413-426.
    Abstract

  514. GRIVAS P, Veeranki P, Chiu K, Pawar V, et al
    Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients.
    Future Oncol. 2023;19:369-383.
    Abstract

  515. GUZMAN SJ, Kleinschmidt-DeMasters BK
    Urothelial carcinoma metastases impacting the CNS: A 20-year retrospective series.
    Ann Diagn Pathol. 2023;64:152109.
    Abstract

  516. PEREZ-AIZPURUA X, Monzo-Gardiner JI, Maqueda-Arellano J, Buendia-Gonzalez E, et al
    BCG shortage for intravesical instillation is associated with early tumoral recurrence in patients with high-risk non-muscle invasive bladder tumours.
    Actas Urol Esp (Engl Ed). 2023;47:250-258.
    Abstract

  517. VARADI M, Nagy N, Reis H, Hadaschik B, et al
    Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomas.
    Cancer Med. 2023;12:9041-9054.
    Abstract

  518. JIANG Y, Peng Y, Ding S, Zheng Y, et al
    Kidney-sparing surgery for distal high-risk ureteral carcinoma: Clinical efficacy and preliminary experiences in 22 patients.
    Cancer Med. 2023;12:7835-7843.
    Abstract

  519. XU YK, Bai J
    Multiple urinary bladder tumors: A case report.
    Asian J Surg. 2023;46:2221-2222.
    Abstract

  520. DOMINGUEZ GARCIA A, Munoz Rodriguez J, Prats Lopez J, Almirall Daly J, et al
    Metabolic acidosis after ileal urinary diversion and radical cystectomy. Do we know as much as we think we do? A systematic review.
    Actas Urol Esp (Engl Ed). 2023;47:195-210.
    Abstract

  521. TERRITO A, Fontanet S, Meneghetti I, Gallioli A, et al
    Management of primary upper urinary tract carcinoma in situ diagnosed by ureteroscopic biopsy: Is bacillus Calmette-Guerin an alternative to nephroureterectomy?
    Actas Urol Esp (Engl Ed). 2023;47:221-228.
    Abstract

  522. ALLAEYS C, De Backer P, Decaestecker K, Berquin C, et al
    Peritoneal tuberculosis caused by intravesical instillation with Bacillus Calmette-Guerin (BCG) following nephroureterectomy in a patient with bladder and upper tract urothelial cancer: a case report.
    Acta Clin Belg. 2023;78:257-260.
    Abstract

  523. TANG YC, Yang CS, Liang MX, Zhang Y, et al
    Development and evaluation of an adenosine-to-inosine RNA editing-based prognostic model for survival prediction of bladder cancer patients.
    Medicine (Baltimore). 2023;102:e33719.
    Abstract

  524. SEILER R, Egger M, De Menna M, Wehrli S, et al
    Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial.
    BMC Urol. 2023;23:89.
    Abstract

  525. ZHANG B, Liu T, He Y, Han D, et al
    Clinical application and efficacy analysis of partial cystectomy combined with intravesical chemotherapy in muscle-invasive bladder cancer.
    BMC Urol. 2023;23:91.
    Abstract

  526. ZHENG Y, Wang X, Yang X, Xing N, et al
    Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancer.
    Cell Oncol (Dordr). 2023 May 11. doi: 10.1007/s13402-023-00820.
    Abstract

  527. NURMINEN P, Nummi A, Kesti O, Ettala O, et al
    Comparison of Bacillus Calmette-Guerin Maintenance Therapy with Monthly Instillations and the Southwest Oncology Group Protocol in the Treatment of Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 May 9:S2405-4569(23)00110-4. doi: 10.1016/j.euf.2023.
    Abstract

  528. KENNELLEY GE, Amaye-Obu T, Foster BA, Tang L, et al
    Mechanistic review of sulforaphane as a chemoprotective agent in bladder cancer.
    Am J Clin Exp Urol. 2023;11:103-120.
    Abstract

  529. BAZARGANI S, Lall C, Gopireddy DR, Liu S, et al
    Extramural venous invasion: a novel magnetic resonance imaging biomarker for adverse pathology in bladder cancer.
    Am J Clin Exp Urol. 2023;11:185-193.
    Abstract

  530. ZHANG S, Li L, Yu P, Wu C, et al
    A deep learning model for drug screening and evaluation in bladder cancer organoids.
    Front Oncol. 2023;13:1064548.
    Abstract

  531. OHTSU A, Arai S, Fujizuka Y, Fukuda R, et al
    Retroperitoneal urothelial carcinoma arising after bladder diverticulectomy: a case report.
    BMC Urol. 2023;23:88.
    Abstract

  532. HINDERBERGER P, Winters N
    Mistletoe for Bladder Cancer: Call for More Case Reports Using the Intravesical Route.
    Altern Ther Health Med. 2023;29:18-19.
    Abstract

  533. TIAN G, Li Y, Nie L, Liu S, et al
    Cervical lymph node metastasis of bladder cancer: a case report and review of literature.
    Aging Male. 2023;26:2205935.
    Abstract

  534. JIANG T, Jin P, Huang G, Li SC, et al
    The function of guanylate binding protein 3 (GBP3) in human cancers by pan-cancer bioinformatics.
    Math Biosci Eng. 2023;20:9511-9529.
    Abstract

  535. YU J, Lee J, Ha S, Baek JW, et al
    Impact of Chart-Derived Frailty Index on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
    Ann Surg Oncol. 2023 May 9. doi: 10.1245/s10434-023-13565.
    Abstract

  536. WANG L, Huang S, Zhang P, Li H, et al
    The application of gemcitabine and pirarubicin in patients with non-muscle invasive bladder cancer.
    J Cancer Res Clin Oncol. 2023 May 9. doi: 10.1007/s00432-023-04739.
    Abstract

  537. HAJEBRAHIMI S, Talebpour A, Kabiri N, Ahmadian N, et al
    Promoting post-discharge telephone follow-up of patients with transurethral resection for bladder cancer: a best practice implementation project.
    JBI Evid Implement. 2023 May 10. doi: 10.1097/XEB.0000000000000374.
    Abstract

  538. REN L, Yang X, Liu J, Wang W, et al
    An innovative model based on N7-methylguanosine-related lncRNAs for forecasting prognosis and tumor immune landscape in bladder cancer.
    Cancer Cell Int. 2023;23:85.
    Abstract

  539. LUO Y, Zhang Y, Pang S, Min J, et al
    PCBP1 protects bladder cancer cells from mitochondria injury and ferroptosis by inducing LACTB mRNA degradation.
    Mol Carcinog. 2023 May 8. doi: 10.1002/mc.23533.
    Abstract

  540. MOU Z, Chen Y, Zhang Z, Chen X, et al
    Cryoablation inhibits the recurrence and progression of bladder cancer by enhancing tumour-specific immunity.
    Clin Transl Med. 2023;13:e1255.
    Abstract

  541. ABUGOMAA A, Elbadawy M, Ishihara Y, Yamamoto H, et al
    Anti-cancer activity of Chaga mushroom (Inonotus obliquus) against dog bladder cancer organoids.
    Front Pharmacol. 2023;14:1159516.
    Abstract

  542. SHEN J, Hou H, Liang B, Guo X, et al
    Effect of renin-angiotensin-aldosterone system inhibitors on survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Front Immunol. 2023;14:1155104.
    Abstract

  543. DU Y, Liu Y, Cao J, Jiang X, et al
    LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
    Front Immunol. 2023;14:1113756.
    Abstract

  544. ZHAO S, Wang L, Ding W, Ye B, et al
    Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Front Endocrinol (Lausanne). 2023;14:1180404.
    Abstract

  545. ANWAR M, Ejaz M, Ijaz M, Ahmad G, et al
    Association of IL-17A promoter region SNP-rs2275913 with urinary bladder cancer.
    Int J Health Sci (Qassim). 2023;17:33-38.
    Abstract

  546. REVESZ J, Posfai B, Pajor L, Papdan T, et al
    Correlation between fibroblast growth factor receptor mutation, programmed death ligand-1 expression and survival in urinary bladder cancer based on real-world data.
    Pathol Oncol Res. 2023;29:1611077.
    Abstract

  547. WANG H, Gao Y, Qin L, Zhang M, et al
    Identification of a novel de novo mutation of SETBP1 and new findings of SETBP1 in tumorgenesis.
    Orphanet J Rare Dis. 2023;18:107.
    Abstract

  548. LORENZO JF, Lopez Arquillo IM, Rey JV
    Primary aortoenteric fistula after intravesical instillation of Bacillus Calmette-Guerin for bladder cancer.
    Vascular. 2023 May 6:17085381231174923. doi: 10.1177/17085381231174923.
    Abstract

  549. NAIK M, Rao BV, Challa S, Fonseca D, et al
    Utility of GATA-3 and associated immunohistochemical markers in the differential diagnosis of poorly differentiated urothelial carcinoma.
    J Cancer Res Ther. 2023;19.
    Abstract

  550. AHMAD U, Abdullah S, Chau M, Chia SL, et al
    Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer.
    Sci Rep. 2023;13:7323.
    Abstract

  551. CZECH AK, Gronostaj K, Fronczek J, Frydrych J, et al
    Diagnostic accuracy of bimanual palpation in bladder cancer patients undergoing cystectomy: A prospective study.
    Urol Oncol. 2023 May 3:S1078-1439(23)00122-9. doi: 10.1016/j.urolonc.2023.
    Abstract

  552. HSIEH TY, Sung WW, Chang YC, Yu CY, et al
    Melatonin induces cell cycle arrest and suppresses tumor invasion in urinary bladder urothelial carcinoma.
    Aging (Albany NY). 2023;15:3107-3119.
    Abstract

  553. JANA S, Brahma S, Arora S, Wladyka CL, et al
    Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression.
    Cancer Cell. 2023;41:853-870.
    Abstract

  554. BOLENZ C, Zengerling F
    [Neoadjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma: current evidence].
    Urologie. 2023;62:522-524.
    Abstract

  555. DAVIS D, Seely D, Morash C, Armstrong J, et al
    Complete Remission of BCG-Refractory High-grade Bladder CIS with Pharmacologic Ascorbate and Mistletoe.
    Altern Ther Health Med. 2023;29:6-17.
    Abstract

  556. ROUPRET M, Brouquet A, Colrat F, Diez-Andreu P, et al
    Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
    World J Urol. 2023;41:1069-1075.
    Abstract

  557. VAN WIJNGAARDEN C, Bus MTJ, Ruiter AEC, Lagerveld BW, et al
    A 6-month maintenance schedule of mitomycin C after radical nephroureterectomy for upper tract urothelial carcinoma for the prevention of intravesical recurrence: a retrospective, single center study.
    World J Urol. 2023;41:1077-1083.
    Abstract

  558. DENG Y, Fu Y, Chua SL, Khoo BL, et al
    Biofilm Potentiates Cancer-Promoting Effects of Tumor-Associated Macrophages in a 3D Multi-Faceted Tumor Model.
    Small. 2023;19:e2205904.
    Abstract

  559. KE C, Hu Z, Yang C
    Preoperative accuracy of diagnostic evaluation of urachal carcinoma.
    Cancer Med. 2023;12:9106-9115.
    Abstract

  560. MORI K, Yanagisawa T, Katayama S, Laukhtina E, et al
    Impact of sex on outcomes after surgery for non-muscle-invasive and muscle-invasive bladder urothelial carcinoma: a systematic review and meta-analysis.
    World J Urol. 2023;41:909-919.
    Abstract

  561. DICKMAN KG, Chen CH, Grollman AP, Pu YS, et al
    Aristolochic acid-containing Chinese herbal medicine and upper urinary tract urothelial carcinoma in Taiwan: a narrative review.
    World J Urol. 2023;41:899-907.
    Abstract

  562. MURTHY V, Maitre P, Singh M, Pal M, et al
    Study Protocol of the Bladder Adjuvant RadioTherapy (BART) Trial: A Randomised Phase III Trial of Adjuvant Radiotherapy Following Cystectomy in Bladder Cancer.
    Clin Oncol (R Coll Radiol). 2023 May 5:S0936-6555(23)00178.
    Abstract

  563. YANG Y, Bai Y, Wang X, Guo Y, et al
    Clock gene NR1D1 might be a novel target for the treatment of bladder cancer.
    Urol Oncol. 2023 May 18:S1078-1439(23)00141.
    Abstract

  564. KUSMARTSEV S, Ku JH, Grizzi F
    Editorial: Tumor microenvironment in bladder cancer.
    Front Oncol. 2023;13:1208196.
    Abstract

  565. WANG Y, Xie K, Chen W, Fang Y, et al
    Synergistic ferroptosis-starvation therapy for bladder cancer based on hyaluronic acid modified metal-organic frameworks.
    Bioeng Transl Med. 2023;8:e10515.
    Abstract

  566. WEINBERG MS, Zafar A, Magdamo C, Chung SY, et al
    Association of BCG Vaccine Treatment With Death and Dementia in Patients With Non-Muscle-Invasive Bladder Cancer.
    JAMA Netw Open. 2023;6:e2314336.
    Abstract

  567. CHANTAPRASOPSUK S, Rees-Punia E, Patel AV
    Physical activity, obesity, and bladder cancer incidence.
    Cancer Causes Control. 2023 May 18. doi: 10.1007/s10552-023-01711.
    Abstract

  568. DAVARO F, Jain R, Li R
    Immune Checkpoint Inhibitor Toxicity Management in Non-muscle-invasive Bladder Cancer: What Urologists Need To Know.
    Eur Urol Focus. 2023 May 16:S2405-4569(23)00109.
    Abstract

  569. REN D, Li L, Wang S, Zuo Y, et al
    The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells.
    Tissue Cell. 2023;82:102096.
    Abstract

  570. ZHAO F, Yang T, Zhou L, Li R, et al
    Sig1R activates extracellular matrix-induced bladder cancer cell proliferation and angiogenesis by combing beta-integrin.
    Aging (Albany NY). 2023;15.
    Abstract

  571. WARRICK JI, Al-Ahmadie H, Berman DM, Black PC, et al
    International Society of Urological Pathology Consensus Conference on Current Issues in Bladder Cancer. Working Group 4: Molecular Subtypes of Bladder Cancer-Principles of Classification and Emerging Clinical Utility.
    Am J Surg Pathol. 2023 May 18. doi: 10.1097/PAS.0000000000002053.
    Abstract

  572. WANG J, Shi H, Fan Z, Yang J, et al
    Prognostic nutritional index combined with NLR to construct a survival prediction model and decision analysis of patients with muscle-invasive bladder cancer after surgery.
    Cancer Med. 2023 May 18. doi: 10.1002/cam4.6088.
    Abstract

  573. DAS S, Gu L, Eve CT, Parrish J, et al
    The Impact of Blue Light Cystoscopy Use Among Nonmuscle Invasive Bladder Cancer Patients in an Equal Access Setting: Implications on Recurrence and Time to Recurrence.
    Clin Genitourin Cancer. 2023 Apr 28:S1558-7673(23)00098.
    Abstract

  574. HEINZELBECKER J, Spieler N, Kuehn M, Fischer C, et al
    Adjuvant vs. progression-triggered treatment with gemcitabine in platinum-ineligible high-risk bladder cancer patients: Long-term follow-up of a randomized phase 3 trial.
    Urol Oncol. 2023 May 15:S1078-1439(23)00134.
    Abstract

  575. ZHANG C, Xiao J, Yuan T, He Y, et al
    Molecular vasculogenic mimicry-Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts.
    Front Pharmacol. 2023;14:1163115.
    Abstract

  576. SHADAB R, Nerli RB, Bidi SR, Ghagane SC, et al
    Risk Factors for Bladder Cancer: Results of a Survey of Hospital Patients.
    J Cancer Allied Spec. 2023;9:485.
    Abstract

  577. KIMURA T, Ishikawa H, Nagumo Y, Sekino Y, et al
    Efficacy and safety of Bladder Preservation Therapy in combination with Atezolizumab and Radiation Therapy (BPT-ART) for invasive bladder cancer: Interim analysis from a multicenter, open-label, prospective phase II trial.
    Int J Radiat Oncol Biol Phys. 2023 May 15:S0360-3016(23)00461.
    Abstract

  578. LIN J, Zhan X, Chen R, Chen T, et al
    Increased Burden of Second Bladder Cancer and Rectal Cancer in Prostate Cancer Treated With Radiotherapy: Results From Surveillance, Epidemiology, and End Results.
    Cancer Control. 2023;30:10732748231177544.
    Abstract

  579. BOU ZERDAN M, Bratslavsky G, Jacob J, Ross J, et al
    Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
    Mol Diagn Ther. 2023 May 17. doi: 10.1007/s40291-023-00647.
    Abstract

  580. VAN STRATEN CGJI, Bruins MH, Dijkstra S, Cornel EB, et al
    The accuracy of cystoscopy in predicting muscle invasion in newly diagnosed bladder cancer patients.
    World J Urol. 2023 May 17. doi: 10.1007/s00345-023-04428.
    Abstract

  581. CELIK S, Gokbayrak O, Erol A, Yorukoglu K, et al
    Anna Karenina principle in personalized treatment of bladder cancer according to oncogram: which drug for which patient?
    Per Med. 2023 May 17. doi: 10.2217/pme-2022-0134.
    Abstract

  582. STRAUSS D, Kaplunov B, Kutikov A, Geynisman DM, et al
    Between the Hammer and Anvil: Resolution of unresectable muscle invasive bladder cancer in a renal transplant patient after cessation of immunosuppressive therapy.
    Urol Case Rep. 2023;48:102399.
    Abstract

  583. AN MH, Kim MS, Kim C, Noh TI, et al
    Association of 5alpha-Reductase Inhibitor Prescription With Bladder Cancer Progression in Males in South Korea.
    JAMA Netw Open. 2023;6:e2313667.
    Abstract

  584. RELOUW S, Dugbartey GJ, Sener A
    Non-Invasive Imaging Modalities in Intravesical Murine Models of Bladder Cancer.
    Cancers (Basel). 2023;15:2381.
    Abstract

  585. LEDDEROSE S, Rodler S, Eismann L, Ledderose G, et al
    P2X1 and P2X7 Receptor Overexpression Is a Negative Predictor of Survival in Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:2321.
    Abstract

  586. EL AZZOUZI M, El Ahanidi H, Hafidi Alaoui C, Chaoui I, et al
    The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer.
    Diagnostics (Basel). 2023;13:1471.
    Abstract

  587. LI X, Li L, Xiong X, Kuang Q, et al
    Identification of the Prognostic Biomarkers CBX6 and CBX7 in Bladder Cancer.
    Diagnostics (Basel). 2023;13:1393.
    Abstract

  588. VANEMAN J, van Beekhuizen HJ, Boormans JL, Ewing-Graham PC, et al
    Pelvic lymph node dissection for cervical or bladder cancer: embedding residual fat tissue offers no added value.
    Virchows Arch. 2023 May 15. doi: 10.1007/s00428-023-03559.
    Abstract

  589. LINDSKROG SV, Schmokel SS, Nordentoft I, Lamy P, et al
    Single-nucleus and Spatially Resolved Intratumor Subtype Heterogeneity in Bladder Cancer.
    Eur Urol Open Sci. 2023;51:78-88.
    Abstract

  590. VON DEIMLING M, Mertens LS, van Rhijn BWG, Lotan Y, et al
    Carboplatin Induction Chemotherapy in Clinically Lymph Node-positive Bladder Cancer.
    Eur Urol Open Sci. 2023;51:39-46.
    Abstract

  591. ZLOTTA AR, Ballas LK, Niemierko A, Lajkosz K, et al
    Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.
    Lancet Oncol. 2023 May 12:S1470-2045(23)00170.
    Abstract

  592. ARAYA M, Ishikawa H, Nishioka K, Maruo K, et al
    Proton beam therapy for muscle-invasive bladder cancer: A systematic review and analysis with Proton-Net, a multicenter prospective patient registry database.
    J Radiat Res. 2023 Apr 25:rrad027. doi: 10.1093.
    Abstract

  593. BLOUDEK L, Wright P, McKay C, Derleth CL, et al
    Systematic Literature Review (SLR) and Network Meta-Analysis (NMA) of First-Line Therapies (1L) for Locally Advanced/Metastatic Urothelial Carcinoma (la/mUC).
    Curr Oncol. 2023;30:3637-3647.
    Abstract

  594. YU J, Lee J, Ha S, Baek JW, et al
    ASO Visual Abstract: Impact of Chart-Derived Frailty Index (CFI) on 1-Year Mortality After Radical Cystectomy in 1004 Patients with Bladder Cancer.
    Ann Surg Oncol. 2023 May 15. doi: 10.1245/s10434-023-13618.
    Abstract


  595. Chen, Y, Zhang, W, Kadier, A, Zhang, H, Yao, X. MicroRNA-769-5p suppresses cell growth and migration via targeting NUSAP1 in bladder cancer. J Clin Lab Anal. 2020; 34:e23193.
    J Clin Lab Anal. 2023 May 14:e24893. doi: 10.1002/jcla.24893.
    Abstract

  596. ISHII M, Yamamoto Y, Yoshimura A, Hayashi T, et al
    [A Case of Primary Signet Ring Cell Carcinoma of the Urinary Bladder Showing Effectiveness of Chemotherapy with Gemcitabine and Cisplatin].
    Hinyokika Kiyo. 2023;69:107-112.
    Abstract

  597. HU B, Chen R, Jiang M, Xiong S, et al
    EIF4A3 serves as a prognostic and immunosuppressive microenvironment factor and inhibits cell apoptosis in bladder cancer.
    PeerJ. 2023;11:e15309.
    Abstract

  598. GU L, Guo H, Wu LX, Yuan JB, et al
    Prognostic analysis and validation of lncRNAs in bladder cancer on the basis of neutrophil extracellular traps.
    J Gene Med. 2023 May 13:e3525. doi: 10.1002/jgm.3525.
    Abstract

  599. GUDOWSKA-SAWCZUK M, Kudelski J, Olkowicz M, Mlynarczyk G, et al
    The Clinical Significance of Serum Free Light Chains in Bladder Cancer.
    J Clin Med. 2023;12:3294.
    Abstract

  600. MALKIEWICZ B, Jedrzejuk D, Gurwin A, Wilk K, et al
    Diagnostic Value of the Sentinel Lymph Node Technique in Patients with Muscle-Invasive Bladder Cancer.
    J Clin Med. 2023;12:3092.
    Abstract

  601. RYU D, Kim TM, Lee YH, Ha US, et al
    Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer.
    Int J Mol Sci. 2023;24:8418.
    Abstract

  602. SZYDLAK R, Ovreeide IH, Luty M, Zielinski T, et al
    Bladder Cancer Cells Interaction with Lectin-Coated Surfaces under Static and Flow Conditions.
    Int J Mol Sci. 2023;24:8213.
    Abstract

  603. PACKEISER EM, Engels L, Nolte I, Goericke-Pesch S, et al
    MDR1 Inhibition Reverses Doxorubicin-Resistance in Six Doxorubicin-Resistant Canine Prostate and Bladder Cancer Cell Lines.
    Int J Mol Sci. 2023;24:8136.
    Abstract

  604. GANDIN V, Hoeschele JD, Margiotta N
    Special Issue "Cisplatin in Cancer Therapy: Molecular Mechanisms of Action 3.0".
    Int J Mol Sci. 2023;24:7917.
    Abstract

  605. KUBIK A, das Virgens IPA, Szabo A, Varadi M, et al
    Comprehensive Analysis of the Prognostic Value of Circulating MMP-7 Levels in Urothelial Carcinoma: A Combined Cohort Analysis, Systematic Review, and Meta-Analysis.
    Int J Mol Sci. 2023;24:7859.
    Abstract

  606. GRANT SR, Tang L, Wei L, Foster BA, et al
    Mutation Hotspots Found in Bladder Cancer Aid Prediction of Carcinogenic Risk in Normal Urothelium.
    Int J Mol Sci. 2023;24:7852.
    Abstract

  607. MIYAKE M, Nishimura N, Ohnishi S, Oda Y, et al
    Diagnostic and Prognostic Roles of Urine Nectin-2 and Nectin-4 in Human Bladder Cancer.
    Cancers (Basel). 2023;15:2565.
    Abstract

  608. NIE Z, Gao Y, Chen M, Peng Y, et al
    Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
    Cancers (Basel). 2023;15:2487.
    Abstract

  609. WANG Z, Zhao C, Li Y, Wang J, et al
    Photostable Cascade Activatable Peptide Self-assembly on a Cancer Cell Membrane for High-Performance Identification of Human Bladder Cancer.
    Adv Mater. 2023 May 12:e2210732. doi: 10.1002/adma.202210732.
    Abstract

  610. LI TY, Zhang B, Zhang J
    A case report and literature review on primary solitary fibrous tumor of the bladder.
    Medicine (Baltimore). 2023;102:e33708.
    Abstract

  611. HABIL MR, Hein DW
    Effects of dose and human N-acetyltransferase 1 genetic polymorphism in benzidine metabolism and genotoxicity.
    Arch Toxicol. 2023;97:1765-1772.
    Abstract

  612. PENG L, Mehmud I, Meng C, Tang D, et al
    ASO Author Reflections: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3817-3818.
    Abstract

  613. EGGER V, Hutterer GC, Mischinger J, Seles M, et al
    Preoperative fibrinogen/CRP score predicts survival in upper urothelial tract carcinoma patients undergoing radical curative surgery.
    World J Urol. 2023;41:1359-1364.
    Abstract

  614. LEE JL, Desai C, Park SH, Tsuchiya N, et al
    Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Urol Oncol. 2023;41:256.
    Abstract

  615. BUSETTO GM, Finati M, Chirico M, Cinelli F, et al
    Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?
    World J Urol. 2023;41:1329-1335.
    Abstract

  616. KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
    The efficacy of ultrasonography for the detection of upper tract urothelial carcinoma.
    J Med Ultrason (2001). 2023;50:197-203.
    Abstract

  617. PYCHA S, Trenti E, Mian C, Schwienbacher C, et al
    Diagnostic value of Xpert(R) BC Detection, Bladder Epicheck(R), Urovysion(R) FISH and cytology in the detection of upper urinary tract urothelial carcinoma.
    World J Urol. 2023;41:1323-1328.
    Abstract

  618. PENG L, Mehmud I, Meng C, Tang D, et al
    ASO Visual Abstract: Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3819.
    Abstract

  619. PENG L, Mehmud I, Meng C, Tang D, et al
    Comparison of Perioperative Outcomes and Complications of Laparoscopic and Robotic Nephroureterectomy Approaches in Patients with Upper-Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2023;30:3805-3816.
    Abstract

  620. PARIMI V, Choi W, Feng M, Fong M, et al
    Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
    Histopathology. 2023;82:991-1002.
    Abstract

  621. JIN J, Li J, Peng C, Chen J, et al
    Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment.
    Anticancer Drugs. 2023;34:797-802.
    Abstract

  622. ROUMIGUIE M, Wong A, Belanger E, Wang G, et al
    Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design.
    Urol Oncol. 2023;41:254.
    Abstract

  623. MIURA H, Hatakeyama S, Tanaka T, Fujita N, et al
    Oncological and functional outcomes of female reproductive organ-sparing radical cystectomy and ileal neobladder construction.
    Urol Oncol. 2023;41:254.
    Abstract

  624. MORTON E, Kaul S, Fleishman A, Korets R, et al
    Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection.
    Urol Oncol. 2023;41:255.
    Abstract

  625. MAISCH P, Koll F, Bolenz C, Chun FK, et al
    Combination of radiation and immunotherapy in the treatment of genitourinary malignancies: A systematic review and meta-analysis.
    Urol Oncol. 2023;41:219-232.
    Abstract

  626. KUCKUCK EC, Hennenlotter J, Todenhofer T, Brunn LA, et al
    Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria.
    Urol Oncol. 2023;41:254.
    Abstract

  627. NEUMANN I, Borrelli M, Al Kallaa M, Parker RT, et al
    Rare periorbital, pseudocystic metastasis of squamous cell carcinoma of the bladder: Case report and review of the literature.
    Orbit. 2023;42:336-342.
    Abstract

  628. TYAGI P, Moon CH, Connell M, Ganguly A, et al
    Intravesical Contrast-Enhanced MRI: A Potential Tool for Bladder Cancer Surveillance and Staging.
    Curr Oncol. 2023;30:4632-4647.
    Abstract

  629. BITAM S, Hamadache M, Hanini S
    Targeting bladder cancer with Trigonella foenum-graecum: a computational study using network pharmacology and molecular docking.
    J Biomol Struct Dyn. 2023 May 26:1-8. doi: 10.1080/07391102.2023.2217926.
    Abstract

  630. ZHAO J, Li J, Zhang R
    Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer.
    Biochim Biophys Acta Rev Cancer. 2023 May 23:188926.
    Abstract

  631. LI W, Wang Z, Jiang Z, Yan Y, et al
    MiR-3960 inhibits bladder cancer progression via targeting of DEXI.
    Biochem Biophys Res Commun. 2023;668:8-18.
    Abstract

  632. OSSOLINSKI K, Ruman T, Copie V, Tripet BP, et al
    Targeted and untargeted urinary metabolic profiling of bladder cancer.
    J Pharm Biomed Anal. 2023;233:115473.
    Abstract

  633. WIRTZ HS, Hepp Z, Grewal S, Wright P, et al
    Health care resource utilization, quality metrics, and costs of bladder cancer within the Oncology Care Model.
    Am J Manag Care. 2023;29:e136-e142.
    Abstract

  634. BENABDALLAH W, Ben Othmane M, Ouahchi I, Mestiri S, et al
    Plasmacytoid bladder cancer: a rare case report.
    Ann Med Surg (Lond). 2023;85:1885-1887.
    Abstract

  635. MIRTO BF, Scafuri L, Sicignano E, Luca C, et al
    Nature's hidden gem: quercitrin's promising role in preventing prostate and bladder cancer.
    Future Sci OA. 2023;9:FSO867.
    Abstract

  636. BAUDEWYNS A, Jabbour T, Bourgeno HA, Peltier A, et al
    Late-onset enteric fistula following radical cystectomy for bladder cancer: A case report.
    Urol Case Rep. 2023;49:102431.
    Abstract

  637. HRBACEK J, Hanacek V, Kadleckova D, Cirbusova A, et al
    Urinary shedding of common DNA viruses and their possible association with bladder cancer: a qPCR-based study.
    Neoplasma. 2023;70:311-318.
    Abstract

  638. UCHIDA H, Obinata D, Takada S, Yoshizawa T, et al
    Real-world retrospective review of monotherapy following platinum-based chemotherapy for metastatic urothelial cancer.
    J Int Med Res. 2023;51:3000605231173319.
    Abstract

  639. MAAS M, Todenhofer T, Black PC
    Urine biomarkers in bladder cancer - current status and future perspectives.
    Nat Rev Urol. 2023 May 24. doi: 10.1038/s41585-023-00773.
    Abstract

  640. HUDDART R, Hafeez S, Omar A, Alonzi R, et al
    Acute Toxicity of Hypofractionated and Conventionally Fractionated (Chemo)Radiotherapy Regimens for Bladder Cancer: An Exploratory Analysis from the RAIDER Trial.
    Clin Oncol (R Coll Radiol). 2023 May 9:S0936-6555(23)00180.
    Abstract

  641. JOHANNSEN M, Klier J, Konig F, Schonfelder R, et al
    [National Registries for Urothelial Cancer (UroNAT) and Prostate Cancer (ProNAT) by d-uo].
    Aktuelle Urol. 2023;54:202-207.
    Abstract

  642. DOEHN C, Johannsen M, Eichenauer R, Klier J, et al
    [The cancer registry notification seen from the perspective of the German Society of Uro-Oncologists (d-uo)].
    Aktuelle Urol. 2023;54:189-195.
    Abstract


  643. [Not Available].
    Aktuelle Urol. 2023;54:185.
    Abstract

  644. DE JONG FC, Laajala TD, Hoedemaeker RF, Jordan KR, et al
    Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Guerin.
    Sci Transl Med. 2023;15:eabn4118.
    Abstract

  645. DENG Z, Dong W, Xiong S, Jin D, et al
    Machine learning models combining computed tomography semantic features and selected clinical variables for accurate prediction of the pathological grade of bladder cancer.
    Front Oncol. 2023;13:1166245.
    Abstract

  646. LONATI C, Soria F, Pradere B, D'Andrea D, et al
    Comment on: "Accuracy of the European Association of Urology (EAU) NMIBC 2021 scoring model in predicting progression in a large cohort of HG T1 NMIBC patients treated with BCG".
    Minerva Urol Nephrol. 2023;75:407-409.
    Abstract

  647. ASERO V, Scornajenghi CM, Krajewski W, Szydelko T, et al
    Comment on: "Animal model assessment of a new design for a coated mitomycin-eluting biodegradable ureteral stent for intracavitary instillation as an adjuvant therapy in upper urothelial carcinoma".
    Minerva Urol Nephrol. 2023;75:401-403.
    Abstract

  648. KHODADADI F, Khorashadizadeh M, Ghasemi F
    Thymoquinone enhanced the antitumor activity of cisplatin in human bladder cancer 5637 cells in vitro.
    Mol Biol Rep. 2023 May 23. doi: 10.1007/s11033-023-08472.
    Abstract

  649. DE LIMA CSA, Rial-Hermida MI, de Freitas LF, Pereira-da-Mota AF, et al
    Mucoadhesive gellan gum-based and carboxymethyl cellulose -based hydrogels containing gemcitabine and papain for bladder cancer treatment.
    Int J Biol Macromol. 2023 May 20:124957. doi: 10.1016/j.ijbiomac.2023.124957.
    Abstract

  650. LIU SS, Li JS, Xue M, Wu WJ, et al
    LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
    Int J Biol Sci. 2023;19:2599-2612.
    Abstract

  651. XIE S, He J, Feng B, Rao D, et al
    A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer.
    Heliyon. 2023;9:e15897.
    Abstract

  652. SCHELTES DA, van der Steen-Banasik EM, Smits GAHJ
    Quality of life of muscle-invasive bladder cancer patients after brachytherapy-based treatment: A cross-sectional study.
    J Contemp Brachytherapy. 2023;15:110-116.
    Abstract

  653. WANG X, Zhang Y, Wu Y, Cheng H, et al
    The role of E3 ubiquitin ligases and deubiquitinases in bladder cancer development and immunotherapy.
    Front Immunol. 2023;14:1202633.
    Abstract

  654. LIU H, Xiang P, Miao W, Liu H, et al
    Analysis of the Regulatory Effect of ACTG2 on Biological Behavior of Bladder Cancer Cells Based on Database Screening.
    Cell Mol Biol (Noisy-le-grand). 2023;69:125-130.
    Abstract

  655. LIU H, Wang X, Guo Z, Sun G, et al
    LncRNA BCLET variant confers bladder cancer susceptibility through alternative splicing of MSANTD2 exon 1.
    Cancer Med. 2023 May 21. doi: 10.1002/cam4.6072.
    Abstract

  656. SARAVANABAVAN S, Prakash GJ, Joshi A, Pal M, et al
    Patterns of Utilization and Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced-urothelial Bladder Cancer (LABC)-Real World Data From an Indian Tertiary Care Cancer Center.
    Clin Genitourin Cancer. 2023 Apr 11:S1558-7673(23)00082.
    Abstract

  657. CHUNG R, Moran GW, Movassaghi M, Pohl D, et al
    Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy.
    Urol Oncol. 2023 May 18:S1078-1439(23)00137.
    Abstract

  658. SANYA DRA, Onesime D
    Roles of non-coding RNAs in the metabolism and pathogenesis of bladder cancer.
    Hum Cell. 2023 May 20. doi: 10.1007/s13577-023-00915.
    Abstract

  659. YUAN H, Xiu Y, Liu T, Fan Y, et al
    The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma.
    Front Immunol. 2023;14:1126247.
    Abstract

  660. HUA X, Li J, Shang M, He W, et al
    Pathogenesis of psoriasis via miR-149-5p/AKT1axis by long noncoding RNA BLACAT1.
    Skin Res Technol. 2023;29:e13339.
    Abstract

  661. WIECZOREK E, Wolniakowska A, Roszak J, Rodrigues RM, et al
    Gene-occupation interactions: a review of the literature on bladder and prostate cancer.
    Med Pr. 2023;74:127-144.
    Abstract

  662. TAPPERO S, Cano Garcia C, Incesu RB, Piccinelli ML, et al
    Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy.
    Surg Oncol. 2023;48:101947.
    Abstract

  663. TAN WS, Tan MY, Alhalabi O, Campbell MT, et al
    Evolving systemic management of urothelial cancers.
    Curr Opin Oncol. 2023;35:186-199.
    Abstract

  664. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Regional differences in total hospital costs for radical cystectomy in the United States.
    Surg Oncol. 2023;48:101924.
    Abstract

  665. LO YC, Bauer AH, Odintsov I, Siegmund SE, et al
    Integrating Molecular Sequencing Into the Pathological Diagnosis of Clinically Suspected Non-Small Cell Lung Carcinomas.
    Mod Pathol. 2023;36:100126.
    Abstract

  666. MUSANGILE FY, Matsuzaki I, Iwamoto R, Sagan K, et al
    Targeted Next-Generation Sequencing of Flat Urothelial Lesions Reveals Putative Pathobiological Pathways, Potential Biomarkers, and Rational Therapeutic Targets.
    Mod Pathol. 2023;36:100120.
    Abstract

  667. BASU M, Mukhopadhyay D, Chakraborty B, Ghosh S, et al
    Differential operation of MLH1/MSH2 and FANCD2 crosstalk in chemotolerant bladder carcinoma: a clinical and therapeutic intervening study.
    Mol Cell Biochem. 2023;478:1599-1610.
    Abstract

  668. BRAVI CA, Piazza P, Mazzone E, Dell'Oglio P, et al
    Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up.
    J Robot Surg. 2023;17:1143-1150.
    Abstract

  669. VISWAMBARAM P, McCombie SP, Hawks C, Wallace DMA, et al
    Centralization and prospective audit of cystectomy are necessary: a commentary on the case for centralization, supported by a contemporary series utilizing the ANZUP cystectomy database.
    Asia Pac J Clin Oncol. 2023;19:290-295.
    Abstract

  670. YAMADA Y, Ikeda M, Hirayama T, Murakami Y, et al
    Noninferior oncological outcomes in adults aged 80 years or older compared with younger patients who underwent radical nephroureterectomy for upper tract urothelial carcinoma.
    Asia Pac J Clin Oncol. 2023;19:305-311.
    Abstract

  671. GELLRICH AL, Eraky A, Hamann C, Hugelmann K, et al
    [Cystectomy of a young patient with squamous cell metaplasia of the bladder and manifestation of condyloma].
    Aktuelle Urol. 2023;54:223-227.
    Abstract

  672. BAIRD B, Bilgili A, Anderson A, Carames G, et al
    Oncological outcomes of visibly complete transurethral resection prior to neoadjuvant chemotherapy for bladder cancer.
    Int Braz J Urol. 2023;49:479-489.
    Abstract

  673. ELSAYED DH, Elfarargy OM, Elderey MS, Mandour D, et al
    Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.
    Contemp Oncol (Pozn). 2023;27:1-9.
    Abstract

  674. YANG C, Li Q, Chen X, Zhang Z, et al
    Correction for: Circular RNA circRGNEF promotes bladder cancer progression via miR-548/KIF2C axis regulation.
    Aging (Albany NY). 2023;undefined.
    Abstract

  675. RETZ M, Kirchhoff FP, von Amsberg G, De Santis M, et al
    [Sequential therapy of advanced bladder cancer after prior perioperative systemic treatment : Recommendations from the Interdisciplinary Bladder Carcinoma Working Group (IABC) of the DKG e. V.].
    Urologie. 2023 Jun 1. doi: 10.1007/s00120-023-02098.
    Abstract

  676. LIU Y, Hu B, Pei X, Li J, et al
    A non-G-Quadruplex DNA Aptamer Targeting NCL for Diagnosis and Therapy in Bladder Cancer.
    Adv Healthc Mater. 2023 Jun 1:e2300791. doi: 10.1002/adhm.202300791.
    Abstract

  677. MACDONALD A, Mehrnoush V, Ismail A, Di Matteo L, et al
    History of infantile BCG immunization did not predict lamina propria invasion and/or high-grade in patients with non-muscle invasive bladder cancer.
    Arch Ital Urol Androl. 2023 May 31:11380. doi: 10.4081/aiua.2023.11380.
    Abstract

  678. ZHANG L, Liu B, Deng QH, Li JX, et al
    Retraction Note: LncRNA BRE-AS1 acts as a tumor suppressor factor in bladder cancer via mediating STAT3.
    Eur Rev Med Pharmacol Sci. 2023;27:4326.
    Abstract

  679. VAN HOOGSTRATEN LMC, Man CCO, Witjes JA, Meijer RP, et al
    Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    World J Urol. 2023 May 31:1-9. doi: 10.1007/s00345-023-04443.
    Abstract

  680. YAN B, Li X, Peng M, Zuo Y, et al
    The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression.
    Exp Mol Med. 2023 Jun 1. doi: 10.1038/s12276-023-00997.
    Abstract

  681. CHAPPIDI MR, Escobar D, Meng MV, Washington SL 3rd, et al
    Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols.
    Urol Oncol. 2023 May 29:S1078-1439(23)00172.
    Abstract

  682. WANG D, Liu Y
    Comment on "The prognostic impact of tumor necrosis in non-muscle invasive bladder cancer".
    Rev Assoc Med Bras (1992). 2023;69:e20230295.
    Abstract

  683. SIREGAR GP, Parwati I, Noegroho BS, Safridai F, et al
    The association between serum hypoxia inducible factor-1alpha level and urothelial bladder cancer: A preliminary study.
    Arch Ital Urol Androl. 2023 May 29:11292. doi: 10.4081/aiua.2023.11292.
    Abstract

  684. SOHNGEN C, Thomas DJ, Skowron MA, Bremmer F, et al
    CD24 targeting with NK-CAR immunotherapy in testis, prostate, renal and (luminal-type) bladder cancer and identification of direct CD24 interaction partners.
    FEBS J. 2023 May 31. doi: 10.1111/febs.16880.
    Abstract

  685. ZHANGHUANG C, Zhang Z, Wang J, Yao Z, et al
    Surveillance of prognostic risk factors in patients with SCCB using artificial intelligence: a retrospective study.
    Sci Rep. 2023;13:8727.
    Abstract

  686. ZENG N, Xu MY, Sun JX, Liu CQ, et al
    Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette-Guerin instillation in non-muscle-invasive bladder cancer: a network meta-analysis.
    Front Oncol. 2023;13:1164932.
    Abstract

  687. DU Y, Miao W, Jiang X, Cao J, et al
    Corrigendum: The epithelial to mesenchymal transition related gene calumenin is an adverse prognostic factor of bladder cancer correlated with tumor microenvironment remodeling, gene mutation, and ferroptosis.
    Front Oncol. 2023;13:1185029.
    Abstract

  688. UEMATSU R, Teishima J, Sakata H, Mita Y, et al
    Peritoneal and pulmonary tuberculosis following intravesical administration of Bacillus Calmette-Guerin for bladder cancer.
    Int Cancer Conf J. 2023;12:221-225.
    Abstract

  689. KONO S, Hashimoto Y, Shirai Y, Kunihiro Y, et al
    A long-term survival case of bladder cancer with distant metastases: abscopal effect of brain metastases after stereotactic radiotherapy with immune checkpoint blockade therapy to lung metastases.
    Int Cancer Conf J. 2023;12:205-209.
    Abstract

  690. DOLNY M, Czajkowski M, Czajkowska K, Sokolowska-Wojdylo M, et al
    Penile metastasis secondary to urothelial bladder cancer.
    Urol Case Rep. 2023;49:102428.
    Abstract

  691. TORTORA D, Roberts ME, Kumar G, Kotapalli SS, et al
    A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer.
    iScience. 2023;26:106525.
    Abstract

  692. COSTA L, Alexandre T, Mansinho A, Sousa R, et al
    Health outcomes and budget impact projection of anti-PD-(L)1s in cancer care in Portugal.
    Front Public Health. 2023;11:1133959.
    Abstract

  693. ZHANG ZC, Zhao HF, Sun Z, Li Y, et al
    Tripartite motif-containing 9 promoted proliferation and migration of bladder cancer cells through CEACAM6-Smad2/3 axis.
    J Cell Commun Signal. 2023 May 30. doi: 10.1007/s12079-023-00766.
    Abstract

  694. LIU Y, Yu H, Zeng B, Gou X, et al
    miR-383-5p serves as a tumor suppressor in bladder cancer by suppressing PI3K/AKT signaling pathway.
    Cancer Biomark. 2023 May 18. doi: 10.3233/CBM-220379.
    Abstract

  695. ZHU PY, Wang L, Li KP, Yin S, et al
    Perioperative and oncologic outcomes of transperitoneal versus retroperitoneal laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and pooled analysis of comparative outcomes.
    World J Surg Oncol. 2023;21:163.
    Abstract

  696. MALALASEKERA A, Neththikumara N, Somasundaram P, Pathirana S, et al
    Clinical Exome Gene Panel Analysis of a Cohort of Urothelial Bladder Cancer Patients from Sri Lanka.
    Asian Pac J Cancer Prev. 2023;24:1533-1542.
    Abstract

  697. CHEN Y, Zhang Y, Wang X, Qiao S, et al
    Methylseleninic acid induces apoptosis of human bladder cancer cells through the ROS-mediated mitochondrial pathway.
    J Biochem Mol Toxicol. 2023 May 29:e23387. doi: 10.1002/jbt.23387.
    Abstract

  698. DOWNES MR, Hartmann A, Shen S, Tsuzuki T, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1: Comparison of Bladder Cancer Grading System Performance.
    Am J Surg Pathol. 2023 May 29. doi: 10.1097/PAS.0000000000002059.
    Abstract

  699. ZHANG N, Bian Q, Gao Y, Wang Q, et al
    The Role of Fascin-1 in Human Urologic Cancers: A Promising Biomarker or Therapeutic Target?
    Technol Cancer Res Treat. 2023;22:15330338231175733.
    Abstract

  700. GALLUZZO A, Danti G, Bicci E, Mastrorosato M, et al
    The Role of Dual-Energy CT in the Study of Urinary Tract Tumors: Review of Recent Literature.
    Semin Ultrasound CT MR. 2023;44:136-144.
    Abstract

  701. SHI X, Dong A, Yang Y, Zheng G, et al
    Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    J Cancer Res Clin Oncol. 2023 May 27. doi: 10.1007/s00432-023-04881.
    Abstract

  702. CLAPS F, Rossin G, van Rhijn BWG, Mir MC, et al
    The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer.
    Medicina (Kaunas). 2023;59:926.
    Abstract

  703. MOHANTY SK, Lobo A, Mishra SK, Cheng L, et al
    Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
    J Pers Med. 2023;13:756.
    Abstract

  704. EINERHAND SMH, Zuur LG, Wondergem MJ, Boellaard TN, et al
    The Implementation of FDG PET/CT for Staging Bladder Cancer: Changes in the Detection and Characteristics of Occult Nodal Metastases at Upfront Radical Cystectomy?
    J Clin Med. 2023;12:3367.
    Abstract

  705. SZALLASI A
    "ThermoTRP" Channel Expression in Cancers: Implications for Diagnosis and Prognosis (Practical Approach by a Pathologist).
    Int J Mol Sci. 2023;24:9098.
    Abstract

  706. WATANABE R, Miura N, Kurata M, Kitazawa R, et al
    Spatial Gene Expression Analysis Reveals Characteristic Gene Expression Patterns of De Novo Neuroendocrine Prostate Cancer Coexisting with Androgen Receptor Pathway Prostate Cancer.
    Int J Mol Sci. 2023;24:8955.
    Abstract

  707. SMITH V, Lee D, Reardon M, Shabbir R, et al
    Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;24:8956.
    Abstract

  708. OKUNO Y, Hattori-Kato M, Tanaka H, Tonooka A, et al
    Relationship between the Reduced Expression of Zinc Finger Protein 668 in Bladder Cancer and Its Invasiveness.
    Int J Mol Sci. 2023;24:8668.
    Abstract

  709. WANG BR, Chang WS, Liao CH, Wang YC, et al
    Impacts of Mir146a Genotypes on Bladder Cancer Risk in Taiwan.
    Biomedicines. 2023;11:1396.
    Abstract

  710. SPIRITO L, Maturi R, Credendino SC, Manfredi C, et al
    Differential Expression of LncRNA in Bladder Cancer Development.
    Diagnostics (Basel). 2023;13:1745.
    Abstract

  711. STRAUSS J, Deville JL, Sznol M, Ravaud A, et al
    First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma.
    J Immunother Cancer. 2023;11:e005813.
    Abstract

  712. JIANG LJ, Guo SB, Huang ZY, Li XL, et al
    PHB promotes bladder cancer cell epithelial-mesenchymal transition via the Wnt/beta-catenin signaling pathway.
    Pathol Res Pract. 2023;247:154536.
    Abstract

  713. YANG CH, Hsu CY, Lin YS, Tung MC, et al
    One-Step Robot-Assisted Complete Urinary Tract Extirpation in Man with End-Stage Renal Disease on Dialysis: The First Case Report.
    Curr Oncol. 2023;30:5093-5102.
    Abstract

  714. DAI S, Liu C, Jiang Z, Teng X, et al
    Three-port approach vs conventional laparoscopic radical cystectomy with orthotopic neobladder: a single-center retrospective study.
    World J Surg Oncol. 2023;21:160.
    Abstract

  715. SAVELEVA MS, Lobanov ME, Gusliakova OI, Plastun VO, et al
    Mucoadhesive Emulsion Microgels for Intravesical Drug Delivery: Preparation, Retention at Urothelium, and Biodistribution Study.
    ACS Appl Mater Interfaces. 2023;15:25354-25368.
    Abstract

  716. TANG Q, Li S, Huang G, Liu H, et al
    Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
    Int Immunopharmacol. 2023;119:110158.
    Abstract

  717. ANIS O, Yogev D, Dotan A, Tsur AM, et al
    Autoimmune disorders caused by intravesical bacillus Calmette-Guerine treatment: A systematic review.
    Autoimmun Rev. 2023;22:103329.
    Abstract

  718. ZHONG B, Wang Y, Liao Y, Liang J, et al
    MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
    Apoptosis. 2023;28.
    Abstract

  719. BAHCECI D, Nguyen JK, Sangoi AR, Stohr BA, et al
    Urothelial carcinoma in situ with "overriding" features can evade detection by mimicking umbrella cells.
    Hum Pathol. 2023;136:56-62.
    Abstract

  720. GONZALEZ N, Rao N, Dean M, Lee D, et al
    Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors.
    Cancer Epidemiol Biomarkers Prev. 2023;32:840-847.
    Abstract

  721. SU R, Chen Z, Hong D, Jiang S, et al
    Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study.
    Cancer Med. 2023;12:10587-10596.
    Abstract

  722. MOON JH, Nikas IP, Moon KC, Kim B, et al
    Clinical application of the anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) immunocytochemistry in liquid-based urine cytology: A prospective, single institute study.
    Cancer Med. 2023;12:10363-10370.
    Abstract

  723. TURAL D, Arslan C, Selcukbiricik F, Olmez OF, et al
    Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice.
    Clin Genitourin Cancer. 2023;21:334-341.
    Abstract

  724. PATEL KN, Salunke A, Sharma M, Puj K, et al
    Development and Internal Validation of a Nomogram Predicting Overall Survival Based on Log ODDS of Positive Lymph-Nodes for Post Radical Cystectomy Patients in Muscle Invasive Carcinoma of Bladder.
    Clin Genitourin Cancer. 2023;21:e153-e165.
    Abstract

  725. GELLINGS P, Galeas-Pena M, Morici LA
    Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.
    Clin Exp Med. 2023;23:519-527.
    Abstract

  726. ZHENG P, Wu K, Gao Z, Li H, et al
    [Retracted] KIF4A promotes the development of bladder cancer by transcriptionally activating the expression of CDCA3.
    Int J Mol Med. 2023;52:62.
    Abstract

  727. VAN DER KWAST TH, Bubendorf L, Cheng L
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Progresses and Challenges.
    Am J Surg Pathol. 2023 Jun 8. doi: 10.1097/PAS.0000000000002066.
    Abstract

  728. ZHOU H, Wang P, Qin X, Zhang X, et al
    Comparative transcriptomic analysis and mechanistic characterization revealed the use of formononetin for bladder cancer treatment.
    Food Funct. 2023 Jun 8. doi: 10.1039/d2fo03962.
    Abstract

  729. VOLZ Y, Trappmann R, Ebner B, Eismann L, et al
    Absence of detrusor muscle in TUR-BT specimen - can we predict who is at highest risk?
    BMC Urol. 2023;23:106.
    Abstract

  730. ERDIK A, Cimen HI, Kose O, Ates OF, et al
    Can pelvic diameter measurement have an effect on surgical outcomes in radical cystectomy?
    BMC Urol. 2023;23:105.
    Abstract

  731. LU J, Li X, Chen M, Yang P, et al
    Perivesical Fat Invasive Pattern as Prognostic Factor and Predictor of Response to Adjuvant Chemotherapy in T3 Stage Bladder Cancer.
    Clin Genitourin Cancer. 2023 May 7:S1558-7673(23)00105.
    Abstract

  732. PETRAUSCH U, Spahn M, Schneider M, Hayoz S, et al
    Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol
    BMJ Open. 2023;13:e067634.
    Abstract

  733. ZHANG W, Mao S, Shi D, Zhang J, et al
    Corrigendum: MicroRNA-153 decreases tryptophan catabolism and inhibits angiogenesis in bladder cancer by targeting indoleamine 2,3-dioxygenase 1.
    Front Oncol. 2023;13:1208728.
    Abstract

  734. XU C, Zou W, Zhang L, Xu R, et al
    Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer.
    Front Immunol. 2023;14:1162580.
    Abstract

  735. WU W, Chen L, Jia G, Tang Q, et al
    Inhibition of FGFR3 upregulates MHC-I and PD-L1 via TLR3/NF-kB pathway in muscle-invasive bladder cancer.
    Cancer Med. 2023 Jun 7. doi: 10.1002/cam4.6172.
    Abstract

  736. XU C, Chen A, Mao C, Cui B, et al
    Construction of prognostic risk model of bladder cancer based on cuproptosis-related long non-coding RNAs.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:139-147.
    Abstract

  737. LINDNER AK, Lackner F, Tymoszuk P, Barth DA, et al
    Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
    Biol Sex Differ. 2023;14:38.
    Abstract

  738. WU R, Teng X, Song Q, Chen S, et al
    Single-cell RNA sequencing reveals sexual diversity in the human bladder and its prospective impacts on bladder cancer and urinary tract infection.
    BMC Med Genomics. 2023;16:122.
    Abstract

  739. ZHENG J, Miao F, Wang Z, Ma Y, et al
    Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
    Life Sci. 2023 Jun 3:121832. doi: 10.1016/j.lfs.2023.121832.
    Abstract

  740. YANG CJ, Tan ZL, Yang JD, Hsu FT, et al
    Fluoxetine inactivates STAT3/NF-kappaB signaling and promotes sensitivity to cisplatin in bladder cancer.
    Biomed Pharmacother. 2023;164:114962.
    Abstract

  741. DONG Y, Xu C, Su G, Li Y, et al
    Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and in vitro validation.
    Front Immunol. 2023;14:1122570.
    Abstract

  742. HERRANZ R, Oto J, Hueso M, Plana E, et al
    Bladder cancer patients have increased NETosis and impaired DNaseI-mediated NET degradation that can be therapeutically restored in vitro.
    Front Immunol. 2023;14:1171065.
    Abstract

  743. DERGAMOUN H, El Gdaouni A, Taoufik A, Ziouziou I, et al
    Inflammatory myofibroblastic tumor of the urinary bladder: a case report.
    Pan Afr Med J. 2023;44:119.
    Abstract

  744. LIU X, Li X, Kuang Q, Luo H, et al
    Screening of immunotherapy-related genes in bladder cancer based on GEO datasets.
    Front Oncol. 2023;13:1176637.
    Abstract

  745. KAGAMI LP, Goncalves IL, da Silva AC, Silva AC, et al
    LaSOM 335, active against bladder cancer cells, interferes with Let-60 (hRas) and reduces CD73 expression/activity.
    Chem Biol Drug Des. 2023 Jun 5. doi: 10.1111/cbdd.14273.
    Abstract

  746. SODA T, Tashiro Y, Koike S, Ikeuchi R, et al
    Evaluation of incidence, predictive factors and treatment considerations for asymptomatic genitourinary granulomas after intravesical bacillus Calmette-Guerin therapy.
    Actas Urol Esp (Engl Ed). 2023;47:317-326.
    Abstract

  747. WANG S, Ge C
    High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid.
    J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04867.
    Abstract

  748. LICHTBROUN B, Srivastava A, Ghodoussipour S
    A Restaging Transurethral Resection of Bladder Tumor Is Always Necessary For High-grade T1 Non-muscle-invasive Bladder Cancer.
    Eur Urol Focus. 2023 Jun 1:S2405-4569(23)00121-9. doi: 10.1016/j.euf.2023.
    Abstract

  749. WU S, Hong G, Lin T
    Artificial intelligence-based model for lymph node metastases detection in bladder cancer - Authors' reply.
    Lancet Oncol. 2023;24:e234.
    Abstract

  750. MAI Z, Zhou Y, Zhou Z, Yan W, et al
    Artificial intelligence-based model for lymph node metastases detection in bladder cancer.
    Lancet Oncol. 2023;24:e233.
    Abstract

  751. ZOU K, Lu M, Peng Y, Tang X, et al
    Artifical intelligence-based model for lymph node metastases detection in bladder cancer.
    Lancet Oncol. 2023;24:e232.
    Abstract

  752. WANG C, Liu T, Wang J, Cheng C, et al
    CircHIPK3 negatively regulates autophagy by blocking VCP binding to the Beclin 1 complex in bladder cancer.
    Discov Oncol. 2023;14:86.
    Abstract

  753. SUN YF, Chen L, Xia QJ, Wang TH, et al
    Identification of necroptosis-related long non-coding RNAs prognostic signature and the crucial lncRNA in bladder cancer.
    J Cancer Res Clin Oncol. 2023 Jun 3. doi: 10.1007/s00432-023-04886.
    Abstract

  754. CHEN C, Chao Y, Zhang C, Hu W, et al
    TROP2 translation mediated by dual m(6)A/m(7)G RNA modifications promotes bladder cancer development.
    Cancer Lett. 2023 May 31:216246. doi: 10.1016/j.canlet.2023.216246.
    Abstract

  755. HUANG EY, Tai MC, Chung HJ, Chang YH, et al
    Effects of different combinations of radical nephroureterectomy and bladder cuff excision procedures for upper tract urothelial carcinoma on bladder recurrence.
    Int Braz J Urol. 2023;49:469-478.
    Abstract

  756. KRANZ J, Hoffmann M, Alexa R, Kuppe C, et al
    [Urothelial carcinoma of the upper urinary tract].
    Urologie. 2023;62:640-650.
    Abstract

  757. GAVRILOVSKA-BRZANOV A, Seidi S, Stavridis S, Ivanovski O, et al
    Obturator Nerve Block for Transurethral Resection of Bladder Tumors.
    Med Arch. 2023;77:118-122.
    Abstract

  758. KARTTUNEN E, Oldenburg J, Thoresen S, Ullen A, et al
    Response to M. Brehmer: Register-based research. Accurate data and analysis, crucial for correct conclusions. Comment on 'Incidence, mortality, and relative survival of patients with cancer of the bladder and upper urothelial tract in the Nordic count
    Scand J Urol. 2023;58:20.
    Abstract

  759. CHEN X, Cheng Y, Tian X, Li J, et al
    Urinary microbiota and metabolic signatures associated with inorganic arsenic-induced early bladder lesions.
    Ecotoxicol Environ Saf. 2023;259:115010.
    Abstract

  760. SONG Y, Xu T
    Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder.
    World J Urol. 2023;41:1697-1698.
    Abstract

  761. MAGOON R, Jose J, Suresh V
    Assessing postradical cystectomy outcomes in the enhanced recovery era: "enhancing" the corresponding research outlook.
    Urol Oncol. 2023;41:292.
    Abstract

  762. VAHLENSIECK W
    [Interstitial cystitis/bladder pain syndrome (IC/BPS)].
    Urologie. 2023;62:582-589.
    Abstract

  763. KUMAR R, Matulewicz R, Mari A, Moschini M, et al
    Impact of smoking on urologic cancers: a snapshot of current evidence.
    World J Urol. 2023;41:1473-1479.
    Abstract

  764. BRUCH PG, Plage H, Hofbauer S, Kornienko K, et al
    Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder.
    Exp Mol Pathol. 2023;131:104860.
    Abstract

  765. DIAMANTOPOULOS LN, Makrakis D, Korentzelos D, Alevizakos M, et al
    Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma.
    Urol Oncol. 2023;41:296.
    Abstract

  766. ZHU Y, Geng Z, Lin Q
    Primary intestinal adenocarcinoma after orthotopic ileal neobladder.
    Asian J Surg. 2023;46:2321-2322.
    Abstract

  767. HARVEY SE, VandenBussche CJ
    Nuclear membrane irregularity in high-grade urothelial carcinoma cells can be measured by using circularity and solidity as morphometric shape definitions in digital image analysis of urinary tract cytology specimens.
    Cancer Cytopathol. 2023;131:351-359.
    Abstract

  768. CHIN CP, Smith WH, Cesaretti J, Terk M, et al
    Clinical and treatment characteristics of secondary bladder malignancies following low dose rate brachytherapy for prostate cancer.
    Urol Oncol. 2023;41:296.
    Abstract

  769. BAI SJ, Chen XB, Zeng TB
    Treatment progress of cystitis glandularis.
    Asian J Surg. 2023;46:2444.
    Abstract

  770. SHEN H, Lv C
    Multiple primary trans-systemic triple carcinoma: A rare case report.
    Asian J Surg. 2023;46:2466-2467.
    Abstract

  771. BAIRD BA, Taylor T, Brennan E, Borkar S, et al
    Disparities in access to high-volume centers and in hospital discharge status following radical cystectomy in Florida.
    Urol Oncol. 2023;41:294.
    Abstract

  772. FONTANET S, Gallioli A, Baboudjian M, Huguet J, et al
    Topical instillation of BCG immunotherapy for biopsy-proven primary upper urinary tract carcinoma in situ: A single institution series and systematic review.
    Urol Oncol. 2023;41:274-283.
    Abstract

  773. DUDINEC JV, Ortiz-Melo DI, Lipkin ME, Abern MR, et al
    Advanced chronic kidney disease; A comparison between nephroureterectomy and nephron-sparing surgery for upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:295.
    Abstract

  774. TAI P, Wang Z, Chen X, Chen A, et al
    Multi-omics analysis of the oncogenic value of copper Metabolism-Related protein COMMD2 in human cancers.
    Cancer Med. 2023;12:11941-11959.
    Abstract

  775. VELEZ TORRES JM, Gonzalez ML, Duarte EM, Zein-Sabatto B, et al
    Urine Cytology Findings in Cases of Pseudocarcinomatous Urothelial Hyperplasia of the Bladder Often Represent a Diagnostic Challenge.
    Arch Pathol Lab Med. 2023;147:716-721.
    Abstract

  776. YOO Y, Kim JM, Choi E, Park HS, et al
    The Effect of Complete Prostate Examination of Radical Cystoprostatectomy Specimen on the Final Stage of Urothelial Carcinoma of the Urinary Bladder and the Detection of Prostate Cancer.
    Arch Pathol Lab Med. 2023;147:665-675.
    Abstract

  777. SHI T, Yuan Z, He Y, Zhang D, et al
    Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer.
    Cell Oncol (Dordr). 2023 Jun 16. doi: 10.1007/s13402-023-00823.
    Abstract

  778. LIU X, Wu Y, Zhou Z, Huang M, et al
    [Corrigendum] Celecoxib inhibits the epithelial‑to‑mesenchymal transition in bladder cancer via the miRNA‑145/TGFBR2/Smad3 axis.
    Int J Mol Med. 2023;52:64.
    Abstract

  779. CHEN H, Yang W, Li Y, Ma L, et al
    Leveraging a disulfidptosis-based signature to improve the survival and drug sensitivity of bladder cancer patients.
    Front Immunol. 2023;14:1198878.
    Abstract

  780. XUE Y, Zhao G, Pu X, Jiao F, et al
    Construction of T cell exhaustion model for predicting survival and immunotherapy effect of bladder cancer based on WGCNA.
    Front Oncol. 2023;13:1196802.
    Abstract

  781. BOOT IWA, Wesselius A, Yu EYW, White E, et al
    Dietary vitamin D intake and the bladder cancer risk: A pooled analysis of prospective cohort studies.
    Clin Nutr. 2023 May 22:S0261-5614(23)00152-8. doi: 10.1016/j.clnu.2023.
    Abstract

  782. YANG X, Zhang S, He J, Zhao L, et al
    Brazilin inhibits bladder cancer by promoting cell necroptosis.
    Clin Exp Pharmacol Physiol. 2023 Jun 15. doi: 10.1111/1440-1681.13800.
    Abstract

  783. GALLAGHER K, Bhatt N, Clement K, Zimmermann E, et al
    Audit, Feedback, and Education to Improve Quality and Outcomes in Transurethral Resection and Single-Instillation Intravesical Chemotherapy for Nonmuscle Invasive Bladder Cancer Treatment: Protocol for a Multicenter International Observational Study W
    JMIR Res Protoc. 2023;12:e42254.
    Abstract

  784. LIU S, Liu Z, Shang A, Xun J, et al
    CD44 is a potential immunotherapeutic target and affects macrophage infiltration leading to poor prognosis.
    Sci Rep. 2023;13:9657.
    Abstract

  785. STEELE TM, Tsamouri MM, Siddiqui S, Lucchesi CA, et al
    Cisplatin-induced increase in heregulin 1 and its attenuation by the monoclonal ErbB3 antibody seribantumab in bladder cancer.
    Sci Rep. 2023;13:9617.
    Abstract

  786. STONE BV, Labban M, Filipas DK, Beatrici E, et al
    The Risk of Catastrophic Healthcare Expenditures Among Prostate and Bladder Cancer Survivors in the United States.
    Clin Genitourin Cancer. 2023 May 27:S1558-7673(23)00135.
    Abstract

  787. LU XS, Huang ML, Chen LB, Liu SC, et al
    SCARA5 as a downstream factor of PCAT29, inhibits proliferation, migration, and invasion of bladder cancer.
    Genomics. 2023 Jun 12:110667. doi: 10.1016/j.ygeno.2023.110667.
    Abstract

  788. JIANG C, Perimbeti S, Deng L, Xing J, et al
    Medicaid Expansion and Racial Disparity in Timely Multidisciplinary Treatment in Muscle Invasive Bladder Cancer.
    J Natl Cancer Inst. 2023 Jun 14:djad112. doi: 10.1093.
    Abstract

  789. WANG L, Qi F, Bi L, Yan J, et al
    Targeted hollow pollen silica nanoparticles for enhanced intravesical therapy of bladder cancer.
    Biomater Sci. 2023 Jun 14. doi: 10.1039/d3bm00631.
    Abstract

  790. DALJIT T, Melgandi W, Ansari FA, Rathi AK, et al
    Cutaneous metastasis in bladder cancer.
    J Cancer Res Ther. 2023;19:501-504.
    Abstract

  791. ALAM MN, Agrawal S, Rastogi N, Saxena R, et al
    Chemotherapy or chemotherapy followed by consolidation chemoradiation in postoperative (simple cholecystectomy) gall bladder cancer with residual disease, unsuitable for revision surgery? Risk stratification and outcomes.
    J Cancer Res Ther. 2023;19:259-264.
    Abstract

  792. WU C, Duan L, Li H, Liu X, et al
    PD1(hi) CD200(hi) CD4(+) exhausted T cell increase immunotherapy resistance and tumour progression by promoting epithelial-mesenchymal transition in bladder cancer.
    Clin Transl Med. 2023;13:e1303.
    Abstract

  793. AL-HUMAIRI RMA, Hashim Mohammad T, Thanoon Ahmed S, Ad'hiah AH, et al
    Systemic Interleukin-6 Response after Intravesical Instillation of Bacillus Calmette-Guerin and Mitomycin C in Superficial Bladder Cancer.
    Arch Razi Inst. 2023;78:353-360.
    Abstract

  794. NAMIKI S, Ueda S, Takeuchi Y, Kawase M, et al
    [A Case of Refractory Lymphatic Leakage after Robot-Assisted Radical Cystectomy].
    Hinyokika Kiyo. 2023;69:137-142.
    Abstract

  795. WANG Y, Song Y, Qin C, Zhang C, et al
    Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysis of eight retrospective cohort studies.
    BMC Anesthesiol. 2023;23:201.
    Abstract

  796. ROUPRET M, Burger M, Stenzl A
    Letter to the Editor on the systematic review "Narrow band imaging versus white light cystoscopy alone for transurethral resection of non-muscle invasive bladder cancer".
    World J Urol. 2023 Jun 13. doi: 10.1007/s00345-023-04435.
    Abstract

  797. KIM JY, Yoon JH, Yoo KB, Lee WR, et al
    Disparity of Bladder Cancer Incidence among Male Workers across Industries: A Population-based Cohort Study from South Korea.
    J Occup Environ Med. 2023 Jun 12. doi: 10.1097/JOM.0000000000002907.
    Abstract

  798. WANG H, Ma X, Li S, Su J, et al
    KIF20A as a potential biomarker of renal and bladder cancers based on bioinformatics and experimental verification.
    Aging (Albany NY). 2023;15.
    Abstract

  799. CHEN Y, Huang M, Lu J, Zhang Q, et al
    Establishment of a prognostic model to predict chemotherapy response and identification of RAC3 as a chemotherapeutic target in bladder cancer.
    Environ Toxicol. 2023 Jun 13. doi: 10.1002/tox.23860.
    Abstract

  800. KUKREJA JB
    Non-muscle-invasive Bladder Cancer: Side-by-Side Guideline Comparison.
    Eur Urol Focus. 2023 Jun 10:S2405-4569(23)00115.
    Abstract

  801. CHEN Y, Yin L, Hao M, Xu W, et al
    Medicarpin induces G1 arrest and mitochondria-mediated intrinsic apoptotic pathway in bladder cancer cells.
    Acta Pharm. 2023;73:211-225.
    Abstract

  802. LIU B, Dan W, Wei Y, Zhang Y, et al
    beta-asarone inhibits the migration, invasion, and EMT of bladder cancer through activating ER stress.
    Cancer Med. 2023 Jun 12. doi: 10.1002/cam4.6059.
    Abstract

  803. LIU YS, Thaliffdeen R, Han S, Park C, et al
    Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review.
    Expert Rev Pharmacoecon Outcomes Res. 2023.
    Abstract

  804. HONG KU, Hein DW
    N-acetyltransferase 2 haplotype modifies risks for both dyslipidemia and urinary bladder cancer.
    Pharmacogenet Genomics. 2023 May 29. doi: 10.1097/FPC.0000000000000500.
    Abstract

  805. FAN X, He W, Huang J
    Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives.
    Transl Androl Urol. 2023;12:802-808.
    Abstract

  806. HAO L, Fang J, Xu R, Liu S, et al
    Significance of the FGFR3 mutation in Chinese patients with bladder cancer.
    Transl Androl Urol. 2023;12:761-769.
    Abstract

  807. HU W, Zhang Y, Ning J, Li M, et al
    Corrigendum to "Anti-tumor effect of AZD8055 against bladder cancer and bladder cancer-associated macrophages" [Heliyon 9(3) (March 2023) e14272].
    Heliyon. 2023;9:e15303.
    Abstract

  808. NASSIR A, Saada H, Bakry S, Al-Zahrani S, et al
    Assessment of the knowledge and awareness of urinary bladder cancer among the general population in Western Saudi Arabia.
    Urol Ann. 2023;15:220-225.
    Abstract

  809. ALBAKRI M, Abu-Hijlih R, Salah S, Al-Ibraheem A, et al
    Bladder cancer in young adults: Disease and treatment characteristics of patients treated at a tertiary cancer center.
    Urol Ann. 2023;15:207-210.
    Abstract

  810. VILLOLDO GM, Pombo MT, Aris M, Chemi J, et al
    A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Guerin in patients with non-muscle invasive bladder carcinoma: A retrospective study.
    Oncol Res. 2023;31:207-220.
    Abstract

  811. ERIKSSON P, Berg J, Bernardo C, Bobjer J, et al
    Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection.
    Eur Urol Open Sci. 2023;53:78-82.
    Abstract

  812. YIN J, Cai G, Wang H, Chen W, et al
    SIRT4 is an independent prognostic factor in bladder cancer and inhibits bladder cancer growth by suppressing autophagy.
    Cell Div. 2023;18:9.
    Abstract

  813. XU PH, Chen S, Wang Y, Jin S, et al
    FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
    Comput Biol Med. 2023;162:106976.
    Abstract

  814. XIA Z, Wang Q, Lu P
    LncRNA LINC00885 promotes bladder cancer progression by targeting the miR-98-5p/PBX3 axis.
    Cell Mol Biol (Noisy-le-grand). 2023;69:163-168.
    Abstract

  815. KHOURY R, Saleh K, Khalife N, Saleh M, et al
    Mechanisms of Resistance to Antibody-Drug Conjugates.
    Int J Mol Sci. 2023;24:9674.
    Abstract

  816. PAPASAVVA M, Amvrosiou S, Pilala KM, Soureas K, et al
    Deregulated Expression of IL-37 in Patients with Bladder Urothelial Cancer: The Diagnostic Potential of the IL-37e Isoform.
    Int J Mol Sci. 2023;24:9258.
    Abstract

  817. MEHUS AA, Jones M, Trahan M, Kinnunen K, et al
    Pevonedistat Inhibits SOX2 Expression and Sphere Formation but Also Drives the Induction of Terminal Differentiation Markers and Apoptosis within Arsenite-Transformed Urothelial Cells.
    Int J Mol Sci. 2023;24:9149.
    Abstract

  818. ZHENG Q, Jian J, Wang J, Wang K, et al
    Predicting Lymph Node Metastasis Status from Primary Muscle-Invasive Bladder Cancer Histology Slides Using Deep Learning: A Retrospective Multicenter Study.
    Cancers (Basel). 2023;15:3000.
    Abstract

  819. BACCHIANI M, Salamone V, Massaro E, Sandulli A, et al
    Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence.
    Cancers (Basel). 2023;15:2951.
    Abstract

  820. SU YL, Xiao LY, Huang SY, Wu CC, et al
    Inhibiting WEE1 Augments the Antitumor Efficacy of Cisplatin in Urothelial Carcinoma by Enhancing the DNA Damage Process.
    Cells. 2023;12:1471.
    Abstract

  821. NOEL OD, Stewart E, Cress R, Dall'Era MA, et al
    Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006-2018: Effect of race, age and socioeconomic status on treatment disparities.
    Urol Oncol. 2023 Jun 8:S1078-1439(23)00194-1. doi: 10.1016/j.urolonc.2023.
    Abstract

  822. ALI MY, Aboelsaad AY, Abdel Gawad AM, Abouelgreed TA, et al
    HER2/neu expression status of post BCG recurrent non-muscle-invasive bladder urothelial carcinomas in relation to their primary ones.
    Arch Ital Urol Androl. 2023;95:11313.
    Abstract

  823. GRIZZI F, Chiriva-Internati M, Miranda E, Zaharie R, et al
    Sperm protein antigen 17 and Sperm flagellar 1 cancer testis antigens are expressed in a rare case of ciliated foregut cyst of the common hepatic duct.
    Pathol Res Pract. 2023;247:154546.
    Abstract

  824. CISTERNINO A, Capone L, Rosati A, Latiano C, et al
    New concept in urologic surgery: The total extended genital sparing radical cystectomy in women.
    Arch Ital Urol Androl. 2023;95:11058.
    Abstract

  825. NAGAHISA C, Unagami K, Banno T, Oki R, et al
    Kidney Transplantation After Multiple Urinary Tract Conversion with an Ileal Conduit: A Case Report.
    Transplant Proc. 2023 May 14:S0041-1345(23)00252.
    Abstract

  826. HANZE J, Schulte-Herbruggen J, Hofmann R, Hegele A, et al
    Modulation of immune checkpoint regulators in interferon gamma induced urothelial carcinoma and activated T-lymphocyte cells by cytostatics.
    Genes Immun. 2023;24:149-153.
    Abstract

  827. DELL'OGLIO P, Tappero S, Panunzio A, Antonelli A, et al
    Age represents the main driver of surgical decision making in patients candidate to radical cystectomy.
    J Surg Oncol. 2023;128:142-154.
    Abstract

  828. AMIR M, Javed S
    Elucidation of binding dynamics of tyrosine kinase inhibitor tepotinib, to human serum albumin, using spectroscopic and computational approach.
    Int J Biol Macromol. 2023;241:124656.
    Abstract

  829. SPARWASSER P, Frey L, Fischer ND, Thomas A, et al
    First Comparison of Retroperitoneal Versus Transperitoneal Robot-Assisted Nephroureterectomy with Bladder Cuff: A Single Center Study.
    Ann Surg Oncol. 2023;30:4531-4539.
    Abstract

  830. MATSUKAWA A, Kimura S, Koike Y, Ajisaka S, et al
    Feasibility of Novel Technique of Flexible Cystoscopic En Bloc Snare Resection of Bladder Tumor: f-ESRBT.
    J Endourol. 2023;37:713-717.
    Abstract

  831. SAKUMO K, Morihashi K, Nakamura A, Nukaya T, et al
    The usefulness of nuclear area in the diagnosis of high-grade urothelial carcinoma cells in voided urine cytology.
    Cytopathology. 2023;34:295-301.
    Abstract

  832. CHEN M, Yao K, Cao M, Liu H, et al
    HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study.
    Cancer Immunol Immunother. 2023;72:2309-2318.
    Abstract

  833. NIELSEN TJ, Varga MG, Cronister CT, Ring BZ, et al
    The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort.
    Cancer Immunol Immunother. 2023;72:2075-2086.
    Abstract

  834. YAMADA S, Miyata H, Isono M, Hori K, et al
    Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
    Cancer Immunol Immunother. 2023;72:2057-2065.
    Abstract

  835. CHOUDHURY S, Kamble V, Jana D, Pal DK, et al
    Thulium laser enucleation of bladder tumour (Thulebt): Changing paradigm in the management of nonmuscle invasive urinary bladder carcinoma.
    Urologia. 2023;90:266-271.
    Abstract

  836. SAMI MM, Sherief MH, El-Abaseri TB, El-Sakka AI, et al
    Expression of epidermal growth factor receptor and human epidermal growth factor receptor 2 in urothelial bladder carcinoma in an Egyptian cohort: Clinical implication and prognostic significance.
    Urologia. 2023;90:248-260.
    Abstract

  837. FISCHER AH, Wong JY, Baris D, Koutros S, et al
    Urine pH and Risk of Bladder Cancer in Northern New England.
    Cancer Epidemiol Biomarkers Prev. 2023 Jun 23:EPI-22-0801.
    Abstract

  838. DENG Z, Tang N, Xiong W, Lei X, et al
    Inflammation-related research within the field of bladder cancer: a bibliometric analysis.
    Front Oncol. 2023;13:1126897.
    Abstract

  839. WU Y, Deng Y, Dai Z, Ma Y, et al
    Estimates of bladder cancer burden attributable to high fasting plasma glucose: Findings of the Global Burden of Disease Study 2019.
    Cancer Med. 2023 Jun 23. doi: 10.1002/cam4.6219.
    Abstract

  840. ISALI I, Khooblall P, Helstrom E, Bukavina L, et al
    Targeting bladder cancer: A sex sensitive perspective in mutations and outcomes.
    Urol Oncol. 2023 Jun 20:S1078-1439(23)00166.
    Abstract

  841. DIEFENBACH MA, Marziliano A, Siembida EJ, Mistretta T, et al
    Cancer Resource and Information Support (CRIS) for Bladder Cancer Survivors and Their Caregivers: Development and Usability Testing Study.
    JMIR Form Res. 2023;7:e41876.
    Abstract

  842. AYDH A, Sari Motlagh R, Alamri A, Yanagisawa T, et al
    Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes.
    World J Urol. 2023 Jun 22. doi: 10.1007/s00345-023-04478.
    Abstract

  843. HE L, Wang X, Chen P, Du C, et al
    Knockdown of ZNF280A inhibits cell proliferation and promotes cell apoptosis of bladder cancer.
    Histol Histopathol. 2023 Jun 13:18640. doi: 10.14670.
    Abstract

  844. ZHI Y, Cai C, Xu T, Sun F, et al
    Silencing of FGF6 hampers aerobic glycolysis and angiogenesis in bladder cancer by regulating PI3K/Akt and MAPK signaling pathways.
    J Biochem Mol Toxicol. 2023 Jun 22:e23399. doi: 10.1002/jbt.23399.
    Abstract

  845. GEDERAAS OA, Sharma A, Mbarak S, Sporsheim B, et al
    Proteomic analysis reveals mechanisms underlying increased efficacy of bleomycin by photochemical internalization in bladder cancer cells.
    Mol Omics. 2023 Jun 22. doi: 10.1039/d2mo00337.
    Abstract

  846. LEE D, Lee W, Kim HP, Kim M, et al
    Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA.
    Cancers (Basel). 2023;15:2868.
    Abstract

  847. TICHANEK F, Forsti A, Hemminki A, Hemminki O, et al
    Survival in Kidney and Bladder Cancers in Four Nordic Countries through a Half Century.
    Cancers (Basel). 2023;15:2782.
    Abstract

  848. YOU C, Li Q, Yang Y, Qing L, et al
    Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis.
    Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13744.
    Abstract

  849. BUNDELL S, Petric Howe N
    Why bladder cancer cells that shed their Y chromosome become more aggressive.
    Nature. 2023 Jun 21. doi: 10.1038/d41586-023-02069.
    Abstract

  850. MEI Y, Wu Y, Ma L, Zhang H, et al
    Retraction Note: Overexpression of ROCK1 promotes cancer cell proliferation and is associated with poor prognosis in human urothelial bladder cancer.
    Mamm Genome. 2023 Jun 21. doi: 10.1007/s00335-023-10002.
    Abstract

  851. MARK JR, Gomella LG, Lallas CD, Smentkowski KE, et al
    Enhancing bladder cancer care through the multidisciplinary clinic approach.
    Can J Urol. 2023;30:11526-11531.
    Abstract

  852. GHALI F, Vakar-Lopez F, Roudier MP, Garcia J, et al
    Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Clin Genitourin Cancer. 2023 May 25:S1558-7673(23)00132.
    Abstract

  853. CASTRO-ALONSO FJ, Beas-Lozano E, Remolina-Bonilla YA, Flaig TW, et al
    Erdafitinib in the Treatment of Metastatic Urothelial Carcinoma.
    Oncology (Williston Park). 2023;37:256-261.
    Abstract

  854. HANNA K
    Erdafitinib's Road to Approval and Use in Urothelial Carcinoma.
    Oncology (Williston Park). 2023;37:260-261.
    Abstract

  855. YOU C, Dong Z
    ASO Author Reflections: A Safe and Feasible Procedure for Bladder Cancer-Extraperitoneal Radical Cystectomy.
    Ann Surg Oncol. 2023 Jun 21. doi: 10.1245/s10434-023-13789.
    Abstract

  856. CHOI J, Jung TY, Kim JH, Maeng S, et al
    Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model.
    Investig Clin Urol. 2023;64:296-305.
    Abstract

  857. WANG S, Yuan X, Shen Z, Zhao J, et al
    Therapeutic responses to chemotherapy or immunotherapy by molecular subtype in bladder cancer patients: A meta-analysis and systematic review.
    Investig Clin Urol. 2023;64:229-241.
    Abstract

  858. KIM KH, Lee HW, Ha HK, Seo HK, et al
    Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Investig Clin Urol. 2023;64:202-218.
    Abstract

  859. HU M, Pan D, Wei Y, Ye L, et al
    Atypical Recurrent Renal Cell Carcinoma of the Ipsilateral Ureter Showing Typical Symptoms of Upper Urinary Tract Urothelial Carcinoma: A Case Report and Literature Review.
    Arch Esp Urol. 2023;76:238-244.
    Abstract

  860. ZHOU Y, Yang H, Liang Z
    Efficiency and Safety of Laparoscopic Radical Cystectomy for Muscle-Invasive Bladder Cancer, and Postoperative Recurrence.
    Arch Esp Urol. 2023;76:196-202.
    Abstract

  861. LU X, Chen L, Liu S, Cao Y, et al
    m(6)A-mediated upregulation of lncRNA RMRP boosts the progression of bladder cancer via epigenetically suppressing SCARA5.
    Epigenomics. 2023 Jun 20. doi: 10.2217/epi-2023-0062.
    Abstract

  862. VERGHOTE F, Van Praet C, De Maeseneer D, Berquin C, et al
    Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium.
    Cancer Manag Res. 2023;15:511-521.
    Abstract

  863. LU Z, Lu Z, Lai Y, Zhou H, et al
    A comprehensive analysis of FBN2 in bladder cancer: A risk factor and the tumour microenvironment influencer.
    IET Syst Biol. 2023 Jun 19. doi: 10.1049/syb2.12067.
    Abstract

  864. WEI F, Li T, Li J, Zhang Y, et al
    Prognostic and Immunological Role of Asporin across Cancers and Exploration in Bladder Cancer.
    Gene. 2023 Jun 17:147573. doi: 10.1016/j.gene.2023.147573.
    Abstract

  865. LA MAESTRA S, Benvenuti M, D'Agostini F, Micale RT, et al
    Comet-FISH analysis of urothelial cells. A screening opportunity for bladder cancer?
    Expert Rev Mol Diagn. 2023 Jun 21:1-11. doi: 10.1080/14737159.2023.2227381.
    Abstract

  866. GRABE-HEYNE K, Henne C, Mariappan P, Geiges G, et al
    Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs.
    Front Oncol. 2023;13:1170124.
    Abstract

  867. RADOSAVLJEVIC V, Milic N
    Bladder cancer screening: The new selection and prediction model.
    Open Med (Wars). 2023;18:20230723.
    Abstract

  868. MUKHERJEE D, Romano E, Walshaw R, Zeef LAH, et al
    Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1.
    Oncoimmunology. 2023;12:2223094.
    Abstract

  869. CRUPI E, de Padua TC, Marandino L, Raggi D, et al
    Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
    Eur Urol Oncol. 2023 Jun 15:S2588-9311(23)00111.
    Abstract

  870. OH TJ, Lee JY, Seo Y, Woo MA, et al
    Evaluation of Sensitive Urine DNA-based PENK Methylation Test for Detecting Bladder Cancer in Patients with Hematuria.
    J Mol Diagn. 2023 Jun 15:S1525-1578(23)00131.
    Abstract

  871. VANNESTE M, van der Heij B, Christiaansen CE, Berendsen CL, et al
    Implications of the COVID19 pandemic on the need and timing of second transurethral bladder tumour resection in high-grade non-muscle invasive bladder cancer.
    World J Urol. 2023 Jun 17. doi: 10.1007/s00345-023-04469.
    Abstract

  872. ERYURUK U, Tasdemir MN, Aslan S
    Comparison of the diagnostic performance of biparametric and multiparametric MRI in detecting muscle invasion of bladder cancer located at the ureteral orifice.
    Abdom Radiol (NY). 2023 Jun 16. doi: 10.1007/s00261-023-03979.
    Abstract

  873. NIZIOL J, Ossolinski K, Plaza-Altamer A, Kolodziej A, et al
    Untargeted urinary metabolomics for bladder cancer biomarker screening with ultrahigh-resolution mass spectrometry.
    Sci Rep. 2023;13:9802.
    Abstract

  874. TAN WS, Hall E, Kamat AM, Kelly JD, et al
    Clinical trial design for non-muscle-invasive bladder cancer.
    Nat Rev Urol. 2023 Jun 16. doi: 10.1038/s41585-023-00789.
    Abstract

  875. YANG L, Huang W, Bai X, Wang H, et al
    Androgen dihydrotestosterone promotes bladder cancer cell proliferation and invasion via EPPK1-mediated MAPK/JUP signalling.
    Cell Death Dis. 2023;14:363.
    Abstract

  876. SINGH P, Rotte A, Golsorkhi AA, Girish S, et al
    Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective.
    Expert Rev Clin Pharmacol. 2023;16:533-548.
    Abstract

  877. HUGAR LA, Geiss C, Chavez MN, Gore LR, et al
    Exploring knowledge, perspectives, and misperceptions of palliative care: A mixed methods analysis.
    Urol Oncol. 2023;41:327.
    Abstract

  878. KHORSANDI N, Ding CC, VandenBussche CJ, Verduzco CS, et al
    Urine cytology in patients with gender confirmation surgery and hormone therapy: evaluation of urine cytology performance in an underserved patient population.
    J Am Soc Cytopathol. 2023;12:267-274.
    Abstract

  879. ZHANG C, Wang M, Ying Y, Meng F, et al
    Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cells.
    Cancer Med. 2023;12:12581-12592.
    Abstract

  880. COOK EE, Harrison BT, Hirsch MS
    TRPS1 expression is sensitive and specific for primary extramammary Paget disease.
    Histopathology. 2023;83:104-108.
    Abstract

  881. HENSLEY PJ, Seiler R, Herr H, Mouw KW, et al
    Bladder preservation after neoadjuvant therapy - 2021 IBCN updates part 1.
    Urol Oncol. 2023;41:307-312.
    Abstract

  882. FERREIRA GM, Lima APB, Pereira GR, Silva GND, et al
    Synthesis, characterization and antiproliferative effects of naphtho [2,3-b] thiophen-4,9-quinone on bladder tumor cells.
    Nat Prod Res. 2023;37:2285-2292.
    Abstract

  883. CHI Z, Balani J, Gopal P, Hammer S, et al
    GATA3 positivity is associated with poor prognosis in patients with oesophageal squamous cell carcinoma.
    J Clin Pathol. 2023;76:474-479.
    Abstract

  884. ZHOU R, Zhou J, Muhuitijiang B, Zeng X, et al
    Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  885. BHONGIR AV, Sampath S, Bonthapally RK, Gudivada KK, et al
    Sequential Application and Post-Test Probability for Screening of Bladder Cancer Using Urinary Proteomic Biomarkers: A Review based Probabilistic Analysis.
    Asian Pac J Cancer Prev. 2023;24:2021-2027.
    Abstract

  886. OFFICE FE
    Retraction: Long noncoding RNA SNHG1 activates autophagy and promotes cell invasion in bladder cancer.
    Front Oncol. 2023;13:1228367.
    Abstract

  887. BOGUMIL D, Cortessis VK, Wilkens LR, Le Marchand L, et al
    Interethnic Differences in Bladder Cancer Incidence and the Association between Type 2 Diabetes and Bladder Cancer in the Multiethnic Cohort Study.
    Cancer Res Commun. 2023;3:755-762.
    Abstract

  888. GUAN X, Lu D, Chen Z, Wang Z, et al
    Non-invasive detection of bladder cancer via microfluidic immunoassay of the protein biomarker NMP22.
    Anal Methods. 2023 Jun 28. doi: 10.1039/d3ay00664.
    Abstract

  889. NIKULAINEN I, Salminen AP, Seikkula H, Hogerman M, et al
    Nationwide analysis of survival after radical cystectomy for bladder cancer in Finland.
    Acta Oncol. 2023 Jun 28:1-7. doi: 10.1080/0284186X.2023.2228446.
    Abstract

  890. MYINT ZW, Chahine Z, Jayswal R, Bachert E, et al
    Association of CD47 Expression with Clinicopathologic Characteristics and Survival Outcomes in Muscle Invasive Bladder Cancer.
    J Pers Med. 2023;13:885.
    Abstract

  891. GILYAZOVA I, Enikeeva K, Rafikova G, Kagirova E, et al
    Epigenetic and Immunological Features of Bladder Cancer.
    Int J Mol Sci. 2023;24:9854.
    Abstract

  892. JORDAENS S, Oeyen E, Willems H, Ameye F, et al
    Protein Biomarker Discovery Studies on Urinary sEV Fractions Separated with UF-SEC for the First Diagnosis and Detection of Recurrence in Bladder Cancer Patients.
    Biomolecules. 2023;13:932.
    Abstract

  893. LUI G, Minnar CM, Soon-Shiong P, Schlom J, et al
    Exploiting an Interleukin-15 Heterodimeric Agonist (N803) for Effective Immunotherapy of Solid Malignancies.
    Cells. 2023;12:1611.
    Abstract

  894. ABDELAZIZ A, Sultan M, Hammad MA, Martinez JR Jr, et al
    Endophytic upper tract urothelial carcinoma in a solitary kidney treated by cryotherapy: an unorthodox case for successful management.
    BMC Urol. 2023;23:111.
    Abstract

  895. LEE YJ, Kang SG, Kim CH
    Over-expression of Long Non-coding RNA Urothelial Cancer-associated 1 as a Predictive Marker for Prostate Cancer.
    In Vivo. 2023;37:1511-1516.
    Abstract

  896. WILLIAMS SB, Janes JL, Howard LE, Yang R, et al
    Exposure to Agent Orange and Risk of Bladder Cancer Among US Veterans.
    JAMA Netw Open. 2023;6:e2320593.
    Abstract

  897. SHIRONO Y, Bilim V, Anraku T, Kuroki H, et al
    Targeting Pro-Survival Autophagy Enhanced GSK-3beta Inhibition-Induced Apoptosis and Retarded Proliferation in Bladder Cancer Cells.
    Curr Oncol. 2023;30:5350-5365.
    Abstract

  898. PANUNZIO A, Gozzo A, Mazzucato G, Ornaghi PI, et al
    Impairment in Activities of Daily Living Assessed by the Barthel Index Predicts Adverse Oncological Outcomes After Radical Cystectomy for Bladder Cancer.
    Clin Genitourin Cancer. 2023 Jun 9:S1558-7673(23)00141.
    Abstract

  899. SHEN C, Zhang S, Zhang Z, Yang S, et al
    Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
    Funct Integr Genomics. 2023;23:211.
    Abstract

  900. LEVY JJ, Chan N, Marotti JD, Rodrigues NJ, et al
    Examining longitudinal markers of bladder cancer recurrence through a semiautonomous machine learning system for quantifying specimen atypia from urine cytology.
    Cancer Cytopathol. 2023 Jun 26. doi: 10.1002/cncy.22725.
    Abstract

  901. A BUENO AP, Clark O, Turnure M, Moreira ES, et al
    Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact((R)) Survey 2020.
    Future Oncol. 2023 Jun 26. doi: 10.2217/fon-2022-1066.
    Abstract

  902. CAGLAYAN A, Horsanali MO
    Can Peripheral Blood Systemic Immune Response Parameters Predict Oncological Outcomes in Patients with Non-Muscle-Invasive Bladder Cancer?
    Niger J Clin Pract. 2023;26:591-598.
    Abstract

  903. HONG BA, Zhao Q, Ji YP, Cao YD, et al
    [The preliminary efficacy of "quadri-combination" therapy on the treatment of bladder cancer].
    Zhonghua Yi Xue Za Zhi. 2023;103:1855-1859.
    Abstract

  904. CAYUELA L, Medina-Lopez R, Lendinez-Cano G, Cayuela A, et al
    Bladder cancer mortality trends in Spain: 1980-2021.
    Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00070.
    Abstract

  905. PYRGIDIS N, Sokolakis I, Haltmair G, Hatzichristodoulou G, et al
    The perioperative and long-term outcomes of patients with variant histology bladder cancer undergoing radical cystectomy: A propensity score-matched analysis with pure urothelial carcinoma.
    Actas Urol Esp (Engl Ed). 2023 Jun 22:S2173-5786(23)00071.
    Abstract

  906. ZHAO Y, Lu K, Yin ZX, Peng YH, et al
    Systematic review and meta-analysis of completely retroperitoneoscopic nephroureterectomy versus traditional retroperitoneoscopic nephroureterectomy in upper tract urothelial carcinoma.
    Medicine (Baltimore). 2023;102:e34112.
    Abstract

  907. SUN JX, Xia QD, Zhong XY, Liu Z, et al
    The bladder microbiome of NMIBC and MIBC patients revealed by 2bRAD-M.
    Front Cell Infect Microbiol. 2023;13:1182322.
    Abstract

  908. SINGH AM, Guevara-Patino JA, Wang X, Li R, et al
    Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    BioDrugs. 2023;37:505-520.
    Abstract

  909. XIONG CC, Zhu SS, Yan DH, Yao YD, et al
    Rapid and precise detection of cancers via label-free SERS and deep learning.
    Anal Bioanal Chem. 2023;415:3449-3462.
    Abstract

  910. TAGUCHI S, Kawai T, Buti S, Bersanelli M, et al
    Validation of a drug-based score in advanced urothelial carcinoma treated with pembrolizumab.
    Immunotherapy. 2023;15:827-837.
    Abstract

  911. SHI R, Le Tan MT, Lim GH, Du J, et al
    Prognostic Value of Tumor Budding in Urothelial Carcinoma: A Meta-Analysis and Systematic Review.
    Lab Invest. 2023;103:100136.
    Abstract

  912. WONG MN, Wu DJ, Lee CT, Zynger DL, et al
    Renal Pelvic Urothelial Carcinoma With Invasion Into Renal Medulla Can Be Redefined as pT2 to Improve Correlation With Survival.
    Mod Pathol. 2023;36:100140.
    Abstract

  913. KOWALEWSKI KF, Wieland VLS, Kriegmair MC, Uysal D, et al
    Robotic-assisted Versus Laparoscopic Versus Open Radical Cystectomy-A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
    Eur Urol Focus. 2023;9:480-490.
    Abstract

  914. WANG LJ, Liu ZX, Hu W, Liu Y, et al
    [Research Progress in Preoperative Evaluation of Lymph Node Metastasis of Bladder Cancer].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:464-470.
    Abstract

  915. ECKE TH, Meisl CJ, Schlomm T Prof, Rabien A, et al
    BTA stat(R), NMP22(R) BladderChek(R), UBC(R) Rapid Test, and CancerCheck(R) UBC(R) rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study.
    Urol Oncol. 2023 Jul 3:S1078-1439(23)00225-9. doi: 10.1016/j.urolonc.2023.
    Abstract

  916. ADOMI S, Fujita K, Kita H, Kuwahara K, et al
    Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
    Cancer Diagn Progn. 2023;3:484-490.
    Abstract

  917. SUHARA Y, Urabe F, Hashimoto M, Nakazono M, et al
    A case of eosinophilic cystitis coexisting of superficial bladder cancer, mimicking muscle-invasive cancer.
    IJU Case Rep. 2023;6:230-234.
    Abstract

  918. MURATA Y, Shinojima T, Nakahira Y, Hamada M, et al
    Recurrent urethral tumor with neuroendocrine differentiation in a female patient after radical cystectomy for bladder cancer.
    IJU Case Rep. 2023;6:199-202.
    Abstract

  919. NIE J, Liu T, Mao T, Yang H, et al
    Transcriptome sequencing and single-cell sequencing analysis identify GARS1 as a potential prognostic and immunotherapeutic biomarker for multiple cancers, including bladder cancer.
    Front Immunol. 2023;14:1169588.
    Abstract

  920. SHAKHSSALIM N, Talebi A, Pahlevan-Fallahy MT, Sotoodeh K, et al
    Lifestyle and occupational risks assessment of bladder cancer using machine learning-based prediction models.
    Cancer Rep (Hoboken). 2023 Jul 5:e1860. doi: 10.1002/cnr2.1860.
    Abstract

  921. ALAMEDDINE R, Mallea P, Shahab F, Zakharia Y, et al
    Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives.
    Curr Treat Options Oncol. 2023 Jul 5. doi: 10.1007/s11864-023-01114.
    Abstract

  922. SHOAYDAROV MA, Martov AG, Andronov AS, Dutov SV, et al
    [Experience in the use of confocal laser endomicroscopy for the diagnosis of bladder papillary tumors].
    Urologiia. 2023;:99-106.
    Abstract

  923. GUIGNAND A, Bouleftour W, Vassal C, Tinquaut F, et al
    The Impact of an Enrolment in Clinical Trial on Tolerance and Pathological Response for Patients Treated by Neoadjuvant MVAC Against an Invasive Bladder Cancer. A Retrospective Comparative Study.
    Clin Genitourin Cancer. 2023 Jun 15:S1558-7673(23)00145.
    Abstract

  924. RAFIEI S, Kheradkhah G, Kotronoulas G, Doustmehraban M, et al
    Quality of life in bladder cancer: systematic review and meta-analysis.
    BMJ Support Palliat Care. 2023 Jul 3:spcare-2023-004185.
    Abstract

  925. LI Y, Chen T, Fu B, Luo Y, et al
    Survival nomogram for high-grade bladder cancer patients after surgery based on the SEER database and external validation cohort.
    Front Oncol. 2023;13:1164401.
    Abstract

  926. ZHANG M, Zhu J, Zhang P, Li L, et al
    Development and validation of cancer-associated fibroblasts-related gene landscape in prognosis and immune microenvironment of bladder cancer.
    Front Oncol. 2023;13:1174252.
    Abstract

  927. ZIANI I, Ibrahimi A, Zaoui Y, El Sayegh H, et al
    Role of preoperative neutrophil to lymphocyte ratio in prediction of recurrence, progression, and BCG failure in non-muscle invasive bladder cancer: a retrospective study.
    Pan Afr Med J. 2023;44:145.
    Abstract

  928. AGRAWAL M, Malvi G, Agrawal N, Narayanaswamy S, et al
    Ileal neobladder adenocarcinoma occurring twenty-five years post ileocystoplasty: a case report.
    Pan Afr Med J. 2023;44:149.
    Abstract

  929. ZHAN Y, Chen Z, Li Y, He A, et al
    Correction: Long non-coding RNA DANCR promotes malignant phenotypes of bladder cancer cells by modulating the miR-149/MSI2 axis as a ceRNA.
    J Exp Clin Cancer Res. 2023;42:157.
    Abstract

  930. LI Z, Fu H, Liu J, Song W, et al
    LncRNA PVT1 promotes bladder cancer progression by forming a positive feedback loop with STAT5B.
    Pathol Res Pract. 2023;248:154635.
    Abstract

  931. JU M, Wu W, Qu J, Sun Y, et al
    Downregulation of circular RNA hsa_circ_0087856 sensitizes bladder cancer cells to cisplatin through targeting miR-1184/CITED2 signaling.
    Environ Mol Mutagen. 2023 Jul 1. doi: 10.1002/em.22561.
    Abstract

  932. YANG L, Wu X, Zhou J, Song P, et al
    Second malignant tumors and non-tumor causes of death for patients with localized and regional kidney cancer after diagnosis.
    Eur J Med Res. 2023;28:206.
    Abstract

  933. CANO VELASCO J, Polanco Pujol L, Moreno Cortes JC, Lafuente Puentedura A, et al
    Bladder Epicheck(R) for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience.
    Actas Urol Esp (Engl Ed). 2023 Jun 28:S2173-5786(23)00075.
    Abstract

  934. QIU S, Qiu Y, Deng L, Nie L, et al
    Cell softness reveals tumorigenic potential via ITGB8/AKT/glycolysis signaling in a mice model of orthotopic bladder cancer.
    Chin Med J (Engl). 2023 Jun 30. doi: 10.1097/CM9.0000000000002710.
    Abstract

  935. FENG J, Wang M, Du GS, Peng K, et al
    Crosstalk between autophagy and bladder transitional cell carcinoma by autophagy-related lncRNAs.
    Medicine (Baltimore). 2023;102:e34130.
    Abstract

  936. TERLEVIC R, Ulamec M, Stimac G, Murgic J, et al
    Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5/6 and p16.
    Biomol Biomed. 2023 Jun 21. doi: 10.17305/bb.2023.9242.
    Abstract

  937. DIXON S, Hill H, Flight L, Khetrapal P, et al
    Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer.
    JAMA Netw Open. 2023;6:e2317255.
    Abstract

  938. TANG Y, Lin L, Xiao Y, Meng L, et al
    Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
    Clin Transl Oncol. 2023 Jun 30. doi: 10.1007/s12094-023-03264.
    Abstract

  939. SATCHITHANANTHAM V, Babiker T, Riding G, Banihani M, et al
    A case of mycotic infrarenal abdominal aortic aneurysm after bacillus Calmette-Guerin immunotherapy for bladder cancer and a review of the literature.
    J Vasc Surg Cases Innov Tech. 2023;9:101213.
    Abstract

  940. LONGEVITY OMAC
    Retracted: LINC00958 Inhibits Autophagy of Bladder Cancer Cells via Sponge Adsorption of miR-625-5p to Promote Tumor Angiogenesis and Oxidative Stress.
    Oxid Med Cell Longev. 2023;2023:9812826.
    Abstract


  941. Y Chromosome Loss Drives Bladder Cancer Aggressiveness and Immune Evasion.
    Cancer Discov. 2023 Jun 30:OF1. doi: 10.1158/2159-8290.CD-RW2023.
    Abstract

  942. YANG YJ, Xu XQ, Zhang YC, Hu PC, et al
    Establishment of a prognostic model related to tregs and natural killer cells infiltration in bladder cancer.
    World J Clin Cases. 2023;11:3444-3456.
    Abstract

  943. SONG W, Li Z, Yang K, Gao Z, et al
    Antisense lncRNA-RP11-498C9.13 promotes bladder cancer progression by enhancing reactive oxygen species-induced mitophagy.
    J Gene Med. 2023 Jun 29:e3527. doi: 10.1002/jgm.3527.
    Abstract

  944. ZHANG M, Qin J, Guo X, Li Z, et al
    Recognition Imaging of Trace E-cadherins on the Bladder Cancer Cells Surface during Epithelial-Mesenchymal Transition by Force-Distance Curve-Based AFM.
    Nano Lett. 2023 Jun 29. doi: 10.1021/acs.nanolett.3c01667.
    Abstract

  945. PANER GP, Kamat A, Netto GJ, Samaratunga H, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non
    Am J Surg Pathol. 2023 Jun 29. doi: 10.1097/PAS.0000000000002077.
    Abstract

  946. KOTERAZAWA S, Somiya S, Ito K, Haitani T, et al
    The useful technique of laparoscopic segmental ureterectomy with ureteral reimplantation for distal upper tract urothelial carcinoma.
    Asian J Endosc Surg. 2023;16:666-672.
    Abstract

  947. FRANZ A, Plage H, Fendler A, Schlomm T, et al
    [Precision oncology options in urological cancers].
    Urologie. 2023;62:696-704.
    Abstract

  948. GRIMM MO, Foller S, Leeder M, Leucht K, et al
    [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Urologie. 2023;62:679-684.
    Abstract

  949. YAMAMOTO D, Kotake M, Ishibayashi K, Fujimori D, et al
    Robot-assisted low anterior resection for a rectal cancer patient with ileal conduit: A case report.
    Asian J Endosc Surg. 2023;16:608-612.
    Abstract

  950. GALFFY G, Lugowska I, Poddubskaya EV, Cho BC, et al
    A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer.
    ESMO Open. 2023;8:101173.
    Abstract

  951. NAKAMURA K, Ishiyama Y, Nemoto Y, Ishihara H, et al
    Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
    Int J Clin Oncol. 2023;28:913-921.
    Abstract

  952. NAKAGAWA R, Nohara T, Naito R, Kadomoto S, et al
    Intravesical BCG therapy with photodynamic diagnosis-guided transurethral resection of bladder tumors improves recurrence-free survival.
    Photodiagnosis Photodyn Ther. 2023;42:103574.
    Abstract

  953. MIYAKE M, Hori S, Fujii T, Nishimura N, et al
    Clinical practice of UroVysion(R) urine test in patients with bladder carcinoma in situ treated with intravesical Bacillus Calmette-Guerin.
    Jpn J Clin Oncol. 2023;53:629-632.
    Abstract

  954. ROSE KM, Huelster HL, Meeks JJ, Faltas BM, et al
    Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease.
    Nat Rev Urol. 2023;20:406-419.
    Abstract

  955. CASTELLARNAU S, Gaya JM, Espinosa J, Sierra P, et al
    Clinical impact of the suspension of the ERAS protocol on patients undergoing radical cystectomy during the COVID-19 pandemic.
    Actas Urol Esp (Engl Ed). 2023;47:369-375.
    Abstract

  956. PANACH-NAVARRETE J, Devis-Peiro A, Lloret-Dura MA, Sanchez-Gimeno S, et al
    Quality of life in patients with non-muscle invasive bladder tumor undergoing adjuvant intravesical treatment.
    Actas Urol Esp (Engl Ed). 2023;47:360-368.
    Abstract

  957. CHUNG CJ, Lee HL, Chang CH, Wu CD, et al
    Determination of potential sources of heavy metals in patients with urothelial carcinoma in central Taiwan: a biomonitoring case-control study.
    Environ Geochem Health. 2023;45:5401-5414.
    Abstract

  958. MA J, Yu C, Li X, Zhang Y, et al
    A rare case of perivascular epithelioid-cell tumor of the bladder.
    Asian J Surg. 2023;46:2748-2749.
    Abstract

  959. CHING D, Chiu SK, Van Vliet C, Jasim A, et al
    Primary ALK-Negative TP63-Rearranged Anaplastic Large Cell Lymphoma in the Bladder: Potential for Misdiagnosis.
    Int J Surg Pathol. 2023;31:612-615.
    Abstract

  960. ELLERKAMP V, Schmidt A, Warmann SW, Eckert F, et al
    Detailed functional results after bladder-preserving surgery and high-dose-rate brachytherapy in pediatric bladder/prostate rhabdomyosarcoma.
    J Cancer Res Clin Oncol. 2023;149:3161-3170.
    Abstract

  961. MELLGARD G, Patel VG, Zhong X, Joshi H, et al
    Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors.
    J Cancer Res Clin Oncol. 2023;149:2833-2841.
    Abstract

  962. GILES M, Crabb SJ
    Systemic Treatment-Decision Algorithms in Muscle-Invasive Bladder Cancer: Clinical Complexities and Navigating for Improved Outcomes.
    Res Rep Urol. 2023;15:321-331.
    Abstract

  963. ZHU Z, Li X, Liu D, Li Z, et al
    A novel signature of aging-related genes associated with lymphatic metastasis for survival prediction in patients with bladder cancer.
    Front Oncol. 2023;13:1140891.
    Abstract

  964. TAN WS, Grajales V, Contieri R, Hensley P, et al
    Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes.
    Eur Urol Open Sci. 2023;53:16-22.
    Abstract

  965. YU G, Rice S, Heer R, Lewis R, et al
    Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Tr
    Eur Urol Open Sci. 2023;53:67-77.
    Abstract

  966. NAKAMURA R, Hasegawa G, Ikeda Y, Hara N, et al
    Complete remission following pembrolizumab therapy for a patient with nephroureterectomy positive-margin carcinoma in situ and bladder cancer unresponsive to Bacille Calmette-Guerin therapy.
    SAGE Open Med Case Rep. 2023;11:2050313X231185444.
    Abstract


  967. Effect of SMYD3 on Biological Behavior and H3K4 Methylation in Bladder Cancer [Retraction].
    Cancer Manag Res. 2023;15:625-626.
    Abstract

  968. YOU C, Li Q, Yang Y, Qing L, et al
    ASO Visual Abstract: Extraperitoneal Versus Intraperitoneal Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-analysis.
    Ann Surg Oncol. 2023 Jul 12. doi: 10.1245/s10434-023-13855.
    Abstract

  969. ZHOU T, Chen H, Wang Y, Wen S, et al
    Key Molecules in Bladder Cancer Affect Patient Prognosis and Immunotherapy Efficacy: Further Exploration for CNTN1 and EMP1.
    JCO Precis Oncol. 2023;7:e2200630.
    Abstract

  970. VISSING M, Munch Larsen L, Christensen AJ, Owall L, et al
    Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report.
    Acta Oncol. 2023 Jul 12:1-7. doi: 10.1080/0284186X.2023.2226330.
    Abstract

  971. SHAKHSSALIM N, Dadpour M, Sharifiaghdas F, Narouie B, et al
    Evaluating the Effectiveness of Intravesical Instillation of BCG by Modified Maintenance Method in Patients With High-Risk Ta and T1 Bladder Cancer: A Randomized Clinical Trial.
    Clin Med Insights Oncol. 2023;17:11795549231184682.
    Abstract

  972. XIONG S, Dong W, Deng Z, Jiang M, et al
    Value of the application of computed tomography-based radiomics for preoperative prediction of unfavorable pathology in initial bladder cancer.
    Cancer Med. 2023 Jul 11. doi: 10.1002/cam4.6225.
    Abstract

  973. JIANG W, Pan C, Guo W, Xu Z, et al
    Pathologic collision of urinary bladder urothelial carcinoma with small cell carcinoma: a case report.
    Diagn Pathol. 2023;18:80.
    Abstract

  974. WANG Y, Zhu H, Xu H, Qiu Y, et al
    Senescence-related gene c-Myc affects bladder cancer cell senescence by interacting with HSP90B1 to regulate cisplatin sensitivity.
    Aging (Albany NY). 2023;15.
    Abstract

  975. CHANG TC, Shkolyar E, Del Giudice F, Eminaga O, et al
    Real-time Detection of Bladder Cancer Using Augmented Cystoscopy with Deep Learning: a Pilot Study.
    J Endourol. 2023 Jul 11. doi: 10.1089/end.2023.0056.
    Abstract

  976. MIYAJIMA K, Suzuki H, Urabe F, Iwatani K, et al
    Clinical characteristics of secondary bladder cancer developing after low-/high-dose-rate brachytherapy to treat localized prostate cancer.
    Int J Clin Oncol. 2023 Jul 11. doi: 10.1007/s10147-023-02383.
    Abstract

  977. FAROOQI AA, Venera R, Kapanova G, Tanbayeva G, et al
    TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.
    Med Oncol. 2023;40:236.
    Abstract

  978. PENG K, Ding D, Wang N, Du T, et al
    ITIH5, as a predictor of prognosis and immunotherapy response for P53-like bladder cancer, is related to cell proliferation and invasion.
    Mol Omics. 2023 Jul 11. doi: 10.1039/d2mo00322.
    Abstract

  979. SINGH A, Osbourne AS, Koshkin VS
    Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.
    Curr Treat Options Oncol. 2023 Jul 10. doi: 10.1007/s11864-023-01113.
    Abstract

  980. COBELLIS G, Torino G, Lisi G, Ilari M, et al
    Pneumovesicoscopic management of bladder neoplasms in children: three case reports.
    Pediatr Med Chir. 2023;45.
    Abstract

  981. GU Y, Zhuo H
    Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
    Aging Male. 2023;26:2233609.
    Abstract

  982. LI Z, Yao Y, Qi T, Wu Z, et al
    ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts.
    Front Pharmacol. 2023;14:1222512.
    Abstract

  983. ZENG J, Funk J, Lee BR, Hsu CH, et al
    Gemcitabine as first-line therapy for high-grade non-muscle invasive bladder cancer: results from a tertiary center in the contemporary BCG-shortage era.
    Transl Androl Urol. 2023;12:960-966.
    Abstract

  984. OKOBI TJ, Uhomoibhi TO, Akahara DE, Odoma VA, et al
    Immune Checkpoint Inhibitors as a Treatment Option for Bladder Cancer: Current Evidence.
    Cureus. 2023;15:e40031.
    Abstract

  985. ZHONG Q, Jiang K, Zhang F, Tian Y, et al
    Exploring the correlation of glycolysis-related chondroitin polymerizing factor (CHPF) with clinical characteristics, immune infiltration, and cuproptosis in bladder cancer.
    Am J Cancer Res. 2023;13:2213-2233.
    Abstract

  986. HUANG CP, Lu HL, Shyr CR
    Anti-tumor activity of intratumoral xenogeneic urothelial cell monotherapy or in combination with chemotherapy in syngeneic murine models of bladder cancer.
    Am J Cancer Res. 2023;13:2285-2306.
    Abstract

  987. WU L, Chen W, Cao Y, Chen B, et al
    A novel cuproptosis-related lncRNAs signature predicts prognosis in bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  988. JIANG Q, Zhou J, Chen Q, Huang Y, et al
    Construction and experimental validation of a macrophage cell senescence-related gene signature to evaluate the prognosis, immunotherapeutic sensitivity, and chemotherapy response in bladder cancer.
    Funct Integr Genomics. 2023;23:228.
    Abstract

  989. ZENNAMI K, Takahara K, Nukaya T, Takenaka M, et al
    The Role of Lymph Node Dissection in Patients With Muscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy Following Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2023 Jun 28:S1558-7673(23)00155.
    Abstract

  990. JIANG H, Zhu S, Wu B, Su Y, et al
    CDK2 and CDK4 targeted liensinine inhibits the growth of bladder cancer T24 cells.
    Chem Biol Interact. 2023 Jul 7:110624. doi: 10.1016/j.cbi.2023.110624.
    Abstract

  991. XIAO K, Peng S, Lu J, Zhou T, et al
    UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.
    Cell Death Dis. 2023;14:408.
    Abstract

  992. KATES M, Chu X, Hahn N, Pietzak E, et al
    Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guerin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naive High-grade Non-muscle-invasive Bladder Cancer (BRIDGE).
    Eur Urol Focus. 2023 Jul 6:S2405-4569(23)00146-3. doi: 10.1016/j.euf.2023.
    Abstract

  993. LIU X, Liu L, Wang X, Jin Y, et al
    Necroptosis inhibits autophagy by regulating the formation of RIP3/p62/Keap1 complex in shikonin-induced ROS dependent cell death of human bladder cancer.
    Phytomedicine. 2023;118:154943.
    Abstract

  994. ORJI P, Sun H, Isali I, Bell S, et al
    Female sexual function evaluation and intraoperative vaginal reconstruction in bladder cancer.
    World J Urol. 2023 Jul 7. doi: 10.1007/s00345-023-04502.
    Abstract

  995. KATES M
    Doing Less with More: Towards a New Paradigm of Non-muscle-invasive Bladder Cancer Care.
    Eur Urol Focus. 2023 Jul 5:S2405-4569(23)00147-5. doi: 10.1016/j.euf.2023.
    Abstract

  996. GUPTA S, Norgan AP, Erickson LA
    Schistosomiasis of the Urinary Bladder.
    Mayo Clin Proc. 2023;98:1100-1101.
    Abstract

  997. LEE J, Kim SH, Jeong SH, Han JH, et al
    Pyuria as an independent predictor of intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial carcinoma.
    Investig Clin Urol. 2023;64:353-362.
    Abstract

  998. KIM D, Nam W, Kyung YS, You D, et al
    Effect of decreased renal function on poor oncological outcome after radical cystectomy.
    Investig Clin Urol. 2023;64:346-352.
    Abstract

  999. ESTEVES M, Duarte M, Oliveira PA, Gil da Costa RM, et al
    SKELETAL MUSCLE SENSITIVITY TO WASTING INDUCED BY UROTHELIAL CARCINOMA.
    Exp Oncol. 2023;45:107-119.
    Abstract

  1000. GARMANCHUK LV, Yakovlev PG, Ostrovska GV, Stupak YA, et al
    COMPARISON OF 2D AND 3D PRIMARY CELL CULTURES OBTAINED FROM EXPLANT OF HIGH-GRADE UROTHELIAL BLADDER CANCER.
    Exp Oncol. 2023;45:130-136.
    Abstract

  1001. TANG Z, Peng J, Wu S, Zhao F, et al
    Combined use of a 980‑nm diode laser and preoperative intravesical instillation of pirarubicin for the prevention of short‑term recurrence of non‑muscle invasive bladder cancer: A pilot study.
    Oncol Lett. 2023;26:322.
    Abstract

  1002. SU Y, Chen L, Yang J
    Network pharmacology and in vitro experiments reveal that Noscapine induces ROS-mediated apoptosis and cell cycle arrest via PI3K/Akt/FoxO3a signaling pathway in human bladder cancer cells.
    Curr Cancer Drug Targets. 2023 Jul 6. doi: 10.2174/1568009623666230706153936.
    Abstract

  1003. RODRIGUES L, Watson J, Feng Y, Lewis B, et al
    Shared hotspot mutations in oncogenes position dogs as an unparalleled comparative model for precision therapeutics.
    Sci Rep. 2023;13:10935.
    Abstract

  1004. YU H, Bai K, Cheng Y, Lv J, et al
    Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  1005. RELPH K, Arif M, Pandha H, Annels N, et al
    Analysis of ICAM-1 Expression on Bladder Carcinoma Cell Lines and Infectivity and Oncolysis by Coxsackie Virus A21.
    Methods Mol Biol. 2023;2684:319-327.
    Abstract

  1006. GRANDI P, Darilek A, Moscu A, Pradhan A, et al
    Intravesical Infusion of Oncolytic Virus CG0070 in the Treatment of Bladder Cancer.
    Methods Mol Biol. 2023;2684:303-317.
    Abstract

  1007. NIEGISCH G
    Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:293-301.
    Abstract

  1008. BAHLINGER V, Eckstein M, Hartmann A, Stohr R, et al
    Evaluation of FGFR Alteration Status in Urothelial Tumors.
    Methods Mol Biol. 2023;2684:283-291.
    Abstract

  1009. MENECEUR S, Grunewald CM, Niegisch G, Hoffmann MJ, et al
    Epigenetic Priming and Development of New Combination Therapy Approaches.
    Methods Mol Biol. 2023;2684:259-281.
    Abstract

  1010. BAHLINGER V, Hartmann A, Eckstein M
    Assessment of PD-L1 Status in Urothelial Cancer.
    Methods Mol Biol. 2023;2684:249-255.
    Abstract

  1011. NIKKOLA J, Black P
    Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
    Methods Mol Biol. 2023;2684:229-247.
    Abstract

  1012. ZVEREVA M, Hosen MI, Forey N, Sheikh M, et al
    Simplex Droplet Digital PCR Assays for the Detection of TERT Promoter Mutations in Urine Samples for the Non-invasive Diagnosis of Urothelial Cancer.
    Methods Mol Biol. 2023;2684:213-228.
    Abstract

  1013. ECKE TH, Benderska-Soder N, Bismarck E, van Rhijn BWG, et al
    Considering the Effects of Modern Point-of-Care Urine Biomarker Assays in Follow-Up of Patients with High-Risk Non-muscle-Invasive Bladder Cancer.
    Methods Mol Biol. 2023;2684:199-212.
    Abstract

  1014. NORDENTOFT I, Birkenkamp-Demtroder K, Dyrskjot L
    NGS-Based Tumor-Informed Analysis of Circulating Tumor DNA.
    Methods Mol Biol. 2023;2684:179-197.
    Abstract

  1015. DONELAN W, Crispen PL, Kusmartsev S
    Tissue Slice Culture and Analysis of Tumor-Associated Hyaluronan in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:167-175.
    Abstract

  1016. MANTWILL K, Nawroth R
    Genome-Wide CRISPR Screening for the Identification of Therapy Resistance-Associated Genes in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:155-165.
    Abstract

  1017. PARK Y, Lelo A, Harris B, Berry DL, et al
    Identification of STAG2-Mutant Bladder Cancers by Immunohistochemistry.
    Methods Mol Biol. 2023;2684:145-151.
    Abstract

  1018. RAMPIAS T, Klinakis A
    Using Sister Chromatid Exchange Assay to Detect Homologous Recombination Deficiency in Epigenetically Deregulated Urothelial Carcinoma Cells.
    Methods Mol Biol. 2023;2684:133-144.
    Abstract

  1019. SEILLIER L, Peifer M
    Reconstructing Phylogenetic Relationship in Bladder Cancer: A Methodological Overview.
    Methods Mol Biol. 2023;2684:113-132.
    Abstract

  1020. PETER C, Schulz WA, Whongsiri P
    Characterization of Native COMPASS Complex in Urothelial Carcinoma Cells by Size Exclusion Chromatography.
    Methods Mol Biol. 2023;2684:101-109.
    Abstract

  1021. MOKOU M, Narayanasamy S, Stroggilos R, Balaur IA, et al
    A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures.
    Methods Mol Biol. 2023;2684:59-99.
    Abstract

  1022. OLAH C, Szarvas T
    A Panel-Based Method for the Reproduction of Distinct Molecular Subtype Classifications of Muscle-Invasive Urothelial Bladder Cancer.
    Methods Mol Biol. 2023;2684:27-43.
    Abstract

  1023. BOSHERZ MS, Samarska IV, Gaisa NT
    Scoring Systems for Immunohistochemistry in Urothelial Carcinoma.
    Methods Mol Biol. 2023;2684:3-25.
    Abstract

  1024. REIGNIER PL, Gauthier H, Hennequin C, Aussedat Q, et al
    Survival after sequential neoadjuvant chemotherapy followed by trimodal treatment or radical cystectomy for muscle-invasive bladder cancer.
    World J Urol. 2023 Jul 6. doi: 10.1007/s00345-023-04506.
    Abstract

  1025. KAWADA T, Yanagisawa T, Bekku K, Laukhtina E, et al
    Low-dose or -number of BCG in non-muscle invasive bladder cancer: updated systematic review and meta-analysis.
    Immunotherapy. 2023;15:933-943.
    Abstract

  1026. FARSHADPOUR F, Taherkhani R, Farzaneh M
    Human papillomaviruses and bladder cancer risk: first report in south of Iran.
    Virusdisease. 2023;34:257-262.
    Abstract

  1027. BUDENBENDER B, Kother AK, Kriegmair MC, Grune B, et al
    Getting specific: participation preference in urooncological decision-making.
    BMC Med Inform Decis Mak. 2023;23:114.
    Abstract

  1028. GU YM, Liang XL, Zhang YG, Zhao HY, et al
    [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023;45:429-435.
    Abstract

  1029. PARK JY, Baek JW, Yu J, Kim CS, et al
    Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
    J Clin Anesth. 2023;89:111191.
    Abstract

  1030. ABDELBARY AM, Atwa HA, Elfarargy OM, Qasem ER, et al
    Prognostic Implications of CD24, SOX2, and Nanog Expression in Invasive Urothelial Carcinoma.
    Appl Immunohistochem Mol Morphol. 2023;31:421-428.
    Abstract

  1031. KANNO T, Kobori G, Ito K, Nakagawa H, et al
    Atypical Oncologic Failure After Laparoscopic Radical Nephroureterectomy in a Japanese Multicenter Study.
    J Endourol. 2023;37:793-800.
    Abstract

  1032. YU J, Lee J, Kim CS, Park JY, et al
    ASO Author Reflections: Chart-Derived Frailty Index and 1-Year Mortality After Radical Cystectomy.
    Ann Surg Oncol. 2023;30:5304-5305.
    Abstract

  1033. MATTHEW-ONABANJO AN, Nortey G, Matulewicz RS, Basak R, et al
    Diversity, equity, and inclusion in genitourinary clinical trials leading to FDA novel drug approval: An assessment of the FDA center for drug evaluation and research drug trials snapshot.
    Curr Probl Cancer. 2023;47:100958.
    Abstract

  1034. HACKING SM, Pavlick D, Wang Y, Carneiro BA, et al
    Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Oncologist. 2023;28:e508-e519.
    Abstract

  1035. SHI Y, Wang S, Liu W, Sherryn S, et al
    Single-Position Complete Retroperitoneoscopic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Urinary Tract Urothelial Carcinoma.
    J Endourol. 2023;37:768-774.
    Abstract

  1036. ZHAO Q, Wu L, Yang F, Chen D, et al
    A Modified and Practical Surgical Technique for Pure Transperitoneal Laparoscopic Radical Nephroureterectomy in a Single Position and Research Outcomes.
    J Laparoendosc Adv Surg Tech A. 2023;33:691-697.
    Abstract

  1037. SUN JX, An Y, Xu MY, Liu CQ, et al
    Development of a dynamic risk system for predicting the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer after thulium laser resection of bladder tumor or transurethral resection of bladder tumor followed by intra
    Front Oncol. 2023;13:1133161.
    Abstract

  1038. CHAI J, Yin S, Feng W, Zhang T, et al
    The Role of Hypoxia-inducible Factor-1 in Bladder Cancer.
    Curr Mol Med. 2023 Jul 20. doi: 10.2174/1566524023666230720163448.
    Abstract

  1039. ALBARAKATI N, Al-Ghamdi H, Al-Sowayan B, Alshareeda A, et al
    Homologous recombination mRNAs (RAD21, RAD50 and BARD1) have a potentially poor prognostic role in ERBB2-low bladder cancer patients.
    Sci Rep. 2023;13:11738.
    Abstract

  1040. CHEN G, Fan X, Wang T, Zhang E, et al
    A machine learning model based on MRI for the preoperative prediction of bladder cancer invasion depth.
    Eur Radiol. 2023 Jul 20. doi: 10.1007/s00330-023-09960.
    Abstract

  1041. ANDRADE DL, Jalalizadeh M, Salustiano ACC, Reis LO, et al
    Bladder cancer immunomodulatory effects of intravesical Nitazoxanide, Rapamycin, Thalidomide and Bacillus Calmette-Guerin (BCG).
    World J Urol. 2023 Jul 20. doi: 10.1007/s00345-023-04526.
    Abstract

  1042. GOYAL S, Vias P, Periasamy K, Madan R, et al
    Delineating and sparing the ileal conduit in adjuvant radiotherapy for bladder cancer with modulated radiotherapy.
    J Cancer Res Ther. 2023;19:731-737.
    Abstract

  1043. KUMAR A, Kumar M, Semwal MK, Singh U, et al
    Management of surgically inoperable muscle-invasive bladder cancer in a resource constraint setting at a tertiary care center by bladder preservation protocol: Case series.
    J Cancer Res Ther. 2023;19:725-730.
    Abstract

  1044. MOHANTY P, Mohapatra AS, Sabat D, Nayak J, et al
    Unusual histomorphological spectrum of urinary bladder cancers and their treatment modalities revisited: Our experience with series of five cases.
    J Cancer Res Ther. 2023;19:617-623.
    Abstract

  1045. AKBULUT F, Pazir Y, Esmeray A, Erbin A, et al
    The efficacy of hyperthermic intravesical chemotherapy in high-risk non-muscle-invasive bladder cancer patients with BCG intolerance.
    Urologia. 2023 Jul 20:3915603231189022. doi: 10.1177/03915603231189022.
    Abstract

  1046. ECKE TH, Lotan Y, Massfelder T
    Editorial: Identifying novel biomarkers in bladder cancer.
    Front Oncol. 2023;13:1191736.
    Abstract

  1047. RAHMAN KMM, Foster BA, You Y
    Preclinical evaluation of singlet oxygen-cleavable prodrugs in combination with protoporphyrin IX-photodynamic therapy in an orthotopic rat model of non-muscle-invasive bladder cancer(dagger).
    Photochem Photobiol. 2023 Jul 20. doi: 10.1111/php.13838.
    Abstract

  1048. TAN WS, McElree IM, Davaro F, Steinberg RL, et al
    Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Jul 18:S2588-9311(23)00143.
    Abstract

  1049. FARMANI F, Soleimani N, Razeghi M, Zamani A, et al
    Uninvited guest, Balantidium coli in urine in a patient with bladder cancer: A case report and review of the literature.
    Clin Case Rep. 2023;11:e7494.
    Abstract

  1050. ZHAN Y, Chen Z, He S, Gong Y, et al
    Correction: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2.
    Mol Cancer. 2023;22:115.
    Abstract

  1051. GUAN H, Wang G, Wang W, Zhou Y, et al
    Postoperative adjuvant radiotherapy for patients with upper tract urothelial carcinoma (UTUC) who underwent kidney-sparing surgery (KSS): a single-center study.
    Radiat Oncol. 2023;18:120.
    Abstract

  1052. LIU W, Xiong J, Wang H, Li S, et al
    Racial disparities in conditional survival of patients with bladder cancer: a population-based study.
    BMC Urol. 2023;23:122.
    Abstract

  1053. KOUHEN F, Dahbi Z, Afif M, Chihabeddine M, et al
    Bladder carcinosarcoma treated by cystectomy and adjuvant chemotherapy with good outcomes: a case report.
    J Med Case Rep. 2023;17:320.
    Abstract

  1054. LAUKHTINA E, Shariat SF
    Smoking, ethnicity and bladder cancer - implications for public health and clinical practice.
    Nat Rev Urol. 2023 Jul 18. doi: 10.1038/s41585-023-00804.
    Abstract

  1055. WANG P, Joiner M, Dzul S, Miller SR, et al
    Adenocarcinoma involving the urinary bladder.
    BMJ Case Rep. 2023;16:e252747.
    Abstract

  1056. SHEN C, Liu J, Jiao W, Zhang X, et al
    A feed-forward loop based on aerobic glycolysis and TGF-beta between tumor-associated macrophages and bladder cancer cells promoted malignant progression and immune escape.
    J Cancer Res Clin Oncol. 2023 Jul 18. doi: 10.1007/s00432-023-05164.
    Abstract

  1057. RASTEGAR-POUYANI N, Montazeri V, Marandi N, Aliebrahimi S, et al
    The impact of Cancer-Associated Fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in Bladder Cancer: A comparison between recurrent and non-recurrent patient-derived CAFs.
    Cancer Invest. 2023 Jul 18:1-16. doi: 10.1080/07357907.2023.2237576.
    Abstract

  1058. ABE T, Yamada S, Kikuchi H, Sazawa A, et al
    Impact of postoperative complications on long-term survival in bladder cancer patients.
    Jpn J Clin Oncol. 2023 Jul 17:hyad079. doi: 10.1093.
    Abstract

  1059. PING Q, Wang C, Cheng X, Zhong Y, et al
    TGF-beta1 dominates stromal fibroblast-mediated EMT via the FAP/VCAN axis in bladder cancer cells.
    J Transl Med. 2023;21:475.
    Abstract

  1060. ARTYMOWICZ M, Struck-Lewicka W, Wiczling P, Markuszewski M, et al
    Targeted quantitative metabolomics with a linear mixed-effect model for analysis of urinary nucleosides and deoxynucleosides from bladder cancer patients before and after tumor resection.
    Anal Bioanal Chem. 2023 Jul 18. doi: 10.1007/s00216-023-04826.
    Abstract

  1061. XIA T, Zhou F, Zhang D, Jin X, et al
    Deep-profiling of phospholipidome via rapid orthogonal separations and isomer-resolved mass spectrometry.
    Nat Commun. 2023;14:4263.
    Abstract

  1062. MURAOKA K, Fukasawa M, Fukushima M, Kumagai M, et al
    [The Effect of Naldemedine Tosylate on the Postoperative Course of Robot-Assisted Radical Cystectomy].
    Hinyokika Kiyo. 2023;69:147-150.
    Abstract

  1063. HE K, Wang J, Zhou Y, Huang Z, et al
    Network pharmacology analysis of icariside II against bladder cancer.
    Eur J Pharmacol. 2023 Jul 15:175914. doi: 10.1016/j.ejphar.2023.175914.
    Abstract

  1064. MATAR M, Prince G, Hamati I, Baalbaky M, et al
    Implication of KDM6A in bladder cancer.
    Pharmacogenomics. 2023 Jul 17. doi: 10.2217/pgs-2023-0027.
    Abstract

  1065. QI G, Liu J, Tao S, Fan W, et al
    A retrospective study on expression and clinical significance of PHH3, Ki67 and P53 in bladder exophytic papillary urothelial neoplasms.
    PeerJ. 2023;11:e15675.
    Abstract

  1066. ZHANG Y, Liu M, Wang J, Han K, et al
    Bibliometric analysis of the association between drinking water pollution and bladder cancer.
    Front Oncol. 2023;13:1170700.
    Abstract

  1067. YI X, Pi J, Liu C, Xiong Y, et al
    The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model.
    Front Oncol. 2023;13:1189086.
    Abstract

  1068. WANG XX, Wu HY, Yang Y, Ma MM, et al
    CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.
    Exp Ther Med. 2023;26:382.
    Abstract

  1069. WANG Y, Kong Q, Li M, Gu J, et al
    Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients.
    Heliyon. 2023;9:e17690.
    Abstract

  1070. SU Y, Ai J, Jia M, Yue G, et al
    The Relationship between VEGF and AGT Gene Single Nucleotide Polymorphisms and Susceptibility to Renal and Bladder Cancers.
    Arch Esp Urol. 2023;76:298-308.
    Abstract

  1071. SHAHAIT M, Abu-Hijlih R, Farkouh A, Obeidat S, et al
    Fluorodeoxyglucose positron emission tomography (18F-FDG PET)-computed tomography (CT) in the initial staging of bladder cancer: a single institution experience.
    J Egypt Natl Canc Inst. 2023;35:21.
    Abstract

  1072. TAPPERO S, Chierigo F, Parodi S, Bandini M, et al
    Radical cystectomy in bladder cancer patients previously treated for prostate cancer: Insights from a large European multicentric series.
    Surg Oncol. 2023;50:101973.
    Abstract

  1073. CHEN H, Yang W, Li Y, Ji Z, et al
    PLAGL2 promotes bladder cancer progression via RACGAP1/RhoA GTPase/YAP1 signaling.
    Cell Death Dis. 2023;14:433.
    Abstract

  1074. SUBRAMANYA SK, Li R, Wang Y, Miyamoto H, et al
    Deep learning for histopathological segmentation of smooth muscle in the urinary bladder.
    BMC Med Inform Decis Mak. 2023;23:122.
    Abstract

  1075. GRASSAUER J, Schmidt J, Cowan A, Gilbert SM, et al
    Downstaging and Survival Associated with Neoadjuvant Immunotherapy Before Radical Cystectomy for Muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Jul 14:S2588-9311(23)00118.
    Abstract

  1076. WISSING MD, O'Flaherty A, Dragomir A, Tanguay S, et al
    Chronic prednisone, metformin, and nonsteroidal anti-inflammatory drug use and clinical outcome in a cohort of bladder cancer patients undergoing radical cystectomy in Quebec, Canada.
    BMC Urol. 2023;23:119.
    Abstract

  1077. CHEN H, Xu C, Fang Z, Mao S, et al
    Cell-Free DNA, MicroRNAs, Proteins, and Peptides as Liquid Biopsy Biomarkers in Prostate Cancer and Bladder Cancer.
    Methods Mol Biol. 2023;2695:165-179.
    Abstract

  1078. CUI Y, Cao M
    Liquid Biopsy in Bladder Cancer.
    Methods Mol Biol. 2023;2695:111-120.
    Abstract

  1079. YUAN P, Li S, Xiong S, Zheng F, et al
    Development of a butyrate metabolism-related gene-based molecular subtypes and scoring system for predicting prognosis and immunotherapy response in bladder cancer.
    J Cancer Res Clin Oncol. 2023 Jul 14. doi: 10.1007/s00432-023-05067.
    Abstract

  1080. BIERI U, Kranzbuhler B, Wettstein MS, Fankhauser CD, et al
    Limited Value of Bladder Wash Cytology During Follow-Up of Patients With Non-muscle Invasive Bladder Cancer.
    Cureus. 2023;15:e40283.
    Abstract

  1081. AVETA A, Cilio S, Contieri R, Spena G, et al
    Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.
    Int J Mol Sci. 2023;24:10846.
    Abstract

  1082. JAKUS D, Solic I, Juric I, Borovac JA, et al
    The Impact of the Initial Clinical Presentation of Bladder Cancer on Histopathological and Morphological Tumor Characteristics.
    J Clin Med. 2023;12:4259.
    Abstract

  1083. DANESHDOUST D, Yin M, Luo M, Sundi D, et al
    Conditional Reprogramming Modeling of Bladder Cancer for Clinical Translation.
    Cells. 2023;12:1714.
    Abstract

  1084. FERRO M, Falagario UG, Barone B, Maggi M, et al
    Artificial Intelligence in the Advanced Diagnosis of Bladder Cancer-Comprehensive Literature Review and Future Advancement.
    Diagnostics (Basel). 2023;13:2308.
    Abstract

  1085. BOCA B, Caraiani C, Telecan T, Pintican R, et al
    MRI-Based Radiomics in Bladder Cancer: A Systematic Review and Radiomics Quality Score Assessment.
    Diagnostics (Basel). 2023;13:2300.
    Abstract

  1086. BORGHERESI A, Agostini A, Sternardi F, Cesari E, et al
    Vascular Enlargement as a Predictor of Nodal Involvement in Bladder Cancer.
    Diagnostics (Basel). 2023;13:2227.
    Abstract

  1087. MCELREE IM, Orzel J, Stubbee R, Steinberg RL, et al
    Sequential intravesical gemcitabine and docetaxel for treatment-naive and previously treated intermediate-risk nonmuscle invasive bladder cancer.
    Urol Oncol. 2023 Jul 11:S1078-1439(23)00228.
    Abstract

  1088. MA J, Roumiguie M, Hayashi T, Kohada Y, et al
    Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary?
    Eur Urol Focus. 2023 Jul 11:S2405-4569(23)00153.
    Abstract

  1089. DAHL DM, Karrison TG, Michaelson MD, Pham HT, et al
    Long-term Outcomes of Chemoradiation for Muscle-invasive Bladder Cancer in Noncystectomy Candidates. Final Results of NRG Oncology RTOG 0524-A Phase 1/2 Trial of Paclitaxel + Trastuzumab with Daily Radiation or Paclitaxel Alone with Daily Irradiation.
    Eur Urol Oncol. 2023 Jul 11:S2588-9311(23)00115.
    Abstract

  1090. MIR MA, Pandith AA, Mansoor S, Baba SM, et al
    Differential expression of SLITRK6 gene as a potential therapeutic target for urothelial carcinoma in particular upper tract cancer.
    Gene. 2023;878:147583.
    Abstract

  1091. ABDEL-HAFIZ HA, Schafer JM, Chen X, Xiao T, et al
    Y chromosome loss in cancer drives growth by evasion of adaptive immunity.
    Nature. 2023;619:624-631.
    Abstract

  1092. GOBBO A, Fasulo V, Contieri R, Uleri A, et al
    Clinical and pathological predictors of persistent T1 HG at second resection.
    Urologia. 2023;90:482-490.
    Abstract

  1093. TIAN BW, Han CL, Wang HC, Yan LJ, et al
    Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Clin Exp Metastasis. 2023;40:255-287.
    Abstract

  1094. YONESE I, Ito M, Waseda Y, Kobayashi S, et al
    Impact of diagnostic ureteral catheterization on intravesical tumour recurrence following radical nephroureterectomy for upper tract urothelial carcinoma.
    World J Urol. 2023;41:1869-1875.
    Abstract

  1095. YANAGISAWA T, Kawada T, Quhal F, Bekku K, et al
    Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis.
    World J Urol. 2023;41:1763-1774.
    Abstract

  1096. MOAVRO DE, Andrini L, Iribarne A, Colaci P, et al
    HLA-G expression in transitional bladder carcinoma. Relationship with tumor invasion level and patient survival: Experience in a public hospital in Argentina.
    Hum Immunol. 2023;84:423-427.
    Abstract

  1097. CHEN M, Jiang J, Chen J, Wang M, et al
    The Clinical Safety and Efficacy of Targeted PD-L1 Therapy with Durvalumab in Solid Tumors.
    Curr Drug Targets. 2023;24:584-598.
    Abstract

  1098. CERRATO C, Pandolfo SD, Autorino R, Panunzio A, et al
    Gender-specific counselling of patients with upper tract urothelial carcinoma and Lynch syndrome.
    World J Urol. 2023;41:1741-1749.
    Abstract

  1099. CHAN TC, Pan CT, Hsieh HY, Vejvisithsakul PP, et al
    The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGFbeta/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma.
    Cell Oncol (Dordr). 2023;46:933-951.
    Abstract

  1100. DJORDJEVIC D, Dragicevic S, Vukovic M
    Mini-laparotomy radical cystectomy with limited bowel externalization during ileal conduit urinary diversion reduces the rate of postoperative complications: a match-paired, single centered analysis.
    Acta Chir Belg. 2023;123:362-368.
    Abstract

  1101. REBEZ G, Runti O, Rizzo M, Trombetta C, et al
    Radical cystectomy and orthotopic neobladder in a patient with a preexisting three-components inflatable penile prosthesis.
    Urologia. 2023;90:584-586.
    Abstract

  1102. SYMVOULIDIS P, Tsioutis C, Zamboglou C, Agouridis AP, et al
    The Effect of Statins on the Incidence and Prognosis of Bladder Cancer: A Systematic Review and Meta-Analysis.
    Curr Oncol. 2023;30:6648-6665.
    Abstract

  1103. KODERA A, Mohammed M, Lim P, Abdalla O, et al
    The Management of Bacillus Calmette-Guerin (BCG) Failure in High-Risk Non-muscle Invasive Bladder Cancer: A Review Article.
    Cureus. 2023;15:e40962.
    Abstract

  1104. BUI TT, Jang E, Shin JH, Kim TH, et al
    Feasibility of Raman spectroscopic identification of gall bladder cancer using extracellular vesicles extracted from bile.
    Analyst. 2023 Jul 28. doi: 10.1039/d3an00806.
    Abstract

  1105. TABAEI S, Haghshenas MR, Ariafar A, Gilany K, et al
    Comparative proteomics analysis in different stages of urothelial bladder cancer for identification of potential biomarkers: highlighted role for antioxidant activity.
    Clin Proteomics. 2023;20:28.
    Abstract

  1106. XUE XL, Zhao S, Xu MC, Li Y, et al
    Circular RNA_0000326 accelerates breast cancer development via modulation of the miR-9-3p/YAP1 axis.
    Neoplasma. 2023;70:430-442.
    Abstract

  1107. CAO T, Zhou X, Wu X, Zou Y, et al
    Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction.
    Front Immunol. 2023;14:1207544.
    Abstract

  1108. WANG M, Zhang Z, Li Z, Zhu Y, et al
    E3 ubiquitin ligases and deubiquitinases in bladder cancer tumorigenesis and implications for immunotherapies.
    Front Immunol. 2023;14:1226057.
    Abstract

  1109. ZHANG J, Duan H, Feng Z, Han X, et al
    Retraction Note: Acetyl-CoA synthetase 3 promotes bladder cancer cell growth under metabolic stress.
    Oncogenesis. 2023;12:39.
    Abstract

  1110. YANAGISAWA T, Kawada T, von Deimling M, Bekku K, et al
    Repeat Transurethral Resection for Non-muscle-invasive Bladder Cancer: An Updated Systematic Review and Meta-analysis in the Contemporary Era.
    Eur Urol Focus. 2023 Jul 24:S2405-4569(23)00173.
    Abstract

  1111. SINGH A, Choudhary A, Pai V, Viswanath K, et al
    Uncovering the Uncommon: Institutional Insights Into the Clinical and Epidemiological Characteristics of Rarer Forms of Bladder Cancer Beyond Transitional Cell Carcinoma.
    Cureus. 2023;15:e40879.
    Abstract

  1112. HOSHINA H, Taguchi S, Suyama H, Kishitani K, et al
    Surgical resection of retinoblastoma-associated bladder leiomyosarcoma during pregnancy: a case report.
    BMC Urol. 2023;23:125.
    Abstract

  1113. BARAL BK, Poudel PR, Rajbhandari M, Karki AJ, et al
    Ultrasound versus Nerve Stimulator Guided Obturator Nerve Block in Patients Undergoing Transurethral Resection of Bladder Tumor.
    J Nepal Health Res Counc. 2023;20:998-1002.
    Abstract

  1114. SASAKI Y, Daizumoto K, Fukuta K, Shiozaki K, et al
    Lymph node dissection during radical cystectomy for bladder cancer: A two-center comparative study of robotic versus open surgery.
    Asian J Endosc Surg. 2023 Jul 25. doi: 10.1111/ases.13234.
    Abstract

  1115. SHI ZD, Sun Z, Zhu ZB, Liu X, et al
    Integrated single-cell and spatial transcriptomic profiling reveals higher intratumour heterogeneity and epithelial-fibroblast interactions in recurrent bladder cancer.
    Clin Transl Med. 2023;13:e1338.
    Abstract

  1116. ALAM SM, Larson M, Srinivasan P, Genz N, et al
    Evaluation of sarcopenia in patients receiving intravesical Bacillus Calmette-Guerin for non-muscle invasive bladder cancer.
    Urol Oncol. 2023 Jul 22:S1078-1439(23)00198.
    Abstract

  1117. TANG NT, Robinson R, Snook RD, Brown M, et al
    Classification of formalin-fixed bladder cancer cells with laser tweezer Raman spectroscopy.
    Analyst. 2023 Jul 24. doi: 10.1039/d3an00119.
    Abstract

  1118. SONG Y, Xu T
    Letter to the editor for the article "Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer".
    World J Urol. 2023 Jul 24. doi: 10.1007/s00345-023-04541.
    Abstract

  1119. STEWART R, Richards HL, Houghton S, Sweeney P, et al
    'I Had It. I Don't Think I Have It...But I Do Feel It Will Come Back Somewhere': A Qualitative Investigation of the Experience of People With Non-Muscle Invasive Bladder Cancer.
    Qual Health Res. 2023 Jul 24:10497323231170089. doi: 10.1177/10497323231170089.
    Abstract

  1120. YAMAMOTO K, Yamamoto K, Nakai G, Fujitani T, et al
    Detection of the Vesical Arteries Using Three-dimensional Digital Subtraction Angiography Relevant to Intra-arterial Infusion Chemotherapy for Bladder Cancer Using Double-balloon Catheters.
    Interv Radiol (Higashimatsuyama). 2023;8:64-69.
    Abstract

  1121. XIAO X, Peng J, Chen Y, Lu X, et al
    Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer.
    Iran J Public Health. 2023;52:1225-1237.
    Abstract

  1122. ERDIK A, Cimen HI, Atik YT, Gul D, et al
    Sarcopenia is an independent predictor of survival in patients undergoing radical cystectomy for bladder cancer: a single-centre, retrospective study.
    Cent European J Urol. 2023;76:81-89.
    Abstract

  1123. WASFIE T, Atherton JM, Villegas SJ, Korbitz H, et al
    Small bowel obstruction secondary to metastatic urothelial bladder cancer.
    SAGE Open Med Case Rep. 2023;11:2050313X231176356.
    Abstract

  1124. LI Y, Zheng H, Luo Y, Lin Y, et al
    An HGF-dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis.
    Cancer Commun (Lond). 2023 Jul 22. doi: 10.1002/cac2.12470.
    Abstract

  1125. ELMEKAWY S, Taha DE, Nabeeh HE, Ibrahim A, et al
    Comparison of holmium laser, bipolar and conventional monopolar transurethral resection of bladder tumour in primary non-muscle invasive bladder cancer.
    J Pak Med Assoc. 2023;73.
    Abstract

  1126. AHMED NOR EM, Saied EM, Alshenawy HA, Shams Eldeen AA, et al
    The Value Of PD-L1 Immunohistochemical Expression In Egyptian Urinary Bladder Carcinoma Patients.
    J Pak Med Assoc. 2023;73.
    Abstract

  1127. MO R, Dawulieti J, Chi N, Wu Z, et al
    Self-polymerized platinum (II)-Polydopamine nanomedicines for photo-chemotherapy of bladder Cancer favoring antitumor immune responses.
    J Nanobiotechnology. 2023;21:235.
    Abstract

  1128. BOONCHAI S, Tanthanuch M, Bejrananda T
    Comparison of the Y-pouch orthotopic neobladder and the Studer technique after radical cystectomy: surgical and functional outcomes from a single-center series.
    World J Surg Oncol. 2023;21:218.
    Abstract

  1129. DE HERTOGH O
    [Bladder preservation treatments for bladder cancer: Trimodality therapy, an overview of clinical practices in 2023].
    Cancer Radiother. 2023 Jul 20:S1278-3218(23)00124.
    Abstract

  1130. JIANG P, Ning J, Yu W, Rao T, et al
    FLRT2 suppresses bladder cancer progression through inducing ferroptosis.
    J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17855.
    Abstract

  1131. LI L, Zhang Y, Hu W, Zou F, et al
    MTHFD2 promotes PD-L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer.
    J Cell Mol Med. 2023 Jul 21. doi: 10.1111/jcmm.17863.
    Abstract

  1132. ZHU S, Li H, Fan Y, Tang C, et al
    Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    BMC Urol. 2023;23:124.
    Abstract

  1133. WANG Z, Muthusamy V, Petrylak DP, Anderson KS, et al
    Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy.
    NPJ Precis Oncol. 2023;7:70.
    Abstract

  1134. WANG D, Wang C, Zhou FH
    Identification of the diagnostic value of urine SLC1A5 in bladder cancer based on GEO database.
    Asian J Surg. 2023 Jul 19:S1015-9584(23)01045.
    Abstract

  1135. ZHANG B, Yang L, He Y, Han D, et al
    Role and mechanisms of noncoding RNAs in the regulation of metabolic reprogramming in bladder cancer (Review).
    Int J Mol Med. 2023;52:79.
    Abstract

  1136. GHATALIA P, Kaur J, Sonpavde G
    Muscle invasive bladder cancer: where is the field headed?
    Expert Opin Biol Ther. 2023 Jul 21:1-15. doi: 10.1080/14712598.2023.2238607.
    Abstract

  1137. LI B, Hu Y, Li QY, Tang YM, et al
    Procoagulant genes may affect angiogenesis, epithelial-mesenchymal transition, survival prognosis and tumor immune microenvironment in patients with urothelial carcinoma.
    Aging (Albany NY). 2023;15:6429-6444.
    Abstract

  1138. SAINT-JACQUES N, Brown PE, Purcell J, Rainham DG, et al
    The Nova Scotia Community Cancer Matrix: A geospatial tool to support cancer prevention.
    Soc Sci Med. 2023;330:116038.
    Abstract

  1139. GUERRA NL, Matas-Garcia A, Serra-Garcia L, Morgado-Carrasco D, et al
    Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
    Autoimmun Rev. 2023;22:103375.
    Abstract

  1140. SAVIN Z, Kupershmidt A, Phollan D, Lazarovich A, et al
    The role of malnutrition universal screening tool in predicting outcomes after radical cystectomy.
    Surg Oncol. 2023;49:101962.
    Abstract

  1141. RAMOS KS, Li J, Wijdeveld LFJ, van Schie MS, et al
    Long Noncoding RNA UCA1 Correlates With Electropathology in Patients With Atrial Fibrillation.
    JACC Clin Electrophysiol. 2023;9.
    Abstract

  1142. CHOU LP, Hsu CW, Yang SF, Lee CT, et al
    Clinicopathologic Analysis of Micropapillary Urothelial Carcinoma of the Upper Urinary Tract: Implications for HER2-Targeted Therapy.
    Clin Genitourin Cancer. 2023;21:508.
    Abstract

  1143. SEKAR RR, Diamantopoulos LN, Bakaloudi DR, Khaki AR, et al
    Sarcomatoid Urothelial Carcinoma Is Associated With Limited Response to Neoadjuvant Chemotherapy and Poor Oncologic Outcomes After Radical Cystectomy.
    Clin Genitourin Cancer. 2023;21:507.
    Abstract

  1144. BELLMUNT J, Chang J, Pavilack-Kirker M, Cappelleri JC, et al
    Evaluating Real-World Characteristics of Patients With Advanced Urothelial Carcinoma Eligible for Avelumab Maintenance Therapy: A Multicountry Retrospective Medical Chart Review.
    Clin Genitourin Cancer. 2023;21:459-466.
    Abstract

  1145. SLOTMAN A, Xu M, Lindale K, Hardy C, et al
    Quantitative Nuclear Grading: An Objective, Artificial Intelligence-Facilitated Foundation for Grading Noninvasive Papillary Urothelial Carcinoma.
    Lab Invest. 2023;103:100155.
    Abstract

  1146. RAY CH, Davaro F, Hamilton ZA, Raza J, et al
    Perioperative outcomes of open versus robot-assisted radical cystectomy in octogenarians: a population based analysis.
    J Robot Surg. 2023;17:1629-1635.
    Abstract

  1147. CHENG L, Lopez-Beltran A, Wang M, Whaley RD, et al
    Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder.
    Mod Pathol. 2023;36:100151.
    Abstract

  1148. LI KP, Chen SY, Wang CY, Wan S, et al
    Comparison between robot-assisted versus open nephroureterectomy for upper tract urothelial carcinoma: outcomes from a pooled analysis.
    J Robot Surg. 2023;17:1227-1238.
    Abstract

  1149. GUPTA N, Kucirka L, Semerjian A, Pierorazio PM, et al
    Practice Patterns Regarding Female Reproductive Organ-Sparing and Nerve-Sparing Radical Cystectomy Among Urologic Oncologists in the United States.
    Clin Genitourin Cancer. 2023;21:e236-e241.
    Abstract

  1150. SUN ZJ, Zhao JW, Zhao M, Chen Y, et al
    CD3 high and FoxP3 - tumor-infiltrating lymphocytes in the invasive margin as a favorable prognostic marker in patients with invasive urothelial carcinoma of the bladder.
    Anticancer Drugs. 2023;34:844-851.
    Abstract

  1151. HEALTHCARE ENGINEERING JO
    Retracted: Clinical Value Analysis of Xiaozheng Decoction Combined with Bladder Perfusion for Postoperative Treatment of Bladder Cancer and Its Effect on Serum miR-143 and miR-92a.
    J Healthc Eng. 2023;2023:9785158.
    Abstract

  1152. SUN Z, Sun X, Qin G, Li Y, et al
    FTO promotes proliferation and migration of bladder cancer via enhancing stability of STAT3 mRNA in an m6A-dependent manner.
    Epigenetics. 2023;18:2242688.
    Abstract

  1153. CHEN S, Ran J, Fan Z, Liu M, et al
    Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
    Sci Rep. 2023;13:12625.
    Abstract

  1154. KLOSKOWSKI T, Fekner Z, Szeliski K, Paradowska M, et al
    Effect of four fluoroquinolones on the viability of bladder cancer cells in 2D and 3D cultures.
    Front Oncol. 2023;13:1222411.
    Abstract

  1155. GIL DA COSTA RM, Levesque C, Bianchi-Frias D, Chatterjee P, et al
    Pharmacological NF-kappaB inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
    Mol Oncol. 2023 Aug 3. doi: 10.1002/1878-0261.13504.
    Abstract

  1156. ALI AH, Benterud A, Holmoy T, Myro AZ, et al
    Progressive encephalomyelitis with rigidity and myoclonus (PERM) associated with anti-glycine receptor antibodies and urothelial carcinoma: a case report.
    J Med Case Rep. 2023;17:330.
    Abstract

  1157. FLEISCHMANN M, Rodel C
    [Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer].
    Strahlenther Onkol. 2023 Aug 2. doi: 10.1007/s00066-023-02134.
    Abstract

  1158. ZHONG J, Xu A, Xu P, Su M, et al
    Circ_0000235 targets MCT4 to promote glycolysis and progression of bladder cancer by sponging miR-330-5p.
    Cell Death Discov. 2023;9:283.
    Abstract

  1159. HAO Y, Zhu Y, Sun F, Xu D, et al
    MicroRNA-30c-5p arrests bladder cancer G2/M phase and suppresses its progression by targeting PRC1-mediated blocking of CDK1/Cyclin B1 axis.
    Cell Signal. 2023 Jul 31:110836. doi: 10.1016/j.cellsig.2023.110836.
    Abstract

  1160. CHENG Y, Yu H, Li K, Lv J, et al
    Hsa_circ_0003098 promotes bladder cancer progression via miR-377-5p/ACAT2 axis.
    Genomics. 2023 Jul 31:110692. doi: 10.1016/j.ygeno.2023.110692.
    Abstract

  1161. RIBEIRO DE SOUZA B, Brum Reis I, Cardoso de Arruda Camargo G, Oliveira G, et al
    A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad(R) immunotherapy associated with platelet-rich plasma.
    Int Immunopharmacol. 2023;123:110723.
    Abstract

  1162. MEHMANDAR-OSKUIE A, Jahankhani K, Rostamlou A, Arabi S, et al
    Molecular landscape of LncRNAs in bladder cancer: From drug resistance to novel LncRNA-based therapeutic strategies.
    Biomed Pharmacother. 2023;165:115242.
    Abstract

  1163. DEMIRCI A, Ordu M
    The prognostic effect of immunohistochemical staining rates in patients with non-muscle-invasive bladder cancer.
    Indian J Pathol Microbiol. 2023;66:502-510.
    Abstract

  1164. LI Y, Kong Y, An M, Luo Y, et al
    ZEB1-mediated biogenesis of circNIPBL sustains the metastasis of bladder cancer via Wnt/beta-catenin pathway.
    J Exp Clin Cancer Res. 2023;42:191.
    Abstract

  1165. CHEN JQ, Salas LA, Wiencke JK, Koestler DC, et al
    Genome-scale methylation analysis identifies immune profiles and age acceleration associations with bladder cancer outcomes.
    Cancer Epidemiol Biomarkers Prev. 2023 Aug 1:EPI-23-0331.
    Abstract

  1166. FAN Z, Shi H, Luo J, Guo X, et al
    Diagnostic and therapeutic effects of fluorescence cystoscopy and narrow-band imaging in bladder cancer: A systematic review and network meta-analysis.
    Int J Surg. 2023 Aug 1. doi: 10.1097/JS9.0000000000000592.
    Abstract

  1167. KUANG X, Zhang Z, Li D, Bao W, et al
    Peptidase inhibitor (PI16) impairs bladder cancer metastasis by inhibiting NF-kappaB activation via disrupting multiple-site ubiquitination of NEMO.
    Cell Mol Biol Lett. 2023;28:62.
    Abstract

  1168. CHABALLOUT BH, Chang EM, Parikh NR, Min Y, et al
    Assessing utilities for muscle-invasive bladder cancer-related health states.
    Urol Oncol. 2023 Jul 29:S1078-1439(23)00239.
    Abstract

  1169. JIANG C, Xiao Y, Xu D, Huili Y, et al
    Prognosis Prediction of Disulfidptosis-Related Genes in Bladder Cancer and a Comprehensive Analysis of Immunotherapy.
    Crit Rev Eukaryot Gene Expr. 2023;33:73-86.
    Abstract

  1170. MICHAEL SN, Masood PF, Sharma U, Bhat FI, et al
    Giant right hydronephrosis with underlying double malignancy: a case report.
    Pan Afr Med J. 2023;45:21.
    Abstract

  1171. ELSAWY AA, Laymon M, Mansour I, Elghareeb A, et al
    Can we offer additional BCG therapy for three-month BCG refractory high grade/T1, Tis bladder cancer patients?
    Arab J Urol. 2023;21:142-149.
    Abstract

  1172. AWAD M, Harraz AM, Farg H, Gabr HS, et al
    Microscopic hematuria and pelvic ultrasonography could rule out flexible cystoscopy during surveillance for T1-low grade non-muscle invasive bladder cancer.
    Arab J Urol. 2023;21:150-155.
    Abstract

  1173. PICHLER R, Diem G, Hackl H, Koutnik J, et al
    Intravesical BCG in bladder cancer induces innate immune responses against SARS-CoV-2.
    Front Immunol. 2023;14:1202157.
    Abstract

  1174. KOLAT D, Kaluzinska-Kolat Z, Kosla K, Orzechowska M, et al
    LINC01137/miR-186-5p/WWOX: a novel axis identified from WWOX-related RNA interactome in bladder cancer.
    Front Genet. 2023;14:1214968.
    Abstract

  1175. JIN Y, Huang S, Wang Z
    Identify and validate RUNX2 and LAMA2 as novel prognostic signatures and correlate with immune infiltrates in bladder cancer.
    Front Oncol. 2023;13:1191398.
    Abstract

  1176. DOU X, Ma X, Meng W, Zhang W, et al
    HEATR3 involved in the cell proliferation, metastasis and cell cycle development of bladder cancer acts as a tumor suppressor.
    Mol Genet Genomics. 2023 Jul 31. doi: 10.1007/s00438-023-02046.
    Abstract

  1177. BRUCK K, Meijer RP, Boormans JL, Kiemeney LA, et al
    Disease-free survival of patients with muscle invasive bladder cancer treated with radical cystectomy versus bladder preserving therapy: a nationwide study.
    Int J Radiat Oncol Biol Phys. 2023 Jul 28:S0360-3016(23)07686.
    Abstract

  1178. WIBERG E, Vega A, Eriksson V, Banday V, et al
    A Validation Study of cT-Categories in the Swedish National Urinary Bladder Cancer Register-Norrland University Hospital.
    J Pers Med. 2023;13:1163.
    Abstract

  1179. HSU CY, Yang WT, Lin JH, Lu CH, et al
    Sertindole, an Antipsychotic Drug, Curbs the STAT3/BCL-xL Axis to Elicit Human Bladder Cancer Cell Apoptosis In Vitro.
    Int J Mol Sci. 2023;24:11852.
    Abstract

  1180. LUCCHESI CA, Vasilatis DM, Mantrala S, Chandrasekar T, et al
    Pesticides and Bladder Cancer: Mechanisms Leading to Anti-Cancer Drug Chemoresistance and New Chemosensitization Strategies.
    Int J Mol Sci. 2023;24:11395.
    Abstract

  1181. PARK EG, Lee DH, Kim WR, Lee YJ, et al
    Human Endogenous Retrovirus-H-Derived miR-4454 Inhibits the Expression of DNAJB4 and SASH1 in Non-Muscle-Invasive Bladder Cancer.
    Genes (Basel). 2023;14:1410.
    Abstract

  1182. OSTROWSKI DA, Chelluri RR, Herzig M, Xia L, et al
    Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:3746.
    Abstract

  1183. DROSOS Y, Konstantakou EG, Bassogianni AS, Nikolakopoulos KS, et al
    Microtubule Dynamics Deregulation Induces Apoptosis in Human Urothelial Bladder Cancer Cells via a p53-Independent Pathway.
    Cancers (Basel). 2023;15:3730.
    Abstract

  1184. LOZANO F, Raventos CX, Carrion A, Dinares C, et al
    Xpert Bladder Cancer Monitor for the Early Detection of Non-Muscle Invasive Bladder Cancer Recurrences: Could Cystoscopy Be Substituted?
    Cancers (Basel). 2023;15:3683.
    Abstract

  1185. MENG X, Li S, He K, Hu H, et al
    Evaluation of Whole-Tumor Texture Analysis Based on MRI Diffusion Kurtosis and Biparametric VI-RADS Model for Staging and Grading Bladder Cancer.
    Bioengineering (Basel). 2023;10:745.
    Abstract

  1186. YU J, Wu S, Li R, Jiang Y, et al
    Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    J Hematol Oncol. 2023;16:85.
    Abstract

  1187. ZHAN Y, Lin J, Liu Y, Chen M, et al
    Correction: Up-regulation of long non-coding RNA PANDAR is associated with poor prognosis and promotes tumorigenesis in bladder cancer.
    J Exp Clin Cancer Res. 2023;42:185.
    Abstract

  1188. LI H, Zhou J, Chen R, Zhu J, et al
    The efficacy and timing of adjuvant chemotherapy in upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:356.
    Abstract

  1189. D'ANDREA D, Shariat SF, Soria F, DI Trapani E, et al
    Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy.
    Minerva Urol Nephrol. 2023;75:452-459.
    Abstract

  1190. BURGESS EF, Livasy CA, Symanowski JT, Matulay JT, et al
    Low co-expression of PD-L1 and oncogenic receptor tyrosine kinases HER2 and cMET in urothelial carcinoma is associated with discordant expression between primary and metastatic sites.
    Urol Oncol. 2023;41:357.
    Abstract

  1191. CLARK-GARVEY S, Damrauer JS, Milowsky MI
    Cancer Associated Fibroblasts: An Understudied but Critical Component of the Tumor Microenvironment in Urothelial Cancer.
    Eur Urol Oncol. 2023;6:376-377.
    Abstract

  1192. TAKASE R, Hagiya H, Fujimori T, Yokoyama Y, et al
    Super acute-onset disseminated BCG infection: A case report.
    J Infect Chemother. 2023;29:919-921.
    Abstract

  1193. KAWAMURA K, Miyai K, Sato K, Matsukuma S, et al
    Copy number gain of ACTN4 is associated with poor prognosis in patients with upper urinary tract urothelial carcinoma.
    Cancer Sci. 2023;114:3411-3422.
    Abstract

  1194. MORGANS AK, Galsky MD, Wright P, Hepp Z, et al
    Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility.
    Urol Oncol. 2023;41:357.
    Abstract

  1195. NICOLETTI R, Gauhar V, Castellani D, Enikeev D, et al
    Current Techniques for En Bloc Transurethral Resection of Bladder Tumor: A Hands-on Guide Through the Energy Landscape.
    Eur Urol Focus. 2023;9:567-570.
    Abstract

  1196. MAFFEZZOLI M, Campobasso D, Rebuzzi SE, Banna GL, et al
    Prognostic models for patients with metastatic urothelial carcinoma: why use them?
    Minerva Urol Nephrol. 2023;75:419-421.
    Abstract

  1197. DRESSLER FF, Hinrichs S, Roesch MC, Perner S, et al
    EpCAM tumor specificity and proteoform patterns in urothelial cancer.
    J Cancer Res Clin Oncol. 2023;149:8913-8922.
    Abstract

  1198. LIMA W, Wang Y, Miyamoto H
    The impact of routine frozen section analysis during nephroureterectomy or segmental ureterectomy for urothelial carcinoma on final surgical margin status and long-term oncologic outcome.
    Urol Oncol. 2023;41:357.
    Abstract

  1199. WANG J, Zuo X, Zhang Y, Wang W, et al
    The impact of histological variants in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy.
    J Cancer Res Clin Oncol. 2023;149:8279-8288.
    Abstract

  1200. LIAO CI, Fang HC, Lee PT, Hsu CY, et al
    Trends in the incidence of urothelial carcinoma in Taiwan after the ban on aristolochic acid-containing Chinese herbal preparations, 2001-2018: a national population-based cohort study.
    J Cancer Res Clin Oncol. 2023;149:8201-8211.
    Abstract

  1201. CAO Y
    A case of rare metachronous four primary carcinoma.
    J Cancer Res Clin Oncol. 2023;149:7471-7477.
    Abstract

  1202. CHEN T, Zheng Y, Roskos L, Mager DE, et al
    Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma.
    J Pharmacokinet Pharmacodyn. 2023;50:251-265.
    Abstract

  1203. SJODAHL G, Bernardo C, Eriksson P, Hoglund M, et al
    Tumor Biomarkers for Bacillus Calmette-Guerin Response: What We Get Is Not What We Want.
    Eur Urol Focus. 2023;9:582-583.
    Abstract

  1204. CELIK B, Kavas G
    Atypical Category of the Johns Hopkins Template Has Higher Risk of Malignancy than the Paris System but the Paris System Is More Applicable for Suspicious Category.
    Acta Cytol. 2023;67:425-433.
    Abstract

  1205. MUILWIJK T, Akand M, Raskin Y, Jorissen C, et al
    Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry.
    Eur Urol Oncol. 2023;6:422-430.
    Abstract


  1206. Correction to "G-protein-coupled receptor 137 accelerates proliferation of urinary bladder cancer cells in vitro".
    Biotechnol Appl Biochem. 2023;70:1560.
    Abstract


  1207. Retraction Statement: KLF8 is required for bladder cancer cell proliferation and migration.
    Biotechnol Appl Biochem. 2023;70:1555.
    Abstract

  1208. LIU L, Sun FZ, Zhang PY, Xiao Y, et al
    Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study.
    Eur J Med Res. 2023;28:279.
    Abstract

  1209. DENG H, Deng L, Chao H, Yu Z, et al
    RAB14 promotes epithelial-mesenchymal transition in bladder cancer through autophagy‑dependent AKT signaling pathway.
    Cell Death Discov. 2023;9:292.
    Abstract

  1210. HOSOMI T, Shibasaki N, Otsuka H, Uketa S, et al
    [Advanced Bladder Cancer with Multiple Pulmonary Metastases Treated with Paclitaxel/Ifosfamide/Nedaplatin Therapy : Two Case Reports].
    Hinyokika Kiyo. 2023;69:183-188.
    Abstract

  1211. CONTIERI R, Hensley PJ, Tan WS, Grajales V, et al
    Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
    Eur Urol Oncol. 2023 Aug 7:S2588-9311(23)00157-8. doi: 10.1016/j.euo.2023.
    Abstract

  1212. FONTUGNE J, Xylinas E, Krucker C, Dixon V, et al
    RNA-seq profiling of upper tract urothelial carcinoma: bladder cancer consensus classification relevance, molecular heterogeneity and differential immune signatures.
    Mod Pathol. 2023 Aug 7:100300. doi: 10.1016/j.modpat.2023.100300.
    Abstract

  1213. DUMONT C, Aregui A, Hauchecorne M, Lefevre M, et al
    Safety and efficacy of preoperative chemotherapy for muscle-invasive bladder cancer in elderly patients.
    World J Urol. 2023 Aug 9. doi: 10.1007/s00345-023-04561.
    Abstract

  1214. SCANLON L, Canavan J, Babiker Z, Shilling C, et al
    Leiomyoma of the Bladder: A case report and review.
    Ir Med J. 2023;116:792.
    Abstract

  1215. RASMUSSEN AM, Okholm TLH, Knudsen M, Vang S, et al
    Circular stable intronic RNAs possess distinct biological features and are deregulated in bladder cancer.
    NAR Cancer. 2023;5:zcad041.
    Abstract

  1216. WANG J, Zhu J, Hu J, Wang Z, et al
    A novel in vitro prognostic model of bladder cancer based on urine-derived living tumor cells.
    Genes Dis. 2022;10:2586-2596.
    Abstract

  1217. TAN W, Gao L, Yuan Y, Huang H, et al
    Relationship between testosterone and male bladder cancer.
    Sci Rep. 2023;13:12881.
    Abstract

  1218. FU Z, Tian Z, Chen Y, Jia Z, et al
    Analysis of the efficacy of a single subumbilical stoma for bilateral cutaneous ureterostomy after radical cystectomy.
    Eur J Med Res. 2023;28:273.
    Abstract

  1219. GUO R, Wang L, Bai S, Kang D, et al
    Specific subsets of urothelial bladder carcinoma infiltrating T cells associated with poor prognosis.
    Sci Rep. 2023;13:12801.
    Abstract

  1220. LEOW JJ, Yong DZ, Chong YL
    Value-based healthcare for bladder cancer patients undergoing robot-assisted radical cystectomy.
    Eur J Surg Oncol. 2023;49:1329-1330.
    Abstract

  1221. HSU FT, Liu WL, Lee SR, Jeng LB, et al
    Unveiling nature's potential weapon: Magnolol's role in combating bladder cancer by upregulating the miR-124 and inactivating PKC-delta/ERK axis.
    Phytomedicine. 2023;119:154947.
    Abstract

  1222. DEL GIUDICE F, Belladelli F, Glover F, Basran S, et al
    5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data.
    World J Urol. 2023 Aug 7. doi: 10.1007/s00345-023-04551.
    Abstract

  1223. JIA X, Shkolyar E, Laurie MA, Eminaga O, et al
    Tumor detection under cystoscopy with transformer-augmented deep learning algorithm.
    Phys Med Biol. 2023;68.
    Abstract

  1224. SUN C, Zhou X, Lou J
    A Survival Model for Patients with Upper Tract Urothelial Carcinoma.
    Arch Esp Urol. 2023;76:357-362.
    Abstract

  1225. SHUMAN L, Pham J, Wildermuth T, Wu XR, et al
    Urothelium-specific expression of mutationally activated Pik3ca initiates early lesions of non-invasive bladder cancer.
    Am J Pathol. 2023 Aug 4:S0002-9440(23)00272-9. doi: 10.1016/j.ajpath.2023.
    Abstract

  1226. HUANG L, Jia K, Yao K, Liu D, et al
    Effect of neoadjuvant chemotherapy on survival in patients with T1 high-grade non-muscle-invasive bladder cancer who underwent radical cystectomy.
    Medicine (Baltimore). 2023;102:e34501.
    Abstract

  1227. WARE AP, Satyamoorthy K, Paul B
    Integrated multiomics analysis of chromosome 19 miRNA cluster in bladder cancer.
    Funct Integr Genomics. 2023;23:266.
    Abstract

  1228. LIU H, Zhou Z, Yao H, Mao Q, et al
    Robot-assisted radical cystectomy vs open radical cystectomy in patients with bladder cancer: a systematic review and meta-analysis of randomized controlled trials.
    World J Surg Oncol. 2023;21:240.
    Abstract

  1229. ZHAO X, Chen J, Zhang C, Xie G, et al
    LncRNA AGAP2-AS1 interacts with IGF2BP2 to promote bladder cancer progression via regulating LRG1 mRNA stability.
    Cell Signal. 2023 Aug 2:110839. doi: 10.1016/j.cellsig.2023.110839.
    Abstract

  1230. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed - Authors' reply.
    Lancet Oncol. 2023;24:e325-e326.
    Abstract

  1231. JENA R, Issa R, Perry M
    Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed.
    Lancet Oncol. 2023;24:e324.
    Abstract

  1232. PANT S, Schuler M, Iyer G, Witt O, et al
    Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
    Lancet Oncol. 2023;24:925-935.
    Abstract


  1233. [First-line maintenance therapy of adult patients with BCG-naive high-risk non-muscle-invasive bladder cancer - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-2
    Aktuelle Urol. 2023;54:272-273.
    Abstract

  1234. CHEN J, Zhang Z, Nie Z, Qiu J, et al
    Effects of intravenous chemotherapy after TURBT for high-risk nonmuscle invasive bladder cancer: results of a retrospective study.
    J Cancer Res Clin Oncol. 2023 Aug 4. doi: 10.1007/s00432-023-05206.
    Abstract

  1235. ZHENG B, Wang S, Zhang J, Ge C, et al
    Expression, Prognostic Value, and immune infiltration of MTHFD family in bladder cancer.
    Curr Cancer Drug Targets. 2023 Aug 4. doi: 10.2174/1568009623666230804152603.
    Abstract

  1236. ZENG Z, Wu X, Peng K, Ren D, et al
    Robot-assisted laparoscopic enucleation in the treatment of leiomyosarcoma of urinary bladder: A case report.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023;48:782-788.
    Abstract

  1237. SHIBUTANI K, Ishikawa K, Mori N
    Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.
    Am J Case Rep. 2023;24:e940375.
    Abstract

  1238. JAIN K, Jain E, DiLena R, Saleeb R, et al
    Urachal xanthogranuloma: a rare but important case presenting as a urachal mass.
    BMC Urol. 2023;23:132.
    Abstract

  1239. TRIPATHI A, Lerner SP
    Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma.
    JCO Precis Oncol. 2023;7:e2300293.
    Abstract

  1240. TURNER R, Powari M, Stevenson T
    From haematuria to nephroureterectomy via urine cytology-A case study.
    Cytopathology. 2023;34:494-496.
    Abstract

  1241. WANG S, Zhang D, Bai Y, Liu F, et al
    Clinical Outcomes of Pelvic Lymph Node Dissection Before Versus After Robot-Assisted Laparoscopic Radical Cystectomy.
    J Laparoendosc Adv Surg Tech A. 2023;33:776-781.
    Abstract

  1242. BAGHERY F, Lau LDW, Mohamadi M, Vazirinejad R, et al
    Risk of urinary tract cancers following arsenic exposure and tobacco smoking: a review.
    Environ Geochem Health. 2023;45:5579-5598.
    Abstract

  1243. ZHOU L, Shao Z, Liu Y, Yan X, et al
    HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population.
    Oncologist. 2023;28:e617-e624.
    Abstract

  1244. XUE G, Liu Y, Ji X, Zhang H, et al
    Wound dehiscence in enhanced recovery after open radical cystectomy: A meta-analysis.
    Int Wound J. 2023;20:2634-2639.
    Abstract

  1245. EUGENIA L, Giovanni A, Andrea M, Maria Rosaria R, et al
    Mucinous appendiceal adenocarcinoma invading the bladder: not always an easy diagnosis. A case report.
    Anticancer Drugs. 2023;34:967-969.
    Abstract

  1246. SILVA JF, Pereira P, Macedo G
    A rare case of ulcerative colitis following Bacillus Calmette-Guerin therapy.
    Rev Esp Enferm Dig. 2023;115:403.
    Abstract

  1247. MJAESS G, Diamand R, Aoun F, Assenmacher G, et al
    Cost-analysis of robot-assisted radical cystectomy in Europe: A cross-country comparison.
    Eur J Surg Oncol. 2023;49:1511-1518.
    Abstract

  1248. GU L, Hu G, Hu J, Wen F, et al
    Construction and comprehensive analysis of a novel prognostic signature associated with immunogenic cell death molecular subtypes in patients with bladder cancer.
    Heliyon. 2023;9:e18848.
    Abstract

  1249. LIU C, Xu P, Shao S, Wang F, et al
    The value of urinary exosomal lncRNA SNHG16 as a diagnostic biomarker for bladder cancer.
    Mol Biol Rep. 2023 Aug 17. doi: 10.1007/s11033-023-08667.
    Abstract

  1250. MERTENS LS, Psutka SP, Mir MC
    Bladder cancer oligometastases - definition and treatment.
    Nat Rev Urol. 2023 Aug 17. doi: 10.1038/s41585-023-00815.
    Abstract

  1251. FONT A, Domenech M, Ramirez JL, Marques M, et al
    Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
    Front Oncol. 2023;13:1155244.
    Abstract

  1252. CHEN R, Hao X, Chen J, Zhang C, et al
    Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1.
    J Transl Med. 2023;21:549.
    Abstract

  1253. XIA C, Zhao X, Li B, Qi B, et al
    Loneliness, spiritual well-being, and death perception, as well as their risk factors in urological cancer patients.
    Braz J Med Biol Res. 2023;56:e12915.
    Abstract

  1254. XING Z, Ji M, Shan Y, Dong Z, et al
    Using the Multidimensional Health Locus of Control Scale Form C to Investigate Health Beliefs About Bladder Cancer Prevention and Treatment Among Male Patients: Cross-Sectional Study.
    JMIR Form Res. 2023;7:e43345.
    Abstract

  1255. YANG C, Ou Y, Zhou Q, Liang Y, et al
    Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment.
    Cell Death Dis. 2023;14:525.
    Abstract

  1256. VANIN MORENO N, Whitehead M, Siemens DR
    Real-life benchmarking bladder cancer care: A population-based study.
    Can Urol Assoc J. 2023;17:268-273.
    Abstract

  1257. LIU W, Chen R, Liu X, Zhou B, et al
    Differentiation of bladder cancer stages using the vesical imaging -reporting and data system and apparent diffusion coefficient.
    Quant Imaging Med Surg. 2023;13:4897-4907.
    Abstract

  1258. LI HZ, Zhu J, Weng GJ, Li JJ, et al
    Application of nanotechnology in bladder cancer diagnosis and therapeutic drug delivery.
    J Mater Chem B. 2023 Aug 15. doi: 10.1039/d3tb01323.
    Abstract

  1259. ZHOU Q, Wu H, Miao F, Cao Y, et al
    Codelivery of ERCC2 small interfering RNA and cisplatin with macrophage-derived mimetic nanovesicles for enhanced bladder cancer treatment.
    Anticancer Drugs. 2023 Aug 15. doi: 10.1097/CAD.0000000000001528.
    Abstract

  1260. SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
    Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis.
    Ann Surg Oncol. 2023 Aug 14. doi: 10.1245/s10434-023-14051.
    Abstract

  1261. LIN F, Ke ZB, Xue YT, Chen JY, et al
    A novel CD8(+) T cell-related gene signature for predicting the prognosis and immunotherapy efficacy in bladder cancer.
    Inflamm Res. 2023 Aug 14. doi: 10.1007/s00011-023-01772.
    Abstract

  1262. WONG MCS, Huang J, Wang HHX, Yau STY, et al
    Risk prediction of bladder cancer among diabetes patients: a derivation and validation study.
    Diabet Med. 2023 Aug 14:e15199. doi: 10.1111/dme.15199.
    Abstract

  1263. CHANG S, Giannico GA, Haugen E, Jardaneh A, et al
    Multiparameter interferometric polarization-enhanced imaging differentiates carcinoma in situ from inflammation of the bladder: an ex vivo study.
    J Biomed Opt. 2023;28:102907.
    Abstract

  1264. ROHITH G, Gaur AS, Nayak P, Mandal S, et al
    Socio-economic, education, and insurance-related factors associated with the treatment completion rates in patients with nonmetastatic urinary bladder cancer: A Retrospective cohort study.
    Indian J Urol. 2023;39:228-235.
    Abstract

  1265. YAN D, He Q, Pei L, Yang M, et al
    The APC/C E3 ligase subunit ANAPC11 mediates FOXO3 protein degradation to promote cell proliferation and lymph node metastasis in urothelial bladder cancer.
    Cell Death Dis. 2023;14:516.
    Abstract

  1266. HSU CW, Cheng NC, Liao MY, Cheng TY, et al
    Correction: Hsu et al. Development of Folic Acid-Conjugated and Methylene Blue-Adsorbed Au@TNA Nanoparticles for Enhanced Photodynamic Therapy of Bladder Cancer Cells. Nanomaterials 2020, 10, 1351.
    Nanomaterials (Basel). 2023;13:2233.
    Abstract

  1267. FIORENTINO V, Pizzimenti C, Franchina M, Rossi ED, et al
    Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples.
    Int J Mol Sci. 2023;24:12489.
    Abstract

  1268. PATWARDHAN MV, Mahendran R
    The Bladder Tumor Microenvironment Components That Modulate the Tumor and Impact Therapy.
    Int J Mol Sci. 2023;24:12311.
    Abstract

  1269. MURALISANKAR M, Chen JR, Haribabu J, Ke SC, et al
    Effective and Selective Ru(II)-Arene Complexes Containing 4,4'-Substituted 2,2' Bipyridine Ligands Targeting Human Urinary Bladder Cancer Cells.
    Int J Mol Sci. 2023;24:11896.
    Abstract

  1270. SERRANO M, Munoz-Unceta N, Alonso LA, Azueta A, et al
    Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience.
    Clin Transl Oncol. 2023 Aug 11. doi: 10.1007/s12094-023-03277.
    Abstract

  1271. BASAK D, Mondal S, Srivastava SK, Sarkar D, et al
    Intratumoral PD1(+)CD38(+)Tim3(+) CD8(+) T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer.
    Cells. 2023;12:1939.
    Abstract

  1272. RASTI A, Abazari O, Dayati P, Kardan Z, et al
    Identification of Potential Key Genes Linked to Gender Differences in Bladder Cancer Based on Gene Expression Omnibus (GEO) Database.
    Adv Biomed Res. 2023;12:157.
    Abstract

  1273. LV J, Wu Q, Li K, Bai K, et al
    Lysine N-methyltransferase SETD7 promotes bladder cancer progression and immune escape via STAT3/PD-L1 cascade.
    Int J Biol Sci. 2023;19:3744-3761.
    Abstract

  1274. CHENG H, Liu Y, Chen G
    Identification of potential DNA methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis.
    BMC Urol. 2023;23:135.
    Abstract

  1275. STONE L
    Subtypes in small cell bladder cancer.
    Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00813.
    Abstract

  1276. STONE L
    Proteomic characterization of bladder cancer.
    Nat Rev Urol. 2023 Aug 10. doi: 10.1038/s41585-023-00814.
    Abstract

  1277. ECKSTEIN M, Matek C, Wagner P, Erber R, et al
    Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes.
    Eur Urol Oncol. 2023 Aug 8:S2588-9311(23)00153-0. doi: 10.1016/j.euo.2023.
    Abstract

  1278. LIU Z, Zheng X, Chen J, Zheng L, et al
    NFYC-37 promotes tumor growth by activating the mevalonate pathway in bladder cancer.
    Cell Rep. 2023;42:112963.
    Abstract

  1279. FUNAKOSHI Y, Kanda S, Akihama S, Horikawa Y, et al
    [A Case of Inflammatory Myofibroblastic Tumor of The Bladder Treated with Partial Cystectomy].
    Hinyokika Kiyo. 2023;69:179-182.
    Abstract

  1280. HASELAGER D, Dorigo-Zetsma W, Schroder M, Heidt J, et al
    An 80-Year-Old Man With Respiratory Insufficiency After Intravesical Mycobacterium bovis BCG Immunotherapy.
    Chest. 2023;164:e39-e43.
    Abstract

  1281. SONG Y, Peng Y, Qin C
    Relationship between sex and immune checkpoint inhibitors in urothelial carcinoma and renal cell carcinoma.
    World J Urol. 2023;41:2301-2302.
    Abstract

  1282. BRUSASCO C, Di Domenico A, Ennas M, Benelli A, et al
    Application of a protocol for enhanced recovery after radical cystectomy: a before-and-after cohort study.
    World J Urol. 2023;41:2273-2280.
    Abstract

  1283. CHANG YH, Hsu WL, Lee YK, Chiang CJ, et al
    Trends and sex-specific incidence of upper urinary tract cancer in Taiwan: A birth cohort study.
    Cancer Med. 2023;12:15350-15357.
    Abstract

  1284. HE W, Chen C, Lin T, Xu Q, et al
    Epidemiology, treatments, and related biomarkers of locally advanced or metastatic urothelial carcinoma in Chinese population: A scoping review.
    Cancer Med. 2023;12:15384-15403.
    Abstract

  1285. WU S, Li R, Jiang Y, Yu J, et al
    Liquid biopsy in urothelial carcinoma: Detection techniques and clinical applications.
    Biomed Pharmacother. 2023;165:115027.
    Abstract

  1286. JI J, Yao Y, Sun L, Yang Q, et al
    Development and validation of a preoperative nomogram to predict lymph node metastasis in patients with bladder urothelial carcinoma.
    J Cancer Res Clin Oncol. 2023;149:10911-10923.
    Abstract

  1287. SANTONI M, Myint ZW, Buttner T, Takeshita H, et al
    Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study.
    Cancer Immunol Immunother. 2023;72:2961-2970.
    Abstract

  1288. LIN J, Ding M, Qin C, Song Y, et al
    A robust gene prognostic index composed of GZMB, IRF1, and TP63 can stratify the risk of two metastatic urothelial carcinoma cohorts based on immune checkpoint blockade therapy.
    J Cancer Res Clin Oncol. 2023;149:9877-9890.
    Abstract

  1289. HUANG H, Li L, Cao Q, Tan H, et al
    Ectopic prostate tissue at the bladder.
    Am J Med Sci. 2023;366:e37.
    Abstract

  1290. REISWICH V, Schmidt CE, Lennartz M, Hoflmayer D, et al
    GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
    Pathobiology. 2023;90:219-232.
    Abstract

  1291. ZIDAN ASA, Ibrahim ABM, Aly AAM, Mosbah HK, et al
    Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against Cancer Cells.
    Biol Trace Elem Res. 2023;201:4688-4696.
    Abstract

  1292. LOBO J, Lobo C, Leca L, Rodrigues A, et al
    Evaluation of the Implementation and Diagnostic Accuracy of the Paris Classification for Reporting Urinary Cytology in Voided Urine Specimens: A Cyto-Histological Correlation Study in a Cancer Center.
    Pathobiology. 2023;90:233-240.
    Abstract

  1293. ZHANG T, Chen L, Xu X, Shen C, et al
    Knockdown of Long Noncoding RNA Urothelial Carcinoma-Associated 1 Represses Gallbladder Cancer Advancement by Regulating SPOCK1 Expression Through Sponging miR-613.
    Cancer Biother Radiopharm. 2023;38:354-363.
    Abstract

  1294. RYSANKOVA K, Gumulec J, Grepl M, Krhut J, et al
    Acquired haemophilia as a complicating factor in treatment of non-muscle invasive bladder cancer: A case report.
    World J Clin Cases. 2023;11:5338-5343.
    Abstract

  1295. LI H, Jiang H, Huang Z, Chen Z, et al
    Construction and validation of cuproptosis-related lncRNA prediction signature for bladder cancer and immune infiltration analysis.
    Aging (Albany NY). 2023;15.
    Abstract

  1296. LI K, Li S, Tang S, Zhang M, et al
    [Retracted] KIF22 promotes bladder cancer progression by activating the expression of CDCA3.
    Int J Mol Med. 2023;52:92.
    Abstract

  1297. SHEN J, Du M, Liang S, Wang L, et al
    Construction of a cuproptosis-associated lncRNA prognostic signature for bladder cancer and experimental validation of cuproptosis-related lncRNA UBE2Q1-AS1.
    Front Med (Lausanne). 2023;10:1222543.
    Abstract

  1298. ALYUSUF Z, Hassan A, Maki R, Hasan W, et al
    Intravesical urachal cyst masquerading as a bladder malignancy: a case report.
    J Med Case Rep. 2023;17:364.
    Abstract

  1299. ZHUANG J, Mo J, Huang Z, Yan Y, et al
    Mechanisms of Xiaozheng decoction for anti-bladder cancer effects via affecting the GSK3beta/beta-catenin signaling pathways: a network pharmacology-directed experimental investigation.
    Chin Med. 2023;18:104.
    Abstract

  1300. ZHANG D, Yin G, Zheng S, Chen Q, et al
    Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023.
    Abstract

  1301. KUMADA N, Nakane K, Yamada T, Tomioka-Inagawa R, et al
    Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.
    Minim Invasive Ther Allied Technol. 2023.
    Abstract

  1302. JIANG PC, Xu LZ, Ning JZ, Cheng F, et al
    GREM1 is a potential biomarker for the progression and prognosis of bladder cancer.
    World J Surg Oncol. 2023;21:255.
    Abstract

  1303. TOREN P, Wilkins A, Patel K, Burley A, et al
    The sex gap in bladder cancer survival - a missing link in bladder cancer care?
    Nat Rev Urol. 2023 Aug 21. doi: 10.1038/s41585-023-00806.
    Abstract

  1304. BASILE G, Pradere B, Bellmunt J, Roupret M, et al
    A Plea for the Use of Video-recorded Cystoscopy for Blinded Independent Central Review of Tumor Response in Open-label Non-muscle invasive Bladder Cancer Trials.
    Eur Urol Oncol. 2023 Aug 19:S2588-9311(23)00147.
    Abstract

  1305. FUKUHARA H, Hagiwara Y, Oba K, Inoue K, et al
    Real-world experience with 5-aminolevulinic acid for photodynamic diagnosis of bladder cancer (3rd report): cost impact of transurethral resection of bladder tumor in Japan.
    Photodiagnosis Photodyn Ther. 2023 Aug 19:103758.
    Abstract

  1306. HAN D, Guan L, Zhang Y, Yang H, et al
    FGF13A interacts with NPM1 and UBF and inhibits the invasion of bladder cancer cells.
    Biochem Biophys Res Commun. 2023;678:1-10.
    Abstract

  1307. WEI X, Chai Y, Li Z, Che X, et al
    Up-regulated serum lactate dehydrogenase could become a poor prognostic marker in patients with bladder cancer by an evidence-based analysis of 2,182 patients.
    Front Oncol. 2023;13:1233620.
    Abstract

  1308. FANG D, He Y, Yi Y, Mei J, et al
    Hub gene associated with prognosis in bladder cancer is a novel therapeutic target.
    PeerJ. 2023;11:e15670.
    Abstract

  1309. TAN Z, Chen X, Zuo J, Fu S, et al
    Integrating Bulk and Single-Cell RNA Sequencing Reveals Heterogeneity, Tumor Microenvironment, and Immunotherapeutic Efficacy Based on Sialylation-Related Genes in Bladder Cancer.
    J Inflamm Res. 2023;16:3399-3417.
    Abstract

  1310. SU W, Sui W, Cheng X, Zong Y, et al
    Morphology, immunohistochemistry characteristics, and clinical presentation of microcystic urothelial carcinoma: a series of 10 cases.
    Diagn Pathol. 2023;18:94.
    Abstract

  1311. KIM DK, Kim JH, Park JY, Gwon YN, et al
    Neoadjuvant Chemotherapy Prior to Radical Cystectomy for Muscle-Invasive Bladder Cancer With Variant Histology: A Systematic Review and Meta-Analysis of Survival Outcomes and Pathological Features.
    Clin Genitourin Cancer. 2023 Jul 8:S1558-7673(23)00172.
    Abstract

  1312. ELSALEM L, Al Shatnawi A, A Alfaqih M, Alshoh A, et al
    Discovery of a novel genetic variant in the N-acetyltransferase2 (NAT2) gene that is associated with bladder cancer risk.
    Acta Biochim Pol. 2023 Aug 18. doi: 10.18388/abp.2020_6590.
    Abstract

  1313. CHEN X, Liao C, Zou X, Zhang B, et al
    A gene signature of cancer-associated fibroblasts predicts prognosis and treatment response in bladder cancer.
    Clin Transl Oncol. 2023 Aug 18. doi: 10.1007/s12094-023-03270.
    Abstract

  1314. KIM S, Park J, Ho JN, Kim D, et al
    3D vascularized microphysiological system for investigation of tumor-endothelial crosstalk in anti-cancer drug resistance.
    Biofabrication. 2023;15.
    Abstract

  1315. KONOREV D, Bellamri M, Wu CF, Wu MT, et al
    High-Field Asymmetric Waveform Ion Mobility Spectrometry Analysis of Carcinogenic Aromatic Amines in Tobacco Smoke with an Orbitrap Tribrid Mass Spectrometer.
    Chem Res Toxicol. 2023;36:1419-1426.
    Abstract

  1316. LIU Z, Wei S, Tang J
    Clinicopathologic Features of Noninvasive Inverted Urothelial Papillary Tumor.
    Am J Clin Oncol. 2023;46:409-413.
    Abstract

  1317. LU J, Cai S, Wang F, Wu PY, et al
    Development of a prediction model for gross residual in high-grade serous ovarian cancer by combining preoperative assessments of abdominal and pelvic metastases and multiparametric MRI.
    Acad Radiol. 2023;30:1823-1831.
    Abstract

  1318. ZHANG J, Li Z
    Diagnostic accuracy of MUC7 expression for bladder cancer: A systematic review and meta-analysis.
    Medicine (Baltimore). 2023;102:e34828.
    Abstract

  1319. CHICK J, Alexander S, Herbert T, Huddart R, et al
    Evaluation of non-vendor magnetic resonance imaging sequences for use in bladder cancer magnetic resonance image guided radiotherapy.
    Phys Imaging Radiat Oncol. 2023;27:100481.
    Abstract

  1320. MA X, Wei X, Yang G, Li S, et al
    A novel Natural killer cell-related gene signature for improving the prediction of prognosis and immunotherapy response in bladder cancer.
    Comb Chem High Throughput Screen. 2023.
    Abstract

  1321. CUI Y, Yu L, Ma G, Wu J, et al
    Construction of enhanced CT radiomics model for noninvasive prediction of CXCL13's expression and immune infiltrates in bladder cancer based on logistic regression and support vector machine algorithm.
    Asian J Surg. 2023 Aug 29:S1015-9584(23)01299.
    Abstract

  1322. HOU L, Li H, Dong Q
    Clinical experience of modified percutaneous ureterostomy in bladder cancer patients receiving radical cystectomy.
    Asian J Surg. 2023 Aug 29:S1015-9584(23)01281.
    Abstract

  1323. NOH JI, Ahn EJ, Noh MG, Moon KS, et al
    Orthotopic Mouse Models of Urinary Bladder Cancer.
    In Vivo. 2023;37:2039-2043.
    Abstract

  1324. LI H, Wang L, Li H, Zheng P, et al
    Analysis of risk factors for recurrence after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer: 2-year follow-up outcomes.
    Oncology. 2023 Aug 30. doi: 10.1159/000533410.
    Abstract

  1325. LIU X, Qiu Z, Zhang X, Su Z, et al
    Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Environ Toxicol. 2023 Aug 30. doi: 10.1002/tox.23949.
    Abstract

  1326. PLAMBECK BD, Tazegul TE, McElree IM, Steinberg RL, et al
    Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS.
    Urol Case Rep. 2023;50:102516.
    Abstract

  1327. ZHANG D, Yin G, Zheng S, Chen Q, et al
    Construction of a prediction model for prognosis of bladder cancer based on the expression of ion channel-related genes.
    Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023;52:499-509.
    Abstract

  1328. SAKAI D, Hirami Y, Sugita S, Maeda A, et al
    A CASE OF RAPIDLY PROGRESSIVE RETINOPATHY ASSOCIATED WITH PEMBROLIZUMAB IMMUNOTHERAPY FOR METASTATIC UROTHELIAL CARCINOMA.
    Retin Cases Brief Rep. 2023;17:630-634.
    Abstract

  1329. LIU L, Sun FZ, Zhang PY, Xiao Y, et al
    Primary high-grade urothelial carcinoma of prostate with prostatic hyperplasia: a rare case report and review of the literature.
    Aging Male. 2023;26:2252102.
    Abstract

  1330. HENDRI AZ, Soerohardjo I, Heriyanto DS, Khalilullah SA, et al
    Prognostic Significance of PD-L2 Expression in Association with Neutrophil-to-Lymphocyte Ratio in Urothelial Carcinoma of the Bladder.
    Asian Pac J Cancer Prev. 2023;24:2673-2679.
    Abstract

  1331. SU X, Dong C, Liao W, Liu W, et al
    Oncological effectiveness of bladder-preserving trimodal therapy versus radical cystectomy for the treatment of muscle-invasive bladder cancer: a system review and meta-analysis.
    World J Surg Oncol. 2023;21:271.
    Abstract

  1332. MOON S, Pandya V, McDonald A, Basu A, et al
    Analysis of treatment of muscle invasive bladder cancer using the national cancer database: Factors associated with receipt of aggressive therapy.
    Urol Oncol. 2023 Aug 26:S1078-1439(23)00264.
    Abstract

  1333. MARIOTTI A, Spatafora P, Sessa F, Saieva C, et al
    Gender and cystectomy for bladder cancer: A high-volume tertiary urologic care center experience.
    Eur J Surg Oncol. 2023;49:107034.
    Abstract

  1334. ZHANG Y, Chen Y, Wen W
    Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.
    Front Immunol. 2023;14:1152806.
    Abstract

  1335. HUANG LK, Lin YC, Chuang HH, Chuang CK, et al
    Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor.
    Front Oncol. 2023;13:1180888.
    Abstract

  1336. JIA X, Zhang D, Zhou C, Yan Z, et al
    Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer.
    Front Oncol. 2023;13:1175183.
    Abstract

  1337. CHAN K, Hampson A, Hayes J, Rabinowitz J, et al
    Blue light transurethral resection and biopsy of bladder cancer with hexaminolevulinate: Histopathological characteristics and recurrence rates in a single UK centre study.
    BJUI Compass. 2023;4:568-574.
    Abstract

  1338. ZNAIDER VK, Mikkelsen LH, Jensen CFS, Sonksen J, et al
    Primary mucosal melanomas of the urogenital tract: a clinical, pathological, and genetic nationwide survey of Danish patients 1990-2019.
    Scand J Urol. 2023;58:52-59.
    Abstract

  1339. WONG K, Abascal F, Ludwig L, Aupperle-Lellbach H, et al
    Cross-species oncogenomics offers insight into human muscle-invasive bladder cancer.
    Genome Biol. 2023;24:191.
    Abstract

  1340. ALFANO M, Alchera E, Sacchi A, Gori A, et al
    A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on alpha5beta1-targeted gold nanorods.
    J Nanobiotechnology. 2023;21:301.
    Abstract

  1341. DEVLIES W, de Jong JJ, Hofmann F, Bruins HM, et al
    The Diagnostic Accuracy of Cystoscopy for Detecting Bladder Cancer in Adults Presenting with Haematuria: A Systematic Review from the European Association of Urology Guidelines Office.
    Eur Urol Focus. 2023 Aug 24:S2405-4569(23)00184.
    Abstract

  1342. WANG W, Wang K, Qiu J, Li W, et al
    MRI-based radiomics analysis of bladder cancer: prediction of pathological grade and histological variant.
    Clin Radiol. 2023 Aug 12:S0009-9260(23)00327-6. doi: 10.1016/j.crad.2023.
    Abstract

  1343. LALANI AA
    How I Do It: Maintenance avelumab.
    Can J Urol. 2023;30:11633-11638.
    Abstract

  1344. TAN Z, Fu S, Zuo J, Wang J, et al
    Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  1345. YOO D, Min KW, Pyo JS, Kim NY, et al
    Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.
    Medicina (Kaunas). 2023;59:1452.
    Abstract

  1346. RADIC SAVIC Z, Coric V, Vidovic S, Vidovic V, et al
    GPX3 rs8177412 Polymorphism Modifies Risk of Upper Urothelial Tumors in Patients with Balkan Endemic Nephropathy.
    Medicina (Kaunas). 2023;59:1421.
    Abstract

  1347. CLAPS F, Pavan N, Ongaro L, Tierno D, et al
    BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Current Treatment Landscape and Novel Emerging Molecular Targets.
    Int J Mol Sci. 2023;24:12596.
    Abstract

  1348. CHIN FW, Chan SC, Veerakumarasivam A
    Homeobox Gene Expression Dysregulation as Potential Diagnostic and Prognostic Biomarkers in Bladder Cancer.
    Diagnostics (Basel). 2023;13:2641.
    Abstract

  1349. CHIN FW, Hussin H, Chau DM, Ong TA, et al
    Differential Protein Expression Patterns of HOXA13 and HOXB13 Are Associated with Bladder Cancer Progression.
    Diagnostics (Basel). 2023;13:2636.
    Abstract

  1350. KOUKOURIKIS P, Papaioannou M, Georgopoulos P, Apostolidis I, et al
    A Study of DNA Methylation of Bladder Cancer Biomarkers in the Urine of Patients with Neurogenic Lower Urinary Tract Dysfunction.
    Biology (Basel). 2023;12:1126.
    Abstract

  1351. WALZ S, Pollehne P, Vollmer P, Aicher WK, et al
    Effects of Scaffolds on Urine- and Urothelial Carcinoma Tissue-Derived Organoids from Bladder Cancer Patients.
    Cells. 2023;12:2108.
    Abstract

  1352. WANG D, Qiu Z, Wu C
    Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer.
    World J Surg Oncol. 2023;21:267.
    Abstract

  1353. SHAO F, Jin K, Li B, Liu Z, et al
    Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.
    Urol Oncol. 2023 Aug 23:S1078-1439(23)00254.
    Abstract

  1354. LI S, Pan M, Wu X, Bai Y, et al
    miR-152-3p Inhibits Proliferation, Invasion and Autophagy in UMUC3 and TCCSUP Bladder Cancer Cell Lines via Suppressing HMGA2 Expression.
    Ann Clin Lab Sci. 2023;53:607-618.
    Abstract

  1355. LUO Q, Huang C, Chen M
    Comprehensive analysis of N1-methylandenosine regulators and m1A-related mRNAs and lncRNAs as prognostic factors in bladder cancer.
    Gene. 2023 Aug 23:147735. doi: 10.1016/j.gene.2023.147735.
    Abstract

  1356. MINAMI T, Inoue M, Yamaji T, Iwasaki M, et al
    Reproductive factors in the risk of bladder cancer and upper urinary tract cancer: The Japan Public Health Center-based Prospective Study.
    Cancer Epidemiol Biomarkers Prev. 2023 Aug 25:EPI-23-0201.
    Abstract

  1357. HUI G, Stefanoudakis D, Zektser Y, Isaacs DJ, et al
    Do Cancer Genetics Impact Treatment Decision Making? Immunotherapy and Beyond in the Management of Advanced and Metastatic Urothelial Carcinoma.
    Curr Oncol. 2023;30:7398-7411.
    Abstract

  1358. MAO C, Xu N
    Single-cell sequencing data reveals aggressive CD68-type macrophages and prognostic models in bladder cancer.
    Curr Med Chem. 2023 Aug 24. doi: 10.2174/0929867331666230824093312.
    Abstract

  1359. WU X, Xu L, Li X, Zhou Y, et al
    A HER2-targeting antibody-MMAE conjugate RC48 sensitizes immunotherapy in HER2-positive colon cancer by triggering the cGAS-STING pathway.
    Cell Death Dis. 2023;14:550.
    Abstract

  1360. PETTIT MS, Crowder SL, Ackerman RS, Hafez O, et al
    Preoperative Nutritional Status and Enhanced Recovery after Surgery (ERAS) Prior to Radical Cystectomy: A Review of the Literature.
    Nutr Cancer. 2023;75:1743-1751.
    Abstract

  1361. SCHWARZOVA L, Varchulova Novakova Z, Danisovic L, Ziaran S, et al
    Molecular classification of urothelial bladder carcinoma.
    Mol Biol Rep. 2023;50:7867-7877.
    Abstract

  1362. TUDERTI G, Mastroianni R, Chiacchio G, Anceschi U, et al
    Long-term oncologic and functional outcomes following robot-assisted radical cystectomy and intracorporeal Padua ileal bladder: results from a single high-volume center.
    World J Urol. 2023;41:2359-2366.
    Abstract

  1363. FERREIRO-PANTIN M, Anido-Herranz U, Betancor YZ, Cebey-Lopez V, et al
    Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
    ESMO Open. 2023;8:101611.
    Abstract

  1364. LEBRET T, Paoletti X, Pignot G, Roumiguie M, et al
    Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
    World J Urol. 2023;41:2381-2388.
    Abstract

  1365. BAHLBURG H, Schuster F, Tully KH, Butea-Bocu MC, et al
    Prospective evaluation of functional outcomes in 395 patients with an ileal neobladder 1 year after radical cystectomy.
    World J Urol. 2023;41:2367-2374.
    Abstract

  1366. CHO BC, Penkov K, Bondarenko I, Kurochkin A, et al
    A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
    ESMO Open. 2023;8:101589.
    Abstract

  1367. KIM M, Lee JL, Shin SJ, Bae WK, et al
    Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
    ESMO Open. 2023;8:101588.
    Abstract

  1368. LUO Z, Jiao B, Huang T, Zhao H, et al
    Development and external validation of a novel nomogram to predict intravesical recurrence after radical nephroureterectomy: a multicenter study.
    J Cancer Res Clin Oncol. 2023;149:11223-11231.
    Abstract

  1369. SONG J, Sun X, Wang T, Yan L, et al
    Construction and validation of a cuproptosis-related lncRNA prognosis signature in bladder carcinoma.
    J Cancer Res Clin Oncol. 2023;149:11207-11221.
    Abstract

  1370. WU M, Pang Y, Zheng X, Zhao J, et al
    Camrelizumab as adjuvant therapy in urothelial carcinomas after radical surgery in people living with HIV.
    Int J STD AIDS. 2023;34:720-727.
    Abstract

  1371. KOVACS SA, Fekete JT, Gyorffy B
    Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
    Acta Pharmacol Sin. 2023;44:1879-1889.
    Abstract

  1372. SANCHEZ CANOVAS M, Fernandez Garay D, Adoamnei E, Guirao Garcia E, et al
    Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group.
    Clin Transl Oncol. 2023;25:3021-3031.
    Abstract

  1373. ZWAKENBERG MA, Westra JM, Halmos GB, Wedman J, et al
    Narrow-Band Imaging in Transoral Laser Surgery for Early Glottic Cancer: A Randomized Controlled Trial.
    Otolaryngol Head Neck Surg. 2023;169:606-614.
    Abstract

  1374. SU C, Xue J, Liu N
    Cox Regression Analysis of Prognostic Factors of Intensity-Modulated Radiotherapy in Patients with Bladder Cancer.
    Arch Esp Urol. 2023;76:411-417.
    Abstract

  1375. YU Q, Lan T, Ma Z, Wang Z, et al
    Lobaplatin induces apoptosis in T24 and 5637 bladder cancer cells by regulating Bcl-2 and Bax expression and inhibiting the PI3K/Akt signaling pathway.
    Transl Androl Urol. 2023;12:1296-1307.
    Abstract

  1376. SUNG WW
    Re: Wei Shen Tan, Ian M. McElree, Facundo Davaro, et al. Sequential Intravesical Gemcitabine and Docetaxel Is an Alternative to Bacillus Calmette-Guerin for the Treatment of Intermediate-risk Non-muscle-invasive Bladder Cancer. Eur Urol Oncol. In pres
    Eur Urol Oncol. 2023 Sep 5:S2588-9311(23)00171-2. doi: 10.1016/j.euo.2023.
    Abstract

  1377. CATTO JW, North B, Goff M, Carter A, et al
    Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk.
    BMJ Open. 2023;13:e076612.
    Abstract

  1378. HWANG TJ, Davies BJ, Preston MA
    Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer.
    JAMA Oncol. 2023 Sep 7. doi: 10.1001/jamaoncol.2023.3304.
    Abstract

  1379. LIU X, Chen C, Xu P, Chen B, et al
    Development and experimental validation of a folate metabolism-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
    Funct Integr Genomics. 2023;23:291.
    Abstract

  1380. LI B, Li X
    A preliminary study on the establishment of a cyst and cystic neoplasm tissue-mimicking model.
    J Cancer Res Ther. 2023;19:988-994.
    Abstract

  1381. ZHENG J, Liu F, Zhang K, Xiang Y, et al
    High-power green-light laser endoscopic submucosal dissection for non-muscle-invasive bladder cancer: A technical improvement and its initial application.
    J Cancer Res Ther. 2023;19:945-950.
    Abstract

  1382. BENJAMIN DJ, Hsu R
    Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Front Immunol. 2023;14:1258388.
    Abstract

  1383. WANG J, Xiao Y, Yu Q, Zhang C, et al
    HSD17B1 could serve as a prognostic biomarker for bladder cancer patients.
    Asian J Surg. 2023 Sep 4:S1015-9584(23)01094.
    Abstract

  1384. RODEL C
    [Radical cystectomy or trimodal therapy for bladder cancer: where do we stand?].
    Urologie. 2023 Sep 5. doi: 10.1007/s00120-023-02194.
    Abstract

  1385. NIE Z, Guo N, Peng Y, Gao Y, et al
    Duality of the SVIL expression in bladder cancer and its correlation with immune infiltration.
    Sci Rep. 2023;13:14595.
    Abstract

  1386. MA Z, Li Z, Mao Y, Ye J, et al
    AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer.
    Nat Commun. 2023;14:5415.
    Abstract

  1387. REN C, Wang Q, Xu Z, Pan Y, et al
    Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment.
    J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05352.
    Abstract

  1388. SONG Y, Xu T
    Letter to the editor for the article "Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a systematic review and network meta-analysis of oncologic outcomes".
    World J Urol. 2023 Sep 5. doi: 10.1007/s00345-023-04575.
    Abstract

  1389. KIM GH, Yuk HD, Jeong CW, Kwak C, et al
    Renal function change after radical cystectomy for urothelial carcinoma patients with a solitary kidney may be independent of urinary diversion type.
    Investig Clin Urol. 2023;64:457-465.
    Abstract

  1390. CHAAYA C, Zgheib G, El Karak F
    Pharmacotherapy developments in Autophagy inhibitors for bladder cancer.
    Expert Opin Pharmacother. 2023 Sep 5. doi: 10.1080/14656566.2023.2254697.
    Abstract

  1391. OKA S, Sakaguchi K, Hayashida M, Ito S, et al
    First case report of robot-assisted radical cystectomy for bladder cancer that developed after salvage radiotherapy following radical prostatectomy for prostate cancer.
    IJU Case Rep. 2023;6:310-313.
    Abstract

  1392. LARIZADEH MH, Arabnejad F, Ebadzadeh MR
    Sequential Chemotherapy Followed by Radiotherapy Versus Concurrent Chemo-Radiation in Muscle Invasive Bladder Cancer.
    Urol J. 2023 Jul 31. doi: 10.22037/uj.v20i.7525.
    Abstract

  1393. DOSHI B, Athans SR, Woloszynska A
    Biological differences underlying sex and gender disparities in bladder cancer: current synopsis and future directions.
    Oncogenesis. 2023;12:44.
    Abstract

  1394. FAN YW, Lu IC, Hsu MY, Kuo WT, et al
    Synthetic lethality in human bladder cancer cells by curcumin via concurrent Aurora A inhibition and autophagy induction.
    J Nutr Biochem. 2023 Sep 2:109438. doi: 10.1016/j.jnutbio.2023.109438.
    Abstract

  1395. SAHIB AS, Fawzi A, Zabibah RS, Koka NA, et al
    miRNA/epithelial-mesenchymal axis (EMT) axis as a key player in cancer progression and metastasis: A focus on gastric and bladder cancers.
    Cell Signal. 2023 Sep 2:110881. doi: 10.1016/j.cellsig.2023.110881.
    Abstract

  1396. LI S, Ruan B, Wang Z, Xia J, et al
    Glucose dysregulation promotes oncogenesis in human bladder cancer by regulating autophagy and YAP1/TAZ expression.
    J Cell Mol Med. 2023 Sep 4. doi: 10.1111/jcmm.17943.
    Abstract

  1397. LIU Y, Fan M, Xian S, Hu P, et al
    RBP7 Regulated by EBF1 Affects Th2 Cells and the Oocyte Meiosis Pathway in Bone Metastases of Bladder Urothelial Carcinoma.
    Front Biosci (Landmark Ed). 2023;28:189.
    Abstract

  1398. WU Z, Li X, Gu Z, Xia X, et al
    Pyrimidine metabolism regulator-mediated molecular subtypes display tumor microenvironmental hallmarks and assist precision treatment in bladder cancer.
    Front Oncol. 2023;13:1102518.
    Abstract

  1399. LIU J, Yang TY, Dai LQ, Shi K, et al
    Intravesical chemotherapy synergize with an immune adjuvant by a thermo-sensitive hydrogel system for bladder cancer.
    Bioact Mater. 2023;31:315-332.
    Abstract

  1400. DING Z, Jiao B, Chen X, Chen X, et al
    The function of Foxp1 represses beta-adrenergic receptor transcription in the occurrence and development of bladder cancer through STAT3 activity.
    Open Med (Wars). 2023;18:20230647.
    Abstract

  1401. FENG H, Deng Z, Huang Y, Liu Z, et al
    A novel cuproptosis pattern and tumor immune microenvironment characterization in urothelial carcinoma of the bladder.
    Front Immunol. 2023;14:1219209.
    Abstract

  1402. BAMIAS A, Stenzl A, Zagouri F, Andrikopoulou A, et al
    Defining Oligometastatic Bladder Cancer: A Systematic Review.
    Eur Urol Open Sci. 2023;55:28-37.
    Abstract

  1403. FENG Y, Hao Y, Wang Y, Song W, et al
    Ultrasound Molecular Imaging of Bladder Cancer via Extradomain B Fibronectin-Targeted Biosynthetic GVs.
    Int J Nanomedicine. 2023;18:4871-4884.
    Abstract

  1404. TATE T, Plumber SA, Al-Ahmadie H, Chen X, et al
    Combined Mek inhibition and Pparg activation Eradicates Muscle Invasive Bladder cancer in a Mouse Model of BBN-induced Carcinogenesis.
    bioRxiv. 2023 Aug 21:2023.08.19.553961. doi: 10.1101/2023.08.19.553961.
    Abstract

  1405. LI K, Raveendran A, Xie G, Zhang Y, et al
    Prediction for recurrent non-muscle invasive bladder cancer.
    Cancer Biomark. 2023 Aug 15. doi: 10.3233/CBM-220373.
    Abstract

  1406. ZONG R, Ma X, Shi Y, Geng L, et al
    The assessment of pathological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer patients with DCE-MRI and DWI: a systematic review and meta-analysis.
    Br J Radiol. 2023 Sep 3:20230239. doi: 10.1259/bjr.20230239.
    Abstract

  1407. GREBOWSKI R, Saluk J, Bijak M, Szemraj J, et al
    The role of SOD2 and NOS2 genes in the molecular aspect of bladder cancer pathophysiology.
    Sci Rep. 2023;13:14491.
    Abstract

  1408. ANTHONY R, Rajandram R, Yap NY, Mun KS, et al
    Demethylases of H3 lysine 27 (H3K27) expression in urothelial carcinoma (UC) of the urinary bladder.
    Malays J Pathol. 2023;45:261-269.
    Abstract

  1409. NAWAF C, Shiang A, Chauhan PS, Chaudhuri AA, et al
    Circulating tumor DNA based minimal residual disease detection and adjuvant treatment decision-making for muscle-invasive bladder cancer guided by modern clinical trials.
    Transl Oncol. 2023;37:101763.
    Abstract

  1410. ARAD U, Werren C, White D
    Paraneoplastic sacroiliitis.
    BMJ Case Rep. 2023;16:e252572.
    Abstract

  1411. ZANG J, Zhang R, Jin D, Xie F, et al
    Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
    J Pathol. 2023;261:198-209.
    Abstract

  1412. KUJDOWICZ M, Perez-Guaita D, Chlosta P, Okon K, et al
    Fourier transform IR imaging of primary tumors predicts lymph node metastasis of bladder carcinoma.
    Biochim Biophys Acta Mol Basis Dis. 2023;1869:166840.
    Abstract

  1413. TAOKA R, Yamada K, Sawanobori Y, Honda T, et al
    Oral 5-aminolevulinic acid administration before transurethral resection of bladder tumor induces perioperative nausea and vomiting.
    Photodiagnosis Photodyn Ther. 2023;43:103707.
    Abstract

  1414. LI H, Chen J, Li Z, Chen M, et al
    S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8(+) T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma.
    Adv Sci (Weinh). 2023;10:e2300110.
    Abstract

  1415. FACCHINETTI F, Hollebecque A, Braye F, Vasseur D, et al
    Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
    Cancer Discov. 2023;13:1998-2011.
    Abstract

  1416. BABOUDJIAN M, Territo A, Gallioli A, Verri P, et al
    Long-Term Oncologic Outcomes of Endoscopic Management of High-Risk Upper Tract Urothelial Carcinoma: The Fundacio Puigvert's Experience.
    J Endourol. 2023;37:973-977.
    Abstract

  1417. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    Dual immunocytochemical staining of annexin A10 and p53 in low-grade and papillary urothelial carcinoma contributes to improvement of diagnostic accuracy in urine cytology.
    Cancer Cytopathol. 2023;131:548-560.
    Abstract

  1418. POYRY E, Nykanen V, Pulkkinen J, Viljanen E, et al
    Atypical urothelial cells classified according to the Paris System for Reporting Urinary Cytology: A 2-year experience with histological correlation from a Finnish tertiary care center-low rate and high risk of malignancy.
    Cancer Cytopathol. 2023;131:574-580.
    Abstract

  1419. LI P, Meng C, Peng L, Gan L, et al
    Perioperative comparison between robot-assisted and laparoscopic radical cystectomy: An update meta-analysis.
    Asian J Surg. 2023;46:3464-3479.
    Abstract

  1420. MESNARD B, de Vergie S, Chelghaf I, Bouchot O, et al
    Robot-assisted radical nephroureterectomy for upper tract urothelial carcinoma: Peri and postoperative outcomes.
    Actas Urol Esp (Engl Ed). 2023;47:441-449.
    Abstract

  1421. PEREZ JH, Faba OR, Gaya Sopena JM, Palou Redorta J, et al
    An aid to a better understanding of the definitions of BCG failure provided by the European Urology Association.
    Actas Urol Esp (Engl Ed). 2023;47:395-397.
    Abstract

  1422. TEKE K, Avci IE, Cinar NB, Baynal EA, et al
    Immune-inflammatory-nutritional status predicts oncologic outcomes after radical cystectomy for urothelial carcinoma of bladder.
    Actas Urol Esp (Engl Ed). 2023;47:430-440.
    Abstract

  1423. MEHMANDAR-OSKUIE A, Tohidfar M, Hajikhani B, Karimi F, et al
    Anticancer Effects of Cell-Free Culture Supernatant of Escherichia coli in Bladder Cancer Cell Line: New Insight into the Regulation of Inflammation.
    Gene. 2023 Sep 12:147795. doi: 10.1016/j.gene.2023.147795.
    Abstract

  1424. DE ARAUJO SOUZA LC, Ribeiro EC, Pinto TDA, de Ulhoa Barbosa TMJ, et al
    Urothelial bladder cancer with cardiac metastasis: Literature review and case report.
    Int J Surg Case Rep. 2023;111:108630.
    Abstract

  1425. SLUSARCZYK A
    ASO Author Reflections: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 14. doi: 10.1245/s10434-023-14301.
    Abstract

  1426. YAO X, Xu Z, Duan C, Zhang Y, et al
    Role of human papillomavirus and associated viruses in bladder cancer: An updated review.
    J Med Virol. 2023;95:e29088.
    Abstract

  1427. ZHANG P, Xie X, Li C, Zhang C, et al
    LRRC59 serves as a novel biomarker for predicting the progression and prognosis of bladder cancer.
    Cancer Med. 2023 Sep 14. doi: 10.1002/cam4.6542.
    Abstract

  1428. MARTINI A, Tholomier C, Mokkapati S, Dinney CPN, et al
    Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval.
    Front Immunol. 2023;14:1260498.
    Abstract

  1429. ZHENG R, Gao F, Mao Z, Xiao Y, et al
    LncRNA BCCE4 Genetically Enhances the PD-L1/PD-1 Interaction in Smoking-Related Bladder Cancer by Modulating miR-328-3p-USP18 Signaling.
    Adv Sci (Weinh). 2023 Sep 13:e2303473. doi: 10.1002/advs.202303473.
    Abstract

  1430. YAO Z, Xu N, Shang G, Wang H, et al
    Proteogenomics of different urothelial bladder cancer stages reveals distinct molecular features for papillary cancer and carcinoma in situ.
    Nat Commun. 2023;14:5670.
    Abstract

  1431. LI L, Yang J, Peng D, Zhang Y, et al
    177Lu-FAP-2286 Therapy in a Case of Recurrent Bladder Cancer With Multiple Metastatic Lesions.
    Clin Nucl Med. 2023 Sep 13. doi: 10.1097/RLU.0000000000004865.
    Abstract

  1432. DENG Y, Deng Y, Wang H, Xie H, et al
    Solitary Axillary Lymph Node Metastasis From Bladder Cancer Detected by FDG PET/CT.
    Clin Nucl Med. 2023 Sep 7. doi: 10.1097/RLU.0000000000004827.
    Abstract

  1433. MULLER G, Butea-Bocu MC, Beyer B, Tully KH, et al
    Prospective evaluation of return to work, health-related quality of life and psychosocial distress after radical cystectomy: 1-year follow-up in 230 employed German bladder cancer patients.
    World J Urol. 2023 Sep 13. doi: 10.1007/s00345-023-04570.
    Abstract

  1434. ZENG Y, Lv C, Wan B, Gong B, et al
    The current landscape of m6A modification in urological cancers.
    PeerJ. 2023;11:e16023.
    Abstract

  1435. ABDEL-HAFIZ HA, Kailasam Mani SK, Huang W, Gouin KH 3rd, et al
    Single-cell profiling of murine bladder cancer identifies sex-specific transcriptional signatures with prognostic relevance.
    iScience. 2023;26:107703.
    Abstract

  1436. ISLAM NU, Jehangir M, Parry AH, Nazir SS, et al
    Diagnostic performance of multiparametric MRI based Vesical Imaging-Reporting and Data System (VI-RADS) scoring in discriminating between non-muscle invasive and muscle invasive bladder cancer.
    Pol J Radiol. 2023;88:e356-e364.
    Abstract

  1437. ZHANG ZG, Shi ZD, Dong JJ, Chen YA, et al
    Novel potential urinary biomarkers for effective diagnosis and prognostic evaluation of high-grade bladder cancer.
    Transl Cancer Res. 2023;12:1992-2007.
    Abstract

  1438. ZHANG C, Kang Y, Miao P, Chang D, et al
    A novel genes-based signature with prognostic value and predictive ability to select patients responsive to Atezolizumab treatment in bladder cancer: an analysis on data from real-world studies.
    Transl Cancer Res. 2023;12:2063-2070.
    Abstract

  1439. LI W, Xiong Y, Zhu J, Jin X, et al
    Establishing a prognostic model with ferroptosis-related long non-coding RNAs in bladder cancer.
    Transl Cancer Res. 2023;12:2023-2032.
    Abstract

  1440. TOPP BG, Channavazzala M, Mayawala K, De Alwis DP, et al
    Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.
    Cancer Cell. 2023;41:1680-1688.
    Abstract

  1441. SONG Y, Xu T
    Letter to the editor for the article "5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (alpha-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data".
    World J Urol. 2023 Sep 12. doi: 10.1007/s00345-023-04607.
    Abstract

  1442. QIN Y, Zu X, Li Y, Han Y, et al
    A cancer-associated fibroblast subtypes-based signature enables the evaluation of immunotherapy response and prognosis in bladder cancer.
    iScience. 2023;26:107722.
    Abstract

  1443. HAN C, Wang J, Chen YL, Guan CP, et al
    The role of Bacillus Calmette-Guerin administration on the risk of dementia in bladder cancer patients: a systematic review and meta-analysis.
    Front Aging Neurosci. 2023;15:1243588.
    Abstract

  1444. TREHAN D, Kumari R, Sharma J, Satuluri SH, et al
    Inhibition of protein kinase C isozymes causes immune profile alteration and possibly decreased tumorigenesis in bladder cancer.
    Am J Cancer Res. 2023;13:3832-3852.
    Abstract

  1445. WANG X, Luo L, Xu J, Lu Q, et al
    Echinatin inhibits tumor growth and synergizes with chemotherapeutic agents against human bladder cancer cells by activating p38 and suppressing Wnt/beta-catenin pathways.
    Genes Dis. 2023;11:1050-1065.
    Abstract

  1446. WANG W, Zhang X, Jiang S, Xu P, et al
    A novel signature constructed by differential genes of muscle-invasive and non-muscle-invasive bladder cancer for the prediction of prognosis in bladder cancer.
    Front Immunol. 2023;14:1187286.
    Abstract

  1447. YANG F, Liu G, Wei J, Dong Y, et al
    Relationship between Bladder Cancer, Nutritional Supply, and Treatment Strategies: A Comprehensive Review.
    Nutrients. 2023;15:3812.
    Abstract

  1448. PURNOMO AF, Daryanto B, Seputra KP, Budaya TN, et al
    Methylenetetrahydrofolate Reductase C677T (rs1801133) Polymorphism Is Associated with Bladder Cancer in Asian Population: Epigenetic Meta-Analysis as Precision Medicine Approach.
    Cancers (Basel). 2023;15:4402.
    Abstract

  1449. SUN D, Hadjiiski L, Gormley J, Chan HP, et al
    Survival Prediction of Patients with Bladder Cancer after Cystectomy Based on Clinical, Radiomics, and Deep-Learning Descriptors.
    Cancers (Basel). 2023;15:4372.
    Abstract

  1450. YAO Q, Jiang H, Niu H, Hu G, et al
    Rotatable Bi-Channel En Bloc Resection of Bladder Tumor for Non-Muscle-Invasive Bladder Cancer in an Ex Vivo Porcine Model.
    Cancers (Basel). 2023;15:4255.
    Abstract

  1451. KARIMI M, Mendez-Pineda S, Blanche H, Boland A, et al
    A Case-Only Genome-Wide Interaction Study of Smoking and Bladder Cancer Risk: Results from the COBLAnCE Cohort.
    Cancers (Basel). 2023;15:4218.
    Abstract

  1452. REYNOLDS T, Gordon M, Monar GVF, Moon D, et al
    Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection.
    Int J Mol Sci. 2023;24:13651.
    Abstract

  1453. XIE B, Lin J, Chen X, Zhou X, et al
    CircXRN2 suppresses tumor progression driven by histone lactylation through activating the Hippo pathway in human bladder cancer.
    Mol Cancer. 2023;22:151.
    Abstract

  1454. YU QX, Wang JC, Liu JF, Ye LX, et al
    Adhesion-regulating molecule 1 (ADRM1) can be a potential biomarker and target for bladder cancer.
    Sci Rep. 2023;13:14803.
    Abstract

  1455. WANG J, Xiao Y, Wu R, Zhang C, et al
    TGM1 could predict overall survival for patients with bladder cancer.
    Asian J Surg. 2023 Sep 6:S1015-9584(23)01104.
    Abstract

  1456. HMAIDY O, Jamal BR, Mayo M, Haidar M, et al
    Non-muscle invasive urothelial bladder cancer in a 17-year-old male: A rare case report.
    Int J Surg Case Rep. 2023;110:108728.
    Abstract

  1457. WALZ S, Pollehne P, Geng R, Schneider J, et al
    A Protocol for Organoids from the Urine of Bladder Cancer Patients.
    Cells. 2023;12:2188.
    Abstract

  1458. LAPUENTE M, Conway D, Wood LS, Kehoe K, et al
    Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Clin J Oncol Nurs. 2023;27:71-80.
    Abstract

  1459. MANSINHO A, Cruz A, Marconi L, Pinto C, et al
    Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Adv Ther. 2023;40:4134-4150.
    Abstract

  1460. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    Clinicopathological significance of TUBB3 in upper tract urothelial carcinoma and possible application in urine cytology.
    Pathol Int. 2023;73:444-455.
    Abstract

  1461. LI J, Zhang H, Wu J, Li L, et al
    Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
    Cancer Biomark. 2023;38:77-102.
    Abstract

  1462. MAYER M, Nachtsheim L, Prinz J, Shabli S, et al
    Nectin-4 is frequently expressed in primary salivary gland cancer and corresponding lymph node metastases and represents an important treatment-related biomarker.
    Clin Exp Metastasis. 2023;40:395-405.
    Abstract

  1463. LI J, Liu X
    Coptisine inhibits the malignancy of bladder carcinoma cells and regulates XPO1 expression.
    Chem Biol Drug Des. 2023;102:805-814.
    Abstract

  1464. BILEN MA, Robinson SB, Schroeder A, Peng J, et al
    Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study).
    Oncologist. 2023;28:790-798.
    Abstract

  1465. MIAO S, He Q, Zhang Y, Wang L, et al
    Management of urinary incontinence after radical cystectomy and orthotopic neobladder: A scoping review of international practices.
    Nurs Open. 2023;10:6618-6634.
    Abstract

  1466. ROCCO B, Sighinolfi MC, Sarchi L, Assumma S, et al
    First case of robot-assisted radical cystectomy and intracorporeal neobladder reconstruction with the Hugo RAS system: step-by-step surgical setup and technique.
    J Robot Surg. 2023;17:2247-2251.
    Abstract

  1467. KURITZA V, Pei S
    Zosteriform cutaneous metastases from urothelial carcinoma: Report of a rare case and literature review.
    J Cutan Pathol. 2023 May 29. doi: 10.1111/cup.14471.
    Abstract

  1468. KAIMAKLIOTIS HZ, Tachibana I, Woldu S, Labbate C, et al
    The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:387.
    Abstract

  1469. CHUA KJ, Patel HV, Srivastava A, Doppalapudi SK, et al
    Annual trends of cystectomy complications: A contemporary analysis of the NSQIP database.
    Urol Oncol. 2023;41:390.
    Abstract

  1470. SOBHANI S, Alsyouf M, Ahmadi H, Ghoreifi A, et al
    Association between early postradical cystectomy kidney injury and perioperative outcome in enhanced recovery era.
    Urol Oncol. 2023;41:389.
    Abstract

  1471. DAVARO F, Davaro E, Rose K, Murthy P, et al
    Impact of surgical margin and extent of lymphadenectomy on oncologic outcomes in plasmacytoid urothelial carcinoma.
    Urol Oncol. 2023;41:389.
    Abstract

  1472. SANGOI AR, Akgul M, Williamson SR
    Artifactual Cystic Spaces in Prostatic Transurethral Resections and Related Specimens: A Potential Diagnostic Confounder.
    Int J Surg Pathol. 2023;31:1048-1056.
    Abstract

  1473. LAI S, Liu J, Lai C, Seery S, et al
    Prognostic variations between "primary" and "progressive" muscle-invasive bladder cancer following radical cystectomy: A novel propensity score-based multicenter cohort study.
    Int J Surg. 2023 Sep 22. doi: 10.1097/JS9.0000000000000790.
    Abstract

  1474. LOPEZ-BELTRAN A, Raspollini MR, Hansel D, Comperat E, et al
    International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer: Working Group 3: Subcategorization of T1 Bladder Cancer.
    Am J Surg Pathol. 2023 Sep 22. doi: 10.1097/PAS.0000000000002121.
    Abstract

  1475. MALIK RF, Berry R, Lau BD, Busireddy KR, et al
    Systematic Evaluation of Imaging Features of Early Bladder Cancer Using Computed Tomography Performed before Pathologic Diagnosis.
    Tomography. 2023;9:1734-1744.
    Abstract

  1476. AHMADIEH N, Zeidan T, Chebel JA, Haddad FG, et al
    Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in a Lebanese experience: in all aspects.
    Gulf J Oncolog. 2023;1:33-39.
    Abstract

  1477. NAVARRO-DOMENECH I, Arulanantham S, Liu ZA, Tjong M, et al
    Clinical and dosimetric outcomes of image-guided, dose-painted radiotherapy in muscle invasive bladder cancer.
    Radiat Oncol. 2023;18:154.
    Abstract

  1478. COE C, Chirputkar K, Joseph L, Jude EB, et al
    Pedal acrometastasis secondary to urothelial carcinoma masquerading as Charcot arthropathy in a patient with diabetes.
    BMJ Case Rep. 2023;16:e254468.
    Abstract

  1479. PISZCZEK R, Krajewski W, Subiela JD, Del Giudice F, et al
    Prognosis of patients with T1 low-grade urothelial bladder cancer treated with bacillus Calmette-Guerin immunotherapy.
    Minerva Urol Nephrol. 2023;75:591-599.
    Abstract

  1480. WANG S, Ge C
    Chronic Obstructive Pulmonary Disease Mortality in Bladder Cancer Patients: A SEER-Based Competing Risk Analysis.
    Urol J. 2023 Sep 17. doi: 10.22037/uj.v20i.7644.
    Abstract

  1481. VAN DORP J, van der Heijden MS
    The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition.
    Front Immunol. 2023;14:1235884.
    Abstract

  1482. HEISHIMA K, Sugito N, Abe C, Hirata A, et al
    Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model.
    Mol Ther Nucleic Acids. 2023;33:960-982.
    Abstract

  1483. HUANG H, Liu A, Liang Y, Xin Y, et al
    A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.
    BMC Med. 2023;21:357.
    Abstract

  1484. GAO D, Wang R, Gong Y, Yu X, et al
    CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway.
    Free Radic Biol Med. 2023 Sep 17:S0891-5849(23)00641.
    Abstract

  1485. SLUSARCZYK A, Zapala P, Zapala L, Borkowski T, et al
    ASO Visual Abstract: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer-A Population-Based Analysis.
    Ann Surg Oncol. 2023 Sep 19. doi: 10.1245/s10434-023-14286.
    Abstract

  1486. SONG H, Yang S, Yu B, Li N, et al
    CT-based deep learning radiomics nomogram for the prediction of pathological grade in bladder cancer: a multicenter study.
    Cancer Imaging. 2023;23:89.
    Abstract

  1487. BREYER J, Eckstein M, Sikic D, Wezel F, et al
    Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial).
    Sci Rep. 2023;13:15437.
    Abstract

  1488. MONDA S, Pratsinis M, Lui H, Noel O, et al
    Secondary Bladder Cancer After Prostate Cancer Treatment: An Age-matched Comparison Between Radiation and Surgery.
    Eur Urol Focus. 2023 Sep 16:S2405-4569(23)00199.
    Abstract

  1489. CHEN Y, Zeng S, Jiao B, Zhang H, et al
    Adherence to the Diabetes Risk Reduction Diet and bladder cancer risk in the Prostate, Lung, Colorectal, Ovarian (PLCO) cohort.
    Cancer Epidemiol Biomarkers Prev. 2023.
    Abstract

  1490. KADHUM T, Selinski S, Blaszkewicz M, Reinders J, et al
    Bladder cancer course, four genetic high-risk variants, and histopathological findings.
    EXCLI J. 2023;22:867-879.
    Abstract

  1491. MA SY, An Y, Sun JX, Xu MY, et al
    The effect of different timing of blood transfusion on oncological outcomes of patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2023;13:1223592.
    Abstract

  1492. FAHMY O, Kochergin M, Asimakopoulos AD, Gakis G, et al
    Practice change: No benefit of extended lymphadenectomy at radical cystectomy in patients with muscle invasive bladder cancer.
    Semin Oncol. 2023 Sep 14:S0093-7754(23)00064.
    Abstract

  1493. DING Q, Tang W, Li X, Ding Y, et al
    Mitochondrial-targeted brequinar liposome boosted mitochondrial-related ferroptosis for promoting checkpoint blockade immunotherapy in bladder cancer.
    J Control Release. 2023 Sep 15:S0168-3659(23)00611.
    Abstract

  1494. BOLL LM, Perera-Bel J, Rodriguez-Vida A, Arpi O, et al
    The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
    Sci Rep. 2023;13:15287.
    Abstract

  1495. YANAGISAWA T, Sato S, Hayashida Y, Okada Y, et al
    Clinical impact of detrusor muscle in en bloc resection for T1 bladder cancer.
    Urol Oncol. 2023 Sep 13:S1078-1439(23)00263.
    Abstract

  1496. ZHANG Y, Rumgay H, Li M, Yu H, et al
    The global landscape of bladder cancer incidence and mortality in 2020 and projections to 2040.
    J Glob Health. 2023;13:04109.
    Abstract

  1497. LUO P, Zheng L, Zou J, Chen T, et al
    Insights into vitamin A in bladder cancer, lack of attention to gut microbiota?
    Front Immunol. 2023;14:1252616.
    Abstract

  1498. STOCKEM CF, Mellema JJJ, van Rhijn BWG, Boellaard TN, et al
    Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial.
    Front Oncol. 2023;13:1246603.
    Abstract

  1499. QU Y, Yao Z, Xu N, Shi G, et al
    Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma.
    Cell Rep Med. 2023;4:101166.
    Abstract

  1500. SOUKUP J, Manethova M, Stejskal V, Hornychova H, et al
    Immunoreactivity of HOXB13 in Neuroendocrine Neoplasms Is a Sensitive and Specific Marker of Rectal Well-Differentiated Neuroendocrine Tumors.
    Endocr Pathol. 2023;34:333-341.
    Abstract

  1501. ASERO V, Scornajenghi CM, Carino D, Pandolfo SD, et al
    Comment on: "Stage-dependent survival in patients treated with neoadjuvant chemotherapy and radical cystectomy".
    Minerva Urol Nephrol. 2023;75:649-651.
    Abstract

  1502. LUO HL, Lee YC, Chang YL, Hsu WC, et al
    MicroRNA-145-5p suppresses cell proliferation, migration, and invasion in upper tract urothelial carcinoma by targeting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase.
    J Cell Biochem. 2023;124:1324-1345.
    Abstract

  1503. HUANG W, Warrick JI, Chen G
    Clinical and pathological characteristics of metastatic tumors to the urinary bladder.
    Ann Diagn Pathol. 2023;66:152179.
    Abstract

  1504. QIU H, Wang J, Zhi Y, Yan B, et al
    Hyaluronic Acid-Conjugated Fluorescent Probe-Shielded Polydopamine Nanomedicines for Targeted Imaging and Chemotherapy of Bladder Cancer.
    ACS Appl Mater Interfaces. 2023 Sep 28. doi: 10.1021/acsami.3c09564.
    Abstract

  1505. ZOU F, Chen W, Song T, Xing J, et al
    SQLE Knockdown inhibits bladder cancer progression by regulating the PTEN/AKT/GSK3beta signaling pathway through P53.
    Cancer Cell Int. 2023;23:221.
    Abstract

  1506. ZHAN Y, Liu Y, Lin J, Fu X, et al
    Author Correction: Synthetic Tet-inducible artificial microRNAs targeting beta-catenin or HIF-1alpha inhibit malignant phenotypes of bladder cancer cells T24 and 5637.
    Sci Rep. 2023;13:16331.
    Abstract

  1507. ZHANG W, Cai K, Sun Z, Xiang Q, et al
    Elevating Second Near-Infrared Photothermal Conversion Efficiency of Hollow Gold Nanorod for a Precise Theranostic of Orthotopic Bladder Cancer.
    ACS Nano. 2023 Sep 28. doi: 10.1021/acsnano.3c04175.
    Abstract

  1508. YANOVA MR, Zhiyanov AP, Antipenko ID, Slobodov SA, et al
    Intracellular Gemcitabine Monophosphate Levels Predict Chemotherapy Efficacy in Gemcitabine-Treated Patients with Bladder Cancer.
    Dokl Biochem Biophys. 2023 Sep 29. doi: 10.1134/S1607672923700503.
    Abstract

  1509. PETEINARIS A, Perros P, Prokopakis I, Fasoulakis Z, et al
    Bladder Cancer during Pregnancy: A Review of the Literature.
    J Pers Med. 2023;13:1418.
    Abstract

  1510. SCHULZ HAGERSTEN E, Ottosson K, Pelander S, Johansson M, et al
    The Risk of Thromboembolism in Patients with Muscle Invasive Bladder Cancer before and after Cystectomy Depending on Blood Group and Neoadjuvant Chemotherapy-A Multicentre Retrospective Cohort Study.
    J Pers Med. 2023;13:1355.
    Abstract

  1511. YE L, Wang Y, Xiang W, Yao J, et al
    Radiomic Analysis of Quantitative T2 Mapping and Conventional MRI in Predicting Histologic Grade of Bladder Cancer.
    J Clin Med. 2023;12:5900.
    Abstract

  1512. FLORES MONAR GV, Reynolds T, Gordon M, Moon D, et al
    Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers.
    Int J Mol Sci. 2023;24:14374.
    Abstract

  1513. ELAHI NAJAFI MA, Yasui M, Teramoto Y, Tatenuma T, et al
    GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer.
    Int J Mol Sci. 2023;24:13733.
    Abstract

  1514. KHORAMINIA F, Fuster S, Kanwal N, Olislagers M, et al
    Artificial Intelligence in Digital Pathology for Bladder Cancer: Hype or Hope? A Systematic Review.
    Cancers (Basel). 2023;15:4518.
    Abstract

  1515. ELKARTA A, Awadalla A, El-Hefnawy A, Mosbah A, et al
    Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study.
    Clin Genitourin Cancer. 2023 Aug 10:S1558-7673(23)00186.
    Abstract

  1516. SACHKO AM, Goryainova OS, Ivanova TI, Nikolaeva IY, et al
    Analysis of Transferrin in the Urine of Patients with Bladder Cancer Using Nanobodies.
    Biochemistry (Mosc). 2023;88:1105-1115.
    Abstract

  1517. TAN M, Pan Q, Gong H, Zhai X, et al
    Super-enhancer-associated SNHG15 cooperating with FOSL1 contributes to bladder cancer progression through the WNT pathway.
    Pharmacol Res. 2023 Sep 25:106940. doi: 10.1016/j.phrs.2023.106940.
    Abstract

  1518. SLUSARCZYK A, Zapala P
    Reply to Letter to Editor: Cancer-Specific Mortality of Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 27. doi: 10.1245/s10434-023-14360.
    Abstract

  1519. SABATE ORTEGA J, Fort Culillas R, Escoda Garcia M, Vasquez-Dongo CA, et al
    Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer.
    Curr Oncol. 2023;30:7802-7809.
    Abstract

  1520. KOGA F
    Selective multimodal bladder-sparing therapy for muscle-invasive bladder cancer: the present and the future.
    Expert Rev Anticancer Ther. 2023 Sep 27:1-13. doi: 10.1080/14737140.2023.2257389
    Abstract

  1521. ZHENG K, Li M
    Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO.
    Mol Biotechnol. 2023 Sep 25. doi: 10.1007/s12033-023-00892.
    Abstract

  1522. LIND AK, Liedberg F, Aljabery F, Blackberg M, et al
    Health-related quality of life prior to and 1 year after radical cystectomy evaluated with FACT-G and FACT-VCI questionnaires.
    Scand J Urol. 2023;58:76-83.
    Abstract

  1523. MAGALHAES JC, Sousa M, Basto R, Fraga T, et al
    Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer.
    Cureus. 2023;15:e45672.
    Abstract

  1524. LIANG T, Tao T, Wu K, Liu L, et al
    Cancer-Associated Fibroblast-Induced Remodeling of Tumor Microenvironment in Recurrent Bladder Cancer.
    Adv Sci (Weinh). 2023 Sep 24:e2303230. doi: 10.1002/advs.202303230.
    Abstract

  1525. WANG L, Song R, Ma M, Chen Y, et al
    Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway.
    Chem Biol Interact. 2023 Sep 21:110725. doi: 10.1016/j.cbi.2023.110725.
    Abstract

  1526. LIU J, Wu P, Lai S, Wang J, et al
    Identifying possible hub genes and biological mechanisms shared between bladder cancer and inflammatory bowel disease using machine learning and integrated bioinformatics.
    J Cancer Res Clin Oncol. 2023 Sep 23. doi: 10.1007/s00432-023-05266.
    Abstract

  1527. LIU T, Fan MQ, Xie XX, Shu QP, et al
    Activation of CTNNB1 by deubiquitinase UCHL3-mediated stabilization facilitates bladder cancer progression.
    J Transl Med. 2023;21:656.
    Abstract

  1528. WANG X, Liu J, Azoitei A, Eiseler T, et al
    Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamics.
    Cell Mol Life Sci. 2023;80:299.
    Abstract

  1529. ZOU F, Rao T, Chen W, Song T, et al
    DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7.
    Cell Signal. 2023;112:110893.
    Abstract

  1530. KOBAYASHI G, Hayashi T, Sentani K, Uraoka N, et al
    MCM4 expression is associated with high-grade histology, tumor progression and poor prognosis in urothelial carcinoma.
    Diagn Pathol. 2023;18:106.
    Abstract

  1531. JIANG R, Wang X, Li Z, Cai H, et al
    Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
    BMC Urol. 2023;23:150.
    Abstract

  1532. LI W, Li C, Liu T, Wang Y, et al
    Self-reported sleep disorders and the risk of all cancer types: evidence from the Kailuan Cohort study.
    Public Health. 2023;223:209-216.
    Abstract

  1533. SPAAS M, Sundahl N, Kruse V, Rottey S, et al
    Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
    JAMA Oncol. 2023;9:1205-1213.
    Abstract

  1534. GODARD L, Lee L, McGuinness B, Shirsat H, et al
    Mycotic Abdominal Aortic Aneurysm Secondary to BCG Therapy for Non-muscle Invasive Urothelial Carcinoma of the Bladder.
    Vasc Endovascular Surg. 2023;57:776-780.
    Abstract

  1535. SEKIGUCHI Y, Nishimura Y, Kanda H, Kawamura M, et al
    A Case of Immune Thrombocytopenia Occurring after Radiotherapy plus Atezolizumab Treatment for Bladder Cancer.
    Gan To Kagaku Ryoho. 2023;50:985-992.
    Abstract

  1536. METHODS IN MEDICINE CAM
    Retracted: MicroRNA-143-3p/TBX3 Axis Represses Malignant Cell Behaviors in Bladder Cancer.
    Comput Math Methods Med. 2023;2023:9763968.
    Abstract

  1537. METHODS IN MEDICINE CAM
    Retracted: The Effect of Narrative Nursing Intervention on Shame in Elderly Patients with Bladder Cancer after Ileal Bladder Replacement: A Cohort Study.
    Comput Math Methods Med. 2023;2023:9761783.
    Abstract

  1538. KIM Y, Ju H, Yoo SY, Jeong J, et al
    Glutathione dynamics is a potential predictive and therapeutic trait for neoadjuvant chemotherapy response in bladder cancer.
    Cell Rep Med. 2023 Sep 27:101224. doi: 10.1016/j.xcrm.2023.101224.
    Abstract

  1539. HUSSEIN AA, Bhat TA, Jing Z, Gomez EC, et al
    Does the urinary microbiome profile change after treatment of bladder cancer?
    World J Urol. 2023 Oct 5. doi: 10.1007/s00345-023-04627.
    Abstract

  1540. HATTORI Y, Kato M, Imamura T, Inaba S, et al
    [Idiopathic Thrombocytopenia Purpura After Pembrolizumab Treatment Against Locally Recurrent Bladder Cancer : A Case Report].
    Hinyokika Kiyo. 2023;69:255-258.
    Abstract

  1541. KIM CJ, Ide H, Nakamura M, Hanada E, et al
    [Occurrence of Distant Metastasis During Bladder Presevation in T1 high-grade Bladder Cancer: Report of Three Cases].
    Hinyokika Kiyo. 2023;69:249-254.
    Abstract

  1542. LI R
    Organ-sparing precision treatment for muscle-invasive bladder cancer.
    Nat Med. 2023 Oct 4. doi: 10.1038/s41591-023-02575.
    Abstract

  1543. MOREO E, Jarit-Cabanillas A, Robles-Vera I, Uranga S, et al
    Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung.
    Nat Commun. 2023;14:6090.
    Abstract

  1544. VIEIRA HM, Kasper DP, Wang R, Smith LM, et al
    Comparison of sequential versus concurrent chemoradiation regimens in non-metastatic muscle-invasive bladder cancer.
    Radiat Oncol J. 2023;41:154-162.
    Abstract

  1545. XIONG S, Li S, Zeng J, Nie J, et al
    Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
    Front Immunol. 2023;14:1253586.
    Abstract

  1546. PAN G, Jiang B, Yi Z, Yin J, et al
    Exosomal miR-105-5p derived from bladder cancer stem cells targets for GPR12 to promote the malignancy of bladder cancer.
    BMC Urol. 2023;23:155.
    Abstract

  1547. INOUE Y, Yamada T, Fujihara A, Miyashita M, et al
    Treatment impact of newly approved therapeutic agents for metastatic urothelial carcinoma in Japan: a single-center retrospective study.
    Sci Rep. 2023;13:16580.
    Abstract

  1548. OKADA M, Shindo T, Fujino K, Maeda T, et al
    Prevention of local symptoms in muscle invasive bladder cancer patients: clinical significance of local radiation therapy.
    Support Care Cancer. 2023;31:607.
    Abstract

  1549. NORGAARD M, Mailhac A, Fagerlund K, Strunz-McKendry T, et al
    Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
    Acta Oncol. 2023 Oct 3:1-7. doi: 10.1080/0284186X.2023.2263154.
    Abstract

  1550. WANG M, Zhang C, Ying Y, Hua M, et al
    PKMYT1 induced by YAP/TEAD1 gives rise to the progression and worse prognosis of bladder cancer.
    Mol Carcinog. 2023 Oct 3. doi: 10.1002/mc.23643.
    Abstract

  1551. ZAIDI N, Siddiqui Z, Sankhwar SN, Srivastava AN, et al
    Urinary microRNA-10a levels in diagnosis and prognosis of urinary bladder cancer.
    J Cancer Res Ther. 2023;19:1324-1329.
    Abstract

  1552. WU T, Li N, Wu X, Du Y, et al
    LncRNA LINC00592 mediates the promoter methylation of WIF1 to promote the development of bladder cancer.
    Open Med (Wars). 2023;18:20230788.
    Abstract

  1553. ZHENG J, Lu S, Huang Y, Chen X, et al
    Preoperative fluorescence in situ hybridization analysis as a predictor of tumor recurrence in patients with non-muscle invasive bladder cancer: a bi-institutional study.
    J Transl Med. 2023;21:685.
    Abstract

  1554. GALSKY MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, et al
    Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
    Nat Med. 2023 Oct 2. doi: 10.1038/s41591-023-02568.
    Abstract

  1555. WANG G, He X, Dai H, Lin L, et al
    WDR4 promotes the progression and lymphatic metastasis of bladder cancer via transcriptional down-regulation of ARRB2.
    Oncogenesis. 2023;12:47.
    Abstract

  1556. ZUO M, Chen H, Liao Y, He P, et al
    Sulforaphane and bladder cancer: a potential novel antitumor compound.
    Front Pharmacol. 2023;14:1254236.
    Abstract

  1557. WANG X, Pan J, Guan Q, Ren N, et al
    Identification of novel lactate metabolism-related lncRNAs with prognostic value for bladder cancer.
    Front Pharmacol. 2023;14:1215296.
    Abstract

  1558. FRERICHS LM, Frerichs B, Petzsch P, Kohrer K, et al
    Tumorigenic effects of human mesenchymal stromal cells and fibroblasts on bladder cancer cells.
    Front Oncol. 2023;13:1228185.
    Abstract

  1559. WU Z, Feng Z, Wei H, Lin C, et al
    Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer.
    Front Med (Lausanne). 2023;10:1193133.
    Abstract

  1560. ROSLAN A, Said DS, Sulaiman N, Mohd Ghani KA, et al
    Cluster of differentiation 147 (CD147) as potential membrane protein biomarker for bladder cancer cells.
    J Pharm Biomed Anal. 2023;236:115729.
    Abstract

  1561. XU JH, Shao GZ, Yang YF, Fan ZQ, et al
    Comment on: Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Sep 30. doi: 10.1245/s10434-023-14355.
    Abstract

  1562. YAN H, Zhang L, Li R
    Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
    Sci Rep. 2023;13:16457.
    Abstract

  1563. SONG Y, Peng Y, Qin C, Wang Y, et al
    Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment.
    J Immunother Cancer. 2023;11:e006643.
    Abstract

  1564. BUDAYA TN, Permatasari HK, Widodo N, Prawiro SR, et al
    The Evolution of Polyclonal Antibody from Specific Epitope 47kDA for Detection of Bladder Cancer.
    Asian Pac J Cancer Prev. 2023;24:3155-3164.
    Abstract

  1565. ASGARI M, Firouzi F, Abolhasani M, Bahadoram M, et al
    The Association of P53, CK29, and FGFR3 Overexpression with the Characteristics of Urothelial Cell Carcinoma of the Bladder.
    Asian Pac J Cancer Prev. 2023;24:3125-3131.
    Abstract

  1566. CHALHOUB IG, Boulos RT, Dagher YG, El Helou S, et al
    Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study.
    Medicine (Baltimore). 2023;102:e34562.
    Abstract

  1567. TORON M, Woloszyn A
    [Organ-sparing treatment of node-positive bladder cancer].
    Strahlenther Onkol. 2023 Sep 29. doi: 10.1007/s00066-023-02156.
    Abstract

  1568. YANG J, Tan Y, Yao C
    Study on anxiety, depression, and subjective wellbeing of patients with bladder cancer in their different chemotherapy stages.
    Front Psychol. 2023;14:1226712.
    Abstract

  1569. LIU Y, Pang ZQ, Wang JS, Wang JF, et al
    Heat shock protein family A member 8 is a prognostic marker for bladder cancer: Evidences based on experiments and machine learning.
    J Cell Mol Med. 2023 Sep 28. doi: 10.1111/jcmm.17977.
    Abstract

  1570. ZHANG X, Hu X, Xie Y, Xie L, et al
    Metformin-Loaded Chitosan Hydrogels Suppress Bladder Tumor Growth in an Orthotopic Mouse Model via Intravesical Administration.
    Molecules. 2023;28:6720.
    Abstract

  1571. YOO D, Min KW, Pyo JS, Kim NY, et al
    Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ.
    Medicina (Kaunas). 2023;59:1609.
    Abstract

  1572. LU XJ, Lai HF, Wu SC, Chen CL, et al
    Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma.
    Int J Mol Sci. 2023;24:14081.
    Abstract

  1573. NAKAMURA M, Tsuru I, Izumi T, Ono A, et al
    Advantages of enhanced recovery after surgery program in robot-assisted radical cystectomy.
    Sci Rep. 2023;13:16237.
    Abstract

  1574. GAMBA T, Paparo J, Panepinto O, Dionisio R, et al
    Poly (ADP-Ribose) Polymerase Inhibitors in Patients With Urothelial Cancer.
    Clin Genitourin Cancer. 2023;21:509-516.
    Abstract

  1575. NISHIYAMA H, Tsuzuki T, Ohyama C, Matsuyama H, et al
    Tumor immune microenvironment and clinical outcomes in stage IV urothelial cancer: YODO study.
    Int J Clin Oncol. 2023;28:1398-1410.
    Abstract

  1576. BETTOLI P, Liu Z, Jara N, Bakal F, et al
    Primary Bladder Sarcoma: A multi-institutional experience from the Rare Cancer Network.
    Arch Ital Urol Androl. 2023;95:11533.
    Abstract

  1577. RAO N, Starrett GJ, Piaskowski ML, Butler KE, et al
    Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
    Cancer Prev Res (Phila). 2023;16:561-570.
    Abstract

  1578. MANCIULLI T, Marangoni D, Salas-Coronas J, Bocanegra C, et al
    Diagnosis and management of complicated urogenital schistosomiasis: a systematic review of the literature.
    Infection. 2023;51:1185-1221.
    Abstract

  1579. COTE G, Alqaisi H, Chan CT, Jiang DM, et al
    Kidney and Cancer Outcomes with Standard Versus Alternative Chemotherapy Regimens for First-Line Treatment of Metastatic Urothelial Carcinoma.
    Kidney360. 2023;4:e1203-e1211.
    Abstract

  1580. KONDO Y, Nagamine Y, Yoshikawa N, Echigo N, et al
    Incidence of perioperative hypotension in patients undergoing transurethral resection of bladder tumor after oral 5-aminolevulinic acid administration: a retrospective multicenter cohort study.
    J Anesth. 2023;37:703-713.
    Abstract

  1581. FERRO M, Crocetto F, Tataru S, Barone B, et al
    Predictors of Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Clin Genitourin Cancer. 2023;21:574-583.
    Abstract

  1582. BAKALOUDI DR, Talukder R, Lin GI, Makrakis D, et al
    Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Clin Genitourin Cancer. 2023;21:584-593.
    Abstract

  1583. LEVY JJ, Chan N, Marotti JD, Kerr DA, et al
    Large-scale validation study of an improved semiautonomous urine cytology assessment tool: AutoParis-X.
    Cancer Cytopathol. 2023;131:637-654.
    Abstract

  1584. ZHONG W, Xia K, Liu L, Cheng S, et al
    Long-term survival after female pelvic organ-sparing radical cystectomy versus standard radical cystectomy: a multi-institutional propensity score-matched analysis.
    Int J Surg. 2023;109:2742-2750.
    Abstract

  1585. JINDAL T, Zhang L, Deshmukh P, Reyes K, et al
    Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
    Clin Genitourin Cancer. 2023;21:e394-e404.
    Abstract

  1586. GREENLAND NY, Khorsandi N, Peng Y, Balassanian R, et al
    Utility and performance of cell blocks in urine cytology: Experience at three teaching hospitals.
    Cancer Cytopathol. 2023;131:614-625.
    Abstract

  1587. PEAK T, Spiess PE, Li R, Grivas P, et al
    Comparative Genomic Landscape of Urothelial Carcinoma of the Bladder Among Patients of East and South Asian Genomic Ancestry.
    Oncologist. 2023;28:e910-e920.
    Abstract

  1588. PIERANTONI F, Dionese M, Basso U, Lai E, et al
    The prognostic Value of Thyroid Hormone Levels in Immunotherapy-Treated Patients With Metastatic Urothelial Carcinoma.
    Clin Genitourin Cancer. 2023;21:e378-e385.
    Abstract

  1589. DANESHPAJOUHNEJAD P, Morrison C, Zhao X, Daniel RE, et al
    Primary Alveolar Soft-Part Sarcoma (ASPS) of the Prostate: Report of a Deceptive Case.
    Int J Surg Pathol. 2023;31:1359-1363.
    Abstract

  1590. STOCKLE M
    [Cystectomy versus trimodal therapy for bladder cancer].
    Urologie. 2023 Oct 12. doi: 10.1007/s00120-023-02195.
    Abstract

  1591. LIU K, Zhao H, Chen X, Nicoletti R, et al
    A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guerin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Oct 10:S2588-9311(23)00206.
    Abstract

  1592. HONG Y, Li Z, Su Y, Pu H, et al
    The ceRNA Mechanism of lncRNA MEG3/miR-21-5p/SPRY2 in Cell Proliferation and Apoptosis in Bladder Cancer.
    Crit Rev Eukaryot Gene Expr. 2024;34:55-68.
    Abstract

  1593. HONG X, Chen X, Wang H, Xu Q, et al
    A HER2-targeted Antibody-Drug Conjugate, RC48-ADC, Exerted Promising Antitumor Efficacy and Safety with Intravesical Instillation in Preclinical Models of Bladder Cancer.
    Adv Sci (Weinh). 2023 Oct 12:e2302377. doi: 10.1002/advs.202302377.
    Abstract

  1594. VAN STRATEN CGJI, Caris C, Grimm MO, Colombel M, et al
    Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guerin Instillations: The EAU-RF NIMBUS Trial.
    Eur Urol Open Sci. 2023;56:15-24.
    Abstract

  1595. ZHOU YX, Hu QC, Zhu YJ, Mu XL, et al
    Comparison of trimodality therapy and neoadjuvant chemotherapy combined with radical cystectomy for the survival of muscle-invasive bladder cancer: a population-based analysis.
    Eur J Med Res. 2023;28:422.
    Abstract

  1596. KONG L, Wen Z, Cai Q, Lin Y, et al
    Amide Proton Transfer-Weighted MRI and Diffusion-Weighted Imaging in Bladder Cancer: A Complementary Tool to the VI-RADS.
    Acad Radiol. 2023 Oct 9:S1076-6332(23)00472-5. doi: 10.1016/j.acra.2023.
    Abstract

  1597. LI R, Jiang B, Zhu Y, Gao L, et al
    Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report.
    Endocr Metab Immune Disord Drug Targets. 2023.
    Abstract

  1598. JENA R, Bhargava P, Tripathi S, Taywade S, et al
    18F-fluoro-2-deoxy-2-d-glucose PET-CT (FDG PET-CT) in staging of high-risk renal and urothelial bladder cancers (COPPER-T) trial protocol.
    BJUI Compass. 2023;4:662-667.
    Abstract

  1599. AN H, Liu K, Shirai K, Kawasaki R, et al
    Physical Activity and Bladder Cancer Risk: Findings of the Japan Collaborative Cohort Study.
    Cancer Res Treat. 2023 Oct 6. doi: 10.4143/crt.2023.
    Abstract

  1600. ZHENG Y, Shi D, Chen L, Yang Y, et al
    UCHL1-PKM2 axis dysregulation is associated with promoted proliferation and invasiveness of urothelial bladder cancer cells.
    Aging (Albany NY). 2023;15.
    Abstract

  1601. ZHANG X, Wu H, Wang S
    [SLC12A8 promotes proliferation, invasiveness, migration and epithelial-mesenchymal transition of bladder cancer cells by activating JAK/STAT singaling].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1613-1621.
    Abstract

  1602. ZHOU Q, Huang W, Xiong J, Guo B, et al
    CDCA8 promotes bladder cancer survival by stabilizing HIF1alpha expression under hypoxia.
    Cell Death Dis. 2023;14:658.
    Abstract

  1603. ECKSTEIN M, Matek C, Wagner P, Erber R, et al
    Corrigendum to "Proposal for a Novel Histological Scoring System as a Potential Grading Approach for Muscle-invasive Urothelial Bladder Cancer Correlating with Disease Aggressiveness and Patient Outcomes" [European Urology Oncology (2023)].
    Eur Urol Oncol. 2023 Oct 7:S2588-9311(23)00215-8. doi: 10.1016/j.euo.2023.
    Abstract

  1604. TAARNHOJ GA, Johansen C, Carus A, Dahlrot RH, et al
    The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
    J Patient Rep Outcomes. 2023;7:99.
    Abstract

  1605. FRESHOUR SL, Chen TH, Fisk B, Shen H, et al
    Endothelial cells are a key target of IFN-g during response to combined PD-1/CTLA-4 ICB treatment in a mouse model of bladder cancer.
    iScience. 2023;26:107937.
    Abstract

  1606. ZHANG Y, Xu Z, Wu S, Zhu T, et al
    Construction of 3D and 2D contrast-enhanced CT radiomics for prediction of CGB3 expression level and clinical prognosis in bladder cancer.
    Heliyon. 2023;9:e20335.
    Abstract

  1607. HUANG L, Xie Q, Deng J, Wei WF, et al
    The role of cancer-associated fibroblasts in bladder cancer progression.
    Heliyon. 2023;9:e19802.
    Abstract

  1608. LIU HR, Peng X, Li SL, Gou X, et al
    [Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment].
    Beijing Da Xue Xue Bao Yi Xue Ban. 2023;55:793-801.
    Abstract

  1609. WEICKHARDT A, Foroudi F, Lawrentschuk N, Xie J, et al
    Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
    Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00201-8. doi: 10.1016/j.euo.2023.
    Abstract

  1610. CONTIERI R, Hensley PJ, Kamat AM
    Reply to Francesco Montorsi, Giuseppe Rosiello, and Giorgio Gandaglia's Letter to the Editor re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscl
    Eur Urol Oncol. 2023 Oct 6:S2588-9311(23)00210-9. doi: 10.1016/j.euo.2023.
    Abstract

  1611. YANG Y, Miao L, Lu Y, Sun Y, et al
    Exosome, the glass slipper for Cinderella of cancer-bladder cancer?
    J Nanobiotechnology. 2023;21:368.
    Abstract

  1612. HUANG WB, Cheng L
    [Research progress in molecular pathology of bladder cancer].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:1074-1078.
    Abstract

  1613. MOSSANEN M, Smith AB, Onochie N, Matulewicz R, et al
    Bladder cancer patient and provider perspectives on smoking cessation.
    Urol Oncol. 2023 Oct 5:S1078-1439(23)00292-2. doi: 10.1016/j.urolonc.2023.
    Abstract

  1614. VALDEZ-FLORES C, Erraguntla N, Budinsky R, Cagen S, et al
    Corrigendum to "An updated lymphohematopoietic and bladder cancers risk evaluation for occupational and environmental exposures to 1,3-butadiene" [Chem. Biol. Interact. 366 (2022) 1-10].
    Chem Biol Interact. 2023;385:110736.
    Abstract

  1615. FAN ZC, Zhang L, Yang GQ, Li S, et al
    MRI radiomics for predicting poor disease-free survival in muscle invasive bladder cancer: the results of the retrospective cohort study.
    Abdom Radiol (NY). 2023 Oct 7. doi: 10.1007/s00261-023-04028.
    Abstract

  1616. AZZAROUALI S, Goudschaal K, Visser J, Hulshof M, et al
    Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers.
    Radiat Oncol. 2023;18:165.
    Abstract

  1617. YU A, Hu J, Fu L, Huang G, et al
    Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8(+) T cell infiltration and functional transition.
    J Immunother Cancer. 2023;11:e007230.
    Abstract

  1618. CHEN J, Li H, Wu Y, Li Y, et al
    Shared genetic links between bladder cancer and obesity-related traits: A conjunctional false discovery rate study.
    Medicine (Baltimore). 2023;102:e35145.
    Abstract

  1619. VAN ZUTPHEN M, Beeren I, Aben KKH, van der Heijden AG, et al
    Body mass index and waist circumference in relation to risk of recurrence and progression after non-muscle invasive bladder cancer.
    Cancer Med. 2023 Oct 6. doi: 10.1002/cam4.6620.
    Abstract

  1620. BELSEY J
    A cost-consequences and budget impact analysis of blue light-guided cystoscopy with Hexvix(R) in patients diagnosed with non-muscle-invasive bladder cancer in France.
    J Med Econ. 2023 Oct 6:1-10. doi: 10.1080/13696998.2023.2267929.
    Abstract

  1621. LI WM, Chan TC, Wei YC, Li CF, et al
    Downregulation of CRTAC1 in Urothelial Carcinoma Promotes Tumor Aggressiveness and Confers Poor Prognosis.
    Front Biosci (Landmark Ed). 2023;28:217.
    Abstract

  1622. TONG G, Wang X, Chen S, Jin Y, et al
    Astragalus polysaccharide inhibits the development of urothelial carcinoma by activating AMPK signaling to induce BENC1-xCT complex formation.
    Aging (Albany NY). 2023;15:9438-9452.
    Abstract

  1623. ROCH C, Para S, Brandhofer C, Seitz AK, et al
    Successful use of Rectal Pregabalin for the Treatment of Chemotherapy-Induced Neuropathic Pain-a Case Report.
    J Palliat Care. 2023;38:412-415.
    Abstract

  1624. DAYCO JS, DeSouza N, Cardozo S
    A cluster of grapes: Right atrial masses of uncertain origin.
    J Vasc Access. 2023;24:821-823.
    Abstract

  1625. ZENG T, Ye J, Wang H, Tian W, et al
    Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer.
    Medicine (Baltimore). 2023;102:e35195.
    Abstract

  1626. HEALTHCARE ENGINEERING JO
    Retracted: Multi-Slice Spiral Computed Tomography Image Features under Hybrid Iterative Reconstruction Algorithm in Staging Diagnosis of Bladder Cancer.
    J Healthc Eng. 2023;2023:9791241.
    Abstract

  1627. LI H, Long G, Tian J
    Efficacy and safety of photodynamic therapy for non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Front Oncol. 2023;13:1255632.
    Abstract

  1628. OZDEMIR H, Azamat S, Sam Ozdemir M
    Can Only the Shape Feature in Radiomics Help Machine Learning Show That Bladder Cancer Has Invaded Muscles?
    Cureus. 2023;15:e45488.
    Abstract

  1629. YUAN F, Sun Y, Dai GC, Yao Q, et al
    Comprehensive Analysis of Prognostic Value and Immune Infiltration of TFAP2 Family Members in Bladder Cancer from Database and FFPE Sample.
    J Cancer. 2023;14:3050-3065.
    Abstract

  1630. KHETRAPAL P, Bains PS, Jubber I, Ambler G, et al
    Digital Tracking of Patients Undergoing Radical Cystectomy for Bladder Cancer: Daily Step Counts Before and After Surgery Within the iROC Randomised Controlled Trial.
    Eur Urol Oncol. 2023 Oct 16:S2588-9311(23)00213.
    Abstract

  1631. DURANT AM, Choudry MM, Madura G, Mi L, et al
    Bacillus Calmette-Guerin (BCG) therapy is safe and effective in non-muscle invasive bladder cancer (NMIBC) patients with immunomodulating conditions.
    Urol Oncol. 2023 Oct 16:S1078-1439(23)00323.
    Abstract

  1632. SHEN C, Han C, Li Z, Yan Y, et al
    Construction and Validation of a Prognostic Model Based on Pyroptosisrelated Genes in Bladder Cancer.
    Comb Chem High Throughput Screen. 2023.
    Abstract

  1633. WANG W, Yang F, Zhang L, Wang M, et al
    Targeting Dna Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate Sting Pathway for Maximizing Chemo-immunotherapy in Bladder Cancer.
    Adv Mater. 2023 Oct 17:e2308762. doi: 10.1002/adma.202308762.
    Abstract

  1634. ZHOU J, Dong C, Tan J, Wang G, et al
    Promoting effect and immunologic role of secretogranin II on bladder cancer progression via regulating MAPK and NF-kappaB pathways.
    Apoptosis. 2023 Oct 17. doi: 10.1007/s10495-023-01898.
    Abstract

  1635. KANG KA, Kim MJ, Kwon GY, Kim CK, et al
    Computed tomography-based prediction model for identifying patients with high probability of non-muscle-invasive bladder cancer.
    Abdom Radiol (NY). 2023 Oct 17. doi: 10.1007/s00261-023-04069.
    Abstract

  1636. BRYAN RT, Pirrie SJ, Abbotts B, Maycock S, et al
    Selenium and Vitamin E for Prevention of Non-Muscle-Invasive Bladder Cancer Recurrence and Progression: A Randomized Clinical Trial.
    JAMA Netw Open. 2023;6:e2337494.
    Abstract

  1637. ZOU Z, Li Z, Sun W, Gao W, et al
    Establishment of prognostic model of bladder cancer based on apoptosis-related genes, in which P4HB promotes BLCA progression.
    BMC Urol. 2023;23:167.
    Abstract

  1638. ZHU CZ, Ting HN, Ng KH, Mun KS, et al
    Dielectric properties of urine in relation to bladder cancer.
    Phys Eng Sci Med. 2023 Oct 16. doi: 10.1007/s13246-023-01341.
    Abstract

  1639. ABOU CHAKRA M, Packiam VT, O'Donnell MA
    Real-word efficacy of adjuvant single-agent intravesical gemcitabine for non-muscle invasive bladder cancer.
    Expert Opin Pharmacother. 2023 Oct 16:1-11. doi: 10.1080/14656566.2023.2271396.
    Abstract

  1640. LIATSOS GD, Manousopoulou G, Poulaki A, Iliaki A, et al
    Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure.
    Access Microbiol. 2023;5:000670.
    Abstract

  1641. NGUYEN TT, Thanh HD, Do MH, Jung C, et al
    Complement Regulatory Protein CD46 Manifests a Unique Role in Promoting the Migration of Bladder Cancer Cells.
    Chonnam Med J. 2023;59:160-166.
    Abstract

  1642. PRINCE MR, Shaish H
    Editorial for "Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System".
    J Magn Reson Imaging. 2023 Oct 15. doi: 10.1002/jmri.29054.
    Abstract

  1643. CARAPITO A, Roque ACA, Carvalho F, Pinto J, et al
    Exploiting volatile fingerprints for bladder cancer diagnosis: A scoping review of metabolomics and sensor-based approaches.
    Talanta. 2023;268.
    Abstract

  1644. AVUDAIAPPAN AP, Prabhakar P, Ganapathi H, VanderVeer-Harris N, et al
    Propensity score matched survival analysis of octogenarians with muscle-invasive bladder cancer: chemoradiation compared to radical cystectomy.
    Can J Urol. 2023;30:11686-11691.
    Abstract

  1645. MONTORSI F, Rosiello G, Gandaglia G
    Re: Roberto Contieri, Patrick J. Hensley, Wei Shen Tan, et al. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non-muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guerin or Early Radical Cystectomy.
    Eur Urol Oncol. 2023 Oct 12:S2588-9311(23)00208.
    Abstract

  1646. DI GIANFRANCESCO L, Crestani A, Amodeo A, Corsi P, et al
    The Role of Checkpoint Inhibitor Expression Directly on Exfoliated Cells from Bladder Cancer: A Narrative Review.
    Diagnostics (Basel). 2023;13:3119.
    Abstract

  1647. LEE J, Yoo S, Choo MS, Cho MC, et al
    Prognostic Role of Preoperative Neutrophil-To-Lymphocyte Ratio (NLR) and Recurrence at First Evaluation after Bacillus Calmette-Guerin (BCG) Induction in Non-Muscle-Invasive Bladder Cancer.
    Diagnostics (Basel). 2023;13:3114.
    Abstract

  1648. MORI K, Matsumoto K, Ikeda M, Koguchi D, et al
    Membranous Expression of Heart Development Protein with EGF-like Domain 1 Is Associated with a Good Prognosis in Patients with Bladder Cancer.
    Diagnostics (Basel). 2023;13:3067.
    Abstract

  1649. JUENGEL E, Rutz J, Meiborg M, Markowitsch SD, et al
    Mistletoe Extracts from Different Host Trees Disparately Inhibit Bladder Cancer Cell Growth and Proliferation.
    Cancers (Basel). 2023;15:4849.
    Abstract

  1650. LIOSIS KC, Marouf AA, Rokne JG, Ghosh S, et al
    Genomic Biomarker Discovery in Disease Progression and Therapy Response in Bladder Cancer Utilizing Machine Learning.
    Cancers (Basel). 2023;15:4801.
    Abstract

  1651. COURBOIN E, Mathieu R, Panetta V, Mjaess G, et al
    Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis.
    Cancers (Basel). 2023;15:4732.
    Abstract

  1652. DAVALIEVA K, Kiprijanovska S, Ivanovski O, Trifunovski A, et al
    Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
    Int J Mol Sci. 2023;24:14938.
    Abstract

  1653. KATSUMATA H, Matsumoto K, Yanagita K, Shimizu Y, et al
    Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy.
    Int J Mol Sci. 2023;24:14536.
    Abstract

  1654. LUO J, Guo L, Chen L, Zhou J, et al
    Efficacy and safety of HIVEC versus ETFT in non-muscle-invasive bladder cancer: A systematic review and meta-analysis.
    Asian J Surg. 2023 Oct 11:S1015-9584(23)01573.
    Abstract

  1655. LI H, Lv Z, Liu M
    A five necroptosis-related lncRNA signature predicts the prognosis of bladder cancer and identifies hot or cold tumors.
    Medicine (Baltimore). 2023;102:e35196.
    Abstract

  1656. GOZUKUCUK R, Cakiroglu B
    [Miliary Pulmonary Tuberculosis After Intravesical BCG Instillation in a Patient with High-Grade Bladder Cancer].
    Mikrobiyol Bul. 2023;57:675-681.
    Abstract

  1657. HAM WS, Park JS, Jang WS, Kim J, et al
    Role of Maximal Transurethral Resection Preceding Partial Cystectomy for Muscle-Invasive Bladder Cancer.
    Ann Surg Oncol. 2023 Oct 26. doi: 10.1245/s10434-023-14449.
    Abstract


  1658. Bladder cancer.
    Nat Rev Dis Primers. 2023;9:59.
    Abstract

  1659. DYRSKJOT L, Hansel DE, Efstathiou JA, Knowles MA, et al
    Bladder cancer.
    Nat Rev Dis Primers. 2023;9:58.
    Abstract

  1660. TAN X, Liu Z, Cai T, Wang Y, et al
    Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guerin-exposed Non-muscle-invasive Bladder Cancer.
    Eur Urol Oncol. 2023 Oct 24:S2588-9311(23)00219.
    Abstract

  1661. SRETENOVIC M, Bojanic N, Grozdic Milojevic I, Bumbasirevic U, et al
    Diagnostic and prognostic impact of preoperative thrombocytosis in muscle invasive bladder cancer: Any role in clinical practice?
    J Clin Ultrasound. 2023 Oct 26. doi: 10.1002/jcu.23600.
    Abstract

  1662. LUO Z, Yan Y, Jiao B, Huang T, et al
    Prognostic value of the systemic immune-inflammation index in patients with upper tract urothelial carcinoma after radical nephroureterectomy.
    World J Surg Oncol. 2023;21:337.
    Abstract

  1663. SHEN C, Bi Y, Chai W, Zhang Z, et al
    Construction and validation of a metabolism-associated gene signature for predicting the prognosis, immune landscape, and drug sensitivity in bladder cancer.
    BMC Med Genomics. 2023;16:264.
    Abstract

  1664. FAROUK SM, Khafaga AF, Abdellatif AM
    Bladder cancer: therapeutic challenges and role of 3D cell culture systems in the screening of novel cancer therapeutics.
    Cancer Cell Int. 2023;23:251.
    Abstract

  1665. LI R, Naidu S, Fan W, Rose K, et al
    Effectiveness of perioperative chemotherapy and radical cystectomy in treating bladder cancer.
    Urol Oncol. 2023 Oct 23:S1078-1439(23)00332.
    Abstract

  1666. UCHIDA Y, Yokoyama M, Fujiwara M, Nakamura Y, et al
    Preservation of Erectile and Ejaculatory Functions After Tetramodal Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against Muscle Invasive Bladder Cancer.
    Urol Res Pract. 2023;49:162-168.
    Abstract

  1667. ALKANLI N, Ay A
    Investigation of the Roles of MTHFR (C677T and A1298C) and MMP-2 (-1306C>T ) Variations in Bladder Cancer Development.
    Urol Res Pract. 2023;49:33-39.
    Abstract

  1668. EFILOGLU O, Cakici MC, Kir G, Iplikci A, et al
    The Impact of Histological Variants on Oncological Outcomes in Patients with Muscle Invasive Bladder Cancer Treated with Radical Cystectomy.
    Urol Res Pract. 2023;49:246-252.
    Abstract

  1669. BERKOVA A, Chovanec Z, Krejcova I, Katolicka J, et al
    A rare case of urothelial carcinoma metastasizing to the gallbladder wall with manifestations as acute cholecystitis.
    Klin Onkol. 2023;36:401-404.
    Abstract

  1670. KHAN SM, Das T, Chakraborty S, Choudhury AMAR, et al
    A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.
    Heliyon. 2023;9:e21058.
    Abstract

  1671. HAO L, Mu D, Mu H
    Sakuranin represses the malignant biological behaviors of human bladder cancer cells by triggering autophagy via activating the p53/mTOR pathway.
    BMC Urol. 2023;23:170.
    Abstract

  1672. WEI Y, Yang X, Zhu H, Zhuang J, et al
    Impact of the COVID-19 pandemic on bladder cancer patients: a multicenter real-world study.
    J Int Med Res. 2023;51:3000605231204465.
    Abstract

  1673. CATTO JWF, Tran B, Roupret M, Gschwend JE, et al
    Erdafitinib in BCG-treated high-risk non-muscle invasive bladder cancer.
    Ann Oncol. 2023 Oct 5:S0923-7534(23)04015-2. doi: 10.1016/j.annonc.2023.09.3116.
    Abstract

  1674. LI B, Li X, Li Z, Yang P, et al
    Magnetic resonance radiographic features which might lead to misdiagnosis of muscle-invasive bladder cancer based on vesical imaging reporting and data system: the application experience of a single center.
    Quant Imaging Med Surg. 2023;13:7258-7268.
    Abstract

  1675. WARLI SM, Prapiska FF, Siregar DIS, Seja IA, et al
    Tumor Markers as Predictors of Acute Kidney Injury Incidence and Staging of the Muscle-Invasive Bladder Cancer Receiving Chemoradiation Therapy.
    World J Oncol. 2023;14:423-429.
    Abstract

  1676. KIM HJ, Kim KH, Lee SW, Swan H, et al
    Familial Risk and Interaction With Smoking and Alcohol Consumption in Bladder Cancer: A Population-Based Cohort Study.
    World J Oncol. 2023;14:382-391.
    Abstract

  1677. ZHANG X, Huang W, Huang T, Zhang J, et al
    Integrative analysis of triphenyl phosphate: contextual interpretation of bladder cancer cohort.
    Front Oncol. 2023;13:1260114.
    Abstract

  1678. ZHANG Z, Wang Y, Liang Z, Meng Z, et al
    Modification of lysine-260 2-hydroxyisobutyrylation destabilizes ALDH1A1 expression to regulate bladder cancer progression.
    iScience. 2023;26:108142.
    Abstract

  1679. WENG M, Deng Z, Huang S, Lin X, et al
    Fraxetin inhibits proliferation and induces apoptosis of bladder cancer through the Akt pathway in vitro and in vivo.
    J Biochem Mol Toxicol. 2023 Oct 23:e23556. doi: 10.1002/jbt.23556.
    Abstract

  1680. ZHANG X, Liu Q
    Systemic Immune Inflammation Index and T-Staging Predict Prognosis in Patients with Muscle-Invasive Bladder Cancer.
    Arch Esp Urol. 2023;76:511-518.
    Abstract

  1681. XIA Y, Xiang L, Yao M, Ai Z, et al
    Proteomics, Transcriptomics, and Phosphoproteomics Reveal the Mechanism of Talaroconvolutin-A Suppressing Bladder Cancer via Blocking Cell Cycle and Triggering Ferroptosis.
    Mol Cell Proteomics. 2023 Oct 20:100672. doi: 10.1016/j.mcpro.2023.100672.
    Abstract

  1682. WANG X, Juncker-Jensen A, Huang G, Nagy ML, et al
    Spatial relationship of tertiary lymphoid structures and tumor-associated neutrophils in bladder cancer and prognostic potential for anti-PD-L1 immunotherapy.
    Cancer Commun (Lond). 2023 Oct 20. doi: 10.1002/cac2.12491.
    Abstract

  1683. WU J, Guo Q, Li J, Yuan H, et al
    Loperamide induces protective autophagy and apoptosis through the ROS/JNK signaling pathway in bladder cancer.
    Biochem Pharmacol. 2023;218:115870.
    Abstract

  1684. WANG Z, Wei B, Ma S
    EGR1/LINC00839/SOX5 axis modulates migration, invasion and Gemcitabine resistance of bladder cancer cells.
    Cancer Biol Ther. 2023;24:2270106.
    Abstract

  1685. KURBANOV AA, Kryukov SR, Chernov DV, Votyakov AY, et al
    [Robot-assisted left-side partial nephrectomy with a segmental resection of left lower ureter and Boari reconstruction].
    Urologiia. 2023;:125-128.
    Abstract

  1686. KOLPACINIDI FG, Sergeev VP, Kyzlasov PS, Volokitin EV, et al
    [Experience of using Experience of using NefroBest-N for rehabilitation of patients undergoing radical laparoscopic cystectomy].
    Urologiia. 2023;:62-68.
    Abstract

  1687. DAMIEV AD, Shpot EV, Akopyan GN, Dymov AM, et al
    [Carboxycryobiopsy and carboxycryoextraction of bladder tumor. Experimental study].
    Urologiia. 2023;:24-29.
    Abstract

  1688. HERRMANN TRW
    En bloc resection of bladder tumors (ERBT) revisited 12 years after reintroduction: too good to be further ignored.
    World J Urol. 2023;41:2577-2582.
    Abstract

  1689. MAISCH P, Hwang EC, Kim K, Narayan VM, et al
    Immunotherapy for advanced or metastatic urothelial carcinoma.
    Cochrane Database Syst Rev. 2023;10:CD013774.
    Abstract

  1690. GOTFREDSEN K, Jandorf S, Zangenberg M, Faber C, et al
    [Not Available].
    Ugeskr Laeger. 2023;185:V04230244.
    Abstract

  1691. WAN S, Li KP, Wang CY, Chen SY, et al
    Exploring potential targets of HPV&BC based on network pharmacology and urine proteomics.
    J Pharm Biomed Anal. 2023;236:115694.
    Abstract

  1692. FIALA O, Buti S, Takeshita H, Okada Y, et al
    Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study.
    Cancer Immunol Immunother. 2023;72:3665-3682.
    Abstract

  1693. GALLIOLI A, Basile G, Territo A, Verri P, et al
    The importance of second-look ureteroscopy implementation in the conservative management of upper tract urothelial carcinoma.
    World J Urol. 2023;41:2743-2749.
    Abstract

  1694. WHITE RE, Linscott JA, Hayn MT, Ryan ST, et al
    Distance to Treatment With Radical Cystectomy in a Rural State: Long Car Rides, Equivalent Outcomes.
    Urol Pract. 2023;10:588-594.
    Abstract

  1695. SU PJ, Xiao Y, Lin AY, Goh C, et al
    A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
    Cancer Rep (Hoboken). 2023;6:e1887.
    Abstract

  1696. QIU J, Deng R, Yu C, Gong K, et al
    The long-term outcome of nephron-sparing surgery versus radical nephroureterectomy for organ-localized upper urinary tract urothelial carcinoma: a population-based study of 1969 patients.
    J Cancer Res Clin Oncol. 2023;149:14869-14878.
    Abstract

  1697. TEOH JY, D'Andrea D, Gallioli A, Yanagisawa T, et al
    En bloc resection of bladder tumour: the rebirth of past through reminiscence.
    World J Urol. 2023;41:2599-2606.
    Abstract

  1698. CHEN YT, Yeh HC, Lee HY, Hsieh PF, et al
    Endoscopic management of upper tract urothelial cancer in a highly endemic area: A Taiwan nationwide collaborative study.
    Asian J Surg. 2023;46:3058-3065.
    Abstract

  1699. BANDARA NA, Zhou XR, Alhamam A, Black PC, et al
    The genitourinary impacts of electronic cigarette use: a systematic review of the literature.
    World J Urol. 2023;41:2637-2646.
    Abstract

  1700. SONG Y, Peng Y, Xu T
    Letter to the editor for the article "Molecular urothelial tumor cell subtypes remain stable during metastatic evolution".
    World J Urol. 2023;41:2869-2870.
    Abstract

  1701. YANG K, Yu W, Liu H, Lou F, et al
    Mutational pattern off homologous recombination repair (HRR)-related genes in upper tract urothelial carcinoma.
    Cancer Med. 2023;12:15304-15316.
    Abstract

  1702. LIU J, Lai S, Wu P, Wang J, et al
    Impact of a novel immune and nutritional score on prognosis in patients with upper urinary tract urothelial carcinoma following radical nephroureterectomy.
    J Cancer Res Clin Oncol. 2023;149:10893-10909.
    Abstract

  1703. DOUGLAWI A, Ghoreifi A, Carbonara U, Yip W, et al
    Impact of Variant Histology on Oncological Outcomes in Upper Tract Urothelial Carcinoma: Results From the ROBUUST Collaborative Group.
    Clin Genitourin Cancer. 2023;21:563-568.
    Abstract

  1704. ENIKEEV D, Morozov A, Shpikina A, Fajkovic H, et al
    A 10-year renaissance of en bloc resection of bladder tumors (ERBT): Are we approaching the peak or is it back to the trough?
    World J Urol. 2023;41:2607-2615.
    Abstract

  1705. KOBAYASHI Y, Arai H, Hamamoto Y, Yoshida K, et al
    High Infiltration of CD163-Positive Macrophages in Intratumor Compartment Predicts Poor Prognosis in Patients With Upper Urinary Tract Urothelial Carcinoma and Radical Nephroureterectomy.
    Clin Genitourin Cancer. 2023;21:e386-e393.
    Abstract

  1706. MORALES-BARRERA R, Villacampa G, Vidal N, Figols M, et al
    Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
    Clin Transl Oncol. 2023;25:3556-3564.
    Abstract

  1707. WANG X, Wang Y, Che X, Zhou Z, et al
    The prognosis and safety of continuous saline bladder irrigation in patients after transurethral resection of bladder tumors: a systematic review and meta-analysis of comparative study.
    Updates Surg. 2023;75:1795-1806.
    Abstract

  1708. NAGASAKI N, Watanabe T, Edamura K, Araki M, et al
    Bladder Tumors with Multiple Cardiac Metastases, with Elevated Serum Granulocyte Colony-Stimulating Factor.
    Am J Med. 2023;136:e161-e162.
    Abstract

  1709. LAZO JF, Rosa B, Catellani M, Fontana M, et al
    Semi-Supervised Bladder Tissue Classification in Multi-Domain Endoscopic Images.
    IEEE Trans Biomed Eng. 2023;70:2822-2833.
    Abstract

  1710. CHEIKHROUHOU T, Ben Dhaou M, Charfi S, Hbaieb M, et al
    Phyllodes Tumor of the Bladder in a 2-Year-Old Boy - An Exceptional Finding.
    Fetal Pediatr Pathol. 2023;42:699-705.
    Abstract

  1711. MATSUZAWA ADACHI M, Sugawara H, Ishii A, Chiba E, et al
    Malignancy-related Hypercalcemia Caused by Metameric Cutaneous Metastasis of Parathyroid Hormone-related Protein-producing Bladder Carcinoma with Squamous Cell Differentiation: An Autopsy Case of Cobb Syndrome.
    Intern Med. 2023 Mar 1. doi: 10.2169/internalmedicine.0893.
    Abstract

  1712. BREDA A, Gallioli A, Diana P, Fontana M, et al
    The DEpth of Endoscopic Perforation scale to assess intraoperative perforations during transurethral resection of bladder tumor: subgroup analysis of a randomized controlled trial.
    World J Urol. 2023;41:2583-2589.
    Abstract

  1713. DIANA P, Gallioli A, Fontana M, Territo A, et al
    Energy source comparison in en-bloc resection of bladder tumors: subanalysis of a single-center prospective randomized study.
    World J Urol. 2023;41:2591-2597.
    Abstract

  1714. GUVEN S, Colecchia M, Oltulu P, Bonfante G, et al
    How do endoscopic bladder tumor resection techniques affect pathology practice? EAU Section of Uro-Technology (ESUT) and Uropathology (ESUP) survey.
    World J Urol. 2023;41:2617-2625.
    Abstract

  1715. CHEN Z, Deng K, Sun L, Qu L, et al
    3D laparoscopic treatment of bladder cancer with pelvic multi-organ invasion: a case report and literature review.
    Front Oncol. 2023;13:1249389.
    Abstract

  1716. GARIONI M, Tschan VJ, Blukacz L, Nuciforo S, et al
    Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer.
    NPJ Precis Oncol. 2023;7:112.
    Abstract

  1717. WEI L, Ji L, Han S, Xu M, et al
    Construction and Validation of a Prognostic Model of Metabolism-Related Genes Driven by Somatic Mutation in Bladder Cancer.
    Front Biosci (Landmark Ed). 2023;28:242.
    Abstract

  1718. KIM SW, Yu H, Kim Y, Nam K, et al
    HER2 overexpression predicts pathological T2 stage and improved survival in de novo muscle-invasive bladder cancer after immediate radical cystectomy: A retrospective cohort study.
    Int J Surg. 2023 Nov 2. doi: 10.1097/JS9.0000000000000859.
    Abstract

  1719. QIN C, Tian Q, Zhou H, Qin Y, et al
    Detecting Muscle Invasion of Bladder Cancer: An Application of Diffusion Kurtosis Imaging Ratio and Vesical Imaging-Reporting and Data System.
    J Magn Reson Imaging. 2023 Nov 2. doi: 10.1002/jmri.29053.
    Abstract

  1720. HU WM, Li M, Ning JZ, Tang YQ, et al
    FAM171B stabilizes vimentin and enhances CCL2-mediated TAM infiltration to promote bladder cancer progression.
    J Exp Clin Cancer Res. 2023;42:290.
    Abstract

  1721. SHUAI H, Duan X, Zhou JJ, Liu Y, et al
    Effect of the TERT mutation on the prognosis of patients with urothelial carcinoma: a systematic review and meta-analysis.
    BMC Urol. 2023;23:177.
    Abstract

  1722. UEKI Y, Kobayashi K, Hashimoto K, Tanaka T, et al
    [Urological Comorbidities in an HIV-Infected Patient: A Case Report].
    Hinyokika Kiyo. 2023;69:299-303.
    Abstract

  1723. PATEL HD, Naha U, Chen VS, Ko C, et al
    Neoadjuvant Chemotherapy Before Radical Cystectomy for Muscle-Invasive Bladder Cancer: Elective and Eligibility Factors Impacting Utilization.
    Urol Pract. 2023 Oct 30:101097UPJ0000000000000467.
    Abstract

  1724. SINGH R, Sharma G, Priyadarshi S, Fauzdar G, et al
    Prognostic significance of preoperative pyuria & Neutrophil to lymphocyte ratio in patients with non-muscle-invasive bladder cancer: A prospective cohort study.
    Urologia. 2023 Nov 1:3915603231203780. doi: 10.1177/03915603231203780.
    Abstract

  1725. SAVCHENKO E, Rosenfeld A, Bunimovich-Mendrazitsky S
    Mathematical modeling of BCG-based bladder cancer treatment using socio-demographics.
    Sci Rep. 2023;13:18754.
    Abstract

  1726. ZHOU Q, Chen X, Chen Q, Hao L, et al
    Factors Influencing Quality of Life and Functional Outcomes in Patients With Bladder Cancer.
    Cancer Control. 2023;30:10732748231212353.
    Abstract

  1727. NARAYAN VM, Siolas D, Meadows ES, Turzhitsky V, et al
    Evaluation of a Natural Language Processing Model to Identify and Characterize Patients in the United States With High-Risk Non-Muscle-Invasive Bladder Cancer.
    JCO Clin Cancer Inform. 2023;7:e2300096.
    Abstract

  1728. DA SILVA AC, Scholl JN, de Fraga Dias A, Weber AF, et al
    Preclinical evaluation of bozepinib in bladder cancer cell lines: modulation of the NPP1 enzyme.
    Purinergic Signal. 2023 Oct 31. doi: 10.1007/s11302-023-09975.
    Abstract

  1729. ZAZA MMA, Salem TAE, El-Sadat AM, Hassan Ali M, et al
    Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer.
    Urologia. 2023 Oct 31:3915603231206603. doi: 10.1177/03915603231206603.
    Abstract

  1730. ABOU CHAKRA M, Shore ND, Dillon R, O'Donnell MA, et al
    US Clinical Practice Patterns of Intravesical Chemotherapy for Bacillus Calmette-Guerin-Unresponsive and Bacillus Calmette-Guerin-Exposed Nonmuscle-Invasive Bladder Cancer.
    Urol Pract. 2023 Oct 30:101097UPJ0000000000000481.
    Abstract

  1731. LV Z, Hou J, Wang Y, Wang X, et al
    Knowledge-map analysis of bladder cancer immunotherapy.
    Hum Vaccin Immunother. 2023;19:2267301.
    Abstract

  1732. FAWZY MS, El Faiomy ARM, El Desoky AMZ, Hussein S, et al
    The relationship between DNA methyltransferase 3B (DNMT3B) and miR 124-3pa expressions in bladder cancer tissues.
    Mol Biol Rep. 2023 Oct 30. doi: 10.1007/s11033-023-08818.
    Abstract

  1733. ZHAO L, Han D, Zhu J, Bi D, et al
    The RNA m6A-Binding Protein YTHDC1 Is Downregulated and Associated With M2 Macrophage Infiltration in Muscle-Invasive Bladder Cancer.
    Clin Med Insights Oncol. 2023;17:11795549231203150.
    Abstract

  1734. BAZARGAN S, Bunch B, Ojwang' AME, Blauvelt J, et al
    Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
    Front Immunol. 2023;14:1275375.
    Abstract

  1735. LU J, Zhou W, He H, Chen J, et al
    Duodenal stenosis caused by locally advanced upper tract urothelial carcinoma: a case report.
    J Int Med Res. 2023;51:3000605231206958.
    Abstract

  1736. LIU J, Lai S, Wu P, Wang J, et al
    Systematic oxidative stress indices predicts prognosis in patients with urothelial carcinoma of the upper urinary tract after radical nephroureterectomy.
    Eur J Med Res. 2023;28:469.
    Abstract

  1737. LIN JH, Hung CH, Huang YC, Chen CS, et al
    The p38-MITOGEN-ACTIVATED PROTEIN KINASE Signaling Pathway Is Involved in Leonurus artemisia Extract-Induced Inhibition of the Proliferation of Human Bladder Cancer BFTC-905 Cells via G1/G0 Arrest and Causes Apoptosis In Vitro.
    Pharmaceuticals (Basel). 2023;16:1338.
    Abstract

  1738. ALI W, Xiao W, Jacobs D, Kajdacsy-Balla A, et al
    Survival and Enrichment Analysis of Epithelial-Mesenchymal Transition Genes in Bladder Urothelial Carcinoma.
    Genes (Basel). 2023;14:1899.
    Abstract

  1739. EMINAGA O, Leyh-Bannurah SR, Shariat SF, Krabbe LM, et al
    Artificial Intelligence Reveals Distinct Prognostic Subgroups of Muscle-Invasive Bladder Cancer on Histology Images.
    Cancers (Basel). 2023;15:4998.
    Abstract

  1740. POTTGEN C, Hoffmann C, Gauler T, Guberina M, et al
    Fractionation versus Adaptation for Compensation of Target Volume Changes during Online Adaptive Radiotherapy for Bladder Cancer: Answers from a Prospective Registry.
    Cancers (Basel). 2023;15:4933.
    Abstract

  1741. HU CY, Hung CF, Chen PC, Hsu JY, et al
    Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer.
    Biomedicines. 2023;11:2598.
    Abstract

  1742. ALFAQIH MA, Elsalem L, Nusier M, Mhedat K, et al
    Serum Leptin Receptor and the rs1137101 Variant of the LEPR Gene Are Associated with Bladder Cancer.
    Biomolecules. 2023;13:1498.
    Abstract

  1743. YU SH, Kim SS, Lee H, Kim S, et al
    Somatic Mutation of the Non-Muscle-Invasive Bladder Cancer Associated with Early Recurrence.
    Diagnostics (Basel). 2023;13:3201.
    Abstract

  1744. FRISHBERG A, Milman N, Alpert A, Spitzer H, et al
    Reconstructing disease dynamics for mechanistic insights and clinical benefit.
    Nat Commun. 2023;14:6840.
    Abstract

  1745. LI Z, Zhou L, Lin C, Pan X, et al
    Corrigendum to "MiR-302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer" [Life Sciences, 209 (2018) 15-23].
    Life Sci. 2023 Oct 25:122169. doi: 10.1016/j.lfs.2023.122169.
    Abstract

  1746. YUE M, Yang Z, Sun J, Liu Z, et al
    A candidate prognostic biomarker: TFEB inhibits tumor progression via elevating CDKN1A in bladder cancer.
    Int Immunopharmacol. 2023;125.
    Abstract

  1747. ZEMLA J, Szydlak R, Gajos K, Kozlowski L, et al
    Plasma Treatment of PDMS for Microcontact Printing (muCP) of Lectins Decreases Silicone Transfer and Increases the Adhesion of Bladder Cancer Cells.
    ACS Appl Mater Interfaces. 2023 Oct 27. doi: 10.1021/acsami.3c09195.
    Abstract

  1748. VARCHULOVA NOVAKOVA Z, Kuniakova M, Ziaran S, Harsanyi S, et al
    Molecular Biomarkers of Bladder Cancer: A Mini-Review.
    Physiol Res. 2023;72.
    Abstract

  1749. PARK HK
    Do Histology and Primary Tumor Location Influence Metastatic Patterns in Bladder Cancer?
    Curr Oncol. 2023;30:9078-9089.
    Abstract

  1750. PRIJOVIC N, Acimovic M, Santric V, Stankovic B, et al
    The Impact of Variant Histology in Patients with Urothelial Carcinoma Treated with Radical Cystectomy: Can We Predict the Presence of Variant Histology?
    Curr Oncol. 2023;30:8841-8852.
    Abstract

  1751. GLUTH L, Ochsenfarth C, Pham PNV, Wischermann JM, et al
    Influence of the Anesthetic Technique on Circulating Extracellular Vesicles in Bladder Cancer Patients Undergoing Radical Cystectomy: A Prospective, Randomized Trial.
    Cells. 2023;12:2503.
    Abstract

  1752. SHAN Z, Tang W, Shi Z, Shan T, et al
    Ferroptosis: An Emerging Target for Bladder Cancer Therapy.
    Curr Issues Mol Biol. 2023;45:8201-8214.
    Abstract

  1753. STARRETT GJ, Foster H, Sigel K, Liu Y, et al
    Brief Report: The Virome of Bladder Tumors Arising in People Living With HIV.
    J Acquir Immune Defic Syndr. 2023;94:337-340.
    Abstract

  1754. LOPEZ-BELTRAN A, Gonzalez-Peramato P, Sanz-Ortega J, Prieto Cuadra JD, et al
    [Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP].
    Rev Esp Patol. 2023;56:261-270.
    Abstract

  1755. KLUMPER N, Wust L, Saal J, Ralser DJ, et al
    PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
    Oncoimmunology. 2023;12:2267744.
    Abstract

  1756. VARADI M, Horvath O, Modos O, Fazekas T, et al
    Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study.
    Sci Rep. 2023;13:17378.
    Abstract

  1757. MARAZ A, Nagy B, Macher T, Jesko J, et al
    Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary.
    Adv Ther. 2023;40:5475-5488.
    Abstract

  1758. WANG H, Ding Y, He Y, Yu Z, et al
    LncRNA UCA1 promotes pancreatic cancer cell migration by regulating mitochondrial dynamics via the MAPK pathway.
    Arch Biochem Biophys. 2023;748:109783.
    Abstract

  1759. LI Y, Wu Q, Lv J, Gu J, et al
    A comprehensive pan-cancer analysis of CDH5 in immunological response.
    Front Immunol. 2023;14:1239875.
    Abstract

  1760. LI M, Fu X, Zu X, Chen J, et al
    Modified Tubeless Ureterocutaneostomy in High-Risk Patients After Radical Cystectomy and its Long-Term Clinical Outcomes.
    Technol Cancer Res Treat. 2023;22:15330338231192906.
    Abstract

  1761. SACHDEVA S, Suresh PK, Basavaiah SH, Sahu KK, et al
    p16 expression in urothelial carcinoma: Experience from a tertiary care center in coastal South India.
    J Cancer Res Ther. 2023;19:1330-1334.
    Abstract

  1762. LIANG H, Yang Q, Zhang Y, Sun H, et al
    Development and validation of a predictive model for the diagnosis of bladder tumors using narrow band imaging.
    J Cancer Res Clin Oncol. 2023;149:15867-15877.
    Abstract

  1763. SHRIVASTAVA N, Jena R, Choudhary GR, Bhargava P, et al
    Correlation between androgen and estrogen receptor expression and clinicopathologic features in carcinoma urinary bladder.
    J Cancer Res Clin Oncol. 2023;149:15795-15804.
    Abstract

  1764. ISCAIFE A, Socarras MR, Gonzalez LL, Rivas JG, et al
    En Bloc Resection of Bladder Tumors (ERBT) using different lasers - Hybrid and Holmium Laser.
    Int Braz J Urol. 2023;49:783-784.
    Abstract

  1765. GAYA JM, Uleri A, Sanz I, Basile G, et al
    Robot-assisted radical cystectomy and ileal conduit with Hugo(TM) RAS system: feasibility, setting and perioperative outcomes.
    Int Braz J Urol. 2023;49:787-788.
    Abstract

  1766. PIVOVARCIKOVA K, Pitra T, Alaghehbandan R, Buchova K, et al
    Lynch syndrome-associated upper tract urothelial carcinoma frequently occurs in patients older than 60 years: an opportunity to revisit urology clinical guidelines.
    Virchows Arch. 2023;483:517-526.
    Abstract

  1767. KIM JM, Lee J, Sung SH
    Application of The Paris System in neobladder washing cytology: Comparison between the original diagnosis and correlation with histopathology.
    Diagn Cytopathol. 2023;51:744-750.
    Abstract

  1768. FOLARIN OS, Siddiqui MT
    Are we on track for diagnosing high-grade urothelial carcinoma with a minimum quantity of five malignant cells in lower tract specimens? Critical analysis of The Paris System Quantitation Criteria.
    Cancer Cytopathol. 2023;131:708-715.
    Abstract

  1769. WANG Y, Yan S, Liu Y, Yan Z, et al
    Dynamic viral integration patterns actively participate in the progression of BK polyomavirus-associated diseases after renal transplantation.
    Am J Transplant. 2023;23:1694-1708.
    Abstract

  1770. GOUBET AG, Rouanne M, Derosa L, Kroemer G, et al
    From mucosal infection to successful cancer immunotherapy.
    Nat Rev Urol. 2023;20:682-700.
    Abstract

  1771. REN K, Feng J, Bi H, Sun Q, et al
    AFM-Based Poroelastic@Membrane Analysis of Cells and its Opportunities for Translational Medicine.
    Small. 2023;19:e2303610.
    Abstract

  1772. GRANT CR, de Kouchkovsky D, Kalebasty AR, Mar N, et al
    Drug extravasation with Enfortumab vedotin.
    J Oncol Pharm Pract. 2023;29:1789-1792.
    Abstract

  1773. PEI L, Yan D, He Q, Kong J, et al
    LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder.
    Cell Oncol (Dordr). 2023;46:1509-1527.
    Abstract

  1774. JONES H, Bhakta A, Jia L, Wojciechowski D, et al
    An Unusual Presentation of Metastatic BK Virus-Associated Urothelial Carcinoma Arising in the Allograft, Persisting After Transplant Nephrectomy.
    Int J Surg Pathol. 2023;31:1586-1592.
    Abstract

  1775. PESCIA C, Pini G, Lopez G, Malfatto M, et al
    A Rare Case of Urinary Bladder Hamartoma Clinically Mimicking an Urothelial Carcinoma: A Case Report and Review of the Literature.
    Int J Surg Pathol. 2023;31:1572-1579.
    Abstract

  1776. MINATO H, Yoshikawa A, Tsuyama S, Katayanagi K, et al
    Ureteral Metastasis of Colonic Adenocarcinoma with Enteroblastic Differentiation: A Rare Case to be Distinguished from Clear Cell Adenocarcinoma of the Urinary Tract.
    Int J Surg Pathol. 2023;31:1553-1558.
    Abstract

  1777. METHODS IN MEDICINE CAM
    Retracted: Computed Tomography Image Features under Deep Learning Algorithm Applied in Staging Diagnosis of Bladder Cancer and Detection on Ceramide Glycosylation.
    Comput Math Methods Med. 2023;2023:9842436.
    Abstract

  1778. AND BIOMECHANICS AB
    Retracted: Applications of Bladder Cancer Data Using a Modified Log-Logistic Model.
    Appl Bionics Biomech. 2023;2023:9789308.
    Abstract

  1779. OGURA R, Ito S, Ueda T, Gabata Y, et al
    Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Sci Rep. 2023;13:19517.
    Abstract

  1780. LAURIE MA, Zhou SR, Islam MT, Shkolyar E, et al
    Bladder Cancer and Artificial Intelligence: Emerging Applications.
    Urol Clin North Am. 2024;51:63-75.
    Abstract

  1781. CAO Y, Zou Z, Wu X, Li W, et al
    LUCAT1 inhibits ferroptosis in bladder cancer by regulating the mRNA stability of STAT3.
    Gene. 2023 Nov 7:147974. doi: 10.1016/j.gene.2023.147974.
    Abstract

  1782. WANG X, Wang Z, Wei Q, Wang H, et al
    Anoikis-associated signatures predict prognosis and immune response in bladder cancer.
    Epigenomics. 2023 Nov 9. doi: 10.2217/epi-2023-0240.
    Abstract

  1783. FARNAZ T, Bhattacharjee P, Ahamad MSU, Rima SA, et al
    The Prevalence of p16 Expression in Urothelial Bladder Cancer in a Tertiary Care Hospital of Chattogram, Bangladesh.
    Iran J Pathol. 2023;18:306-311.
    Abstract

  1784. MOHAMED NE, Leung TM, Benn EK, Korn TG, et al
    Depression and anxiety among patients treated for bladder cancer: examining clinical, demographic, and psychosocial predictors.
    Am J Clin Exp Urol. 2023;11:401-413.
    Abstract

  1785. JIA ZY, Yang F, Zhang W, Li WW, et al
    Application of contrast-enhanced ultrasound in renal space-occupying lesion puncture biopsy.
    BMC Med Imaging. 2023;23:178.
    Abstract

  1786. TANIUCHI M, Yanagi M, Kiriyama T, Akatsuka J, et al
    Primary leiomyoma of the bladder radiologically mimicking a retroperitoneal tumor - a case report.
    J Med Invest. 2023;70.
    Abstract

  1787. CUI A, Li X, Ma X, Song Z, et al
    Quantitative transcriptomic and proteomic analysis reveals corosolic acid inhibiting bladder cancer via suppressing cell cycle and inducing mitophagy in vitro and in vivo.
    Toxicol Appl Pharmacol. 2023 Nov 6:116749. doi: 10.1016/j.taap.2023.116749.
    Abstract

  1788. CHEN B, Shu B, Liu Z, Zhu J, et al
    The diagnostic value of fluorescence in situ hybridization in secondary electroresection of bladder cancer.
    Bladder (San Franc). 2023;10:e21200006.
    Abstract

  1789. GU Y, Lu Y, Xiong Y, Zhan X, et al
    Advances in the bladder cancer research using 3D culture models.
    Bladder (San Franc). 2023;10:e21200005.
    Abstract

  1790. FU W, Zhang X
    Laparoscopic and Robotic-Assisted Extended Pelvic Lymph Node Dissection for Invasive Bladder Cancer: A Review.
    Bladder (San Franc). 2023;10:e21200004.
    Abstract

  1791. LIU T, Gu J, Li C, Guo M, et al
    Alternative polyadenylation-related genetic variants contribute to bladder cancer risk.
    J Biomed Res. 2023 Nov 15:1-13. doi: 10.7555/JBR.37.20230063.
    Abstract

  1792. WEI X, Jiang Y, Yang G, Chang T, et al
    MicroRNA-367-3p directly targets RAB23 and inhibits proliferation, migration and invasion of bladder cancer cells and increases cisplatin sensitivity.
    J Cancer Res Clin Oncol. 2023 Nov 8. doi: 10.1007/s00432-023-05484.
    Abstract

  1793. CHEN H, Ma L, Yang W, Li Y, et al
    POLR3G promotes EMT via PI3K/AKT signaling pathway in bladder cancer.
    FASEB J. 2023;37:e23260.
    Abstract

  1794. WANG J, Luo J, Wu X, Li Z, et al
    WTAP enhances the instability of SYTL1 mRNA caused by YTHDF2 in bladder cancer.
    Histol Histopathol. 2023 Oct 23:18671. doi: 10.14670.
    Abstract

  1795. LI G, Song Z, Ru Y, Zhang J, et al
    Small-molecule nanoprodrug with high drug loading and EGFR, PI3K/AKT dual-inhibiting properties for bladder cancer treatment.
    Exploration (Beijing). 2023;3:20220141.
    Abstract

  1796. JEON J, Ha JS, Shin SJ, Ham WS, et al
    Differences in clinical features between focal and extensive types of cystitis glandularis in patients without a previous history of urinary tract malignancy.
    Investig Clin Urol. 2023;64:597-605.
    Abstract

  1797. DURSUN F, Elshabrawy A, Wang H, Kaushik D, et al
    Impact of rural residence on the presentation, management and survival of patients with non-metastatic muscle-invasive bladder carcinoma.
    Investig Clin Urol. 2023;64:561-571.
    Abstract

  1798. EL AZAB A, Abdelbary A, El Faqeh M Okasha A, Aboulkassem H, et al
    The effect of immediate neoadjuvant electromotive instillation of mitomycin C with Bacillus Calmette-Guerin versus BCG alone in non-muscle-invasive bladder cancer: A randomized controlled trial.
    Investig Clin Urol. 2023;64:554-560.
    Abstract

  1799. JAI-UA C, Limpaiboon C, Siriboonrid S, Binsri N, et al
    Accuracy of Vesical Imaging-Reporting and Data System for muscle-invasive bladder cancer detection from multiparametric magnetic resonance imaging.
    Investig Clin Urol. 2023;64:546-553.
    Abstract

  1800. JANEV A, Ramuta TZ, Jerman UD, Obradovic H, et al
    Human amniotic membrane inhibits migration and invasion of muscle-invasive bladder cancer urothelial cells by downregulating the FAK/PI3K/Akt/mTOR signalling pathway.
    Sci Rep. 2023;13:19227.
    Abstract

  1801. SINGH V, Singh MK, Jain M, Pandey AK, et al
    The relationship between BCG immunotherapy and oxidative stress parameters in patients with nonmuscle invasive bladder cancer.
    Urol Oncol. 2023 Nov 4:S1078-1439(23)00321-6. doi: 10.1016/j.urolonc.2023.
    Abstract

  1802. ADEMAJ A, Puric E, Marder D, Timm O, et al
    Radiotherapy combined with deep regional hyperthermia in elderly and frail patients with muscle-invasive bladder cancer: quality analysis of hyperthermia and impact on clinical results.
    Int J Hyperthermia. 2023;40:2275540.
    Abstract

  1803. RIVEROS C, Ranganathan S, Haque W, Huang E, et al
    Comparative real-world survival outcomes of muscle-invasive bladder cancer treated with bladder-only vs. whole-pelvis concurrent chemoradiation.
    Can Urol Assoc J. 2023 Oct 23. doi: 10.5489/cuaj.8386.
    Abstract

  1804. ARAI Y, Goto Y, Sazuka T, Fujimoto A, et al
    A case of bladder cancer after bilateral lung transplantation following bone marrow transplantation.
    IJU Case Rep. 2023;6:471-474.
    Abstract

  1805. KARAN C, Yaren A, Demirel BC, Dogan T, et al
    Pretreatment PLR Is Preferable to NLR and LMR as a Predictor in Locally Advanced and Metastatic Bladder Cancer.
    Cancer Diagn Progn. 2023;3:706-715.
    Abstract

  1806. XU X, Huang Y, Liu Y, Cai Q, et al
    Multiparametric MRI-based VI-RADS: can it predict 1- to 5-year recurrence of bladder cancer?
    Eur Radiol. 2023 Nov 6. doi: 10.1007/s00330-023-10387.
    Abstract

  1807. ZHANG L, Shao G, Shao J, Zhao J, et al
    Corrigendum to "PRMT5-activated c-Myc promote bladder cancer proliferation and invasion through up-regulating NF-kappaB pathway" [Tissue Cell 76 (2022) 101788].
    Tissue Cell. 2023 Nov 1:102221. doi: 10.1016/j.tice.2023.102221.
    Abstract

  1808. SORIA F, Rosazza M, Livoti S, Dutto D, et al
    Repeat Transurethral Resection (TUR) + Bacillus Calmette-Guerin (BCG) Versus Upfront Induction BCG After TUR in High-risk Non-muscle-invasive Bladder Cancer: Feasibility Phase of a Randomized Controlled Study.
    Eur Urol Focus. 2023 Nov 1:S2405-4569(23)00236-5. doi: 10.1016/j.euf.2023.
    Abstract

  1809. YANG M, Wang J, Quan S, Xu Q, et al
    High-precision bladder cancer diagnosis method: 2D Raman spectrum figures based on maintenance technology combined with automatic weighted feature fusion network.
    Anal Chim Acta. 2023;1282:341908.
    Abstract

  1810. LI D, Liu F, Chen Y, Li P, et al
    Ipsilateral synchronous papillary renal neoplasm with reverse polarity and urothelial carcinoma in a renal transplant recipient: a rare case report with molecular analysis and literature review.
    Diagn Pathol. 2023;18:120.
    Abstract

  1811. LEDFORD H
    Cancer trial results show power of weaponized antibodies.
    Nature. 2023;623:231-232.
    Abstract

  1812. VAN DER HEIJDEN MS, Sonpavde G, Powles T, Necchi A, et al
    Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
    N Engl J Med. 2023;389:1778-1789.
    Abstract

  1813. FALTAS B
    A new era in the treatment of urothelial carcinoma.
    Urol Oncol. 2023;41:395-397.
    Abstract

  1814. KSHATTRY S, Parker TL, Huntington SF
    Peripheral Blasts in a Patient Receiving Chemotherapy.
    JAMA. 2023;330:1581-1582.
    Abstract

  1815. ORTNER G, Somani BK, Guven S, Kitzbichler G, et al
    Experts' recommendations in laser use for the treatment of upper tract urothelial carcinoma: a comprehensive guide by the European Section of Uro-Technology (ESUT) and Training Research in Urological Surgery and Technology (T.R.U.S.T.) group.
    World J Urol. 2023;41:3367-3376.
    Abstract

  1816. GABRIEL PE, Pinar U, Lenfant L, Parra J, et al
    Perioperative, renal function and oncological outcomes of robot-assisted radical nephroureterectomy for patients with upper tract urothelial carcinoma.
    World J Urol. 2023;41:3001-3007.
    Abstract

  1817. KLUMPER N, Eckstein M, Kunath F, Heidegger I, et al
    [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Urologie. 2023;62:1193-1199.
    Abstract

  1818. YING Y, Zhang Z, Xing N, Qian Z, et al
    Preoperative urine sediment chromosomal instability level predicts urothelial cancer prognosis.
    Urol Oncol. 2023;41:433.
    Abstract

  1819. KATIMS AB, Gaffney C, Firouzi S, Yip W, et al
    Feasibility and tissue concordance of genomic sequencing of urinary cytology in upper tract urothelial carcinoma.
    Urol Oncol. 2023;41:433.
    Abstract

  1820. RESNIK N, Visnjar T, Smrkolj T, Kreft ME, et al
    Selective targeting of lectins and their macropinocytosis in urothelial tumours: translation from in vitro to ex vivo.
    Histochem Cell Biol. 2023;160:435-452.
    Abstract

  1821. MORENO MF, Kaul S, Fleishman A, Korets R, et al
    Conditional survival following radical cystectomy for urothelial carcinoma of the bladder.
    Urol Oncol. 2023;41:432.
    Abstract

  1822. HE B, Ye L, Zeng H, Yao J, et al
    Differentiation of urothelial carcinoma and neuroendocrine carcinoma in the urinary bladder based on CT texture analysis.
    Asian J Surg. 2023;46:5053-5054.
    Abstract

  1823. THOMAS J, Sun M, Getz T, Ho B, et al
    Antibody-drug conjugates for urothelial carcinoma.
    Urol Oncol. 2023;41:420-428.
    Abstract

  1824. XIA M, Xiong S, He F, Li X, et al
    Pelvic lipomatosis with mucinous adenocarcinoma: A case report and literature review.
    Asian J Surg. 2023;46:4889-4890.
    Abstract

  1825. YANG B, Wang D, Niu Y, Liu J, et al
    A carcinoma in situ was inadvertently discovered after surgery for urinary bladder contracture.
    Asian J Surg. 2023;46:4897-4898.
    Abstract

  1826. SONG S, Smith A, Hu B
    The patient experience with localized upper tract urothelial cancer.
    Urol Oncol. 2023;41:431.
    Abstract

  1827. PINAR U, Calleris G, Grobet-Jeandin E, Grande P, et al
    The role of perioperative chemotherapy for upper tract urothelial carcinoma patients treated with radical nephroureterectomy.
    World J Urol. 2023;41:3205-3230.
    Abstract

  1828. ATIQ S, Hirshman N, Shariff A, Zhang T, et al
    The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Urol Oncol. 2023;41:410-419.
    Abstract

  1829. HAN X, Zhang T, Ma Q, Chang R, et al
    Gene expression profiles to analyze the anticancer and carcinogenic effects of arsenic in bladder cancer.
    Am J Transl Res. 2023;15:5984-5996.
    Abstract

  1830. CAO P, Chen M, Zhang T, Zheng Q, et al
    A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.
    Eur J Med Res. 2023;28:515.
    Abstract

  1831. BEDKE J, Black PC, Szabados B, Guerrero-Ramos F, et al
    Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition.
    Urol Oncol. 2023 Nov 13:S1078-1439(23)00342.
    Abstract

  1832. SHEN C, Chai W, Han J, Zhang Z, et al
    Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
    Front Immunol. 2023;14:1213947.
    Abstract

  1833. WOO S, Becker AS, Das JP, Ghafoor S, et al
    Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI.
    Cancer Imaging. 2023;23:110.
    Abstract

  1834. GUO P, Dai P, Yang S, Wang Z, et al
    Engineered Macrophages Tune Intratumoral Cytokines through Precisely Controlled Self-Pyroptosis to Enhance Bladder Cancer Immunotherapy.
    Small. 2023 Nov 14:e2306699. doi: 10.1002/smll.202306699.
    Abstract

  1835. KLEE M, Roesch MC, Eggers H, Ivanyi P, et al
    Enfortumab vedotin as a salvage option as 5th line therapy for metastatic urothelial bladder cancer.
    Aktuelle Urol. 2023 Nov 14. doi: 10.1055/a-2148-5799.
    Abstract

  1836. WANG Y, Song Y, Qin C, Zhang C, et al
    Three versus four cycles of neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Ann Med. 2023;55:2281654.
    Abstract

  1837. LIU T, Tang Q, Shan Q, Wang Z, et al
    Identification of potential phytochemical for the inhibition of non-muscle invasive bladder cancer (NMIBC).
    J Biomol Struct Dyn. 2023 Nov 14:1-9. doi: 10.1080/07391102.2023.2280914.
    Abstract

  1838. YU T, Cui X, Liang N, Wu S, et al
    Postoperative Metachronous Metastasis of Bladder Cancer to Penis: A Case Report.
    Arch Esp Urol. 2023;76:622-626.
    Abstract

  1839. LI C, Wan Z, Deng Q, Li Z, et al
    Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Arch Esp Urol. 2023;76:605-621.
    Abstract

  1840. KRISHNAN J, Symington A, Kernohan N, Bray S, et al
    HMG co-reductase expression and response to intravesical Bacillus Calmette-Guerin in patients with high grade non-muscle invasive urinary bladder cancer receiving statins.
    Scott Med J. 2023 Nov 13:369330231213935. doi: 10.1177/00369330231213935.
    Abstract

  1841. D'ANDREA VD, Melnick K, Yim K, Ernandez J, et al
    Evidence-Based Analysis of the Critical Steps of Radical Cystectomy for Bladder Cancer.
    J Clin Med. 2023;12:6845.
    Abstract

  1842. STROBACH D, Haimerl L, Mannell H, Stief CG, et al
    The Characterization of Non-oncologic Chronic Drug Therapy in Bladder Cancer Patients and the Impact on Recurrence-Free and Cancer-Specific Survival: A Prospective Study.
    J Clin Med. 2023;12:6749.
    Abstract

  1843. XIAO LY, Su YL, Huang SY, Chen YH, et al
    Chitinase 3-like-1 Expression in the Microenvironment Is Associated with Neutrophil Infiltration in Bladder Cancer.
    Int J Mol Sci. 2023;24:15990.
    Abstract

  1844. RUIZ DE PORRAS V, Font A
    Molecular Mechanisms of Tumor Progression and New Therapeutic Strategies for Urological Cancers.
    Int J Mol Sci. 2023;24:15795.
    Abstract

  1845. ALSOFYANI AA, Nedjadi T
    Gelsolin, an Actin-Binding Protein: Bioinformatic Analysis and Functional Significance in Urothelial Bladder Carcinoma.
    Int J Mol Sci. 2023;24:15763.
    Abstract

  1846. GARCIA-VALLICROSA C, Falcon-Perez JM, Royo F
    The Role of Longevity Assurance Homolog 2/Ceramide Synthase 2 in Bladder Cancer.
    Int J Mol Sci. 2023;24:15668.
    Abstract

  1847. GAO Y, Wang X, Luo H, Chen C, et al
    Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates Tumorigenesis via the miR-206
    Cancers (Basel). 2023;15:5305.
    Abstract

  1848. HUANG N, Peng L, Yang J, Li J, et al
    FAM111B Acts as an Oncogene in Bladder Cancer.
    Cancers (Basel). 2023;15:5122.
    Abstract

  1849. YILDIZ AK, Oktem C, Keseroglu BB, Kacan T, et al
    A New Scoring System to Differentiate Bladder Cancer from Intravesical Prostatic Protrusion in the Bladder Neck: BCa-IPP Score.
    Curr Med Imaging. 2023 Nov 10. doi: 10.2174/0115734056241577231023064014.
    Abstract

  1850. STRAUB M, Auderset A, de Leval L, Piazzon N, et al
    Nitrogen isotopic composition as a gauge of tumor cell anabolism-to-catabolism ratio.
    Sci Rep. 2023;13:19796.
    Abstract

  1851. SUNGU N, Kiran MM
    Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency.
    Pol J Pathol. 2023;74:161-170.
    Abstract

  1852. ZHOU G, Qin G, Zhang Z, Zhao H, et al
    Identification of tryptophan metabolism- and immune-related genes signature and prediction of immune infiltration landscape in bladder urothelial carcinoma.
    Front Immunol. 2023;14:1283792.
    Abstract

  1853. MOLLER CT, Tafjord G, Blindheim A, Berge V, et al
    Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway.
    Scand J Urol. 2023;58:101-108.
    Abstract

  1854. SODAGUM L, Passarelli R, Pfail J, Patel HV, et al
    Pelvic lymphadenectomy: Evaluating nodal stage migration and will rogers effect in bladder cancer.
    Urol Oncol. 2023 Nov 10:S1078-1439(23)00324.
    Abstract

  1855. WANG J, Li X, Chen S, Cao J, et al
    Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
    Life Sci. 2023;335:122253.
    Abstract

  1856. WANG J, Zuo Z, Yu Z, Chen Z, et al
    Collaborating single-cell and bulk RNA sequencing for comprehensive characterization of the bladder cancer intratumor heterogeneity and prognostic model development for bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  1857. WAN H, Zhan X, Li X, Chen T, et al
    Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.
    BMC Urol. 2023;23:182.
    Abstract

  1858. LI Y, Liu Y, Kang Z, Guo J, et al
    Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses.
    Sci Rep. 2023;13:19563.
    Abstract

  1859. LIANG H, Yang Q, Sun H, Xu Y, et al
    The vascular and morphological characteristics of tumors under narrow-band imaging as predictors for the grade and stage of bladder cancer: a prospective and multi-center study.
    Ann Med. 2023;55:2281656.
    Abstract

  1860. SANTINI D, Banna GL, Buti S, Isella L, et al
    Navigating the Rapidly Evolving Advanced Urothelial Carcinoma Treatment Landscape: Insights from Italian Experts.
    Curr Oncol Rep. 2023;25:1345-1362.
    Abstract

  1861. KIM JM, Choi E, Sung SH, Kang H, et al
    Invasive urothelial carcinoma with chordoid features or abundant myxoid stroma: A reappraisal of morphologic spectrum and risk stratification based on molecular classification.
    Pathol Res Pract. 2023;251:154839.
    Abstract

  1862. DLUBAK A, Karwacki J, Logon K, Tomecka P, et al
    Lymph Node Dissection in Upper Tract Urothelial Carcinoma: Current Status and Future Perspectives.
    Curr Oncol Rep. 2023;25:1327-1344.
    Abstract

  1863. EMINAGA O, Lee TJ, Laurie M, Ge TJ, et al
    Efficient Augmented Intelligence Framework for Bladder Lesion Detection.
    JCO Clin Cancer Inform. 2023;7:e2300031.
    Abstract

  1864. RICH JM, Tillu N, Grauer R, Busby D, et al
    Robot-Assisted Repair of Ureteroenteric Strictures After Cystectomy with Urinary Diversion: Technique Description and Outcomes from the European Robotic Urology Section Scientific Working Group.
    J Endourol. 2023;37:1209-1215.
    Abstract

  1865. IWASAKI S, Takahashi K, Katano H, Suzuki T, et al
    BK Polyomavirus-Associated Urothelial Carcinoma of the Bladder with a Background of BK Polyomavirus Nephropathy in a Kidney Transplant Recipient.
    Nephron. 2023;147 Suppl 1:53-60.
    Abstract

  1866. WU B, Zhou X
    LncRNA UCA1 could regulate the progression of neuropathic pain by regulating miR-135a-5p.
    Mutat Res. 2023;827:111833.
    Abstract

  1867. CELIK S, Aktas T, Gokbayrak O, Erol A, et al
    Genomic Alterations of Signaling and DNA Damage Repair Pathways in Non-muscle Invasive Bladder Cancer.
    Cancer Invest. 2023 Nov 24:1-10. doi: 10.1080/07357907.2023.2288640.
    Abstract

  1868. JIANG Z, Wang Y, Tuo Z
    Comprehensive analysis of Transferrin receptor (TFRC): A prognostic biomarker for patients with bladder cancer.
    Asian J Surg. 2023 Nov 22:S1015-9584(23)01835.
    Abstract

  1869. BEEREN I, Klerks NE, Aben KK, Oddens JR, et al
    Health-related Quality of Life During the First 4 Years After Non-Muscle-invasive Bladder Cancer Diagnosis: Results of a Large Multicentre Prospective Cohort.
    Eur Urol Oncol. 2023 Nov 22:S2588-9311(23)00252.
    Abstract

  1870. WANG D, Ning H, Wu H, Song Y, et al
    Construction and evaluation of a novel prognostic risk model of aging-related genes in bladder cancer.
    Curr Urol. 2023;17:236-245.
    Abstract

  1871. GADELKAREEM RA, Abdelraouf AM, Ahmed AI, El-Taher AM, et al
    Predictors of time-to-nadir serum creatinine after drainage of bilaterally obstructed kidneys due to bladder cancer.
    Curr Urol. 2023;17:246-250.
    Abstract

  1872. IEMURA Y, Miyake M, Fukui S, Fujii T, et al
    Depth of invasion to the bladder wall as a prognostic factor and its association with circulating cell-free DNA levels in patients with muscle-invasive bladder cancer.
    Curr Urol. 2023;17:229-235.
    Abstract

  1873. DI GIANFRANCESCO L
    The association between postvoid residual and response to standard therapy in male and female patients with non-muscle-invasive bladder cancer.
    Curr Urol. 2023;17:251-256.
    Abstract

  1874. JIANG Y, Sun X, Song X, Li Z, et al
    Patient-derived bladder cancer organoid model to predict sensitivity and feasibility of tailored precision therapy.
    Curr Urol. 2023;17:221-228.
    Abstract

  1875. LIEDBERG F, Xylinas E, Gontero P
    Quinolone Prophylaxis in Conjunction with Bacillus Calmette-Guerin Instillations for Bladder Cancer: Time To Reconsider the Evidence and Open the Quinolone Box?
    Eur Urol Focus. 2023 Nov 21:S2405-4569(23)00249.
    Abstract

  1876. MYERS A, Ristau B, Mossanen M, Tyson MD, et al
    Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer.
    Urol Oncol. 2023 Nov 21:S1078-1439(23)00306.
    Abstract

  1877. ZHENG B, Niu L, Xu H, Yang Y, et al
    Engineering redirected NF-kappaB/OIP5 expression programs to enhance tumor responses to chemotherapy in bladder cancer.
    Sci Bull (Beijing). 2023 Nov 14:S2095-9273(23)00781.
    Abstract

  1878. ZHOU Y, Borcsok J, Adib E, Kamran SC, et al
    ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer.
    Sci Adv. 2023;9:eadg2263.
    Abstract

  1879. HERZEEL C, D'Hondt E, Vandeweerd V, Botermans W, et al
    A software package for efficient patient trajectory analysis applied to analyzing bladder cancer development.
    PLOS Digit Health. 2023;2:e0000384.
    Abstract

  1880. WANG Z, He W, Ying Y, Wang M, et al
    Patients With Muscle-Invasive Bladder Cancer With Lymphovascular Invasion in Transurethral Resection Specimen Benefits Most From Platinum-Based Neoadjuvant Chemotherapy.
    Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00234.
    Abstract

  1881. ZENGZHAO W, Xuan L, Xiaohan M, Encun H, et al
    Molecular mechanism of microRNAs, long noncoding RNAs, and circular RNAs regulating lymphatic metastasis of bladder cancer.
    Urol Oncol. 2023 Nov 20:S1078-1439(23)00351.
    Abstract

  1882. KOLL FJ, Doring C, Herwig L, Hoeh B, et al
    Impact of consensus molecular subtypes on survival with and without adjuvant chemotherapy in muscle-invasive urothelial bladder cancer.
    J Clin Pathol. 2023 Nov 21:jcp-2023-208973. doi: 10.1136/jcp-2023-208973.
    Abstract

  1883. LIU G, Zhang T, Gui D, Liu Q, et al
    Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  1884. BALINT IB, Erdodi BT
    Is there a promoting role for artificial sweeteners in the evolution of bladder cancer? A meta-analysis of current literature.
    Minerva Surg. 2023 Nov 21. doi: 10.23736/S2724-5691.23.10000.
    Abstract

  1885. POSFAI B, Santa F, Schubert A, Semjen D, et al
    [Morphological variants of the invasive urothelial cell carcinoma.].
    Orv Hetil. 2023;164:1567-1582.
    Abstract

  1886. SAHU R, Shah K, Malviya R, Paliwal D, et al
    E-Cigarettes and Associated Health Risks: An Update on Cancer Potential.
    Adv Respir Med. 2023;91:516-531.
    Abstract

  1887. MALMSTROM PU, Truls G
    Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up.
    Scand J Urol. 2023;58:109-114.
    Abstract

  1888. MALLET R
    Thulium fiber laser as a novel technique with shallow and accurate cutting, high-quality hemostasis, and no ballistic effect in the treatment of non-muscle invasive bladder cancer.
    Urologia. 2023 Nov 20:3915603231211982. doi: 10.1177/03915603231211982.
    Abstract

  1889. DAUNGSUPAWONG H, Wiwanitkit V
    Knowledge-map analysis and bladder cancer immunotherapy: Comment.
    Hum Vaccin Immunother. 2023;19:2285094.
    Abstract

  1890. DENG W, Chen R, Xiong S, Nie J, et al
    CircFSCN1 induces tumor progression and triggers epithelial-mesenchymal transition in bladder cancer through augmentation of MDM2-mediated p53 silencing.
    Cell Signal. 2023 Nov 17:110982. doi: 10.1016/j.cellsig.2023.110982.
    Abstract

  1891. VAISHAMPAYAN UN, Heilbrun L, Vaishampayan N, Harper FW, et al
    Phase II trial of Concurrent Nivolumab and Radiation therapy in Elderly or Chemotherapy ineligible Muscle Invasive Bladder Cancer.
    Int J Radiat Oncol Biol Phys. 2023 Nov 17:S0360-3016(23)08152.
    Abstract

  1892. KOMURA K, Hirosuna K, Tokushige S, Tsujino T, et al
    The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
    Mol Cancer. 2023;22:185.
    Abstract

  1893. LIU CH, Zhang JJ, Zhang QJ, Dong Y, et al
    METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4.
    Cell Signal. 2023;113:110971.
    Abstract

  1894. BASILE G, Pradere B, Lenfant L, Roupret M, et al
    Re: Katharina Bruck, Richard P. Meijer, Joost L. Boormans, et al. Disease-free Survival of Patients with Muscle-invasive Bladder Cancer Treated with Radical Cystectomy Versus Bladder-preserving Therapy: A Nationwide Study. Int J Radiat Oncol Biol Phys
    Eur Urol Oncol. 2023 Nov 15:S2588-9311(23)00238.
    Abstract

  1895. XU C, Cao J, Zhou T
    Radiogenomics uncovers an interplay between angiogenesis and clinical outcomes in bladder cancer.
    Environ Toxicol. 2023 Nov 17. doi: 10.1002/tox.24038.
    Abstract

  1896. CIVI CETIN K, Oner S, Erdogan B, Simsek G, et al
    Young population bladder neoplasms.
    Eur Rev Med Pharmacol Sci. 2023;27:10454-10461.
    Abstract

  1897. ZHONG X, Pan Y, Wu K, Wang L, et al
    A novel nomogram based on body composition and nutritional indicators to predict the prognosis of patients with muscle-invasive bladder cancer undergoing radical cystectomy.
    Cancer Med. 2023 Nov 16. doi: 10.1002/cam4.6712.
    Abstract

  1898. GARG T, Frank K, Johns A, Rabinowitz K, et al
    Geriatric assessment-derived deficit accumulation and patient-reported treatment burden in older adults with bladder cancer.
    J Am Geriatr Soc. 2023 Nov 16. doi: 10.1111/jgs.18676.
    Abstract

  1899. SRETENOVIC M, Lisicic N, Bulat P, Radisavcevic D, et al
    Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer.
    J Surg Oncol. 2023 Nov 16. doi: 10.1002/jso.27517.
    Abstract

  1900. KIKUCHI H, Abe T, Miyake M, Miyata H, et al
    The impact of second transurethral resection on survival outcomes in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin therapy.
    Jpn J Clin Oncol. 2023 Nov 16:hyad155. doi: 10.1093.
    Abstract


  1901. [Not Available].
    Aktuelle Urol. 2023;54:438-440.
    Abstract


  1902. [Not Available].
    Aktuelle Urol. 2023;54:428-430.
    Abstract


  1903. [Not Available].
    Aktuelle Urol. 2023;54:428.
    Abstract

  1904. ZHANG H, Li D, Chen C
    Comment on: Vitamin C and catheter-related bladder discomfort after transurethral resection of bladder tumor: A double-blind, randomized, placebo-controlled study.
    J Clin Anesth. 2024;92:111273.
    Abstract

  1905. HUANG H, Xu Q, Zhang Y, Zhou Y, et al
    miR-628-5p is a Potential Novel Prognosis Biomarker, Associated with Immune Infiltration in Bladder Urothelial Carcinoma.
    Curr Pharm Des. 2023;29:2477-2488.
    Abstract

  1906. LORIOT Y, Matsubara N, Park SH, Huddart RA, et al
    Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
    N Engl J Med. 2023;389:1961-1971.
    Abstract

  1907. CHAPUR J, Kojic K, Kula M, Flexman AM, et al
    Perioperative cortical hand stroke syndrome mimicking peripheral neuropathy: a case report.
    Can J Anaesth. 2023;70:1839-1844.
    Abstract

  1908. QIANG Z, Jubber I, Lloyd K, Cumberbatch M, et al
    Gene of the month: GATA3.
    J Clin Pathol. 2023;76:793-797.
    Abstract

  1909. GHATALIA P, Plimack ER
    Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
    Nat Rev Clin Oncol. 2023;20:818-819.
    Abstract

  1910. WANG J, Wang T, Feng YK, Liu Y, et al
    Deubiquitinating enzyme PSMD7 promotes bladder cancer development: Involvement of RAB1A stabilization.
    Cell Signal. 2023 Nov 29:110996. doi: 10.1016/j.cellsig.2023.110996.
    Abstract

  1911. CHEN H, Qi Y, Yang C, Tai Q, et al
    Heterogeneous MXene Hybrid-Oriented Exosome Isolation and Metabolic Profiling for Early Screening, Subtyping and Follow-up Evaluation of Bladder Cancer.
    ACS Nano. 2023 Dec 1. doi: 10.1021/acsnano.3c08391.
    Abstract

  1912. LU G, Qiu Y
    SPI1-mediated CXCL12 expression in bladder cancer affects the recruitment of tumor-associated macrophages.
    Mol Carcinog. 2023 Dec 1. doi: 10.1002/mc.23663.
    Abstract

  1913. HANNOUNEH ZA, Hijazi A, Alsaleem AA, Hami S, et al
    Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Cancer Med. 2023 Dec 1. doi: 10.1002/cam4.6768.
    Abstract

  1914. LUO KW, Chen W, Lung WY, Wei XY, et al
    Corrigendum to "EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down-regulation of NF-kappaB and MMP-9" [Journal of Nutritional Biochemistry 41 (2017) 56-64].
    J Nutr Biochem. 2023 Nov 29:109530. doi: 10.1016/j.jnutbio.2023.109530.
    Abstract

  1915. SYNELNYK T, Vovk T, Halenova T, Tytarenko V, et al
    Evaluation of proteolytic activity and serine proteases distribution in plasma from patients with bladder cancer.
    Front Med (Lausanne). 2023;10:1276882.
    Abstract

  1916. MAVRIDIS C, Venihaki M, Dermitzaki E, Deiktakis M, et al
    mRNA expression of CRF family members in urothelial bladder cancer.
    Oncol Lett. 2023;27:13.
    Abstract

  1917. DONG Y, Cheng Y, Guo H, Sun J, et al
    Association of obesity and different metabolic status with prognosis in patients with bladder cancer: a retrospective cohort study.
    Ther Adv Urol. 2023;15:17562872231213720.
    Abstract

  1918. RANGEL MMM, Linhares LCM, de Oliveira KD, Suzuki DOH, et al
    Evaluation of the safety and feasibility of electrochemotherapy with intravenous bleomycin as local treatment of bladder cancer in dogs.
    Sci Rep. 2023;13:21078.
    Abstract

  1919. LIAO J, Zhou Z
    Long-term cardiovascular mortality risk in patients with bladder cancer: a real-world retrospective study of 129,765 cases based on the SEER database.
    Front Cardiovasc Med. 2023;10:1142417.
    Abstract


  1920. LINC-PINT Inhibited Malignant Progression of Bladder Cancer by Targeting miR-155-5p [Retraction].
    Cancer Manag Res. 2023;15:1267-1268.
    Abstract

  1921. KOURIE HR, Zouein J, Succar B, Mardirossian A, et al
    Genetic Polymorphisms Involved in Bladder Cancer: A Global Review.
    Oncol Rev. 2023;17:10603.
    Abstract

  1922. HODARA E, Mades A, Swartz L, Iqbal M, et al
    m(6)A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer.
    NAR Cancer. 2023;5:zcad054.
    Abstract

  1923. CHORBINSKA J, Krajewski W, Nowak L, Bardowska K, et al
    Is the Urinary and Gut Microbiome Associated With Bladder Cancer?
    Clin Med Insights Oncol. 2023;17:11795549231206796.
    Abstract

  1924. TAMADA S, Ikarashi D, Yanagawa N, Toyoshima M, et al
    Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report.
    Front Oncol. 2023;13:1274494.
    Abstract

  1925. WANG Y, Wang J, He J, Ji B, et al
    Comprehensive analysis of PRPF19 immune infiltrates, DNA methylation, senescence-associated secretory phenotype and ceRNA network in bladder cancer.
    Front Immunol. 2023;14:1289198.
    Abstract

  1926. MA YT, Hua F, Zhong XM, Xue YJ, et al
    Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study.
    Front Immunol. 2023;14:1269097.
    Abstract

  1927. DONG L, Lin F, Wu W, Huang W, et al
    Erratum: Transcriptional cofactor Mask2 is required for YAP-induced cell growth and migration in bladder cancer cell: Erratum.
    J Cancer. 2023;14:3521-3522.
    Abstract

  1928. HESSWANI C, Jackson CL, Marcq G, Hardy C, et al
    Feasibility and Impact of Immunohistochemistry-based Molecular Subtyping for Muscle-invasive Bladder Cancer in Patients Treated with Radiation-based Therapy.
    Eur Urol Open Sci. 2023;57:22-29.
    Abstract

  1929. BOHNER P, Pal M, Crettenand F, Roth B, et al
    [Bladder cancer : a comprehensive follow-up for an efficient and personalized care].
    Rev Med Suisse. 2023;19:2250-2253.
    Abstract

  1930. REALE S, Bohner P, Crettenand F, Roth B, et al
    [Radical cystectomy in the geriatric population. Tools for screening postoperative complications].
    Rev Med Suisse. 2023;19:2247-2249.
    Abstract

  1931. CHEN H, Shi D, Guo C, Zhang W, et al
    Can uric acid affect the immune microenvironment in bladder cancer? A single-center multi-omics study.
    Mol Carcinog. 2023 Nov 29. doi: 10.1002/mc.23664.
    Abstract

  1932. LIU Z, Sun L, Zheng B, Wang H, et al
    The value of ATAD3A as a potential biomarker for bladder cancer.
    Cancer Med. 2023 Nov 28. doi: 10.1002/cam4.6759.
    Abstract

  1933. ZHOU G, Li Y, Ren X, Qin G, et al
    Identifying prognostic characteristics of m6A-related glycolysis gene and predicting the immune infiltration landscape in bladder cancer.
    Cancer Cell Int. 2023;23:300.
    Abstract

  1934. MYOEN S, Mochizuki M, Shibuya-Takahashi R, Fujimori H, et al
    CD271 promotes proliferation and migration in bladder cancer.
    Genes Cells. 2023 Nov 28. doi: 10.1111/gtc.13087.
    Abstract

  1935. JIN H, Liu B, Guo X, Qiao X, et al
    MYLK and CALD1 as molecular targets in bladder cancer.
    Medicine (Baltimore). 2023;102:e36302.
    Abstract

  1936. LI J, Zhuang C, Liu Y, Chen M, et al
    Correction: Synthetic tetracycline-controllable shRNA targeting long non-coding RNA HOXD-AS1 inhibits the progression of bladder cancer.
    J Exp Clin Cancer Res. 2023;42:321.
    Abstract

  1937. WANG L, Deng JY, Li KP, Shan-Yin, et al
    Inflammatory bowel disease and bladder cancer risk: based on a Mendelian randomization study.
    BMC Urol. 2023;23:195.
    Abstract

  1938. YUE R, Dutta A
    Reparameterized multiobjective control of BCG immunotherapy.
    Sci Rep. 2023;13:20850.
    Abstract

  1939. GUO C, Li P, Guo X, Wang X, et al
    Identification of bladder cancer subtypes and predictive model for prognosis, immune features, and immunotherapy based on neutrophil extracellular trap-related genes.
    Sci Rep. 2023;13:20791.
    Abstract

  1940. KOBAYASHI Y, Iijima K, Kondo Y, Yamamoto K, et al
    Chronic polyradiculoneuropathy associated with pembrolizumab for bladder cancer.
    Acta Neurol Belg. 2023 Nov 27. doi: 10.1007/s13760-023-02439.
    Abstract

  1941. KISHI S, Mori S, Fujiwara-Tani R, Ogata R, et al
    ERVK13-1/miR-873-5p/GNMT Axis Promotes Metastatic Potential in Human Bladder Cancer though Sarcosine Production.
    Int J Mol Sci. 2023;24:16367.
    Abstract

  1942. SAMARA M, Vlachostergios PJ, Thodou E, Zachos I, et al
    Characterization of a miRNA Signature with Enhanced Diagnostic and Prognostic Power for Patients with Bladder Carcinoma.
    Int J Mol Sci. 2023;24:16243.
    Abstract

  1943. FAHEY CC, Nebhan CA, York S, Davis NB, et al
    Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
    Int J Mol Sci. 2023;24:16109.
    Abstract

  1944. BERNDT-PAETZ M, Han S, Weimann A, Reinhold A, et al
    Cell Line-Based Human Bladder Organoids with Bladder-like Self-Organization-A New Standardized Approach in Bladder Cancer Research.
    Biomedicines. 2023;11:2958.
    Abstract

  1945. AKIN O, Lema-Dopico A, Paudyal R, Konar AS, et al
    Multiparametric MRI in Era of Artificial Intelligence for Bladder Cancer Therapies.
    Cancers (Basel). 2023;15:5468.
    Abstract

  1946. ZHANG Z, Yu Y, Zhang Z, Li D, et al
    Cancer-associated fibroblasts-derived CXCL12 enhances immune escape of bladder cancer through inhibiting P62-mediated autophagic degradation of PDL1.
    J Exp Clin Cancer Res. 2023;42:316.
    Abstract

  1947. KHEDR OS, Wahed ME, Al-Attar AR, Abdel-Rehim EA, et al
    The classification of the bladder cancer based on Vision Transformers (ViT).
    Sci Rep. 2023;13:20639.
    Abstract

  1948. FUJIWARA M, Tanaka H, Kobayashi M, Nakamura Y, et al
    Neoadjuvant Chemoradiotherapy Followed by Radical Cystectomy for Muscle-Invasive Bladder Cancer: Analysis of Efficacy and Safety in 119 Patients.
    Clin Genitourin Cancer. 2023 Nov 2:S1558-7673(23)00232.
    Abstract

  1949. KNAPP DW, Dhawan D, Ruple A, Cooper BR, et al
    Association between cigarette smoke exposure and urinary bladder cancer in Scottish terriers in a cohort study.
    Vet J. 2023 Nov 22:106044. doi: 10.1016/j.tvjl.2023.106044.
    Abstract

  1950. LIU L, Xiao Y, Wei D, Wang Q, et al
    Development and validation of a nomogram for predicting suicide risk and prognostic factors in bladder cancer patients following diagnosis: A population-based retrospective study.
    J Affect Disord. 2023;347:124-133.
    Abstract

  1951. YU J, Lee CU, Chung JH, Song W, et al
    Impact of urinary diversion type on urethral recurrence following radical cystectomy for bladder cancer: Propensity score matched and weighted analyses of retrospective cohort.
    Int J Surg. 2023 Nov 23. doi: 10.1097/JS9.0000000000000904.
    Abstract

  1952. TSILI AC
    VI-RADS scoring system for predicting 1- to 5-year recurrence of bladder cancer.
    Eur Radiol. 2023 Nov 24. doi: 10.1007/s00330-023-10458.
    Abstract

  1953. TEMPO J, Bolton D, O'Callaghan M
    Seminal papers in urology: maintenance Bacillus Calmette-Guerin (BCG) immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study (SWOG-8507).
    BMC Urol. 2023;23:194.
    Abstract

  1954. MEDORI MC, Micheletti C, Madeo G, Maltese PE, et al
    Omics sciences and precision medicine in Urothelial Carcinoma.
    Clin Ter. 2023;174.
    Abstract

  1955. TANG X, Zhan X, Chen X
    Incidence, mortality and survival of transitional cell carcinoma in the urinary system: A population-based analysis.
    Medicine (Baltimore). 2023;102:e36063.
    Abstract


  1956. [Not Available].
    Aktuelle Urol. 2023;54:434.
    Abstract

  1957. SCHALLENBERG S, Plage H, Hofbauer S, Furlano K, et al
    Altered p53/p16 expression is linked to urothelial carcinoma progression but largely unrelated to prognosis in muscle-invasive tumors.
    Acta Oncol. 2023;62:1880-1889.
    Abstract

  1958. DHALL A, Patiyal S, Kaur H, Raghava GPS, et al
    Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
    Comput Biol Med. 2023;167:107594.
    Abstract

  1959. STONE L
    Bladder-sparing neoadjuvant therapy for MIBC.
    Nat Rev Urol. 2023;20:703.
    Abstract

  1960. SANO T, Saito R, Aizawa R, Watanabe T, et al
    Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma.
    Int J Clin Oncol. 2023;28:1573-1584.
    Abstract

  1961. MARJERRISON N, Grimsrud TK, Hansen J, Martinsen JI, et al
    Occupational exposures of firefighting and urinary tract cancer risk among men in the Norwegian Fire Departments Cohort.
    Occup Environ Med. 2023;80:659-666.
    Abstract

  1962. TOYODA T, Kobayashi T, Miyoshi N, Matsushita K, et al
    Mucosal damage and gamma-H2AX formation in the rat urinary bladder induced by aromatic amines with structures similar to o-toluidine and o-anisidine.
    Arch Toxicol. 2023;97:3197-3207.
    Abstract

  1963. LIAO PJ, Lee CH, Wang SL, Chiou HY, et al
    Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area.
    J Epidemiol Glob Health. 2023;13:807-815.
    Abstract

  1964. SAVIN Z, Yossepowitch O, Lazarovich A, Rosenzwieg B, et al
    11-item modified frailty index and outcomes after radical cystectomy.
    J Geriatr Oncol. 2023;14:101627.
    Abstract

  1965. ANDRUSKA N, Waters MR, Fischer-Valuck BW, Smith ZL, et al
    Does Chemo-Radiotherapy Improve Survival Outcomes vs. Radiotherapy Alone for High-Grade cT1 Urothelial Carcinoma of the Bladder?
    Clin Genitourin Cancer. 2023;21:653-659.
    Abstract

  1966. ROSENBERG JE, Powles T, Sonpavde GP, Loriot Y, et al
    EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.
    Ann Oncol. 2023;34:1047-1054.
    Abstract

  1967. BASCIO LS, Chiappa V, Paolini B, Chiarello G, et al
    Urothelial bladder carcinoma recurrence in the uterine cervix: Cytological findings on a cervical cytology test.
    Cytopathology. 2023;34:645-648.
    Abstract

  1968. KIR G, Cecikoglu GE, Topal CS, Sorkun MH, et al
    Clinicopathologic features and prognostic significance of mixed (Low and high-grade) papillary urothelial carcinoma comparison with low and high-grade papillary urothelial carcinoma.
    Virchows Arch. 2023;483:621-634.
    Abstract

  1969. NOGRADI AL, Cope I, Arany-Toth A, Muller L, et al
    Primary Urinary Bladder Tumors in Three Guinea Pigs (Cavia Porcellus).
    Top Companion Anim Med. 2023;56-57:100805.
    Abstract

  1970. AHN H, Kim TM, Hwang SI, Lee HJ, et al
    Tumor contact length with bladder wall provides effective risk stratification for lesions with a VIRADS score of 2-3.
    Eur Radiol. 2023;33:8417-8425.
    Abstract

  1971. KLOSE C, Gordon O, Sparks A, Whalen M, et al
    Trends of Lymph Node Outcomes in Partial Cystectomy for Muscle-Invasive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2023;21:703-709.
    Abstract

  1972. AGRAWAL P, Rostom M, Alam R, Florissi I, et al
    Clinicopathologic and Survival After Cystectomy Outcomes in Squamous Cell Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2023;21:631-638.
    Abstract

  1973. ACAR O, Ayhan M, Demir B, Ekinci F, et al
    HALP Score as a New Prognostic Factor for Patients with Metastatic Bladder Cancer.
    J Coll Physicians Surg Pak. 2023;33:1405-1409.
    Abstract

  1974. LIU T, Xu X, Li J, Bai M, et al
    ALOX5 deficiency contributes to bladder cancer progression by mediating ferroptosis escape.
    Cell Death Dis. 2023;14:800.
    Abstract

  1975. NOEL ODV, Hassouneh Z, Svatek RS, Mukherjee N, et al
    Innate Lymphoid Cells in Bladder Cancer: From Mechanisms of Action to Immune Therapies.
    Cancer Immunol Res. 2023 Dec 7:OF1-OF12. doi: 10.1158/2326-6066.CIR-23-0414.
    Abstract

  1976. WANG Z, Ying Y, Wang M, Chen Q, et al
    Comprehensive identification of onco-exaptation events in bladder cancer cell lines revealed L1PA2-SYT1 as a prognosis-relevant event.
    iScience. 2023;26:108482.
    Abstract

  1977. YANG J, Jiang X, Chen Y, Teng L, et al
    EIF5A2 Promotes Doxorubicin Resistance in Bladder Cancer Cells through the TGF-beta Signaling Pathway.
    Discov Med. 2023;35:1167-1176.
    Abstract

  1978. AN WX, Gupta R, Zhai K, Wang YR, et al
    Current and Potential Roles of Ferroptosis in Bladder Cancer.
    Curr Med Sci. 2023 Dec 7. doi: 10.1007/s11596-023-2814.
    Abstract

  1979. ZHUANG J, Cai L, Sun H, Wu Q, et al
    Vesical imaging reporting and data system (VI-RADS) could predict the survival of bladder-cancer patients who received radical cystectomy.
    Sci Rep. 2023;13:21502.
    Abstract

  1980. LI W, Shen Y, Yang C, Ye F, et al
    Identification of a novel ferroptosis-inducing micropeptide in bladder cancer.
    Cancer Lett. 2023 Dec 4:216515. doi: 10.1016/j.canlet.2023.216515.
    Abstract

  1981. TENG C, Liu Z, Wang J, Shi S, et al
    C15:0 and C17:0 partially mediate the association of milk &dairy products with bladder cancer risk.
    J Dairy Sci. 2023 Dec 4:S0022-0302(23)00830-5. doi: 10.3168/jds.2023-24186.
    Abstract

  1982. HOOGEVEEN F, Blanker MH, Cauberg E, Steffens MG, et al
    Recurrence of non-muscle invasive bladder carcinoma after transurethral resection with hexaminolevulinate photodynamic diagnosis or regular cystoscopy.
    Scand J Urol. 2023;58:120-125.
    Abstract

  1983. ZHENG J, Peng L, Zhang S, Liao H, et al
    Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.
    Front Immunol. 2023;14:1275033.
    Abstract

  1984. EBNER B, Fleckenstein F, Volz Y, Eismann L, et al
    Oncological impact of perioperative blood transfusion in bladder cancer patients undergoing radical cystectomy: Do we need to consider storage time of blood units, donor age, or gender matching?
    Transfusion. 2023 Dec 6. doi: 10.1111/trf.17618.
    Abstract

  1985. DONG X, Wang Y, Wang S, Li C, et al
    Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
    Arch Esp Urol. 2023;76:657-665.
    Abstract

  1986. HAN Y, Kim U, Jung KJ, Lee JY, et al
    Metabolic changes preceding bladder cancer occurrence among Korean men: a nested case-control study from the KCPS-II cohort.
    Cancer Metab. 2023;11:23.
    Abstract

  1987. WU JM, Qiu WR, Liu Z, Xu ZC, et al
    Integrative approach for classifying male tumors based on DNA methylation 450K data.
    Math Biosci Eng. 2023;20:19133-19151.
    Abstract

  1988. JIANG YK, Shuai YJ, Ding HM, Zhang H, et al
    Erratum to: ARID1A Inactivation Increases Expression of circ0008399 and Pro-motes Cisplatin Resistance in Bladder Cancer.
    Curr Med Sci. 2023 Dec 4. doi: 10.1007/s11596-023-2819.
    Abstract

  1989. LI H, Lin G, Cui M, Wang L, et al
    Hub biomarkers in ultrasound-guided bladder cancer and osteosarcoma: Myosin light chain kinase and caldesmon.
    Medicine (Baltimore). 2023;102:e36414.
    Abstract

  1990. ZHU S, Zhao Q, Fan Y, Tang C, et al
    Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
    BMC Urol. 2023;23:199.
    Abstract

  1991. CHI BJ, Duan ZL, Hasan AHAM, Yin XZ, et al
    Effect and Mechanism of Curdione Combined with Gemcitabine on Migration and Invasion of Bladder Cancer.
    Biochem Genet. 2023 Dec 5. doi: 10.1007/s10528-023-10584.
    Abstract

  1992. MAITRE P, Choudhury A
    Bladder Preservation and Immunotherapy: Rebel Without A Cause?
    Int J Radiat Oncol Biol Phys. 2024;118:50-51.
    Abstract

  1993. LIVERINGHOUSE C, Netzley A, Bryant JM, Linkowski LC, et al
    Trimodal Therapy Using an MR-guided Radiation Therapy Partial Bladder Tumor Boost in Muscle Invasive Bladder Cancer.
    Adv Radiat Oncol. 2023;8:101268.
    Abstract

  1994. SINGH P, Parida GK, Bishnoi K, Singhal T, et al
    Delayed Recurrence of Gall Bladder Cancer as Port-site Metastases with Occult Primary Detected on Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: A Tale of Two Cases.
    Indian J Nucl Med. 2023;38:273-275.
    Abstract

  1995. SOLOWAY MS
    Inflection points in urology as witnessed by Mark Soloway. Part 1: bladder cancer.
    Cent European J Urol. 2023;76:263-268.
    Abstract

  1996. WIELAND VLS, Uysal D, Probst P, Grilli M, et al
    Framework for a living systematic review and meta-analysis for the surgical treatment of bladder cancer: introducing EVIglance to urology.
    Int J Surg Protoc. 2023;27:9-15.
    Abstract

  1997. FURUYA H, Sakatani T, Tanaka S, Murakami K, et al
    Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms.
    Res Sq. 2023 Nov 25:rs.3.rs-3635581. doi: 10.21203/rs.3.rs-3635581.
    Abstract

  1998. CAI X, Ruan L, Wang D, Zhang J, et al
    Boosting chemotherapy of bladder cancer cells by ferroptosis using intelligent magnetic targeting nanoparticles.
    Colloids Surf B Biointerfaces. 2023;234:113664.
    Abstract

  1999. LIU Y, Ye F, Yang C, Jiang H, et al
    Use of in vivo Raman spectroscopy and cryoablation for diagnosis and treatment of bladder cancer.
    Spectrochim Acta A Mol Biomol Spectrosc. 2023;308:123707.
    Abstract

  2000. KIM JM, Choi E, Sung SH, Jo J, et al
    Does Bladder Cancer Subtype Influence Pathologic Complete Response (pCR) and Pelvic Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Response Evaluation After Neoadjuvant Chemotherapy? Pathological Perspective.
    Clin Genitourin Cancer. 2023 Nov 10:S1558-7673(23)00240.
    Abstract

  2001. FRANCOLINI G, Ghoshal A, Caini S, Piazzini T, et al
    Quality of life after definitive treatment for bladder cancer: A systematic review and meta-analysis.
    Radiother Oncol. 2023;190:110038.
    Abstract

  2002. MA C, Zhong X, Liu R, Yang X, et al
    Co-delivery of oxaliplatin prodrug liposomes with Bacillus Calmette-Guerin for chemo-immunotherapy of orthotopic bladder cancer.
    J Control Release. 2023;365:640-653.
    Abstract

  2003. JOBST M, Hossain M, Kiss E, Bergen J, et al
    Autophagy modulation changes mechano-chemical sensitivity of T24 bladder cancer cells.
    Biomed Pharmacother. 2023;170:115942.
    Abstract

  2004. QIU Y, Ye W, Wang C, Zang J, et al
    Prognostic significance and immunoinfiltration analysis of genes associated with epithelial-mesenchymal transition and energy metabolism in bladder urothelial carcinoma.
    Aging (Albany NY). 2023;15:13312-13328.
    Abstract

  2005. CHEN J, Chen S, Luo H, Wan X, et al
    The complementary and alternative roles of elemene injection in cancer: An umbrella review.
    Pharmacol Res. 2023;198:107007.
    Abstract

  2006. FIGAROA OJA, Hendriks N, Kamphuis GM, van Moorselaar RJA, et al
    Positioning the role of urine cytology within the diagnostic pathway for UTUC: supportive but inconclusive.
    World J Urol. 2023;41:3429-3435.
    Abstract

  2007. TSUJINO T, Komura K, Inamoto T, Maenosono R, et al
    Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
    World J Urol. 2023;41:3585-3591.
    Abstract

  2008. CHEN JC, Huang TH, Wei TC, Huang IS, et al
    Influence of preoperative body mass index on prognosis for patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
    World J Urol. 2023;41:3575-3583.
    Abstract

  2009. KOELKER M, Bradtke M, Klemm J, von Deimling M, et al
    Rational peri-operative management of antithrombotic therapy in patients undergoing radical cystectomy: A 30-day morbidity analysis based on the updated European Association of Urology guidelines for standardized complication reporting.
    Eur J Surg Oncol. 2023;49:107123.
    Abstract

  2010. RICH JM, Geduldig J, Cumarasamy S, Ranti D, et al
    Eliminating the routine use of postoperative drain placement in patients undergoing robotic-assisted radical cystectomy with intracorporeal urinary diversion.
    Urol Oncol. 2023;41:457.
    Abstract

  2011. WANG B, Ou Z, Zhong W, Huang L, et al
    Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant.
    Cancer Immunol Res. 2023;11:1656-1670.
    Abstract

  2012. ALHALABI O, Wilson N, Xiao L, Lin Y, et al
    Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
    Eur Urol Oncol. 2023;6:611-620.
    Abstract

  2013. GRAHN A, Coleman JA, Eriksson Y, Gabrielsson S, et al
    Consultation on UTUC II Stockholm 2022: diagnostic and prognostic methods-what's around the corner?
    World J Urol. 2023;41:3405-3411.
    Abstract

  2014. MU N, Jylha C, Axelsson T, Syden F, et al
    Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC.
    World J Urol. 2023;41:3421-3427.
    Abstract

  2015. CALLERIS G, Roupret M, Seisen T, Bendjeddou L, et al
    Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756).
    World J Urol. 2023;41:3413-3420.
    Abstract

  2016. YIM K, Melnick K, Mott SL, Carvalho FLF, et al
    Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy.
    Urol Oncol. 2023;41:458.
    Abstract

  2017. SYDEN F, Baard J, Bultitude M, Keeley FX Jr, et al
    Consultation on UTUC II Stockholm 2022: diagnostics, prognostication, and follow-up-where are we today?
    World J Urol. 2023;41:3395-3403.
    Abstract

  2018. BLACHMAN-BRAUN R, Gurayah AA, Mason MM, Hougen HY, et al
    Incidence and predictors of deep incisional and organ/space surgical site infection following radical cystectomy.
    Urol Oncol. 2023;41:455.
    Abstract

  2019. NYAME YA, Baker KK, Montgomery B, Grivas P, et al
    Racial and sex differences in tumor genomics in urothelial carcinoma.
    Urol Oncol. 2023;41:456.
    Abstract

  2020. KAZAN O, Gunduz N, Bakir B, Iplikci A, et al
    Diagnostic validity of the vesical imaging-reporting and data system (VI-RADS): a real-world study.
    Actas Urol Esp (Engl Ed). 2023;47:638-644.
    Abstract

  2021. ROSE KM, Murray KS, Labbate C, Woldu S, et al
    Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
    Eur Urol Focus. 2023;9:807-812.
    Abstract

  2022. RYAN PC, Kelly C, Afridi I, Fawaz A, et al
    Surgical treatment of urachal remnants in an adult population-a single-centre experience.
    Ir J Med Sci. 2023;192:3023-3027.
    Abstract

  2023. MARTINI A, Touzani A, Ploussard G
    Lower Detrusor Apron-sparing Robot-assisted Radical Cystectomy and Intracorporeal Neobladder Reconstruction: Technique and Preliminary Outcomes.
    Eur Urol Focus. 2023;9:760-764.
    Abstract

  2024. ZHANG X, Wen Z, Xing Z, Zhou X, et al
    The causal relationship between osteoarthritis and bladder cancer: A Mendelian randomization study.
    Cancer Med. 2023 Dec 15. doi: 10.1002/cam4.6829.
    Abstract

  2025. BAZARKIN A, Morozov A, Androsov A, Fajkovic H, et al
    Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
    Curr Urol Rep. 2023 Dec 15. doi: 10.1007/s11934-023-01193.
    Abstract

  2026. CARRASCO R, Ingelmo-Torres M, Oriola J, Roldan FL, et al
    Assessment of aggressive bladder cancer mutations in plasma cell-free DNA.
    Front Oncol. 2023;13:1270962.
    Abstract

  2027. TIAN X, Liu D, He P, Li L, et al
    DOK7, a target of miR-299-5p, suppresses the progression of bladder cancer.
    Aging (Albany NY). 2023;15.
    Abstract

  2028. KHAN AR, Awan NUH, Tchier F, Alahmari SD, et al
    An estimation of physiochemical properties of bladder cancer drugs via degree-based chemical bonding topological descriptors.
    J Biomol Struct Dyn. 2023 Dec 14:1-9. doi: 10.1080/07391102.2023.2292792.
    Abstract

  2029. ZHOU Y, Xu W, Zeng Y, Li H, et al
    Global research trends of the application of artificial intelligence in bladder cancer since the 21st century: a bibliometric analysis.
    Front Oncol. 2023;13:1227152.
    Abstract

  2030. METHODS IN MEDICINE CAM
    Retracted: CASC1 Expression in Bladder Cancer Is Regulated by Exosomal miRNA-150: A Comprehensive Pan-Cancer and Bioinformatics Study.
    Comput Math Methods Med. 2023;2023:9867274.
    Abstract

  2031. WANG H, Zhang M, Miao J, Hou F, et al
    Deep learning signature based on multiphase enhanced CT for bladder cancer recurrence prediction: a multi-center study.
    EClinicalMedicine. 2023;66:102352.
    Abstract

  2032. WANG H, Lv Z, Xia H, Tang R, et al
    Cuproptosis-related long noncoding RNAs predicts overall survival and reveal immune microenvironment of bladder cancer.
    Heliyon. 2023;9:e21153.
    Abstract

  2033. MICHAUD E, Mansure JJ, Kassouf W
    INTEGRATING NOVEL IMMUNOTHERAPEUTIC APPROACHES IN ORGAN-PRESERVING THERAPIES FOR BLADDER CANCER.
    Br J Pharmacol. 2023 Dec 13. doi: 10.1111/bph.16300.
    Abstract

  2034. REN Y, Wang G, Wang P, Liu K, et al
    MM-SFENet: multi-scale multi-task localization and classification of bladder cancer in MRI with spatial feature encoder network.
    Phys Med Biol. 2023 Dec 13. doi: 10.1088/1361-6560/ad1548.
    Abstract

  2035. WANG S, Ji Y, Liu Y, Du P, et al
    The values of HER-2 expression in the non-muscle-invasive bladder cancer: a retrospective clinical study.
    Front Oncol. 2023;13:1243118.
    Abstract

  2036. WANG L, Wang W
    Symptom management and nursing interventions for postoperative bladder instillation chemotherapy in bladder cancer patients.
    Minerva Surg. 2023 Dec 13. doi: 10.23736/S2724-5691.23.10162.
    Abstract

  2037. GORE JL, Follmer K, Reynolds J, Nash M, et al
    Interruptions in bladder cancer care during the COVID-19 public health emergency.
    Urol Oncol. 2023 Dec 11:S1078-1439(23)00362.
    Abstract

  2038. YU X, Li W, Sun S, Li J, et al
    Investigating the prognostic value of mTORC1 signaling in bladder cancer via bioinformatics evaluation.
    Sci Rep. 2023;13:22066.
    Abstract

  2039. SLUSARCZYK A, Zapala P, Piecha T, Zapala L, et al
    Upper Urinary Tract Urothelial Cancer After Radical Cystectomy for Bladder Cancer: Survival Outcomes After Radical Nephroureterectomy.
    Ann Surg Oncol. 2023 Dec 12. doi: 10.1245/s10434-023-14710.
    Abstract

  2040. ZOUEIN J, Boueri M, Kourie HR, Kattan J, et al
    Advanced bladder cancer management: history in the making.
    Future Oncol. 2023 Dec 12. doi: 10.2217/fon-2023-0908.
    Abstract

  2041. ZHENG X, Chen J, Deng M, Ning K, et al
    G3BP1 and SLU7 Jointly Promote Immune Evasion by Downregulating MHC-I via PI3K/Akt Activation in Bladder Cancer.
    Adv Sci (Weinh). 2023 Dec 12:e2305922. doi: 10.1002/advs.202305922.
    Abstract

  2042. LEE S, Jue M, Lee K, Paulson B, et al
    Early-stage diagnosis of bladder cancer using surface-enhanced Raman spectroscopy combined with machine learning algorithms in a rat model.
    Biosens Bioelectron. 2023;246:115915.
    Abstract

  2043. HEALTHCARE ENGINEERING JO
    Retracted: Efficacy of Bladder Intravesical Chemotherapy with Three Drugs for Preventing Non-Muscle-Invasive Bladder Cancer Recurrence.
    J Healthc Eng. 2023;2023:9801404.
    Abstract

  2044. METHODS IN MEDICINE CAM
    Retracted: Effects of Nursing Care for the Treatment of Patients with Bladder Cancer: A Systematic Review and Meta-analysis.
    Comput Math Methods Med. 2023;2023:9876720.
    Abstract

  2045. MEGHANI K, Frydenlund N, Yu Y, Choy B, et al
    A Spatial Comparison of Molecular Features Associated with Resistance to Pembrolizumab in BCG Unresponsive Bladder Cancer.
    medRxiv. 2023 Nov 29:2023.11.28.23299093. doi: 10.1101/2023.11.28.23299093.
    Abstract

  2046. CHEN X, Zhang Z, Liao W, Zhao Y, et al
    Assessment tool based on fatty acid metabolic signatures for predicting the prognosis and treatment response in bladder cancer.
    Heliyon. 2023;9:e22768.
    Abstract

  2047. FALLATAH M, Alkahtani AS, Alrumayyan M, Alotaibi MF, et al
    Trimodal therapy versus radical cystectomy for cT2N0M0 urothelial muscle-invasive bladder cancer: Single-center experience.
    Urol Ann. 2023;15:406-411.
    Abstract

  2048. MARX AH, Nowicki DN, Carlson RB, Schultz KM, et al
    Bacille Calmette-Guerin preparation and intravesical administration to patients with bladder cancer: Risks to healthcare personnel and patients, and mitigation strategies.
    Infect Control Hosp Epidemiol. 2023 Dec 11:1-6. doi: 10.1017/ice.2023.
    Abstract

  2049. LIU Y, Han YS, Wang JF, Pang ZQ, et al
    A new immune-related gene signature predicts the prognosis and immune escape of bladder cancer.
    Cancer Biomark. 2023 Nov 7. doi: 10.3233/CBM-230190.
    Abstract

  2050. LIU Z, Du D, Zhang S
    Tumor-derived exosomal miR-1247-3p promotes angiogenesis in bladder cancer by targeting FOXO1.
    Cancer Biol Ther. 2024;25:2290033.
    Abstract

  2051. EL-AGRODY E, Abol-Enein H, Mortada WI, Awadalla A, et al
    Does the Presence of Heavy Metals Influence the Gene Expression and Oxidative Stress in Bladder Cancer?
    Biol Trace Elem Res. 2023 Dec 11. doi: 10.1007/s12011-023-03950.
    Abstract

  2052. CHEN X, Qin Z, Zhu X, Wang L, et al
    Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
    Sci Rep. 2023;13:21816.
    Abstract

  2053. MENG F, Zhang Z
    MicroRNA-152 specifically targets kinesin family member 14 to suppress the advancement of bladder cancer cells via PI3K/AKT pathway.
    Biochem Biophys Res Commun. 2023;692:149337.
    Abstract

  2054. CARRASCO R, Ingelmo-Torres M, Trullas R, Roldan FL, et al
    Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.
    Int J Mol Sci. 2023;24:16578.
    Abstract

  2055. NEDJADI T, Ahmed ME, Ansari HR, Aouabdi S, et al
    Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis.
    Cancers (Basel). 2023;15:5704.
    Abstract

  2056. KHOUYA A, Pottgen C, Hoffmann C, Ringbaek TP, et al
    Adaptation Time as a Determinant of the Dosimetric Effectiveness of Online Adaptive Radiotherapy for Bladder Cancer.
    Cancers (Basel). 2023;15:5629.
    Abstract

  2057. RODRIGUEZ-IZQUIERDO M, Del Canizo CG, Rubio C, Reina IA, et al
    Immune Predictors of Response after Bacillus Calmette-Guerin Treatment in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:5554.
    Abstract

  2058. SANCHEZ-PELLICER P, Boix-Rodriguez C, Hernandez-Belmonte A, Encarnacion-Castellano C, et al
    Bladder Cancer and Probiotics: What Do We Know So Far?
    Cancers (Basel). 2023;15:5551.
    Abstract

  2059. SEMENIUK-WOJTAS A, Modzelewska M, Poddebniak-Strama K, Kolaczynska S, et al
    CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2023;15:5529.
    Abstract

  2060. OH CH
    Clinical efficacy and safety of percutaneous drainage for post-operative fluid collection in patients with bladder cancer undergoing radical cystectomy and urinary diversion.
    Medicine (Baltimore). 2023;102:e36488.
    Abstract

  2061. LIU R, Yang J, Du Y, Yu X, et al
    A "One Arrow Three Eagle" Strategy to Improve CM-272 Primed Bladder Cancer Immunotherapy.
    Adv Mater. 2023 Dec 8:e2310522. doi: 10.1002/adma.202310522.
    Abstract

  2062. LI Z, Li Y, Liu L, Zhang C, et al
    Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
    Environ Toxicol. 2023 Dec 8. doi: 10.1002/tox.24066.
    Abstract

  2063. CHEN H, Zhang Y, Chen X, Xu R, et al
    Hypoxia is correlated with the tumor immune microenvironment: Potential application of immunotherapy in bladder cancer.
    Cancer Med. 2023 Dec 8. doi: 10.1002/cam4.6617.
    Abstract

  2064. ZHANG YH, Xie JJ, Wang JG, Wang Y, et al
    [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhonghua Bing Li Xue Za Zhi. 2023;52:1216-1222.
    Abstract

  2065. CHANG S, Bermoy ME, Chang SS, Scarpato KR, et al
    Enhancing the image quality of blue light cystoscopy through green-hue correction and fogginess removal.
    Sci Rep. 2023;13:21484.
    Abstract

  2066. KWON AG, Brinzevich D, Borovik A, Bhalla R, et al
    Ileal conduit to small intestine fistula following extensive abdominopelvic resection and radiation for metastatic colon cancer.
    BMJ Case Rep. 2023;16:e254170.
    Abstract

  2067. TAKAHASHI K, Urabe F, Suhara Y, Nakano J, et al
    Comparison of neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma in real-world practice: a multicenter retrospective study.
    Jpn J Clin Oncol. 2023;53:1208-1214.
    Abstract

  2068. AL-QUDIMAT AR, Singh K, Ojha LK, Moustafa DA, et al
    Comparing trimodal therapy with radical cystectomy in muscle-invasive bladder cancer: an updated meta-analysis.
    Front Surg. 2023;10:1276746.
    Abstract

  2069. SHI X, Peng X, Chen Y, Shi Z, et al
    Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Front Immunol. 2023;14:1326509.
    Abstract

  2070. MATSON M, Tien T, Yardy G, Allchorne P, et al
    The Use of Hospital Services by Patients With Muscle Invasive Bladder Cancer in the Last Year of Life: Identifying the Areas to Improve Care.
    Cureus. 2023;15:e49175.
    Abstract

  2071. HU H, Lai S, Wang M, Tang X, et al
    Effect of subsequent bladder cancer on survival in upper tract urothelial carcinoma patients post-radical nephroureterectomy: a systematic review and meta-analysis.
    BMC Urol. 2023;23:212.
    Abstract

  2072. CHEN Z, Liu Y, He A, Li J, et al
    Author Correction: Theophylline controllable RNAi-based genetic switches regulate expression of lncRNA TINCR and malignant phenotypes in bladder cancer cells.
    Sci Rep. 2023;13:22896.
    Abstract

  2073. LEBRET T, Bonastre J, Fraslin A, Neuzillet Y, et al
    Cohort profile: COBLAnCE: a French prospective cohort to study prognostic and predictive factors in bladder cancer and to generate real-world data on treatment patterns, resource use and quality of life.
    BMJ Open. 2023;13:e075942.
    Abstract

  2074. BAHLBURG H, Roghmann F
    [Overall survival and cancer-specific mortality in patients with very high-risk non-muscle-invasive bladder cancer (NMIBC) : Retrospective analysis of a US American single-center cohort].
    Urologie. 2023 Dec 21. doi: 10.1007/s00120-023-02252.
    Abstract

  2075. SONG Y, Xu T
    Letter to the editor for the article "Does the urinary microbiome profile change after treatment of bladder cancer?".
    World J Urol. 2023;42:2.
    Abstract

  2076. GALLIOLI A, Baboudjian M, Diana P, Moschini M, et al
    Perioperative and oncological outcomes of distal ureter management during nephroureterectomy for upper urinary tract urothelial carcinoma: a systematic review and meta-analysis.
    Minerva Urol Nephrol. 2023;75:672-682.
    Abstract

  2077. INTELLIGENCE AND NEUROSCIENCE
    Retracted: Comparative Analysis of the Efficacy of Transurethral Bipolar Plasma Needle Electrode and Ring Electrode in the Treatment of Non-Muscle-Invasive Bladder Cancer.
    Comput Intell Neurosci. 2023;2023:9824189.
    Abstract

  2078. HIMURA R, Kawano S, Nagata Y, Kawai M, et al
    Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine/cisplatin resistance in bladder cancer.
    Chem Biol Interact. 2023 Dec 18:110840. doi: 10.1016/j.cbi.2023.110840.
    Abstract

  2079. SARAY KILIC H, Pazar B, Ibrahimoglu O, Naldan ME, et al
    Quality of care perceived by patients during cystoscopy and affecting factors.
    Medicine (Baltimore). 2023;102:e36314.
    Abstract

  2080. XU Y, Li Q, Lin H
    Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
    Cell Signal. 2023 Dec 17:111012. doi: 10.1016/j.cellsig.2023.111012.
    Abstract

  2081. DIAZ ACEDO R, Galvan Banqueri M, Artacho Criado S, Fernandez Parra EM, et al
    Real-world data of atezolizumab in patients with previously treated locally advanced or metastatic urothelial bladder cancer.
    Int J Clin Pharm. 2023 Dec 19. doi: 10.1007/s11096-023-01667.
    Abstract

  2082. MATSUSHITA Y, Miyake M, Nishimura N, Nishimoto K, et al
    Comparative assessment of disease recurrence after transurethral resection of non-muscle-invasive bladder cancer with and without a photodynamic diagnosis using 5-aminolevulinic acid: a propensity score-matching analysis.
    Int J Clin Oncol. 2023 Dec 19. doi: 10.1007/s10147-023-02447.
    Abstract

  2083. PIERINI A, Criscuolo MC, Caccamo R, Bottero E, et al
    A case series of urinary bladder rhabdomyosarcoma in seven dogs.
    Open Vet J. 2023;13:1498-1503.
    Abstract

  2084. PENG M, Chu X, Peng Y, Li D, et al
    Targeted therapies in bladder cancer: signaling pathways, applications, and challenges.
    MedComm (2020). 2023;4:e455.
    Abstract

  2085. PENG J, Weng Z, Zhang C, Zhou G, et al
    Analysis of prognostic factors in patients diagnosed with bladder cancer complicated by hemorrhage treated by drug-eluting bead embolization.
    Transl Androl Urol. 2023;12:1697-1707.
    Abstract

  2086. WANG KR, Simhal RK, Dinatale GG, Li L, et al
    Recurring cystitis cystica and cystitis glandularis masquerading as urothelial carcinoma.
    Can J Urol. 2023;30:11752-11755.
    Abstract

  2087. QIAN Z, Ye J, Friedlander DF, Koelker M, et al
    Impact of COVID-19 pandemic on ambulatory urologic oncology surgeries.
    Can J Urol. 2023;30:11714-11723.
    Abstract

  2088. OGURA R, Ito S, Ueda T, Gabata Y, et al
    Author Correction: Screening for a practical method to monitor the status of patients with metastatic bladder cancer at the circulating cell-gene level.
    Sci Rep. 2023;13:22350.
    Abstract

  2089. DERRE L, Lucca I, Cesson V, Bohner P, et al
    Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
    J Immunother Cancer. 2023;11:e008020.
    Abstract

  2090. WONG C
    The cancer physician who helped to deliver a life-extending treatment.
    Nature. 2023;624:508.
    Abstract

  2091. OBI H, Nagao K, Aoki M, Nagura S, et al
    [Thoracic Endovascular Aortic Repair for Mycotic Thoracic Aortic Aneurysm After BCG Intravesical Therapy].
    Kyobu Geka. 2023;76:1083-1089.
    Abstract

  2092. NAVRIYA SC, Singh V, Choudhary GR, Tripathi S, et al
    Postradical cystectomy delayed urethral recurrence: a rare presentation posing diagnostic dilemma.
    BMJ Case Rep. 2023;16:e256700.
    Abstract

  2093. LIN S, Chai Y, Zheng X, Xu X, et al
    The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.
    Mol Biol Rep. 2023;51:14.
    Abstract

  2094. JAIN K, Datta C, Sengupta M, Pal DK, et al
    Quest to develop a standard screening method for urothelial carcinoma using liquid-based cytology (The Paris System) and CK20.
    Indian J Pathol Microbiol. 2023;66:720-726.
    Abstract

  2095. BAI Y, Wu X, Weng M, Han Q, et al
    The expression of SP263 in muscle invasive bladder carcinoma and its relationship with clinicopathological features.
    Indian J Pathol Microbiol. 2023;66:702-707.
    Abstract

  2096. YUE R, Dutta A
    Koopman-based Impulsive Model Predictive Control of BCG Immunotherapy.
    Annu Int Conf IEEE Eng Med Biol Soc. 2023;2023:1-4.
    Abstract

  2097. SUN J, Zhang Y, Yang L, Zhou L, et al
    [High expression of long noncoding RNA UCA1 promotes invasion, migration and epithelial-mesenchymal transition of trophoblasts in vitro].
    Nan Fang Yi Ke Da Xue Xue Bao. 2023;43:1984-1988.
    Abstract

  2098. LESLIE M
    Tumor-killing viruses score rare success in late-stage trial.
    Science. 2023;382:1101-1102.
    Abstract

  2099. ELLIS JL, Dalimov Z, Chew L, Quek ML, et al
    Preoperative optimization of the radical cystectomy patient: Current state and future directions.
    J Surg Oncol. 2024;129:138-144.
    Abstract

  2100. WU P, Liu J, Wang X, Lai S, et al
    Development and validation of a nomogram based on geriatric nutritional risk index for predicting prognosis and postoperative complications in surgical patients with upper urinary tract urothelial carcinoma.
    J Cancer Res Clin Oncol. 2023;149:18185-18200.
    Abstract

  2101. VARVIL MS, Clark SL, Bailey TW, Ramos-Vara JA, et al
    Canine urothelial carcinoma: a pilot study of microRNA detection in formalin-fixed, paraffin-embedded tissue samples and in normal urine.
    J Vet Diagn Invest. 2024;36:70-77.
    Abstract

  2102. LI J, Huang X, Wang L, Wang X, et al
    Role of Contrast-Enhanced Ultrasound With the Enhancement Pattern and Qualitative Analysis for Differentiating Hypovascular Solid Renal Lesions.
    Ultrasound Med Biol. 2024;50:295-303.
    Abstract

  2103. HAN F, Wu Z, Chen J, Liu M, et al
    The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma.
    Cancer Med. 2023;12:21129-21137.
    Abstract

  2104. WEISS K, Gessner KH, Demzik A, Moreton E, et al
    Molecular characterization of plasmacytoid urothelial carcinoma and the impact on treatment implications.
    Cancer Treat Res Commun. 2023;37:100779.
    Abstract

  2105. CAI TN, Lu JL, Chen Z, Liu ZH, et al
    Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette-Guerin perfusion.
    Cancer Med. 2023;12:21279-21286.
    Abstract

  2106. NADAL R, Valderrama BP, Bellmunt J
    Progress in systemic therapy for advanced-stage urothelial carcinoma.
    Nat Rev Clin Oncol. 2024;21:8-27.
    Abstract

  2107. XU J, Zhang H, Zhang L, Chu X, et al
    Real-world effectiveness and safety of RC48-ADC alone or in combination with PD-1 inhibitors for patients with locally advanced or metastatic urothelial carcinoma: A multicenter, retrospective clinical study.
    Cancer Med. 2023;12:21159-21171.
    Abstract

  2108. SANTONI M, Massari F, Takeshita H, Tapia JC, et al
    Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study.
    Clin Exp Med. 2023;23:5413-5422.
    Abstract


  2109. UC Trials Get Standing Ovation.
    Cancer Discov. 2023;13:2496.
    Abstract

  2110. TYSON MD, Abouassaly R, Durant A, Smith AB, et al
    Budgetary Impact of Including the Urinary Genomic Marker Cxbladder Detect in the Evaluation of Microhematuria Patients.
    Urol Pract. 2024;11:54-60.
    Abstract

  2111. ZHANG WJ, Huang XY, Lin B, Zheng WC, et al
    The effect of body mass index on quality of life in modified single stoma cutaneous ureterostomy or ileal conduit after radical cystectomy.
    Cancer Med. 2023;12:20930-20939.
    Abstract

  2112. OHTSU A, Arai S, Fujizuka Y, Miyazawa Y, et al
    Predictive models of long-term survival outcomes following radical cystectomy.
    Cancer Med. 2023;12:21118-21128.
    Abstract

  2113. GHELANI GH, Zerdan MB, Jacob J, Spiess PE, et al
    HPV-positive clinically advanced squamous cell carcinoma of the urinary bladder (aBSCC): A comprehensive genomic profiling (CGP) study.
    Urol Oncol. 2023;41:486.
    Abstract

  2114. HOU Y, Du W, Wu Q, Chai X, et al
    PDGFRA exhibits potential as an indicator of angiogenesis within the tumor microenvironment and is up-regulated in BLCA.
    Microvasc Res. 2024;151:104614.
    Abstract

  2115. SOLTANTABAR P, Alhadab A, Hibma J, Roychoudhury S, et al
    Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma.
    CPT Pharmacometrics Syst Pharmacol. 2023;12:2001-2012.
    Abstract

  2116. LIU Y, Wang J
    Inflammatory myofibroblastic tumors of the bladder in a 20-year-old female.
    Asian J Surg. 2023;46:5567-5568.
    Abstract

  2117. KOMURA K, Tokushige S, Ishida M, Hirosuna K, et al
    Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
    Cancer Sci. 2023;114:4622-4631.
    Abstract

  2118. JIANG Y, Tang Y, Zhang Q, Liang S, et al
    Development of a nomogram for predicting overall survival in patients with urinary bladder carcinoma in situ based on SEER database analysis.
    Asian J Surg. 2023;46:6015-6017.
    Abstract

  2119. XIAO P, Liu J, Sun W, Wang J, et al
    Large cell neuroendocrine carcinoma of the urinary bladder: A case report and literature review.
    Asian J Surg. 2023;46:6049-6050.
    Abstract

  2120. MAI Z, Yuan R, Wu L, Yan W, et al
    Genetic testing and innovative surgery for familial urinary bladder paraganglioma: Report of two cases and literature review.
    Asian J Surg. 2023;46:6053-6055.
    Abstract

  2121. HE B, Chen Y, Hui Z
    Primary pure bladder large cell neuroendocrine carcinoma: A case report.
    Asian J Surg. 2023;46:5454-5455.
    Abstract

  2122. WANG H, Fei J, Yu X
    Synchronous renal pelvic urothelial carcinoma and oncocytoma: A case report.
    Asian J Surg. 2023;46:5952-5953.
    Abstract

  2123. CIVRIZ AH, Teke K, Akdas EM, Dillioglugil O, et al
    The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
    Urol Oncol. 2023;41:486.
    Abstract

  2124. CANNON E, Ntala C, Joss N, Rahilly M, et al
    High grade urothelial carcinoma in kidney transplant patients with a history of BK viremia - Just a coincidence?
    Clin Transplant. 2023 Aug 31:e15113. doi: 10.1111/ctr.15113.
    Abstract

  2125. YU CC, Chang CH, Fang JK, Huang SK, et al
    Impact of pathological response on oncological outcomes in patients with upper tract urothelial cancer receiving neo-adjuvant chemotherapy.
    J Formos Med Assoc. 2023;122:1274-1281.
    Abstract

  2126. UCCELLO M, Adeleke S, Moschetta M, Ghose A, et al
    Immunotherapy for advanced urothelial carcinoma (UC): rational and current evidence.
    Ann Palliat Med. 2023;12:1345-1354.
    Abstract

  2127. SANDA GE, Shabto JM, Goyal S, Liu Y, et al
    Immune-Related Adverse Events and Clinical Outcomes in Advanced Urothelial Cancer Patients Treated With Immune Checkpoint Inhibitors.
    Oncologist. 2023;28:1072-1078.
    Abstract

  2128. LINEHAN J, Gottlieb J, Woldu SL, Labbate C, et al
    Route of Administration for UGN-101 and Impact on Oncological and Safety Outcomes.
    Eur Urol Focus. 2023;9:1052-1058.
    Abstract

  2129. KATSIMPERIS S, Tzelves L, Tandogdu Z, Ta A, et al
    Complications After Radical Cystectomy: A Systematic Review and Meta-analysis of Randomized Controlled Trials with a Meta-regression Analysis.
    Eur Urol Focus. 2023;9:920-929.
    Abstract

  2130. SAKURAI Y, Furuto Y, Saito T, Namikawa A, et al
    Disseminated Bacillus Calmette-Guerin Infection with Rhabdomyolysis, Acute Kidney Injury, and Interstitial Pneumonia after Bacillus Calmette-Guerin Intravesical Instillation Therapy.
    Intern Med. 2023;62:3707-3712.
    Abstract

  2131. LAUKHTINA E, Quhal F, von Deimling M, Kawada T, et al
    For Which Patients Should Bladder Preservation Be Considered After a Complete Response to Neoadjuvant Chemotherapy.
    Eur Urol Focus. 2023;9:900-902.
    Abstract

  2132. JAHANGIRIAN E, Zargan J, Rabbani H, Zamani J, et al
    Investigating the inhibitory and penetrating properties of three novel anticancer and antimicrobial scorpion peptides via molecular docking and molecular dynamic simulation.
    J Biomol Struct Dyn. 2023;41:15354-15385.
    Abstract

  2133. CHEN X, Chen H, Lin R, Li Y, et al
    Correlation between PD-L1 expression of the tumour cells and lymphocytes infiltration in the invasive front of urothelial carcinoma.
    J Clin Pathol. 2023;77:61-67.
    Abstract

  2134. KIM HJ, Sim JY, Kim MB, Chang SW, et al
    Unusual Cervical Lymph Node Metastasis of Papillary Urothelial Carcinoma.
    Ear Nose Throat J. 2024;103:NP4-NP6.
    Abstract

  2135. WANG Z, Kwan ML, Haque R, Pratt R, et al
    Environmental and Occupational Exposures and Prognosis in Patients with Non-Muscle Invasive Bladder Cancer in the Be-Well Study.
    Am J Epidemiol. 2023 Dec 5:kwad236. doi: 10.1093.
    Abstract

  2136. CHEN SY, Chao CN, Huang HY, Zhao PW, et al
    Artesunate Exhibits Synergy With Cisplatin and Cytotoxicity for Upper Tract and Bladder Urothelial Carcinoma Cells.
    Anticancer Res. 2023;43:1175-1184.
    Abstract

  2137. LI JR, Wang SS, Lu K, Chen CS, et al
    First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Anticancer Res. 2023;43:1331-1339.
    Abstract

  2138. YAMAGUCHI N, Morizane S, Yumioka T, Shimizu R, et al
    Effect of Adjuvant Systemic Chemotherapy on Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma.
    Anticancer Res. 2023;43:1725-1730.
    Abstract

  2139. LUZHA J, Nass N, Czapiewski P, Schroeder N, et al
    Expression of Eukaryotic Translation Initiation Factors in the Urothelial Carcinoma of the Bladder.
    Anticancer Res. 2023;43:1437-1448.
    Abstract

  2140. LEE YH, Wu RC, Mai HC, Huang WL, et al
    The Regulatory Role of Nuclear Respiratory Factor 1 in Bladder Cancer Cells.
    Anticancer Res. 2023;43:1521-1531.
    Abstract

  2141. SANO T, Aizawa R, Ito K, Nakamura K, et al
    Efficacy and Tolerability of Second-line Pembrolizumab With Radiation Therapy in Advanced Urothelial Carcinoma.
    Anticancer Res. 2023;43:2119-2126.
    Abstract

  2142. TACHIBANA M, Tsubouchi K, Fukuhara Y, Aoyagi C, et al
    Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer.
    Anticancer Res. 2023;43:3607-3613.
    Abstract

  2143. ARAI T, Sazuka T, Oka R, Tsukamoto R, et al
    Investigation on the Usefulness of Photodynamic Diagnosis-assisted Targeted Bladder Biopsy: Japanese Real-world Study.
    Anticancer Res. 2023;43:3615-3621.
    Abstract

  2144. MINATO A, Kimuro R, Ohno D, Tanigawa K, et al
    Efficacy and Tolerability of Enfortumab Vedotin for Metastatic Urothelial Carcinoma: Early Experience in the Real World.
    Anticancer Res. 2023;43:4055-4060.
    Abstract

  2145. KASHIWAGI E, Shiota M, Inokuchi J, Tsukahara S, et al
    Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies.
    Anticancer Res. 2023;43:4249-4254.
    Abstract

  2146. SOMMER U, Grosser M, Aust D, Joehrens K, et al
    PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
    Anticancer Res. 2023;43:4365-4371.
    Abstract

  2147. NISHIYAMA N, Kita Y, Ito K, Kato M, et al
    Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary Site.
    Anticancer Res. 2023;43:5041-5050.
    Abstract

  2148. FURUBAYASHI N, Minato A, Tomoda T, Hori Y, et al
    Organ-specific Tumor Response to Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma: A Multicenter Retrospective Study.
    Anticancer Res. 2023;43:5689-5698.
    Abstract

  2149. NURMINEN P, Ettala O, Uusitalo-Seppala R, Hogerman M, et al
    Clinical presentation of bacille Calmette-Guerin (BCG) infections after BCG instillation therapy.
    BJU Int. 2023;131:306-312.
    Abstract

  2150. BESIROGLU H
    Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?
    BJU Int. 2023 Mar 10. doi: 10.1111/bju.16005.
    Abstract

  2151. SMELSER WW, Wang J, Ogden KM, Chang SS, et al
    Intravesical Oncolytic Virotherapy and Immunotherapy for Non-Muscle Invasive Bladder Cancer Mouse Model.
    BJU Int. 2023 Mar 24. doi: 10.1111/bju.16012.
    Abstract

  2152. ROSE KM, Narang G, Rosen G, Labatte C, et al
    Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.
    BJU Int. 2023;131:471-476.
    Abstract

  2153. UCHIMOTO T, Fukushima T, Komura K, Fukuokaya W, et al
    Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
    BJU Int. 2023;131:477-485.
    Abstract

  2154. FREGO N, Contieri R, Diana P, Mancon S, et al
    Inflammatory Markers and Type 2 Diabetes as Prognostic Risk Factors in Low-Risk Bladder Cancer.
    BJU Int. 2023 Apr 5. doi: 10.1111/bju.16026.
    Abstract

  2155. YANAGISAWA T, Miki J, Sato S, Takahashi H, et al
    Reply to Huseyin Besiroglu's Letter to the editor regarding the article 'Do we need repeat transurethral resection after en-bloc resection for pathological T1 bladder cancer?'.
    BJU Int. 2023 Apr 24. doi: 10.1111/bju.16035.
    Abstract

  2156. LAUKHTINA E, Moschini M, Krajewski W, Teoh JY, et al
    Oncological and safety profiles in patients undergoing simultaneous transurethral resection (TUR) of bladder tumour and TUR of the prostate.
    BJU Int. 2023;131:571-580.
    Abstract

  2157. BENJAMIN DJ, Lythgoe MP, Rezazadeh A
    Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma.
    BJU Int. 2023;131:691-693.
    Abstract

  2158. CATTO JWF, Mandrik O, Quayle LA, Hussain SA, et al
    Diagnosis, treatment and survival from bladder, upper urinary tract, and urethral cancers: real-world findings from NHS England between 2013 and 2019.
    BJU Int. 2023;131:734-744.
    Abstract

  2159. TRAIL M, Rahman MSW, Broadhurst WJ, Blackmur JP, et al
    Diagnostic evaluation of upper tract urothelial carcinoma: can we safely omit diagnostic ureteroscopy?
    BJU Int. 2023;131:755-762.
    Abstract

  2160. DEL GIUDICE F, D'Andrea D, Pradere B, Berndl F, et al
    Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators.
    BJU Int. 2023;131:712-719.
    Abstract

  2161. TAN WS, Grajales V, Bree K, Li R, et al
    BCG unresponsive non-muscle invasive bladder cancer: Are the sub-groups equal?
    BJU Int. 2023 May 28. doi: 10.1111/bju.16087.
    Abstract

  2162. RICHTERS A, van Ginkel N, Meijer RP, Wondergem M, et al
    Staging FDG-PET/CT for muscle-invasive bladder cancer: A nationwide population-based study.
    BJU Int. 2023 May 28. doi: 10.1111/bju.16091.
    Abstract


  2163. Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    Abstract

  2164. DIAMAND R, D'Hondt F, Mjaess G, Jabbour T, et al
    Teaching robotic cystectomy: prospective pilot clinical validation of the ERUS training curriculum.
    BJU Int. 2023;132:84-91.
    Abstract

  2165. JAHNSON S, Jancke G, Olsson H, Aljabery F, et al
    Bladder cancer grading using the four-tier combination of the World Health Organization (WHO) 1973 and WHO 2004 classifications.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16100.
    Abstract

  2166. CONTIERI R, Grajales V, Tan WS, Martini A, et al
    Impact of age >70 years on oncological outcomes in patients with non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin.
    BJU Int. 2023 Jul 13. doi: 10.1111/bju.16127.
    Abstract

  2167. LAUKHTINA E, von Deimling M, Pradere B, Yanagisawa T, et al
    Urinary function in female patients after traditional, organ-and nerve-sparing radical cystectomy for bladder cancer: a systematic review and pooled analyses.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16152.
    Abstract

  2168. ZAHRAN MH, Harraz AM, Baset MA, El-Baz R, et al
    Voiding and renal function 10 years after radical cystectomy and orthotopic neobladder in women.
    BJU Int. 2023;132:291-297.
    Abstract

  2169. VRANG ML, Ostergren PB, Fode MM, Vangedal M, et al
    Robot-assisted radical cystectomy with intracorporeal urinary diversion: a Danish 11-year series.
    BJU Int. 2023;132:428-434.
    Abstract

  2170. NECCHI A, Basile G, Gibb EA, Raggi D, et al
    VI-RADS use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 6. doi: 10.1111/bju.16191.
    Abstract

  2171. MCELREE IM, Mott SL, O'Donnell MA, Packiam VT, et al
    Alternative instillation techniques of sequential intravesical gemcitabine and docetaxel for non-muscle-invasive bladder cancer.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16208.
    Abstract

  2172. VON DEIMLING M, Furrer M, Mertens LS, Mari A, et al
    Impact of the Extent of Lymph Node Dissection on Survival Outcomes in Clinically Lymph Node-Positive Bladder Cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16210.
    Abstract

  2173. ROGERS Z, Glaser A, Catto JWF, Bottomley S, et al
    Quality of life after a diagnosis of Bladder Cancer: Longitudinal survey over the first year.
    BJU Int. 2023 Nov 29. doi: 10.1111/bju.16242.
    Abstract

  2174. MASTROIANNI R, Tuderti G, Ferriero M, Anceschi U, et al
    Open versus robot-assisted radical cystectomy: pentafecta and trifecta achievement comparison from a randomised controlled trial.
    BJU Int. 2023;132:671-677.
    Abstract

  2175. HACK J, Douglas J, Makaroff L, Costin M, et al
    Patient Experience of Surveillance Following Radical Treatment for Muscle-Invasive Bladder Cancer.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16261.
    Abstract

  2176. VITUG C, Lajkosz K, Chavarriaga J, Llano A, et al
    Long-term outcomes and cost savings of office fulguration of papillary Ta low-grade bladder cancer.
    BJU Int. 2023 Dec 17. doi: 10.1111/bju.16269.
    Abstract

  2177. VASDEV N
    Multicentric validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring in two prospective cohorts of patients.
    Br J Cancer. 2023 Mar 1. doi: 10.1038/s41416-023-02142.
    Abstract

  2178. YAMAMOTO S, Kato M, Takeyama Y, Azuma Y, et al
    Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma.
    Br J Cancer. 2023;128:2197-2205.
    Abstract

  2179. SHALA NK, Stenehjem JS, Babigumira R, Liu FC, et al
    Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers.
    Br J Cancer. 2023 Jul 18. doi: 10.1038/s41416-023-02357.
    Abstract

  2180. LU J, Lai J, Xiao K, Peng S, et al
    A clinically practical model for the preoperative prediction of lymph node metastasis in bladder cancer: a multicohort study.
    Br J Cancer. 2023 Aug 4. doi: 10.1038/s41416-023-02383.
    Abstract

  2181. LIM EH, Franklin P, Trevenen ML, Nieuwenhuijsen M, et al
    Exposure to low-level ambient air pollution and the relationship with lung and bladder cancer in older men, in Perth, Western Australia.
    Br J Cancer. 2023 Sep 8. doi: 10.1038/s41416-023-02411.
    Abstract

  2182. VIERGEVER BJ, Raats DAE, Geurts V, Mullenders J, et al
    Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation.
    Br J Cancer. 2023 Dec 15. doi: 10.1038/s41416-023-02494.
    Abstract

  2183. ZHUANG J, Shen L, Li M, Sun J, et al
    Cancer-associated fibroblast-derived miR-146a-5p generates a niche that promotes bladder cancer stemness and chemoresistance.
    Cancer Res. 2023 Mar 20:CAN-22-2213. doi: 10.1158/0008-5472.CAN-22-2213.
    Abstract

  2184. ZHANG L, Li Y, Zhou L, Zhou H, et al
    The m6A reader YTHDF2 promotes bladder cancer progression by suppressing RIG-I-mediated immune response.
    Cancer Res. 2023 Mar 20:CAN-22-2485. doi: 10.1158/0008-5472.CAN-22-2485.
    Abstract

  2185. XIE R, Cheng L, Huang M, Huang L, et al
    NAT10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer.
    Cancer Res. 2023 Mar 20:CAN-22-2233. doi: 10.1158/0008-5472.CAN-22-2233.
    Abstract

  2186. OWCZAREK TB, Kobayashi T, Ramirez R, Rong L, et al
    Correction: ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer.
    Cancer Res. 2023;83:1159.
    Abstract

  2187. OUYANG Y, Ou Z, Zhong W, Yang J, et al
    FGFR3 alterations in bladder cancer stimulate serine synthesis to induce immune-inert macrophages that suppress T-cell recruitment and activation.
    Cancer Res. 2023 Sep 28. doi: 10.1158/0008-5472.CAN-23-1065.
    Abstract

  2188. ZHAO Y, Chen J, Zheng H, Luo Y, et al
    SUMOylation-driven mRNA circularization enhances translation and promotes lymphatic metastasis of bladder cancer.
    Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-2278.
    Abstract

  2189. LIU B, Fu X, Du Y, Feng Z, et al
    Pan-cancer analysis of G6PD carcinogenesis in human tumors.
    Carcinogenesis. 2023;44:525-534.
    Abstract

  2190. AGGEN DH, Chu CE, Rosenberg JE
    Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1377-1380.
    Abstract

  2191. KLUMPER N, Ralser DJ, Ellinger J, Roghmann F, et al
    Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Clin Cancer Res. 2023;29:1496-1505.
    Abstract

  2192. JANG HJ, Hostetter G, Macfarlane AW, Madaj Z, et al
    A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.
    Clin Cancer Res. 2023;29:2052-2065.
    Abstract

  2193. ZHANG R, Zang J, Jin D, Xie F, et al
    Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer.
    Clin Cancer Res. 2023 Aug 3:CCR-23-0513. doi: 10.1158/1078-0432.CCR-23-0513.
    Abstract

  2194. JIANG D, Lan X, Cai W
    PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Clin Cancer Res. 2023;29:3259-3261.
    Abstract

  2195. DUAN X, Xia L, Zhang Z, Ren Y, et al
    First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Clin Cancer Res. 2023;29:3395-3407.
    Abstract

  2196. SALARI K, Sundi D, Lee JJ, Wu S, et al
    Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction.
    Clin Cancer Res. 2023;29:3668-3680.
    Abstract

  2197. LI R, Sexton WJ, Dhillon J, Berglund A, et al
    A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder.
    Clin Cancer Res. 2023;29:3875-3881.
    Abstract

  2198. KAMRAN SC, Zhou Y, Otani K, Drumm M, et al
    Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
    Clin Cancer Res. 2023 Oct 19. doi: 10.1158/1078-0432.CCR-23-0792.
    Abstract

  2199. MITRA A, Thompson B, Strange A, Amato CM, et al
    A Population of Tumor-Infiltrating CD4+ T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance.
    Clin Cancer Res. 2023;29:4242-4255.
    Abstract

  2200. DRAKAKI A, Powles T, Bamias A, Martin-Liberal J, et al
    Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
    Clin Cancer Res. 2023;29:4373-4384.
    Abstract

  2201. LERNER SP, McConkey DJ, Tangen CM, Meeks JJ, et al
    Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-0602.
    Abstract

  2202. GUERCIO BJ, Sarfaty M, Teo MY, Ratna N, et al
    Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Clin Cancer Res. 2023;29:4586-4595.
    Abstract

  2203. LINDSKROG SV, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, et al
    Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
    Clin Cancer Res. 2023;29:4797-4807.
    Abstract

  2204. MUIN D, Laukhtina E, Hacker M, Shariat SF, et al
    PET in bladder cancer imaging.
    Curr Opin Urol. 2023 Mar 7. doi: 10.1097/MOU.0000000000001090.
    Abstract

  2205. KATIMS AB, Bochner BH
    Extended pelvic lymph node dissection in muscle invasive bladder cancer.
    Curr Opin Urol. 2023 Apr 7. doi: 10.1097/MOU.0000000000001096.
    Abstract

  2206. BERNDL F, Frerichmann J, Berndl T
    Prevention and management of urinary tract infections after cystectomy.
    Curr Opin Urol. 2023 Mar 3. doi: 10.1097/MOU.0000000000001085.
    Abstract

  2207. KRAJEWSKI W, Laszkiewicz J, Nowak L, Szydelko T, et al
    Current methods facilitating diagnosis of upper tract urothelial carcinoma: a comprehensive literature review.
    Curr Opin Urol. 2023;33:230-238.
    Abstract

  2208. MELLEMA JJ, van Rhijn BWG, van der Heijden MS
    Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jun 3. doi: 10.1097/MOU.0000000000001107.
    Abstract

  2209. YANAGISAWA T, Kawada T, von Deimling M, Laukhtina E, et al
    Need for and extent of lymph node dissection for upper tract urothelial carcinoma: an updated review in 2023.
    Curr Opin Urol. 2023;33:258-268.
    Abstract

  2210. DE ANGELIS M, Basile G, Scornajenghi CM, Asero V, et al
    Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer.
    Curr Opin Urol. 2023 Jul 3. doi: 10.1097/MOU.0000000000001113.
    Abstract

  2211. CANCEL-TASSIN G, Koutros S
    Use of genomic markers to improve epidemiologic and clinical research in urology.
    Curr Opin Urol. 2023;33:414-420.
    Abstract

  2212. GELIKMAN DG, Rais-Bahrami S, Pinto PA, Turkbey B, et al
    AI-powered radiomics: revolutionizing detection of urologic malignancies.
    Curr Opin Urol. 2024;34:1-7.
    Abstract

  2213. IKEDA A, Nosato H
    Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours.
    Curr Opin Urol. 2024;34:27-31.
    Abstract

  2214. CHUNG R, McKiernan J, Arpaia N, Marabelle A, et al
    Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity.
    Eur J Cancer. 2023;187:58-64.
    Abstract

  2215. SYLVESTER RJ, Rodriguez O, Hernandez V, Turturica D, et al
    Erratum to "European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
    Eur Urol. 2023 Feb 23:S0302-2838(23)02579-4. doi: 10.1016/j.eururo.2023.
    Abstract

  2216. STENZL A, Roupret M, Witjes JA, Gontero P, et al
    High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation.
    Eur Urol. 2023;83:193-194.
    Abstract

  2217. GIL-JIMENEZ A, van Dorp J, Contreras-Sanz A, van der Vos K, et al
    Corrigendum to "Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer" [Eur Urol 2023;83:313-17].
    Eur Urol. 2023 Mar 10:S0302-2838(23)02641-6. doi: 10.1016/j.eururo.2023.
    Abstract

  2218. MAITRE P, Sangar V, Choudhury A
    ADAPT and Improvise: Overcoming Bacillus Calmette-Guerin Unresponsiveness in Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Mar 8:S0302-2838(23)02627-1. doi: 10.1016/j.eururo.2023.
    Abstract

  2219. MOLINA GE, Schwartz B, Srinivas S, Shah S, et al
    In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
    Eur Urol. 2023;83:377-378.
    Abstract

  2220. BERGEROT CD, Gupta S
    Time to Rethink Quality of Life Assessment in Patients with Urothelial Cancer in the Current Therapeutic Era?
    Eur Urol. 2023;83:329-330.
    Abstract

  2221. GRIVAS P, Kopyltsov E, Su PJ, Parnis FX, et al
    Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Eur Urol. 2023;83:320-328.
    Abstract

  2222. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?
    Eur Urol. 2023 Mar 18:S0302-2838(23)02637-4. doi: 10.1016/j.eururo.2023.
    Abstract

  2223. MOSCHINI M, Salonia A, Briganti A, Montorsi F, et al
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02649-0. doi: 10.1016/j.eururo.2023.
    Abstract

  2224. CERRATO C, Roupret M, Mir MC
    Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
    Eur Urol. 2023 Mar 23:S0302-2838(23)02643-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2225. CHENG C, Hu J, Chen J
    Re: Alberto Gil-Jimenez, Jeroen van Dorp, Alberto Contreras-Sanz, et al. Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-based Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol. 2023;83:313-7.
    Eur Urol. 2023 Mar 24:S0302-2838(23)02653-2. doi: 10.1016/j.eururo.2023.
    Abstract

  2226. LENFANT L, Pinar U, Roupret M, Seisen T, et al
    Corrigendum to "First-line Intravesical Chemotherapy for Non-muscle-invasive Bladder Cancer: Chimera or "Ne Plus Ultra"?" [Eur Urol 2023].
    Eur Urol. 2023 Apr 17:S0302-2838(23)02714-8. doi: 10.1016/j.eururo.2023.
    Abstract

  2227. GALSKY MD, Bajorin DF, Witjes JA, Gschwend JE, et al
    Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score.
    Eur Urol. 2023;83:432-440.
    Abstract

  2228. JUBBER I, Ong S, Bukavina L, Black PC, et al
    Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.
    Eur Urol. 2023 May 15:S0302-2838(23)02707-0. doi: 10.1016/j.eururo.2023.
    Abstract

  2229. MOSCHINI M, Montorsi F
    Re: Outpatient Photodynamic Diagnosis-guided Laser Destruction of Bladder Tumors Is as Good as Conventional Inpatient Photodynamic Diagnosis-guided Transurethral Tumor Resection in Patients with Recurrent Intermediate-risk Low-grade Ta Bladder Tumors.
    Eur Urol. 2023;83:582.
    Abstract

  2230. BAMIAS A, Stenzl A, Brown SL, Albiges L, et al
    Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty.
    Eur Urol. 2023 May 20:S0302-2838(23)02810-5. doi: 10.1016/j.eururo.2023.
    Abstract

  2231. KOUTROS S, Kiemeney LA, Pal Choudhury P, Milne RL, et al
    Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
    Eur Urol. 2023 May 18:S0302-2838(23)02780-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2232. MAKAROFF LE, Filicevas A, Boldon S, Hensley P, et al
    Patient and Carer Experiences with Bladder Cancer: Results from a Global Survey in 45 Countries.
    Eur Urol. 2023 May 24:S0302-2838(23)02801-4. doi: 10.1016/j.eururo.2023.
    Abstract

  2233. LAUKHTINA E, Shariat SF
    Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
    Eur Urol. 2023 Jun 1:S0302-2838(23)02873-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2234. O'CALLAGHAN M
    Re: Addition of Nintedanib or Placebo to Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Muscle-invasive Bladder Cancer (NEOBLADE): A Double-blind, Randomised, Phase 2 Trial.
    Eur Urol. 2023 Jun 9:S0302-2838(23)02871-3. doi: 10.1016/j.eururo.2023.
    Abstract

  2235. GRIVAS P, Park SH, Voog E, Caserta C, et al
    Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Eur Urol. 2023;84:95-108.
    Abstract

  2236. ROUPRET M, Seisen T, Birtle AJ, Capoun O, et al
    European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update.
    Eur Urol. 2023;84:49-64.
    Abstract

  2237. SCHAFER EJ, Jemal A, Wiese D, Sung H, et al
    Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA.
    Eur Urol. 2023;84:117-126.
    Abstract

  2238. FENG M, Matoso A, Epstein G, Fong M, et al
    Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02830-0. doi: 10.1016/j.eururo.2023.
    Abstract

  2239. GROENEVELD CS, Sanchez-Quiles V, Dufour F, Shi M, et al
    Proteogenomic Characterization of Bladder Cancer Reveals Sensitivity to Apoptosis Induced by Tumor Necrosis Factor-related Apoptosis-inducing Ligand in FGFR3-mutated Tumors.
    Eur Urol. 2023 Jun 27:S0302-2838(23)02885-3. doi: 10.1016/j.eururo.2023.
    Abstract

  2240. BORREGALES LD, Venkat S, Posada Calderon L, Lewicki P, et al
    A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jun 21:S0302-2838(23)02900-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2241. KOTI M, Robert Siemens D
    A Step Closer to Predicting Progression After Bacillus Calmette-Guerin Immunotherapy in High-risk Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Jul 1:S0302-2838(23)02948-2. doi: 10.1016/j.eururo.2023.
    Abstract

  2242. FLAIG TW, Tangen CM, Daneshmand S, Alva AS, et al
    Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
    Eur Urol. 2023 Jul 4:S0302-2838(23)02945-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2243. LABAKI C, Saad E, Choueiri TK, Bellmunt J, et al
    Oligometastatic Bladder Cancer: Defining a Novel Entity.
    Eur Urol. 2023 Jul 4:S0302-2838(23)02898-1. doi: 10.1016/j.eururo.2023.
    Abstract

  2244. CIGLIOLA A, Mercinelli C, Patane D, Raggi D, et al
    Re: Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis.
    Eur Urol. 2023 Jul 12:S0302-2838(23)02962-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2245. BASILE G, Audenet F, Seisen T, Pradere B, et al
    The Impact of Lineage-specific Transcriptional Factors in Small-cell Bladder Cancer in the Patient Selection Process in Future Clinical Trials.
    Eur Urol. 2023 Jul 25:S0302-2838(23)02969-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2246. SUSSMAN J, Konety B, Ahmadi H
    Re: Rakesh Heer, Rebecca Lewis, Thenmalar Vadiveloo, et al. A Randomized Trial of PHOTOdynamic Surgery in Non-muscle-invasive Bladder Cancer. NEJM Evid 2022;1:EVIDoa2200092.
    Eur Urol. 2023 Aug 12:S0302-2838(23)03017-8. doi: 10.1016/j.eururo.2023.
    Abstract

  2247. BLACK PC, Tangen CM, Singh P, McConkey DJ, et al
    Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guerin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605.
    Eur Urol. 2023 Aug 16:S0302-2838(23)03019-1. doi: 10.1016/j.eururo.2023.
    Abstract

  2248. ZLOTTA AR, Lajkosz K, Efstathiou JA
    Reply to Thomas Seisen, Morgan Roupret, and Pierre Blanchard's Letter to the Editor re: Alexandre R. Zlotta, Leslie K. Ballas, Andrzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institut
    Eur Urol. 2023 Sep 1:S0302-2838(23)03066-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2249. SEISEN T, Roupret M, Blanchard P
    Re: Alexandre R. Zlotta, Leslie K. Ballas, Anderzej Niemierko, et al. Radical Cystectomy Versus Trimodality Therapy for Muscle-invasive Bladder Cancer: A Multi-institutional Propensity Score Matched and Weighted Analysis. Lancet Oncol 2023;24:669-81.
    Eur Urol. 2023 Aug 31:S0302-2838(23)03065-8. doi: 10.1016/j.eururo.2023.
    Abstract

  2250. INAMURA K
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Sep 9:S0302-2838(23)03085-3. doi: 10.1016/j.eururo.2023.
    Abstract

  2251. STRANDGAARD T, Nordentoft I, Birkenkamp-Demtroder K, Salminen L, et al
    Field Cancerization Is Associated with Tumor Development, T-cell Exhaustion, and Clinical Outcomes in Bladder Cancer.
    Eur Urol. 2023 Sep 15:S0302-2838(23)03014-2. doi: 10.1016/j.eururo.2023.
    Abstract

  2252. KHETRAPAL P, Wong JKL, Tan WP, Rupasinghe T, et al
    Robot-assisted Radical Cystectomy Versus Open Radical Cystectomy: A Systematic Review and Meta-analysis of Perioperative, Oncological, and Quality of Life Outcomes Using Randomized Controlled Trials.
    Eur Urol. 2023;84:393-405.
    Abstract

  2253. FENG M, Matoso A, Epstein G, Fong M, et al
    Reply to Kentaro Inamura's Letter to the Editor re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://do
    Eur Urol. 2023 Sep 27:S0302-2838(23)03097-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2254. KULKARNI GS, Wettstein MS
    SWOG S1605: Moving Beyond Systemic Immune Checkpoint Inhibitor Monotherapy in Bacillus Calmette-Guerin-unresponsive Non-muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Oct 4:S0302-2838(23)03138-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2255. KLUMPER N, Eckstein M, Holzel M, Herrmann K, et al
    Re: First-in-Human Study of the Radioligand (68)Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma: Navigating Metastatic Urothelial Cancer with Nectin-4 PET/CT.
    Eur Urol. 2023;84:514-515.
    Abstract

  2256. ALFRED WITJES J, Max Bruins H, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines.
    Eur Urol. 2023 Oct 17:S0302-2838(23)03073-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2257. SEISEN T, Roupret M, Trinh QD, Bellmunt J, et al
    Re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients with Clinically Node-positive Nonmetastatic Bladder Cancer. J
    Eur Urol. 2023 Oct 19:S0302-2838(23)03163-9. doi: 10.1016/j.eururo.2023.
    Abstract

  2258. SWINTON M, Hoskin P, Choudhury A
    Reply to Thomas Seisen, Morgan Roupret, Quoc-Dien Trinh, and Joaquim Bellmunt's Letter to the Editor re: Martin Swinton, Neethu Billy Graham Mariam, Jean Ling Tan, et al. Bladder-Sparing Treatment with Radical Dose Radiotherapy Is an Effective Alterna
    Eur Urol. 2023 Oct 19:S0302-2838(23)03162-7. doi: 10.1016/j.eururo.2023.
    Abstract

  2259. MEEKS JJ, Black PC, Galsky M, Grivas P, et al
    Checkpoint Inhibitors in Urothelial Carcinoma-Future Directions and Biomarker Selection.
    Eur Urol. 2023;84:473-483.
    Abstract

  2260. MARTINI A, Falagario UG, Russo A, Mertens LS, et al
    Robot-assisted Radical Cystectomy with Orthotopic Neobladder Reconstruction: Techniques and Functional Outcomes in Males.
    Eur Urol. 2023;84:484-490.
    Abstract

  2261. WANG Z, Zeng S, Xu C
    Re: Mingxiao Feng, Andres Matoso, Gabriel Epstein, et al. Identification of Lineage-specific Transcriptional Factor-defined Molecular Subtypes in Small Cell Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.05.023.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03169-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2262. HENSLEY PJ, Choudhury A, Khaki AR, Grivas P, et al
    The 2023 European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: A Critical Appraisal.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03208-6. doi: 10.1016/j.eururo.2023.
    Abstract

  2263. BECKABIR W, Wobker SE, Damrauer JS, Midkiff B, et al
    Spatial Relationships in the Tumor Microenvironment Demonstrate Association with Pathologic Response to Neoadjuvant Chemoimmunotherapy in Muscle-invasive Bladder Cancer.
    Eur Urol. 2023 Dec 12:S0302-2838(23)03261-X. doi: 10.1016/j.eururo.2023.
    Abstract

  2264. XIE Q, Shen D
    Re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with Haematuria. Eur Urol 2022;82:182-92.
    Eur Urol. 2024;85:e17-e18.
    Abstract

  2265. PRASAD RAI B, Violette PD, Imran Omar M
    Reply to Qingpeng Xie and Dianqiu Shen's Letter to the Editor re: Bhavan P. Rai, Jose Luis Dominguez Escrig, Luis Vale, et al. Systematic Review of the Incidence of and Risk Factors for Urothelial Cancers and Renal Cell Carcinoma Among Patients with H
    Eur Urol. 2024;85:e15-e16.
    Abstract

  2266. HIEN TT, Ambite I, Wan MLY, Cavalera M, et al
    Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
    Int J Cancer. 2023 Mar 9. doi: 10.1002/ijc.34500.
    Abstract

  2267. HOSSEINI B, Zendehdel K, Bouaoun L, Hall AL, et al
    Bladder cancer risk in relation to occupations held in a nationwide case-control study in Iran.
    Int J Cancer. 2023 May 9. doi: 10.1002/ijc.34560.
    Abstract

  2268. YU EY, Tang QY, Chen YT, Zhang YX, et al
    Genome-wide exploration of genetic interactions for bladder cancer risk.
    Int J Cancer. 2023 Aug 28. doi: 10.1002/ijc.34690.
    Abstract

  2269. SJODAHL G, Eriksson P, Holmsten K, Abrahamsson J, et al
    Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
    Int J Cancer. 2023 Sep 6. doi: 10.1002/ijc.34715.
    Abstract

  2270. PRADHAN P, Jia G, Khankari NK, Zheng W, et al
    Evaluating interactions of polygenic risk scores and NAT2 genotypes with tobacco smoking in bladder cancer risk.
    Int J Cancer. 2023 Sep 20. doi: 10.1002/ijc.34736.
    Abstract

  2271. ZHANG S, Zhang C, Liu W, Zheng W, et al
    [Retracted] MicroRNA‑24 upregulation inhibits proliferation, metastasis and induces apoptosis in bladder cancer cells by targeting CARMA3.
    Int J Oncol. 2023;62:67.
    Abstract

  2272. HWANG TI, Cuiu YC, Chen YC, Chen PC, et al
    Tumor suppressive functions of hsa‑miR‑34a on cell cycle, migration and protective autophagy in bladder cancer.
    Int J Oncol. 2023;62:66.
    Abstract

  2273. LI Z, Jiang Y, Liu J, Fu H, et al
    Exosomes from PYCR1 knockdown bone marrow mesenchymal stem inhibits aerobic glycolysis and the growth of bladder cancer cells via regulation of the EGFR/PI3K/AKT pathway.
    Int J Oncol. 2023;63:84.
    Abstract

  2274. WANG Z, Li L, Chu C, Wei X, et al
    CUDC?101 is a potential target inhibitor for the EGFR?overexpression bladder cancer cells.
    Int J Oncol. 2023;63:131.
    Abstract

  2275. MOEEN AM
    Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
    Int J Urol. 2023;30:270-271.
    Abstract

  2276. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
    Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
    Int J Urol. 2023;30:258-263.
    Abstract

  2277. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
    Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
    Int J Urol. 2023;30:328-330.
    Abstract

  2278. SINGH A, Kayina CA, Naik N, Ganesh V, et al
    Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
    Int J Urol. 2023;30:264-270.
    Abstract

  2279. MATSUMOTO K
    Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
    Abstract

  2280. MASTROIANNI R, Torregiani G, Simone G
    Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:373-374.
    Abstract

  2281. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
    Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:366-373.
    Abstract

  2282. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    Abstract

  2283. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
    Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
    Int J Urol. 2023;30:471-472.
    Abstract

  2284. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
    Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
    Int J Urol. 2023;30:464-471.
    Abstract

  2285. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
    Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
    Abstract

  2286. GOTO Y
    Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:647-648.
    Abstract

  2287. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
    Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:634-647.
    Abstract

  2288. KONDO T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:657.
    Abstract

  2289. SAZUKA T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:658.
    Abstract

  2290. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
    Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:649-657.
    Abstract

  2291. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
    Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
    Int J Urol. 2023;30:579-584.
    Abstract

  2292. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    Abstract

  2293. GOTO Y
    Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
    Abstract

  2294. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
    Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
    Abstract

  2295. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
    Abstract

  2296. SZARVAS T
    Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
    Abstract

  2297. SATO T, Sano T, Kawamura S, Ikeda Y, et al
    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
    Abstract

  2298. KIKUCHI E, Hayakawa N
    Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
    Int J Urol. 2023;30:786-787.
    Abstract

  2299. HARA T, Furukawa J, Okamura Y, Bando Y, et al
    The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Int J Urol. 2023;30:779-786.
    Abstract

  2300. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Int J Urol. 2023;30:738-745.
    Abstract

  2301. ITO K, Kita Y, Kobayashi T
    Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:696-703.
    Abstract

  2302. GOTO Y
    Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:704.
    Abstract

  2303. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    Abstract

  2304. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    Abstract

  2305. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    Abstract

  2306. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    Abstract

  2307. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    Abstract

  2308. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
    Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
    Int J Urol. 2023;30:853-858.
    Abstract

  2309. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    Abstract

  2310. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    Abstract

  2311. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    Abstract

  2312. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    Abstract

  2313. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    Abstract

  2314. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    Abstract

  2315. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    Abstract

  2316. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    Abstract

  2317. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    Abstract

  2318. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    Abstract

  2319. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    Abstract

  2320. DEWITT-FOY ME, Anele UA, Accioly JPE, Sharpe MG, et al
    Cancer risk in bladder diverticula: a large institutional analysis of risk and management.
    Int Urol Nephrol. 2023;55:541-546.
    Abstract

  2321. QIU Y, Zhang X, Dong Z, Zhang Y, et al
    Comparable survival benefits of partial ureterectomy to radical nephroureterectomy in non-metastatic ureter carcinoma: a population-matched study.
    Int Urol Nephrol. 2023;55:579-588.
    Abstract

  2322. GRIZZI F, Hegazi MAAA, Taverna G
    Letter to the editor re: "assessing bladder cancer prognosis through circulating tumor cell analysis and Ki-67 measurement".
    Int Urol Nephrol. 2023 Mar 3. doi: 10.1007/s11255-023-03538.
    Abstract

  2323. NISHIHARA D, Kijima T, Arai K, Kamai T, et al
    Increased co-expression of stromal HHLA2 and fibroblast activation protein in upper tract urothelial carcinoma.
    Int Urol Nephrol. 2023;55:867-874.
    Abstract

  2324. FU W, Liu D, Xiong Y, Liu C, et al
    The comparison between contrast-enhanced ultrasound and contrast-enhanced magnetic resonance imaging in diagnosing bladder urothelial carcinoma.
    Int Urol Nephrol. 2023;55:1073-1079.
    Abstract

  2325. YILMAZ H, Cinar NB, Avci IE, Akdas EM, et al
    Evaluation of comprehensive complication index versus Clavien-Dindo classification in prediction of overall survival after radical cystectomy.
    Int Urol Nephrol. 2023;55:1459-1465.
    Abstract

  2326. SLUSARCZYK A, Zapala P, Olszewska-Slusarczyk Z, Radziszewski P, et al
    The prediction of cancer-specific mortality in T1 non-muscle-invasive bladder cancer: comparison of logistic regression and artificial neural network: a SEER population-based study.
    Int Urol Nephrol. 2023 Jun 6. doi: 10.1007/s11255-023-03655.
    Abstract

  2327. KABA M, Pirincci N, Demir M, Kaba S, et al
    The relationship between microRNAs and bladder cancer: are microRNAs useful to predict bladder cancer in suspicious patients?
    Int Urol Nephrol. 2023 Jun 20. doi: 10.1007/s11255-023-03666.
    Abstract

  2328. MOEEN AM, Faragallah MA, Zarzour MA, Elbehairy AA, et al
    Ileal conduit versus single stoma uretero-cutanoustomy after radical cystectomy in patients >/= 75 years; which technique is better? a prospective randomized comparative study.
    Int Urol Nephrol. 2023;55:1719-1726.
    Abstract

  2329. KIM SH, Choi BG, Oh JS, Chun HJ, et al
    Upper tract heparin instillation for maintenance of ureteral stent patency.
    Int Urol Nephrol. 2023;55:1893-1897.
    Abstract

  2330. OPPOLZER IA, Riester J, Buttner R, Burger M, et al
    Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors.
    Int Urol Nephrol. 2023;55:1943-1949.
    Abstract

  2331. WANG Z, Yang Z, Qu C, Li J, et al
    Natural killer cells strengthen antitumor activity of cisplatin by immunomodulation and ameliorate cisplatin-induced side effects.
    Int Urol Nephrol. 2023;55:1957-1970.
    Abstract

  2332. OSMAN Y, Elawdy M, Taha DE, Zahran MH, et al
    Bladder perforation as a complication of transurethral resection of bladder tumors: the predictors, management, and its impact in a series of 1570 at a tertiary urology institute.
    Int Urol Nephrol. 2023;55:2161-2167.
    Abstract

  2333. WANG IK, Yu TM, Yen TH, Lin CL, et al
    Comparison of the risks of renal cell carcinoma or urothelial cancer between hemodialysis and peritoneal dialysis patients.
    Int Urol Nephrol. 2023;55:2267-2274.
    Abstract

  2334. ASSEM A, Kassem A, Sherif M, Lotfi A, et al
    Safety, feasibility, and quality of thulium laser en-bloc resection for treatment of non-muscle invasive bladder cancer.
    Int Urol Nephrol. 2023 Aug 28. doi: 10.1007/s11255-023-03752.
    Abstract

  2335. YOU C, Li Q, Qing L, Li R, et al
    Device-assisted intravesical chemotherapy versus bacillus Calmette-Guerin for intermediate or high-risk non-muscle invasive bladder cancer: a systematic reviewer and meta-analysis.
    Int Urol Nephrol. 2023 Sep 2. doi: 10.1007/s11255-023-03765.
    Abstract

  2336. KHALIFA SE
    Immunohistochemical expression of CD117/KIT, HER2, and Erbeta in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients.
    Int Urol Nephrol. 2023;55:2473-2481.
    Abstract

  2337. XIAOQIN Z, Zhouqi L, Huan P, Xinyi F, et al
    Development of a prognostic signature for immune-associated genes in bladder cancer and exploring potential drug findings.
    Int Urol Nephrol. 2023 Sep 23. doi: 10.1007/s11255-023-03796.
    Abstract

  2338. KAYAR R, Bastug Y, Tokuc E, Topaktas R, et al
    Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Sep 29. doi: 10.1007/s11255-023-03812.
    Abstract

  2339. GERCEK O, Keles I, Saritas TB, Koyuncu B, et al
    Effect of obturator nerve block during transurethral resection of bladder tumors on the disease recurrence, progression and surgery outcomes.
    Int Urol Nephrol. 2023;55:2765-2772.
    Abstract

  2340. GERCEK O, Ulusoy K, Yazar VM, Topal K, et al
    Effects of delayed diagnosis on tumor size, stage and grade in bladder cancer.
    Int Urol Nephrol. 2023 Oct 17. doi: 10.1007/s11255-023-03829.
    Abstract

  2341. WEI C, Deng C, Dong R, Hou Y, et al
    Multi-omics analysis reveals critical metabolic regulators in bladder cancer.
    Int Urol Nephrol. 2023 Oct 26. doi: 10.1007/s11255-023-03841.
    Abstract

  2342. PAZIR Y, Esmeray A, Caglar U, Erbin A, et al
    Comparison of hyperthermic intravesical chemotherapy and Bacillus Calmette-Guerin therapy in high-risk non-muscle invasive bladder cancer: a matched-pair analysis.
    Int Urol Nephrol. 2023 Oct 25. doi: 10.1007/s11255-023-03849.
    Abstract

  2343. MIYAKE M, Nishimura N, Nishioka Y, Fujii T, et al
    Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Int Urol Nephrol. 2023 Nov 1. doi: 10.1007/s11255-023-03851.
    Abstract

  2344. BEIJERT IJ, Hentschel AE, Brundl J, Comperat EM, et al
    Second TURB, restaging TURB or repeat TURB in primary T1 non-muscle invasive bladder cancer: impact on prognosis?
    Int Urol Nephrol. 2023 Nov 19. doi: 10.1007/s11255-023-03867.
    Abstract

  2345. COLEMAN JA, Yip W, Wong NC, Sjoberg DD, et al
    Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
    J Clin Oncol. 2023;41:1618-1625.
    Abstract

  2346. SARFATY M, Golkaram M, Funt SA, Al-Ahmadie H, et al
    Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.
    J Clin Oncol. 2023;41:3225-3235.
    Abstract

  2347. POWLES T, Park SH, Caserta C, Valderrama BP, et al
    Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After >/=2 Years of Follow-Up.
    J Clin Oncol. 2023;41:3486-3492.
    Abstract

  2348. STEIN JP, Lieskovsky G, Cote R, Groshen S, et al
    Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients.
    J Clin Oncol. 2023;41:3772-3781.
    Abstract


  2349. JCO Flashback: Long-Term Outcomes of Radical Cystectomy in Patients With Invasive Bladder Cancer (2001).
    J Clin Oncol. 2023;41:3771.
    Abstract

  2350. BOSL GJ
    Flashback Foreword: Radical Cystectomy in the Treatment of Bladder Cancer.
    J Clin Oncol. 2023;41:3769-3770.
    Abstract

  2351. SWINTON M, Mariam NBG, Tan JL, Murphy K, et al
    Bladder-Sparing Treatment With Radical Dose Radiotherapy Is an Effective Alternative to Radical Cystectomy in Patients With Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Jul 21:JCO2300725. doi: 10.1200/JCO.23.00725.
    Abstract

  2352. VON DER MAASE H, Hansen SW, Roberts JT, Dogliotti L, et al
    Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.
    J Clin Oncol. 2023;41:3881-3890.
    Abstract

  2353. SMALL EJ
    Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
    J Clin Oncol. 2023;41:3879-3880.
    Abstract

  2354. SIEFKER-RADTKE AO, Cauley D, Alhalabi O
    Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma.
    J Clin Oncol. 2023;41:4084-4086.
    Abstract

  2355. KAMAT AM, Apolo AB, Babjuk M, Bivalacqua TJ, et al
    Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
    J Clin Oncol. 2023 Oct 4:JCO2300307. doi: 10.1200/JCO.23.00307.
    Abstract

  2356. CATHOMAS R, Rothschild SI, Hayoz S, Bubendorf L, et al
    Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17.
    J Clin Oncol. 2023;41:5131-5139.
    Abstract

  2357. HE W, Zeng S, Xu C
    Controversy Surrounding Bladder-Sparing Radical Dose Radiotherapy as an Alternative to Radical Cystectomy for Clinically Node-Positive Nonmetastatic Bladder Cancer.
    J Clin Oncol. 2023 Dec 5:JCO2301920. doi: 10.1200/JCO.23.01920.
    Abstract

  2358. PENG CK, Sung WW, Chen SL
    Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients With Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study.
    J Urol. 2023 Mar 9:101097JU0000000000003407. doi: 10.1097/JU.0000000000003407.
    Abstract

  2359. PENG CK, Sung WW
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. Letter.
    J Urol. 2023;209:676-677.
    Abstract

  2360. LOTAN Y, Raman JD, Konety B, Daneshmand S, et al
    Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification.
    J Urol. 2023;209:762-772.
    Abstract

  2361. STEINBERG RL, O'Donnell MA, Packiam VT
    Non-risk Adapted Sequential Intravesical Gemcitabine and Docetaxel for Non-muscle Invasive Bladder Cancer: The Time is Now.
    J Urol. 2023 Mar 31:101097JU0000000000003438. doi: 10.1097/JU.0000000000003438.
    Abstract

  2362. MOSCHINI M, Necchi A, Briganti A, Montorsi F, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003455. doi: 10.1097/JU.0000000000003455.
    Abstract

  2363. TYSON MD, Morris D, Palou J, Rodriguez O, et al
    Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study.
    J Urol. 2023;209:890-900.
    Abstract

  2364. GILBERT SM
    Will Patient-reported Outcomes Be the Key to Demonstrating the Value of Robotic Cystectomy? Data Are Accumulating but Clarity Is Not.
    J Urol. 2023;209:833-835.
    Abstract

  2365. GHOREIFI A, Ladi-Seyedian SS, Piatti P, Chew YC, et al
    A Urine-based DNA Methylation Marker Test to Detect Upper Tract Urothelial Carcinoma: A Prospective Cohort Study.
    J Urol. 2023;209:854-862.
    Abstract

  2366. KIRK PS, Lotan Y, Zargar H, Fairey AS, et al
    Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort.
    J Urol. 2023;209:882-889.
    Abstract

  2367. YIP W, Sjoberg DD, Nogueira LM, Tracey AT, et al
    Final Results of a Phase I Trial of WST-11 (TOOKAD Soluble) Vascular-targeted Photodynamic Therapy for Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:863-871.
    Abstract

  2368. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial.
    J Urol. 2023;209:901-910.
    Abstract

  2369. LABBATE C, Woldu S, Murray K, Rose K, et al
    Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
    J Urol. 2023;209:872-881.
    Abstract

  2370. COLEMAN JA, Clark PE, Bixler BR, Buckley DI, et al
    Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline.
    J Urol. 2023;209:1071-1081.
    Abstract

  2371. WANG HH, Zhang TR, Ramakrishnan VM, Valovska MT, et al
    Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience.
    J Urol. 2023;209:1202-1209.
    Abstract

  2372. BREE KK, Kokorovic A, Westerman ME, Hensley PJ, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 May 22:101097JU0000000000003553. doi: 10.1097/JU.0000000000003553.
    Abstract


  2373. PD44-11 Neoadjuvant Chemotherapy Increases Urinary and Bowel Anastomotic Failure in PT2-T4 Bladder Cancer Undergoing Radical Cystectomy.
    J Urol. 2023;210:222.
    Abstract

  2374. JI J, Lai CH, Wang Q, Hu H, et al
    Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic But Not Therapeutic. Letter.
    J Urol. 2023 Jul 6:101097JU0000000000003613. doi: 10.1097/JU.0000000000003613.
    Abstract

  2375. TAN WS, Contieri R, Buffi NM, Lughezzani G, et al
    International Bladder Cancer Group Intermediate-risk Non-muscle Invasive Bladder Cancer (IBCG IR-NMIBC) Scoring System Predicts Outcomes of Patients on Active Surveillance.
    J Urol. 2023 Aug 3:101097JU0000000000003639. doi: 10.1097/JU.0000000000003639.
    Abstract

  2376. PRASAD SM, Huang WC, Shore ND, Hu B, et al
    Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 +/- Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).
    J Urol. 2023 Aug 7:101097JU0000000000003645. doi: 10.1097/JU.0000000000003645.
    Abstract

  2377. CLEMENTS MB, Beech BB, Atkinson TM, Dalbagni GM, et al
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Reply.
    J Urol. 2023;210:408.
    Abstract

  2378. WONG N, So WZ, Tiong HY
    Health-related Quality of Life After Robotic-assisted vs Open Radical Cystectomy: Analysis of a Randomized Trial. Letter.
    J Urol. 2023;210:407-408.
    Abstract

  2379. PRASAD SM
    Primary Chemoablation for Intermediate-Risk Low-Grade Bladder Cancer: New Paradigm or Added Uncertainty? Letter.
    J Urol. 2023 Sep 28:101097JU0000000000003729. doi: 10.1097/JU.0000000000003729.
    Abstract

  2380. MURTHY PB, Sexton WJ
    Primary Chemoablation for Intermediate-risk Low-grade Bladder Cancer: New Paradigm or Added Uncertainty?
    J Urol. 2023 Sep 27:101097JU0000000000003702. doi: 10.1097/JU.0000000000003702.
    Abstract

  2381. BREE KK, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003704. doi: 10.1097/JU.0000000000003704.
    Abstract

  2382. BREE K, Navai N
    Repeat Transurethral Resection of Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Reply.
    J Urol. 2023 Sep 25:101097JU0000000000003705. doi: 10.1097/JU.0000000000003705.
    Abstract

  2383. SOOD A, Rudzinski JK, Labbate CV, Hensley PJ, et al
    Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience.
    J Urol. 2023 Nov 3:101097JU0000000000003778. doi: 10.1097/JU.0000000000003778.
    Abstract

  2384. SUN J, Zhang H, Wei W, Xiao X, et al
    Regulation of CD8(+) T cells infiltration and immunotherapy by circMGA/HNRNPL complex in bladder cancer.
    Oncogene. 2023 Mar 3. doi: 10.1038/s41388-023-02637.
    Abstract

  2385. NEYRET-KAHN H, Fontugne J, Meng XY, Groeneveld CS, et al
    Epigenomic mapping identifies an enhancer repertoire that regulates cell identity in bladder cancer through distinct transcription factor networks.
    Oncogene. 2023 Mar 22. doi: 10.1038/s41388-023-02662.
    Abstract

  2386. JIA Y, Ding X, Zhou L, Zhang L, et al
    Retraction Note: Mesenchymal stem cells-derived exosomal microRNA-139-5p restrains tumorigenesis in bladder cancer by targeting PRC1.
    Oncogene. 2023 May 30. doi: 10.1038/s41388-023-02726.
    Abstract

  2387. XIE J, Zhang H, Wang K, Ni J, et al
    M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
    Oncogene. 2023 Aug 23. doi: 10.1038/s41388-023-02814.
    Abstract

  2388. RAMAL M, Corral S, Kalisz M, Lapi E, et al
    The urothelial gene regulatory network: understanding biology to improve bladder cancer management.
    Oncogene. 2023 Nov 23. doi: 10.1038/s41388-023-02876.
    Abstract

  2389. YU J, Li M, Ju L, Zhou F, et al
    TRAIP suppresses bladder cancer progression by catalyzing K48-linked polyubiquitination of MYC.
    Oncogene. 2023 Dec 20. doi: 10.1038/s41388-023-02922.
    Abstract

  2390. CHEN JX, Chen DM, Wang D, Xiao Y, et al
    METTL3/YTHDF2 m6A axis promotes the malignant progression of bladder cancer by epigenetically suppressing RRAS.
    Oncol Rep. 2023;49:94.
    Abstract

  2391. LIU X, Tong Y, Huang Q, He Y, et al
    CircRPPH1 accelerates the proliferation and migration of bladder cancer via enhancing the STAT3 signaling pathway.
    Oncol Rep. 2023;49:103.
    Abstract

  2392. ZHANG C, Wang R, Li M, Yang Q, et al
    Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
    Oncol Rep. 2023;49:108.
    Abstract

  2393. HO JN, Jeon JS, Kim DH, Ryu H, et al
    CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
    Oncol Rep. 2023;49:130.
    Abstract

  2394. HAO Y, He W, Wang H, Rui W, et al
    Forkhead box F1 functions as a novel prognostic biomarker and induces caspase‑dependent apoptosis in bladder cancer.
    Oncol Rep. 2023;50:173.
    Abstract

  2395. SONG W, Li Z, Xia M, Xiao W, et al
    Regulation of Drp1 and enhancement of mitochondrial fission by the deubiquitinating enzyme PSMD14 facilitates the proliferation of bladder cancer cells.
    Oncol Rep. 2024;51:6.
    Abstract

  2396. YE G, Tu L, Li Z, Li X, et al
    SYNPO2 promotes the development of BLCA by upregulating the infiltration of resting mast cells and increasing the resistance to immunotherapy.
    Oncol Rep. 2024;51:14.
    Abstract

  2397. CHEN F, Chen X, Yang D, Che X, et al
    [Retracted] Isoquercitrin inhibits bladder cancer progression in vitro and in vivo by regulating the PI3K/Akt and PKC signaling pathways.
    Oncol Rep. 2024;51:25.
    Abstract

  2398. GABRIEL PE, Pinar U, Parra J, Vaessen C, et al
    [Pathological pelvic lymph node involvement in muscle-invasive bladder cancer patients treated with radical cystectomy: A narrative review].
    Prog Urol. 2023;33:145-154.
    Abstract

  2399. CIMIER A, Thach S, Lacroix B, Mariat C, et al
    [Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer].
    Prog Urol. 2023 Mar 9:S1166-7087(23)00062-3. doi: 10.1016/j.purol.2023.
    Abstract

  2400. SOOROJEBALLY Y, Neuzillet Y, Lebret T, Allory Y, et al
    Photodynamic cystoscopy for bladder cancer diagnosis and for NMIBC follow-up: An overview of systematic reviews and meta-analyses.
    Prog Urol. 2023 Apr 21:S1166-7087(23)00083-0. doi: 10.1016/j.purol.2023.
    Abstract

  2401. GABRIEL PE, Lambert T, Dumont C, Gauthier H, et al
    [Preoperative chemotherapy for patients with upper tract urothelial carcinoma: Impact on renal function].
    Prog Urol. 2023;33.
    Abstract

  2402. ARNAUD Q, Sebe P, Colau A, Mouton M, et al
    Management of high-grade papillary Ta or T1 bladder cancer after restaging transurethral resection: A retrospective study comparing Bacillus Calmette-Guerin therapy upfront versus a third resection.
    Prog Urol. 2023 Nov 16:S1166-7087(23)00238-5. doi: 10.1016/j.purol.2023.
    Abstract

  2403. GALLON J, LeMaoult J, Verine J, Dumont C, et al
    [Profile and immune environment of upper tract urothelial carcinoma].
    Prog Urol. 2023;33.
    Abstract

  2404. BRUNEAUX E, Iborra F, Trouche-Sabatier SG, Foucan AS, et al
    [Bladder tumors in the Herault department: Results of the Herault tumor registry registration from1987 to 2019].
    Prog Urol. 2023;33.
    Abstract

  2405. FU Y, Liu K, Jiang X, Zhao L, et al
    Hsa_circ_0008035 Knockdown Inhibits Bladder Cancer Progression through miR-1184/RAP2B Axis.
    Urol Int. 2023 Mar 23:1-14. doi: 10.1159/000527873.
    Abstract

  2406. HAAS M, Knobloch C, Mayr R, Gierth M, et al
    Short-Term and Long-Term Morbidity after Radical Cystectomy in Patients with NMIBC and Comparison with MIBC: Identifying Risk Factors for Severe Short-Term Complications.
    Urol Int. 2023;107:246-256.
    Abstract

  2407. MEYER HJ, Wienke A, Zamsheva M, Surov A, et al
    Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
    Urol Int. 2023;107:219-229.
    Abstract

  2408. CHEN S, Gao Y, Chen F, Wang TB, et al
    ANLN Serves as an Oncogene in Bladder Urothelial Carcinoma via Activating JNK Signaling Pathway.
    Urol Int. 2023;107:310-320.
    Abstract

  2409. HAEUSER L, Marchese M, Noldus J, Kibel AS, et al
    Association between Operative Time and Short-Term Radical Cystectomy Complications.
    Urol Int. 2023;107:273-279.
    Abstract

  2410. GRUNE B, Menold H, Lenhart M, Muhlbauer J, et al
    Patient Compliance in Assessing Electronic Patient-Reported Outcome Measures after Urologic Surgery.
    Urol Int. 2023;107:280-287.
    Abstract

  2411. BOLENZ C, Kunath F, Zengerling F, Wezel F, et al
    Increasing Biomarker Guidance in the Treatment of Urothelial Carcinoma: Systematic Review of International Clinical Trials.
    Urol Int. 2023;107:480-488.
    Abstract

  2412. DU J, Zhan H, Chen J, Wang J, et al
    The Influence of Preoperative Hydronephrosis on the Prognosis after Radical Cystectomy among Patients with Different Pathological Stages of Bladder Cancer.
    Urol Int. 2023 Jun 2:1-8. doi: 10.1159/000531080.
    Abstract

  2413. GRUNE B, Kowalewski KF, Weiss C, Neuberger M, et al
    Predicting Complexity in Transurethral Resection of Bladder Tumours: External Validation and Modification of the Bladder Complexity Score.
    Urol Int. 2023;107:583-590.
    Abstract

  2414. WU YL, Li ZQ, Wu AM
    The Misdiagnosis of Intravesical Ectopic Prostatic Tissue as a Tumor.
    Urol Int. 2023;107:738-741.
    Abstract

  2415. JIAO H, Wang L, Zhou X, Wu J, et al
    Prognostic Ability of Nutritional Indices for Outcomes of Bladder Cancer: A Systematic Review and Meta-Analysis.
    Urol Int. 2023 Aug 29:1-9. doi: 10.1159/000531884.
    Abstract

  2416. CHEN Z
    The Role of Specificity Protein 1 (SP1) in Bladder Cancer Progression through PTEN-Mediated AKT/mTOR Pathway.
    Urol Int. 2023 Sep 4:1-9. doi: 10.1159/000532128.
    Abstract

  2417. STRUCK JP, Ozimek T, Schnoor M, Offermann A, et al
    The Role of Urine and Washing Cytology in Primary Transurethral Resection of Bladder Tumours.
    Urol Int. 2023;107:792-800.
    Abstract

  2418. BOKARICA P, Alfirevic M, Hrkac A, Glas AM, et al
    Letter to the Editor regarding the Article "Postoperative Mortality Rate after Radical Cystectomy: A Systematic Review of Epidemiologic Series".
    Urol Int. 2023;107:839-840.
    Abstract

  2419. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    Abstract

  2420. YUAN P, Li X, Yuan Y, Xu P, et al
    Successful Kidney-Sparing Systemic Therapy for a High-Risk Ureteral Carcinoma Case.
    Urol Int. 2023;107:895-898.
    Abstract

  2421. GUO L, Zhang T, Taisheng L, Chen J, et al
    Laparoscopic Radical Cystectomy With Ileal Orthotopic Neobladder for Bladder Cancer: Current Indications and Outcomes.
    Urol Int. 2023 Nov 23. doi: 10.1159/000535032.
    Abstract

  2422. GUO Y, Li C, Zhang S, Zhu G, et al
    U-Net-Based Assistive Identification of Bladder Cancer: A Promising Approach for Improved Diagnosisc.
    Urol Int. 2023 Dec 11. doi: 10.1159/000535652.
    Abstract

  2423. WANG C, Yu H, Fu W, Chen G, et al
    Transurethral Hem-o-lok Clip Ligation of the Distal Ureter in Retroperitoneal Laparoscopic Radical Nephroureterectomy.
    Urol Int. 2023;107.
    Abstract

  2424. TULONE G, Pavan N, Giannone S, Abrate A, et al
    Double-Layered Hand-Sewn versus Stapled Intestinal Anastomosis in Patients Who Underwent Ileal Urinary Diversion in Radical Cystectomy: A Comparative and Cost Effective Study.
    Urol Int. 2023;107.
    Abstract

  2425. CHUN B, He M, Jones C, Vasan R, et al
    Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
    Urology. 2023 Mar 25:S0090-4295(23)00267-4. doi: 10.1016/j.urology.2023.
    Abstract

  2426. DONAT SM, Sonoda Y, Al-Ahmadie H, Murali R, et al
    Evaluation of Women With a Positive Urine Cytology and no Demonstrable Disease in the Urinary Tract.
    Urology. 2023;173:10-16.
    Abstract

  2427. RAM P, Mandal S, Das MK, Nayak P, et al
    Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guerin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Res
    Urology. 2023;173:229.
    Abstract

  2428. MILLER DT, Sun Z, Grajales V, Pekala KR, et al
    Insurance type and area deprivation are associated with worse overall mortality for patients with muscle-invasive bladder cancer.
    Urology. 2023 Apr 5:S0090-4295(23)00270-4. doi: 10.1016/j.urology.2023.
    Abstract

  2429. ZHANG JH, Starr SL, Chamie K
    Contemporary Systemic Therapies in Urothelial Carcinoma.
    Urology. 2023;174:150-158.
    Abstract

  2430. JUE JS, Armenakas NA
    Upper Tract Tumor En Bloc Enucleation: A Novel Approach to the Diagnosis and Management of Upper Tract Urothelial Carcinoma.
    Urology. 2023;174:196-200.
    Abstract

  2431. SONG SH, Kim JH, Lee S, Hong SK, et al
    Total Intracorporeal Versus Open Bladder Cuffing in Robotic Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.
    Urology. 2023;174:111-117.
    Abstract

  2432. PASTER IC, Zeng J, Recio-Boiles A, Chipollini J, et al
    Gender, racial and ethnic differences in pathologic response following neoadjuvant chemotherapy for bladder cancer patients.
    Urology. 2023 May 23:S0090-4295(23)00446-6. doi: 10.1016/j.urology.2023.
    Abstract

  2433. WAHLEN MM, McElree IM, Packiam VT
    Editorial Comment On: Variation in Statewide Intravesical Treatment Rates for Non-Muscle Invasive Bladder Cancer During the BCG Drug Shortage.
    Urology. 2023 May 19:S0090-4295(23)00371-0. doi: 10.1016/j.urology.2023.
    Abstract

  2434. GROOTEMAAT M, Tjiam I, Sampimon D, Bot F, et al
    Bilateral Adrenal and testicular Tumours; When a Simple Diagnosis Becomes Complicated.
    Urology. 2023;175:e11-e12.
    Abstract

  2435. TAN WP
    An Atypical Bladder Mass: Extra Adrenal Paraganglioma.
    Urology. 2023;176:e8-e9.
    Abstract

  2436. ERGUN O, Alperen Ozturk S, Kircicek F, Gurdal O, et al
    Increased Plasma Ignition Distance Practice may Prevent the Obturator Reflex Occurrences and Compare of its Effectiveness Versus Obturator Block: A Prospective, Randomized, Controlled Study.
    Urology. 2023;176:226-231.
    Abstract

  2437. PASTER IC, Chipollini J
    Reply: Gender, Racial and Ethnic Differences in Pathologic Response Following Neoadjuvant Chemotherapy for Bladder Cancer Patients.
    Urology. 2023 Jul 11:S0090-4295(23)00448-X. doi: 10.1016/j.urology.2023.
    Abstract

  2438. SEKAR RR, Maganty A
    Impact of Race, Ethnicity, and Gender on Response to Neoadjuvant Chemotherapy and Survival in Patients With Muscle-invasive Bladder Cancer.
    Urology. 2023 Jul 11:S0090-4295(23)00447-8. doi: 10.1016/j.urology.2023.
    Abstract

  2439. JEVNIKAR B, Slopnick E, Almassi N
    Clinical Challenge in Urology: Late Genitourinary Toxicity Following Intravesical Bacillus Calmette-Guerin.
    Urology. 2023;177:e8-e9.
    Abstract

  2440. GELDMAKER LE, Baird BA, Hasse CH, Haehn DA, et al
    Analysis of Transurethral Resection of Bladder Tumor Efficiency Utilizing Nonprocedural Operating Room Times.
    Urology. 2023;177:6-11.
    Abstract

  2441. KANABOLO DL, Park S
    Prophylactic Mesh Placement With Ileal Conduit: A Cost-effectiveness Analysis.
    Urology. 2023;177:197-203.
    Abstract

  2442. FENG S, Yang Y, Yu Z, Xiong Q, et al
    Survival and Analysis of Prognostic Factors for Bladder Malignancies in Children and Adolescents: A Population-based Study.
    Urology. 2023;177:156-161.
    Abstract

  2443. SOYSTER ME, Arnold PJ, Burns RT, Zappia JL, et al
    Ileal Ureter Utilization in Patients With Previous Urinary Diversions.
    Urology. 2023;177:184-188.
    Abstract

  2444. RANTI D, Dey L, Bieber C, Grauer R, et al
    Surveillance for Non-Muscle Invasive Bladder Cancer: Identifying the point of Diminishing Returns.
    Urology. 2023 Aug 19:S0090-4295(23)00697-0. doi: 10.1016/j.urology.2023.
    Abstract

  2445. HYMAN MJ, Skolarus TA, Litwack K, Meltzer DO, et al
    Outcomes of Hematuria Evaluation by Advanced Practice Providers and Urologists.
    Urology. 2023;178:67-75.
    Abstract

  2446. LYALL V, Aziz Ould Ismail A, Haggstrom DA, Issa MM, et al
    Accurate Documentation Contributes to Guideline-concordant Surveillance of Non-Muscle Invasive Bladder Cancer: a Multi-site VA Study.
    Urology. 2023 Sep 1:S0090-4295(23)00729-X. doi: 10.1016/j.urology.2023.
    Abstract

  2447. NABAVIZADEH R, Pessoa RR, Dumbrava MG, Packiam VT, et al
    Cutaneous Ureterostomy Following Radical Cystectomy for Bladder Cancer: A Contemporary Series.
    Urology. 2023 Sep 7:S0090-4295(23)00733-1. doi: 10.1016/j.urology.2023.
    Abstract

  2448. PENN T, Borza T, Liou JI, Jason Abel E, et al
    The Impact of Agent Orange Exposure on Non-Muscle Invasive Bladder Cancer Outcomes.
    Urology. 2023 Sep 18:S0090-4295(23)00794-X. doi: 10.1016/j.urology.2023.
    Abstract

  2449. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Acute Kidney Injury within 90 days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Sep 22:S0090-4295(23)00807-5. doi: 10.1016/j.urology.2023.
    Abstract

  2450. VEJLGAARD M, Maibom SL, Joensen UN, Moser C, et al
    Microbial trends in infection-related readmissions following radical cystectomy for bladder cancer.
    Urology. 2023 Sep 22:S0090-4295(23)00805-1. doi: 10.1016/j.urology.2023.
    Abstract

  2451. MAJDALANY SE, Yaguchi G, Arora S, Ray C, et al
    Genital Sparing Robot-Assisted Radical Cystectomy with Intracorporeal Neobladder & Paravaginal Repair.
    Urology. 2023;179:202-203.
    Abstract

  2452. HYLLESTED E, Vejlgaard M, Stroomberg HV, Maibom SL, et al
    Reply by Authors: Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00810-5. doi: 10.1016/j.urology.2023.
    Abstract

  2453. GRECO F, Domanico L, Lembo F
    Editorial Comment to Acute Kidney Injury Within 90Days of Radical Cystectomy for Bladder Cancer: Incidence and Risk Factors.
    Urology. 2023 Oct 21:S0090-4295(23)00809-9. doi: 10.1016/j.urology.2023.
    Abstract

  2454. GALOSI AB, Fave RFD, Perpepaj L, Milanese G, et al
    Does Alexis(c) wound protector/retractor reduce the risk of surgical site infections after open radical cystectomy for bladder cancer? Results from a single center, comparative study.
    Urology. 2023 Nov 6:S0090-4295(23)00951-2. doi: 10.1016/j.urology.2023.
    Abstract

  2455. ARCEO-OLAIZ R, Smith EA, Stokes C, Eaton BR, et al
    Use of Perirectal Hyaluronic Acid Spacer Prior to Radiotherapy in a Pediatric Patient With Bladder Rhabdomyosarcoma: A Case Report.
    Urology. 2023;181:136-140.
    Abstract

  2456. TUA-CARACCIA R, Livingston A, Routh JC
    Recurrent Papillary Bladder Tumors in a Boy With Lynch Syndrome.
    Urology. 2023;181:133-135.
    Abstract

  2457. GUL ZG, Wu S, Raver M, Vasan R, et al
    A Multipronged Intervention to Reduce Readmissions and Readmission Intensity After Radical Cystectomy.
    Urology. 2023;182:155-160.
    Abstract

  2458. ZHU A, Srivastava A
    Editorial Comment: Does Alexis Wound Protector/Retractor Reduce the Risk of Surgical Site Infections After Open Radical Cystectomy for Bladder Cancer? Results From a Single Center, Comparative Study.
    Urology. 2023 Dec 14:S0090-4295(23)00958-5. doi: 10.1016/j.urology.2023.
    Abstract

  2459. YANG X, Zhang S, Cui Y, Li Y, et al
    Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: a protocol for a randomized controlled trial.
    BMC Cancer. 2023;23:320.
    Abstract

  2460. TANG Y, Lei Y, Gao P, Jia J, et al
    Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker.
    BMC Cancer. 2023;23:328.
    Abstract

  2461. HUI P, Ni F, Zheng L, Jia L, et al
    Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer.
    BMC Cancer. 2023;23:355.
    Abstract

  2462. KOLL FJ, Doring C, Olah C, Szarvas T, et al
    Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
    BMC Cancer. 2023;23:504.
    Abstract

  2463. RUTTEN VC, Salhi Y, Robbrecht GJ, de Wit R, et al
    The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer - a non-randomized phase II clinical trial.
    BMC Cancer. 2023;23:539.
    Abstract

  2464. NISHIYAMA H, Tanaka Y, Hamada M, Ozaki M, et al
    Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
    BMC Cancer. 2023;23:565.
    Abstract

  2465. LIU J, Wu P, Lai S, Wang J, et al
    Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    BMC Cancer. 2023;23:574.
    Abstract

  2466. KERZELI IK, Kostakis A, Turker P, Malmstrom PU, et al
    Elevated levels of MMP12 sourced from macrophages are associated with poor prognosis in urothelial bladder cancer.
    BMC Cancer. 2023;23:605.
    Abstract

  2467. LIANG PI, Lai HY, Chan TC, Li WM, et al
    Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    BMC Cancer. 2023;23:599.
    Abstract

  2468. LI W, Liu Z, Jin K, Shao F, et al
    Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:661.
    Abstract

  2469. JIANG Y, Zhu C, Huang H, Huang G, et al
    TUBA1C is a potential new prognostic biomarker and promotes bladder urothelial carcinoma progression by regulating the cell cycle.
    BMC Cancer. 2023;23:716.
    Abstract

  2470. CAI Y, Cheng Y, Wang Z, Li L, et al
    A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    BMC Cancer. 2023;23:725.
    Abstract

  2471. NASR S, Haddad FG, Khazen J, Kattan J, et al
    PD-L1 protein expression by Combined Positive Score (CPS) in patients with muscle invasive or advanced urothelial carcinoma: a single institution experience.
    BMC Cancer. 2023;23:817.
    Abstract

  2472. TSAI TH, Su PJ, Huang SY, Kuo MC, et al
    The prognostic significance of histologic variant on survival outcomes in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2023;23:871.
    Abstract

  2473. WANG Y, Pan J, An F, Chen K, et al
    GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer.
    BMC Cancer. 2023;23:925.
    Abstract

  2474. ALT M, Stecca C, Lin Y, Kazeem G, et al
    Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma.
    BMC Cancer. 2023;23:919.
    Abstract

  2475. HE Q, Wu S, Zhou Y, Liu Y, et al
    Genetic factors, adherence to healthy lifestyle behaviors, and risk of bladder cancer.
    BMC Cancer. 2023;23:965.
    Abstract

  2476. ZHENHAI Z, Qi C, Shuchao Z, Zhongqi W, et al
    MiR-205-3p suppresses bladder cancer progression via GLO1 mediated P38/ERK activation.
    BMC Cancer. 2023;23:956.
    Abstract

  2477. TANABE K, Nakanishi Y, Okubo N, Matsumoto S, et al
    Prevalence and characteristics of patients with upper urinary tract urothelial carcinoma having potential Lynch syndrome identified by immunohistochemical universal screening and Amsterdam criteria II.
    BMC Cancer. 2023;23:940.
    Abstract

  2478. LUO L, Xie Q, Wu Y, Li P, et al
    Circular RNA CCT3 is a unique molecular marker in bladder cancer.
    BMC Cancer. 2023;23:977.
    Abstract

  2479. CHEN JX, Huang WT, Zhang QY, Deng CE, et al
    The optimal intravesical maintenance chemotherapy scheme for the intermediate-risk group non-muscle-invasive bladder cancer.
    BMC Cancer. 2023;23:1018.
    Abstract

  2480. LI Y, Xu K, Zhang Y, Mao H, et al
    Identification of a basement membrane-related genes signature with immune correlation in bladder urothelial carcinoma and verification in vitro.
    BMC Cancer. 2023;23:1021.
    Abstract

  2481. LU L, Chen C, Cheng H, Ding H, et al
    Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1066.
    Abstract

  2482. ROUSSOT N, Fumet JD, Limagne E, Thibaudin M, et al
    A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
    BMC Cancer. 2023;23:1080.
    Abstract

  2483. GORE JL, Wolff EM, Comstock BA, Follmer KM, et al
    Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer.
    BMC Cancer. 2023;23:1127.
    Abstract

  2484. THOMAS R, Wiley CA, Droste EL, Robertson J, et al
    Whole exome sequencing analysis of canine urothelial carcinomas without BRAF V595E mutation: Short in-frame deletions in BRAF and MAP2K1 suggest alternative mechanisms for MAPK pathway disruption.
    PLoS Genet. 2023;19:e1010575.
    Abstract

  2485. WEINBERG L, Aitken SAA, Kaldas P, Fletcher L, et al
    Postoperative complications and hospital costs following open radical cystectomy: A retrospective study.
    PLoS One. 2023;18:e0282324.
    Abstract

  2486. LIU CL, Tsai HW, Peng SL, Chang CP, et al
    CDCP1 (CUB domain containing protein 1) is a potential urine-based biomarker in the diagnosis of low-grade urothelial carcinoma.
    PLoS One. 2023;18:e0281873.
    Abstract

  2487. SMITH-TOGOBO C, Mprah R, Yeboah EA, Anyidoho HK, et al
    Detection of cytological abnormalities in urothelial cells from individuals previously exposed or currently infected with Schistosoma haematobium.
    PLoS One. 2023;18:e0278202.
    Abstract


  2488. Expression of Concern: The prognostic significance of long noncoding RNAs in bladder cancer: A meta-analysis.
    PLoS One. 2023;18:e0284938.
    Abstract

  2489. HAMID ARAH, Syadza YZ, Yausep OE, Christanto RBI, et al
    The expression of stem cells markers and its effects on the propensity for recurrence and metastasis in bladder cancer: A systematic review.
    PLoS One. 2023;18:e0269214.
    Abstract

  2490. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    Abstract

  2491. SATO N, Mori KP, Sakai K, Miyata H, et al
    Exploring the mechanism of BK polyomavirus-associated nephropathy through consensus gene network approach.
    PLoS One. 2023;18:e0282534.
    Abstract

  2492. YUAN Q, Hu J, Yuan F, An J, et al
    Predictive role of pretreatment skeletal muscle mass index for long-term survival of bladder cancer patients: A meta-analysis.
    PLoS One. 2023;18:e0288077.
    Abstract

  2493. LEE J, Kim E, Park J, Choi S, et al
    Pre-analytical handling conditions and protein marker recovery from urine extracellular vesicles for bladder cancer diagnosis.
    PLoS One. 2023;18:e0291198.
    Abstract

  2494. LEONARDO K, Mirza H, Seno DH, Purnomo N, et al
    Transperitoneal vs extraperitoneal radical cystectomy: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0294809.
    Abstract

  2495. WANG E, Hagberg O, Malmstrom PU
    The association between BCG treatment in patients with bladder cancer and subsequent risk of developing Alzheimer and other dementia.-A Swedish nationwide cohort study from 1997 to 2019.
    PLoS One. 2023;18:e0292174.
    Abstract

  2496. WONG JL, Smith P, Angulo-Lozano J, Ranti D, et al
    IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2306782120.
    Abstract

  2497. ZHAO Z, Aoi Y, Philips CN, Meghani KA, et al
    Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment.
    Proc Natl Acad Sci U S A. 2023;120:e2310063120.
    Abstract


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.


;